0001410578-22-001669.txt : 20220516 0001410578-22-001669.hdr.sgml : 20220516 20220516162103 ACCESSION NUMBER: 0001410578-22-001669 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 100 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Petros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001815903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851410058 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39752 FILM NUMBER: 22929454 BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 973-242-0005 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 10-Q 1 tmb-20220331x10q.htm 10-Q
0.010.3110039021000100390210020684723206847230001815903--12-312022Q1trueP60DP60DP60DP60DP0Y0.010.31P90DP6MP7Dhttp://fasb.org/us-gaap/2021-01-31#OtherAssetshttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrentfalse00018159032022-01-012022-01-310001815903us-gaap:CommonStockMember2021-01-262021-01-260001815903us-gaap:PreferredStockMember2021-01-012021-03-310001815903us-gaap:CommonStockMember2021-01-012021-03-310001815903us-gaap:RetainedEarningsMember2022-03-310001815903us-gaap:AdditionalPaidInCapitalMember2022-03-310001815903us-gaap:RetainedEarningsMember2021-12-310001815903us-gaap:AdditionalPaidInCapitalMember2021-12-310001815903us-gaap:RetainedEarningsMember2021-03-310001815903us-gaap:AdditionalPaidInCapitalMember2021-03-310001815903us-gaap:RetainedEarningsMember2020-12-310001815903us-gaap:AdditionalPaidInCapitalMember2020-12-310001815903us-gaap:CommonStockMember2022-03-310001815903us-gaap:CommonStockMember2021-12-310001815903us-gaap:CommonStockMember2021-03-310001815903us-gaap:PreferredStockMember2020-12-310001815903us-gaap:CommonStockMember2020-12-310001815903us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001815903us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-3100018159032020-01-012020-12-310001815903us-gaap:RestrictedStockUnitsRSUMember2022-03-310001815903us-gaap:RestrictedStockUnitsRSUMember2021-12-310001815903us-gaap:RestrictedStockUnitsRSUMember2020-12-3100018159032021-12-222021-12-2200018159032021-12-2200018159032022-01-310001815903us-gaap:SubsequentEventMember2022-04-072022-04-0700018159032022-01-042022-01-040001815903ptpi:TaniaKingMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2022-04-072022-04-070001815903ptpi:MitsubishiTanabePharmaCorporationMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:MitsubishiTanabePharmaCorporationMemberptpi:LicenseAgreementMember2021-01-012021-03-310001815903us-gaap:NonUsMember2022-01-012022-03-310001815903country:US2022-01-012022-03-310001815903us-gaap:NonUsMember2021-01-012021-03-310001815903country:US2021-01-012021-03-3100018159032021-11-032021-11-030001815903us-gaap:OperatingSegmentsMember2022-01-012022-03-310001815903us-gaap:RetainedEarningsMember2022-01-012022-03-310001815903us-gaap:RetainedEarningsMember2021-01-012021-03-310001815903srt:MinimumMember2022-03-310001815903srt:MaximumMember2022-03-310001815903ptpi:TimmMedicalProductMember2022-01-012022-03-310001815903ptpi:StendraProductMember2022-01-012022-03-310001815903ptpi:PtvProductMember2022-01-012022-03-310001815903ptpi:TimmMedicalProductMember2022-03-310001815903ptpi:StendraProductMember2022-03-310001815903ptpi:PtvProductMember2022-03-310001815903ptpi:TimmMedicalProductMember2021-12-310001815903ptpi:StendraProductMember2021-12-310001815903ptpi:PtvProductMember2021-12-310001815903us-gaap:SeniorDebtObligationsMember2020-09-300001815903us-gaap:SeniorDebtObligationsMember2017-11-222017-11-220001815903us-gaap:CorporateNonSegmentMember2022-01-012022-03-310001815903us-gaap:CorporateNonSegmentMember2021-01-012021-03-310001815903us-gaap:SeniorDebtObligationsMember2020-04-130001815903us-gaap:SeniorDebtObligationsMember2020-03-310001815903us-gaap:SeniorDebtObligationsMemberus-gaap:PrimeRateMember2016-09-300001815903ptpi:VivusIncMemberptpi:PromissoryNoteMemberptpi:SettlementAgreementMember2022-03-310001815903us-gaap:NotesPayableOtherPayablesMember2022-03-310001815903us-gaap:SeniorDebtObligationsMemberus-gaap:PrimeRateMember2020-04-132020-04-130001815903us-gaap:SeniorDebtObligationsMemberus-gaap:PrimeRateMember2020-03-312020-03-310001815903ptpi:PrescriptionMedicationSalesMember2021-01-012021-03-310001815903ptpi:MedicalDeviceSalesMember2021-01-012021-03-310001815903us-gaap:PreferredStockMember2021-01-262021-01-260001815903ptpi:ThreeCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001815903ptpi:OneCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001815903ptpi:OneCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-03-310001815903ptpi:TwoCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001815903ptpi:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001815903ptpi:OneCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001815903ptpi:TwoCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001815903ptpi:OneCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001815903ptpi:ExpirationDateOfSeptember162024Member2022-03-310001815903ptpi:ExpirationDateOfSeptember12025Member2022-03-310001815903ptpi:ExpirationDateOfSeptember12024Member2022-03-310001815903ptpi:ExpirationDateOfOctober192026Member2022-03-310001815903ptpi:ExpirationDateOfMarch22025Member2022-03-310001815903ptpi:ExpirationDateOfJune192024Member2022-03-310001815903ptpi:ExpirationDateOfJune172024Member2022-03-310001815903ptpi:ExpirationDateOfJune12025Member2022-03-310001815903ptpi:ExpirationDateOfJune12024Member2022-03-310001815903ptpi:ExpirationDateOfDecember272026Member2022-03-310001815903ptpi:ExpirationDateOfDecember22026Member2022-03-310001815903ptpi:ExpirationDateOfDecember12025TwoMember2022-03-310001815903ptpi:ExpirationDateOfDecember12025ThreeMember2022-03-310001815903ptpi:ExpirationDateOfDecember12025OneMember2022-03-310001815903ptpi:ExpirationDateOfDecember12025FourMember2022-03-310001815903ptpi:ExpirationDateOfDecember12025FiveMember2022-03-310001815903ptpi:ExpirationDateOfDecember12024Member2022-03-310001815903ptpi:ExpirationDateOfAugust232023Member2022-03-3100018159032021-03-3100018159032020-12-310001815903ptpi:MedicalDeviceSalesMember2022-03-310001815903ptpi:MedicalDeviceSalesMember2021-12-310001815903us-gaap:WarrantMember2022-01-012022-03-310001815903us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001815903ptpi:RestrictedStockUnitsMember2022-01-012022-03-310001815903us-gaap:WarrantMember2021-01-012021-03-310001815903us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001815903us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001815903us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001815903ptpi:VivusIncMemberptpi:SettlementAgreementMember2022-01-182022-01-180001815903ptpi:TaniaKingMemberus-gaap:SubsequentEventMemberptpi:ConsultingAndAdvisoryAgreementMember2022-04-072022-04-070001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMembersrt:MaximumMemberptpi:MetuchenPharmaceuticalsLlcMember2022-01-012022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MetuchenPharmaceuticalsLlcMember2022-01-012022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MetuchenPharmaceuticalsLlcMember2021-01-012021-12-310001815903us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001815903us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2022-04-072022-04-070001815903ptpi:TaniaKingMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2022-04-0700018159032022-01-100001815903ptpi:MitsubishiTanabePharmaCorporationMemberptpi:LicenseAgreementMember2022-03-310001815903ptpi:MitsubishiTanabePharmaCorporationMemberptpi:LicenseAgreementMember2021-12-310001815903us-gaap:SeniorDebtObligationsMember2020-09-302020-09-300001815903ptpi:VivusIncMemberptpi:PromissoryNoteMemberptpi:SettlementAgreementMember2022-01-180001815903ptpi:VivusIncMemberus-gaap:OtherCurrentAssetsMemberptpi:SettlementAgreementMember2022-03-310001815903ptpi:VivusIncMemberus-gaap:OtherCurrentAssetsMemberptpi:SettlementAgreementMember2021-12-310001815903ptpi:Mr.KeithLavanMemberptpi:SeparationAgreementMember2020-12-312020-12-310001815903ptpi:HybridMemberptpi:AmendedLicenseAgreementOfH100Member2022-03-242022-03-240001815903ptpi:HybridMemberptpi:AmendedLicenseAgreementOfH100Member2021-12-232021-12-230001815903ptpi:HybridMemberptpi:AmendedLicenseAgreementOfH100Member2021-12-012021-12-010001815903ptpi:HybridMemberptpi:AmendedLicenseAgreementOfH100Member2021-10-312021-10-310001815903ptpi:HybridMemberptpi:AmendedLicenseAgreementOfH100Member2021-10-012021-10-010001815903ptpi:TwoCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-03-310001815903us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001815903us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310001815903us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo500000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-01-012022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo400000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-01-012022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo300000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-01-012022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo250000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-01-012022-03-310001815903ptpi:ServiceAgreementWithIrthCommunicationsLlcMember2021-06-042021-06-040001815903ptpi:CorprominenceLlcMemberptpi:MarketingAndConsultingAgreementMember2021-01-012021-01-010001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo500000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo400000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo300000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-03-310001815903ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMemberptpi:MarketCapitalizationIsGreaterThanOrEqualTo250000000Memberptpi:MetuchenPharmaceuticalsLlcMember2022-03-3100018159032021-01-012021-03-310001815903ptpi:VivusIncMemberptpi:SettlementAgreementMember2022-01-012022-03-310001815903ptpi:PrescriptionMedicationSalesMember2022-01-012022-03-310001815903ptpi:InternationalCustomersMembersrt:MaximumMemberptpi:MedicalDeviceSalesMember2022-01-012022-03-310001815903ptpi:DomesticCustomersMembersrt:MinimumMemberptpi:MedicalDeviceSalesMember2022-01-012022-03-310001815903us-gaap:SeniorDebtObligationsMember2016-09-302016-09-300001815903srt:MinimumMemberus-gaap:SeniorDebtObligationsMember2017-11-220001815903srt:MaximumMemberus-gaap:SeniorDebtObligationsMember2017-11-220001815903us-gaap:SeniorDebtObligationsMember2021-02-012021-02-010001815903us-gaap:SeniorDebtObligationsMember2020-10-012020-10-010001815903us-gaap:SeniorDebtObligationsMember2017-11-220001815903us-gaap:SeniorDebtObligationsMember2016-09-300001815903us-gaap:NotesPayableOtherPayablesMember2022-01-012022-03-310001815903ptpi:PrescriptionMedicationSalesMember2022-03-310001815903ptpi:PrescriptionMedicationSalesMember2021-12-310001815903srt:MinimumMemberptpi:PrescriptionMedicationSalesMember2022-01-012022-03-310001815903srt:MaximumMemberptpi:PrescriptionMedicationSalesMember2022-01-012022-03-310001815903ptpi:MedicalDeviceSalesMember2022-01-012022-03-310001815903ptpi:ScenarioSixMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:ScenarioOneMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:ScenarioFiveMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:VivusIncMemberptpi:ScenarioThreeMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:VivusIncMemberptpi:ScenarioFourMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:MitsubishiTanabePharmaCorporationMemberptpi:ScenarioTwoMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:MitsubishiTanabePharmaCorporationMemberptpi:ScenarioOneMemberptpi:LicenseAgreementMember2022-01-012022-03-310001815903ptpi:HybridMembersrt:MinimumMemberptpi:ExclusiveLicenseToH100Member2020-03-012020-03-310001815903ptpi:HybridMembersrt:MaximumMemberptpi:ExclusiveLicenseToH100Member2020-03-012020-03-310001815903ptpi:HybridMemberptpi:ExclusiveLicenseToH100Member2020-03-310001815903ptpi:HybridMemberptpi:ExclusiveLicenseToH100Member2020-12-012020-12-310001815903ptpi:HybridMemberptpi:ExclusiveLicenseToH100Member2020-10-012020-10-310001815903ptpi:VivusIncMemberptpi:LicenseAgreementMember2016-09-302016-09-300001815903ptpi:ScenarioSixMemberptpi:LicenseAgreementMember2022-03-310001815903ptpi:ScenarioFiveMemberptpi:LicenseAgreementMember2022-03-310001815903ptpi:HybridMemberptpi:ExclusiveLicenseToH100Member2021-03-312021-03-310001815903ptpi:HybridMemberptpi:ExclusiveLicenseToH100Member2020-09-242020-09-240001815903ptpi:HybridMemberptpi:ExclusiveLicenseToH100Member2020-03-012020-03-310001815903ptpi:VivusIncMemberus-gaap:OtherNoncurrentAssetsMemberptpi:SettlementAgreementMember2022-03-310001815903ptpi:VivusIncMemberus-gaap:OtherNoncurrentAssetsMemberptpi:SettlementAgreementMember2021-12-310001815903ptpi:VivusIncMemberptpi:SettlementAgreementMember2022-03-310001815903ptpi:VivusIncMemberptpi:SettlementAgreementMember2021-12-3100018159032021-01-012021-12-3100018159032020-12-070001815903ptpi:VivusIncMemberptpi:SettlementAgreementMember2022-01-180001815903ptpi:TaniaKingMemberptpi:ConsultingAndAdvisoryAgreementMember2021-04-012021-04-0100018159032022-03-3100018159032021-12-3100018159032022-05-1300018159032022-01-012022-03-31xbrli:sharesiso4217:USDxbrli:pureptpi:Dptpi:customerptpi:directoriso4217:USDxbrli:sharesptpi:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended March 31, 2022

Or

    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from                      to                   

Commission File Number: 001-39752

Petros Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

85-1410058

(State of Incorporation)

(I. R. S. Employer Identification No.)

1185 Avenue of the Americas, 3rd Floor, New York, New York

10036

(Address of principal executive offices)

(Zip Code)

(973) 242-0005

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common stock, par value $0.0001

PTPI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of May 13, 2022, there were 20,684,723 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q may contain or incorporate by reference forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements are based upon management’s assumptions, expectations, projections, intentions and beliefs about future events. Except for historical information, the use of predictive, future-tense or forward-looking words such as “intend,” “plan,” “predict,” “may,” “will,” “project,” “target,” “strategy,” “estimate,” “anticipate,” “believe,” “expect,” “continue,” “potential,” “forecast,” “should” and similar expressions, whether in the negative or affirmative, that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. Such forward-looking statements are only predictions, and actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of risks and uncertainties, including, without limitation, Petros’ ability to execute on its business strategy, including its plans to develop and commercialize its product candidates; Petros’ ability to comply with obligations as a public reporting company; the ability of Petros to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; the risk that the financial performance of Petros may not be as anticipated by the merger transactions that resulted in the Company’s creation; risks resulting from Petros’ status as an emerging growth company, including that reduced disclosure requirements may make shares of Petros common stock less attractive to investors; risks related to Petros’ history of incurring significant losses; risks related to Petros’ dependence on the commercialization of a single product, Stendra®; risks related to Petros’ ability to obtain regulatory approvals for, or market acceptance of, any of its products or product candidates; and the expected or potential impact of the novel coronavirus (“COVID 19”) pandemic, including the emergence of new variants, such as the Omicron variant, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are described in this Quarterly Report on Form 10-Q, in “Risk Factor Summary” and in Part I, Item 1A., “Risk Factors,” in Petros’ Annual Report on Form 10-K for the year ended December 31, 2021 and in our other reports filed with the Securities and Exchange Commission (the “SEC”). We advise you to carefully review the reports and documents we file from time to time with the SEC, particularly our annual reports on Form 10-K, our quarterly reports on Form 10-Q and our current reports on Form 8-K. Petros cautions readers that the forward-looking statements included in, or incorporated by reference into, this Quarterly Report on Form 10-Q represent our beliefs, expectations, estimates and assumptions only as of the date hereof and are not intended to give any assurance as to future results. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, Petros cannot assess the effect of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement.

Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We disclaim any obligation to update the forward-looking statements contained in, or incorporated by reference into, this Quarterly Report on Form 10-Q to reflect any new information or future events or circumstances or otherwise, except as required by the federal securities laws.

OTHER INFORMATION

All references to “Petros,” the “Company,” “we,” “us” and “our” in this Quarterly Report on Form 10-Q refer to Petros Pharmaceuticals, Inc. and its subsidiaries.

TABLE OF CONTENTS

    

Page

PART I—FINANCIAL INFORMATION

4

Item 1. Financial Statements

4

Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021

4

Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 (unaudited)

5

Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2022 and 2021 (unaudited)

6

Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited)

7

Notes to Consolidated Financial Statements

8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

26

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

40

Item 4. Controls and Procedures.

40

PART II—OTHER INFORMATION

42

Item 1. Legal Proceedings.

42

Item 1A. Risk Factors.

42

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

42

Item 3. Defaults Upon Senior Securities.

42

Item 4. Mine Safety Disclosures.

42

Item 5. Other Information.

42

Item 6. Exhibits.

43

Signatures.

44

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

PETROS PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

March 31, 

    

December 31, 

2022

2021

    

(Unaudited)

    

(Audited)

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash

$

17,671,871

$

23,847,572

Accounts receivable, net

 

3,740,775

 

2,455,386

Inventories

 

1,942,873

 

519,649

Prepaid expenses and other current assets

 

3,482,586

 

3,720,088

Total current assets

 

26,838,105

 

30,542,695

Fixed assets, net

 

46,842

 

49,397

Intangible assets, net

 

23,734,834

 

25,293,149

API purchase commitment

 

4,796,771

 

11,029,260

Other assets

 

447,595

 

475,557

Total assets

$

55,864,147

$

67,390,058

Liabilities and Stockholders’ Equity

 

 

  

Current liabilities:

 

 

  

Accounts payable

$

3,700,326

$

4,557,969

Accrued expenses

 

5,512,006

 

11,957,384

Accrued inventory purchases

 

 

14,203,905

Other current liabilities

 

352,436

 

260,818

Current portion of promissory note

723,982

Total current liabilities

 

10,288,750

 

30,980,076

Promissory note

9,477,776

Derivative liability

 

 

460,000

Other long-term liabilities

 

371,053

 

405,018

Total liabilities

 

20,137,579

 

31,845,094

Stockholders’ Equity:

 

 

  

Preferred stock (par value of $0.0001 per share, 50,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively)

 

 

Common stock (par value of $0.0001 per share, 150,000,000 shares authorized, 20,684,723 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively)

 

2,068

 

2,068

Additional paid-in capital

 

106,587,544

 

106,231,716

Accumulated deficit

 

(70,863,044)

 

(70,688,820)

Total Stockholders’ Equity

 

35,726,568

 

35,544,964

Total Liabilities and Stockholders' Equity

$

55,864,147

$

67,390,058

The accompanying Notes are an integral part of the Consolidated Financial Statements.

4

PETROS PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

For the Three Months Ended

March 31, 

    

2022

    

2021

Net sales

$

2,465,169

$

4,075,606

Cost of goods sold

472,340

 

643,386

Gross profit

 

1,992,829

 

3,432,220

Operating expenses:

 

 

Selling, general and administrative

 

3,897,738

 

3,881,717

Gain on settlement with Vivus

(3,389,941)

Research and development expense

 

405,360

 

19,181

Depreciation and amortization expense

 

1,560,870

 

1,728,829

Total operating expenses

 

2,474,027

5,629,727

Loss from operations

 

(481,198)

 

(2,197,507)

Change in fair value of derivative liability

 

460,000

 

5,380,000

Interest expense, senior debt

 

 

(173,412)

Interest expense, promissory note

 

(153,026)

 

Net income (loss)

$

(174,224)

$

3,009,081

Net income (loss) per common share

 

 

Basic and Diluted

$

(0.01)

$

0.31

Weighted average common shares outstanding

 

 

Basic

 

20,684,723

 

9,753,086

Effects of common share equivalents

 

 

1,600

Diluted

 

20,684,723

 

9,754,686

The accompanying Notes are an integral part of the Consolidated Financial Statements.

5

PETROS PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

    

    

    

Common

    

Additional

    

    

Preferred 

Common 

Stock 

Paid-in 

Accumulated 

Stock 

Stock

Amount

Capital

Deficit

Total

Three Months Ended March 31, 2022

Balance, December 31, 2021

 

20,684,723

$

2,068

$

106,231,716

$

(70,688,820)

$

35,544,964

Stock-based compensation expense

 

 

 

 

355,828

 

 

355,828

Net loss

 

 

 

 

 

(174,224)

 

(174,224)

Balance, March 31, 2022

 

 

20,684,723

$

2,068

$

106,587,544

$

(70,863,044)

$

35,726,568

Three Months Ended March 31, 2021

Balance, December 31, 2020

500

9,707,655

$

971

$

79,170,225

$

(61,702,144)

$

17,469,052

Conversion of Preferred Stock to Common Stock

(500)

60,606

6

(6)

Non-employee stock-based compensation

30,000

3

97,797

97,800

Stock-based compensation expense

347,207

347,207

Net income

3,009,081

3,009,081

Balance, March 31, 2021

9,798,261

$

980

$

79,615,223

$

(58,693,063)

$

20,923,140

The accompanying Notes are an integral part of the Consolidated Financial Statements.

6

PETROS PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

    

For the Three Months Ended March 31, 

2022

2021

Cash flows from operating activities:

 

  

 

  

Net income (loss)

$

(174,224)

$

3,009,081

Adjustments to reconcile net income (loss) to net cash used in operating activities:

 

 

Depreciation and amortization

 

1,560,870

 

1,728,829

Bad debt expense (recoveries)

 

(115,364)

 

2,984

Inventory and sample inventory reserve

 

3,594

 

48,228

Amortization of deferred financing costs and debt discount

 

 

12,500

Lease expense

 

27,962

 

25,156

Derivative liability

 

(460,000)

 

(5,380,000)

Deferred revenue

(70,343)

Gain on settlement with Vivus

(3,389,941)

Employee stock-based compensation

 

355,828

 

347,207

Non-employee stock-based compensation

97,800

Changes in operating assets and liabilities:

 

 

Accounts receivable

 

(1,170,025)

 

(1,044,213)

Inventories

 

(1,426,818)

 

193,987

Prepaid expenses and other current assets

 

237,502

 

172,051

Accounts payable

 

(857,643)

 

(333,273)

Accrued expenses

 

74,905

 

698,498

Other current liabilities

 

161,961

 

74,992

Other long-term liabilities

 

(33,965)

 

(100,408)

Net cash used in operating activities

 

(5,275,701)

 

(446,581)

Cash flows from financing activities:

 

  

 

  

Payment of promissory note

(900,000)

Payment of senior debt

 

 

(1,592,028)

Payment of portion of senior debt end of term fee

 

 

(534,375)

Net cash used in financing activities

 

(900,000)

 

(2,126,403)

Net decrease in cash

 

(6,175,701)

 

(2,572,984)

Cash, beginning of period

 

23,847,572

 

17,139,694

Cash, end of period

$

17,671,871

$

14,566,710

Supplemental cash flow information:

 

  

 

  

Cash paid for interest during the period

$

$

176,677

Noncash Items:

Noncash decrease in accrued expenses related to Vivus settlement

$

(6,520,283)

$

Noncash decrease in accrued inventory purchases related to Vivus settlement

(14,203,905)

Noncash increase in promissory note related to Vivus settlement

10,201,758

Noncash decrease in API purchase commitment related to Vivus settlement

6,232,489

The accompanying Notes are an integral part of the Consolidated Financial Statements.

7

PETROS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1)    Nature of Operations, Basis of Presentation, and Liquidity

Nature of Operations

Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) is a pharmaceutical company focused on men’s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution.

Petros consists of wholly owned subsidiaries, Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). The Company is engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration (“FDA”) approved PDE 5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”), which we have licensed from Vivus, Inc. (“Vivus”). Petros also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, we have acquired an exclusive global license to develop and commercialize H100™, a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease.

The Company was organized as a Delaware corporation on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Merger Agreement”), by and between Petros, Neurotrope,, PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen. The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly-owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.), a Delaware corporation (“Synaptogenix”), and a wholly-owned subsidiary of Neurotrope.

Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, considered necessary to present fairly our financial position, results of operations and cash flows. However, actual results could differ from those estimates. The unaudited interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission. This Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2021.

All transactions between the consolidated entities have been eliminated in consolidation.

Liquidity

The Company has experienced net losses and negative cash flows from operations since our inception. As of March 31, 2022, the Company had cash of $17.7 million, positive working capital of $16.5 million, an accumulated deficit of $70.9 million and used cash in operations during the three months ended March 31, 2022 of $5.3 million. The Company’s plans include, or may include, utilizing its cash and cash equivalents on hand, as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. In January 2022, the Company executed a promissory note in favor of Vivus in connection with the Vivus Settlement Agreement in the principal amount of $10,201,758. The terms of this promissory note are discussed in Note 8. The Company believes the cash on hand is sufficient to fund operations and debt service through at least May 16, 2023, however for periods after May 16,

8

2023, the Company may need to raise additional funds or curtail certain discretionary expenditures in order to maintain an appropriate level of cash to fund our operations. While the Company is optimistic that it will be successful in its efforts to achieve its plans, there can be no assurances that it will be successful in doing so.

2)    Summary of Significant Accounting Policies

Use of Estimates

The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.

Risks and Uncertainties

The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.

The World Health Organization (“WHO”) declared the coronavirus (“COVID-19”) a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic, including the emergence of any new variants, such as the Omicron variants, will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2022 and beyond.

During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices. In January 2022, the Company sub-leased its Manalapan office and all administrative employees are working remotely for the foreseeable future. The Company has fully resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. Since the beginning of the COVID-19 pandemic, we have experienced a shift from in-person sales to online, telehealth-based sales. These online sales generally have lower gross margins than in-person sales, which has impacted our net revenues.

Revenue Recognition

Prescription Medication Sales

The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition (“Topic 606”), the Company recognizes revenue from prescription medication sales when its performance obligations with a customer has been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide Stendra® upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of Stendra®, which is typically upon delivery. The Company invoices its customers after Stendra® has been delivered and invoice payments are generally due within 30 to 75 days of invoice date.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales

9

net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

As of March 31, 2022 and December 31, 2021, the reserves for sales deductions were $4.7 million and $4.7 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.

Product Returns

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of March 31, 2022 and December 31, 2021, the reserves for product returns were $3.8 million and $3.8 million, respectively, and are included as a component of accrued expenses.

Contract Rebates, Coupon Redemptions and DSA Fees

The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us.

The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. See Note 3 Accounts Receivable, net for further discussion of these reserves.

Medical Device Sales

The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

10

Product Returns

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of March 31, 2022 and December 31, 2021, the reserves for product returns for medical devices were not significant.

Contract Costs

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at March 31, 2022 and December 31, 2021.

Fair Value of Financial Instruments

Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.

Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities. The Company believes that the carrying values of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to the short-term nature of these instruments.

In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of March 31, 2022 and December 31, 2021 was $0 million and $0.5 million, respectively. See Note 9 Stockholders’ Equity.

Stock-Based Compensation

The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant).

The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 10 Stock Options.

11

Income Taxes

The Company is a C corporation, which accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of March 31, 2022 and December 31, 2021, no accrued interest or penalties are recorded in the consolidated balance sheet.

Basic and Diluted Net Loss per Common Share

The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of shares of common stocks outstanding during the period, excluding the anti-dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the three months ended March 31, 2022. See Note 13 Basic and Diluted Net Loss per Common Share.

Recent Accounting Pronouncements

Pending Adoption as of March 31, 2022

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13, together with a series of subsequently issued related ASUs, has been codified in Topic 326. Topic 326 establishes new requirements for companies to estimate expected credit losses when measuring certain financial assets, including accounts receivables. The new guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the effect that the new guidance will have on its consolidated financial statements and related disclosures.

12

3)    Accounts Receivable, net

Accounts receivable, net is comprised of the following:

    

March 31, 

    

December 31, 

2022

2021

Gross accounts receivables

$

4,528,812

$

3,363,827

Distribution service fees

 

(317,247)

 

(371,310)

Chargebacks accrual

 

(5,880)

 

Cash discount allowances

 

(202,589)

 

(159,446)

Allowance for doubtful accounts

 

(262,321)

 

(377,685)

Total accounts receivable, net

$

3,740,775

$

2,455,386

For the three months ended March 31, 2022, gross sales from customers representing 10% or more of the Company’s total gross sales included three customers which represented approximately 30%, 23% and 22% of total gross sales, respectively. For the three months ended March 31, 2021, gross sales from customers representing 10% or more of the Company’s total gross sales included one customer which represented approximately 88% of total gross sales.

Receivables from customers representing 10% or more of the Company’s gross accounts receivable included two customers at March 31, 2022 equal to 35% and 31%, respectively, of the Company’s total gross accounts receivables. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included three customers at December 31, 2021 equal to 40%, 19% and 15%, respectively, of the Company’s total gross accounts receivables.

4)    Inventories

Inventory is comprised of the following:

    

March 31, 2022

    

December 31, 2021

Raw materials

$

1,854,160

$

359,741

Finished goods

 

88,713

 

159,908

Total inventory

$

1,942,873

$

519,649

Finished goods are net of valuation reserves of $386,892 and $383,298 as of March 31, 2022 and December 31, 2021, respectively. Raw materials are net of valuation reserves of $2,872,977 as of March 31, 2022 and December 31, 2021, which is related to bulk inventory that is fully reserved.

5)    Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets are comprised of the following:

    

March 31, 2022

    

December 31, 2021

Prepaid insurance

$

128,004

$

73,223

Prepaid FDA fees

 

554,120

 

831,179

Prepaid coupon fees

 

71,500

 

71,500

API purchase commitment asset (see Note 13)

 

1,419,538

 

1,419,538

Due from wholesalers

609,059

609,059

Other prepaid expenses

 

624,823

 

605,422

Other current assets

 

75,542

 

110,167

Total prepaid expenses and other current assets

$

3,482,586

$

3,720,088

13

6)    Intangible Assets

Balance at December 31, 2020

    

$

32,160,919

Amortization expense

 

(6,867,770)

Balance at December 31, 2021

25,293,149

Amortization expense

 

(1,558,315)

Balance at March 31, 2022

$

23,734,834

The future annual amortization related to the Company’s intangible assets is as follows as of March 31, 2022:

2022 (remaining 9 months)

    

4,633,426

2023

 

5,445,729

2024

 

4,650,787

2025

 

2,716,011

2026

2,201,720

Thereafter

 

4,087,161

Total

$

23,734,834

The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years, 12 years, and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of March 31, 2022 are $17.8 million, $4.6 million and $1.3 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2021 were $19.1 million, $4.9 million and $1.4 million, respectively. The Company determined that no impairment existed as of March 31, 2022.

7)    Accrued Expenses

Accrued expenses are comprised of the following:

    

March 31, 2022

    

December 31, 2021

Accrued price protection (see note 13)

$

$

1,853,979

Accrued product returns

 

3,763,211

 

6,192,845

Accrued contract rebates

 

376,937

 

379,242

Due to Vivus (see Note 13)

 

 

2,267,523

Due to third-party logistics provider

 

349,410

 

479,178

Accrued bonuses

532,729

527,563

Accrued professional fees

 

14,957

 

125,392

Other accrued expenses

 

474,762

 

131,662

Total accrued expenses

$

5,512,006

$

11,957,384

8)    Debt

Promissory Note

In connection with the Settlement Agreement entered into with Vivus (see Note 13), Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the principal amount of $10,201,758. The parties also entered into a Security Agreement to secure Petros’ obligations under the Note.

Under the terms of the Note, the original principal amount of $10,201,758 is payable in consecutive quarterly installments of principal and interest beginning on April 1, 2022 through January 1, 2027. Interest on the principal amount will accrue at a rate of 6% per year. The Company may prepay the Note, in whole or in part, at any time, with no premium or penalty. In the event that the Company defaults under the Security Agreement, all principal outstanding under the Note at the time of the default will bear interest at a rate of 9% per year until the full and final payment of all principal and interest under the Note (regardless of whether any default is waived or cured). Pursuant to the Security Agreement, dated January 18, 2022, the Company granted to Vivus a continuing security interest in all of its Stendra® API and products and its rights under the License Agreement.

During the three months ended March 31, 2022, the Company recorded $153,026 of interest expense related to the Note.

14

Senior Debt

The Company did not have any senior indebtedness as of March 31, 2022 and December 31, 2021.

On September 30, 2016, the Company entered into a loan agreement with Hercules, a third party, for a $35 million term loan (“Senior Debt”) with a stated interest rate of the greater of either (i) Prime plus 7.25% or (ii) 10.75%. The Senior Debt included an additional Paid-In-Kind (“PIK”) interest that increased the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge.

On November 22, 2017, the Company amended its loan agreement with Hercules (“First Amendment”). A covenant was added, in which the Company must achieve a certain minimum EBITDA, as defined, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio (1:1 to 0.9:1) were reduced. The Company was also required to prepay $10,000,000 in principal.

Monthly principal payments, including interest, commenced November 1, 2018 with the outstanding balance of the Senior Debt due in full on November 1, 2020. The end of term charge was being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method.

On April 13, 2020, the Company amended its loan agreement with Hercules. The amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The amendment also included the following changes:

Removed the Adjusted EBITDA and Fixed Cost Coverage Ratio Covenants.
Extended the maturity date from October 1, 2020 to April 2021, which was further extendable to December 1, 2021 upon achieving the Financing Milestone, as defined in the agreement.
Increased the cash interest rate from the greater of (a) 10.75% or (b) 10.75% plus the US WSJ Prime minus 4.50% to the greater of (a) 11.50% or (b) 11.50% plus the US WSJ Prime minus 4.25%.
Removed the PIK interest rate.
Removed the prepayment penalty.

The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020 and $534,375 paid on February 1, 2021.

Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to Loan and Security Agreement (“Third Amendment”) to provide for interest only payments commencing on October 1, 2020 and continuing through December 22, 2020 unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated.

The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt had a maturity date of December 1, 2021.

On November 3, 2021, the Company repaid $1,179,651 towards the senior debt. This payment satisfied the remaining balance of the senior debt as of that date.

Interest expense on the Senior Debt was $173,412 for the three months ended March 31, 2021. As of December 31, 2021, there was $0 of accrued and unpaid interest.

15

9)     Stockholders’ Equity

On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock.

Effective January 1, 2021, the Company entered into a Marketing and Consulting Agreement (the “CorIRAgreement”) with CorProminence, LLC (the “Consultant”) for certain shareholder information and relation services. The term of the CorIRAgreement is for one year with automatic consecutive one-year renewal terms. As consideration for the shareholder information and relation services, the Company will pay the Consultant a monthly retainer of $7,500 and issued 30,000 restricted shares of the Company’s common stock to the Consultant on March 24, 2021 (the “CorIR Grant Date”). The restricted shares vested immediately on the CorIR Grant Date.

Effective April 1, 2021, the Company entered into a Consulting and Advisory Agreement (the “King Agreement”) with Tania King, an employee of Juggernaut Capital Partners LLP, for certain services. The term of the King Agreement is indefinite but may be terminated by either party, with or without cause. As consideration for the consulting and advisory services, the Company will pay Ms. King a monthly fee of $4,000, an additional $12,000 payment included with the first monthly fee for services provided since January 1, 2021, and issue restricted stock units for shares of the Company’s common stock (“RSU’s”) with a cash value of $72,000 as of the date of the grant (the “King Grant Date”). The RSU’s shall vest and settle in full on the one-year anniversary of the King Grant Date. On April 7, 2022, the Company issued an additional grant of 60,505 RSU’s of the Company’s common stock with a value of $72,001 as of the date of the grant. The RSU’s vest and settle in full on the one-year anniversary of the additional grant date.

Effective June 4, 2021, the Company entered into a Service Agreement with IRTH Communications, LLC (“IRTH”) for certain investor relations services (the “IRTH Agreement”). The term of the IRTH Agreement is for one year with an optional one-year renewal term. As consideration for the services, the Company will pay IRTH a fixed fee of $6,750 per month for the term of the IRTH Agreement and issued 28,338 restricted shares of the Company’s common stock with a value of $90,002 as of the date of the grant (the “IRTH Grant Date”). The restricted shares vest immediately on the IRTH Agreement Grant Date.

Contingent Consideration

Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 shares of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period.

Market Capitalization/Gross Proceeds Earnout Payments

In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which was liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment was only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of March 31, 2022, the milestones have not been achieved. The fair value of the derivative liability was $0 and $0.5 million as of March 31, 2022 and December 31, 2021, respectively.

Metuchen equity holders will have the opportunity to receive the following during the period ending December 2022:

a.The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if:
i.Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to $250,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $17.50 on each such trading day; or
ii.Petros receives aggregate gross proceeds of at least $25,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $17.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $250,000,000.

16

b.The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if:
i.Petros’ Market Capitalization is greater than or equal to $300,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $18.75 on each such trading day; or
ii.Petros receives aggregate gross proceeds of at least $30,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $18.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $300,000,000.
c.The Earnout Payment shall be equal to 3,000,000 shares of Petros Common Stock if:
i.Petros’ Market Capitalization is greater than or equal to $400,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $22.50 on each such trading day; or
ii.Petros receives aggregate gross proceeds of at least $40,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $22.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $400,000,000.
d.The Earnout Payment shall be equal to 3,232,090 shares of Petros Common Stock if:
i.Petros’ Market Capitalization is greater than or equal to $500,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $23.75 on each such trading day; or

Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000.

10)    Stock Options and Restricted Stock Units (“RSU’s”)

The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units and other stock-based awards and cash-based awards. On December 22, 2021, our stockholders approved the Second Amendment to the 2020 Plan to increase the total number of shares of common stock issuable under the 2020 Plan by 1,521,654 shares to a total of 2,600,000 shares of common stock. As of March 31, 2022, there were 2,600,000 shares authorized and 1,817,948 shares available for issuance under the 2020 Plan.

17

The following is a summary of stock options for the three months ended March 31, 2022 and for the year ended December 31, 2021:

    

    

Weighted-Average 

    

Weighted-

Remaining 

Aggregate Intrinsic 

Number of 

Average 

Contractual 

Value 

    

Shares

    

Exercise Price

    

Term (Years)

    

($ in thousands)

Options outstanding at December 31, 2020

 

574,331

$

51.43

 

0.9

$

Options granted

 

615,669

 

3.38

 

9.23

 

Less: options forfeited

 

 

 

 

Less: options expired/cancelled

 

(574,331)

 

51.43

 

 

Less: options exercised

 

 

 

 

Options outstanding at December 31, 2021

615,669

3.38

9.23

Options granted

50,000

3.34

9.76

Less: options forfeited

Less: options expired/cancelled

Less: options exercised

Options outstanding at March 31, 2022

 

665,669

$

3.38

 

9.06

$

Options exercisable at March 31, 2022

 

381,752

$

3.44

 

9.07

$

The following is a summary of RSU’s for the three months ended March 31, 2022 and for the year ended December 31, 2021:

Weighted-Average

Weighted-

Remaining

Aggregate Intrinsic

Number of

Average

Contractual

Value

Shares

Exercise Price

Term (Years)

($ in thousands)

RSU’s outstanding at December 31, 2020

 

$

 

$

RSU’s granted

 

116,383

 

3.29

 

9.84

 

Less: RSU’s forfeited

 

 

 

 

Less: RSU’s expired/cancelled

 

 

 

 

Less: RSU’s exercised

 

 

 

 

RSU’s outstanding at December 31, 2021

 

116,383

 

3.29

 

9.84

 

RSU’s granted

 

 

 

 

Less: RSU’s forfeited

 

 

 

 

Less: RSU’s expired/cancelled

 

 

 

 

Less: RSU’s exercised

 

 

 

 

RSU’s outstanding at March 31, 2022

 

116,383

$

3.29

 

9.60

$

RSU’s exercisable at March 31, 2022

 

$

 

$

On January 4, 2022, pursuant to a consulting agreement, the Company awarded a grant of 50,000 options to purchase shares of common stock of the Company at an exercise price of $3.34 per share. The shares of common stock underlying the options vested 100% upon issuance.

On April 7, 2022, the Company awarded the four Directors grants of 248,742 total RSU’s with a stock price of $1.19 per share. The RSU’s shall vest 100% on one year anniversary of the date of grant. Also on April 7, 2022, Tania King, an employee of Juggernaut Capital Partners LLP, pursuant to her contract, was granted 60,505 RSUs with a stock price of $1.19 per share. The RSU’s shall vest 100% on one year anniversary of the date of grant.

Stock-based compensation expense recognized for the three months ended March 31, 2022 and 2021 was $355,828 and $347,207, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations.

18

11)    Common Stock Warrants

The following is a summary of warrants for the three months ended March 31, 2022 and for the year ended December 31, 2021:

    

Number of Shares

Warrants outstanding at December 31, 2020

 

4,407,962

Warrants issued

 

7,853,558

Warrants exercised

 

(2,014,586)

Warrants expired

(207,913)

Warrants outstanding at December 31, 2021 and March 31, 2022

 

10,039,021

As of March 31, 2022, the Company’s warrants by expiration date were as follows:

Number of Warrants

    

Exercise Price

    

Expiration Date

2,780

$

1.60

August 23, 2023

22,800

 

35.65

June 1, 2024

74,864

 

21.85

June 17, 2024

20,043

 

31.25

June 19, 2024

22,800

 

26.55

September 1, 2024

10,500

 

12.738

September 16, 2024

22,800

 

4.30

December 1, 2024

28,000

 

5.65

March 2, 2025

28,000

 

7.30

June 1, 2025

28,000

 

5.50

September 1, 2025

28,000

 

4.705

December 1, 2025

2,221,829

 

7.50

December 1, 2025

908,498

 

17.50

December 1, 2025

623,303

 

51.25

December 1, 2025

157,832

 

125.00

December 1, 2025

1,751,311

1.715

October 19, 2026

2,337,719

3.50

December 2, 2026

1,749,942

3.50

December 27, 2026

10,039,021

 

  

  

12)    Basic and Diluted Net Income (Loss) per Common Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share:

For the Three Months Ended

March 31, 

    

2022

    

2021

Numerator

 

  

 

  

Net income (loss)

$

(174,224)

$

3,009,081

Denominator

 

 

Weighted-average common shares for basic net income (loss) per share

 

20,684,723

 

9,753,086

Effect of common share equivalents within common stock warrants

 

 

1,600

Weighted-average common shares for diluted net (loss) income per share

 

20,684,723

 

9,754,686

Basic and diluted net income (loss) per common share

$

(0.01)

$

0.31

19

The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share because their inclusion would have been antidilutive:

For the Three Months Ended

March 31, 

   

2022

   

2021

Stock Options

 

665,669

 

790,000

RSU’s

116,383

Warrants

 

10,039,021

 

4,405,182

Total

 

10,821,073

 

5,195,182

13)   Marketing, Licensing and Distribution Agreements

(a)    Vivus

On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction.

Under the License Agreement, the Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory.

In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment.

In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement. The License Agreement, was terminated, effective September 30, 2021.

On January 18, 2022, Petros and Vivus entered into a Settlement Agreement (the “Vivus Settlement Agreement”) related to the minimum purchase requirements under the Vivus Supply Agreement in 2018, 2019 and 2020 and certain reimbursement rights asserted by a third-party retailer in connection with quantities of the Company’s Stendra® product that were delivered to the third-party retailer and later returned. In connection with the Vivus Settlement Agreement, Petros retained approximately $7.3 million of API inventory under the Vivus Supply Agreement. In exchange for the API and reduction of current liabilities, Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the original principal amount of $10,201,758, which the Company believes approximates fair value (See Note 8).

20

In addition to the payments to be made in accordance with the Note, the Company further agreed in the Vivus Settlement Agreement to (i) grant to Vivus a right of first refusal to provide certain types of debt and convertible equity (but not preferred equity) until the Note is paid in full, and (ii) undertake to make certain regulatory submissions to effectuate Vivus’ ability to exercise its rights under the License Agreement. On January 18, 2022, the Company made a prepayment of the obligations under the Note in the amount of $900,000, and a payment of $1,542,904 with respect to a purchase order made in 2021 to Vivus. In consideration of these payment and upon the Company’s satisfaction of certain regulatory submissions Vivus released 50% of the quantity of bulk Stendra® tablets on January 18, 2022 under the Company’s existing open purchase order (the “Open Purchase Order”) being held by Vivus, which represents approximately a six-month supply of inventory. Under the Vivus Settlement Agreement Vivus also agreed to release the remaining 50% of the quantity of bulk Stendra® tablets under the Open Purchase Order upon the Company’s satisfaction of the remaining regulatory submission requirements (not to exceed 180 days from the date of the Vivus Settlement Agreement). The Vivus Settlement Agreement stipulated that Vivus is the sole owner of all API unless or until such time as certain quantities of API are shipped to the Company upon the fulfillment of the aforementioned payment conditions.

As a result of entering into the Vivus Settlement Agreement, the Company decreased accrued expenses by $6.5 million and decreased accrued inventory purchases by $14.2 million; which were partially offset by a decrease in API purchase commitments of $6.2 million and an increase to liabilities for the Note of $10.2 million (which is net of the $0.9 million prepayment on the Note). As a result, the Company recorded a $3.4 million gain on settlement for the three months ended March 31, 2022.

As of March 31, 2022 and December 31, 2021, the Company has $0 and $14.2 million, respectively, of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of March 31, 2022 and December 31, 2021, there was $1.4 million and

$1.4 million, respectively, included in other current assets (see Note 5 Prepaid and Other Current Assets). As of March 31, 2022 and December 31, 2021, there was $4.8 million and $11.0 million included as non-current on the accompanying consolidated balance sheets, respectively. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. The Company did not record any reserve for the three months ended March 31, 2022 and 2021.

During the three months ended March 31, 2022 and 2021, the Company incurred royalties to MTPC for Stendra® of $76,238 and $160,032, respectively. Royalties incurred were included in cost of goods sold in the consolidated statements of operations. As of March 31, 2022 and December 31, 2021, the Company had a receivable for royalties of $4,897 and $81,136, respectively, which is included in other current assets in prepaid expenses and other current assets (see Note 5 Prepaid and Other Current Assets).

The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra®.

(b)     Patheon

Following the termination of the Vivus Supply Agreement, Petros, through its subsidiary Metuchen, entered into a Technology Transfer Service Agreement on January 20, 2022 with Patheon Pharmaceuticals Inc., part of Thermo Fisher Scientific (“Patheon”), pursuant to which the Company and Patheon agreed to collaborate as strategic partners for commercial production of Stendra® tablets at Patheon’s facilities in Cincinnati, Ohio. Under the Agreement, Patheon or one of its affiliates will provide pharmaceutical development and technology transfer services in order to establish and validate its ability to manufacture supply of the Company’s Stendra® product. Any

21

commercial sale of product manufactured during the performance of the Agreement must be subject to a subsequent commercial manufacturing services agreement (with associated quality agreement) between the parties before it can be offered for commercial sale.

(c)    Hybrid

In March 2020, the Company acquired the exclusive license to H100™ from Hybrid. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. The Company paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000 and $200,000 due on each of the first, second and third anniversaries of the license agreement and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon ninety (90) days’ notice.

The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired and the upfront payment should be expensed as it was considered an IPR&D asset with no alternative future uses.

On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months to March 24, 2021. In consideration for the extension, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020. On March 31, 2021, the Company and Hybrid, entered into a second letter agreement, pursuant to which the parties agreed to extend the Second Period (as defined in the Hybrid License) for an additional six (6) months to September 24, 2021. Additionally, the Company agreed to pay Hybrid a one-time, non-creditable and non-refundable payment of $200,000, which was paid within seven calendar days of entering into the agreement. On September 24, 2021, the Company entered into an amendment to the license agreement in which the Company exercised its right not to terminate the Hybrid License even though orphan drug status had not yet been granted by the FDA. Along with this election, the Company paid Hybrid $150,000 on October 1, 2021, $200,000 on October 31, 2021, $200,000 on December 1, 2021, $200,000 on December 23, 2021 and $150,000 on March 24, 2022.

14)  Commitments and Contingencies

(a)    Employment Agreements

The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary and performance bonuses.

In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021 and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company.

(b)    Legal Proceedings

On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome.

The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows.

22

(c)    Operating Leases

The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 2.4 years to 4.8 years.

On November 30, 2021, the Company entered into a sublease with respect to its entire headquarters facility. The sublessor delivered a $14,000 security deposit to the Company on the lease commencement date and also agreed to pay $7,000 per month for the term beginning January 10, 2022 and continuing until the expiration of the head lease on August 30, 2024. The Company will account for this sublease as an operating lease in accordance with the lessor accounting guidance within ASC 842.

The components of lease expense were consisted entirely of fixed lease costs related to operating leases. These costs were $44,812 for the three months ended March 31, 2022 and 2021, respectively. Fixed lease costs for the three months ended March 31, 2022 were offset by sublease income of $21,000.

Supplemental balance sheet information related to leases was as follows:

    

As of March 31, 2022

    

As of December 31, 2021

Operating lease ROU asset:

 

  

 

  

Other assets

$

447,595

$

475,557

Operating lease liability:

 

 

Other current liabilities

$

129,458

$

125,579

Other long-term liabilities

 

371,053

 

405,018

Total operating lease liability

$

500,511

$

530,597

Supplemental lease term and discount rate information related to leases was as follows:

    

As of March 31, 2022

As of December 31, 2021

Weighted-average remaining lease terms - operating leases

 

3.4 years

 

3.7 years

Weighted-average discount rate - operating leases

 

12.6

%  

12.6

%

Supplemental cash flow information related to leases was as follows:

For the Three Months 

Ended March 31,

    

2022

    

2021

Cash paid for amounts included in the measurement of lease liabilities:

 

  

 

  

Operating cash flows from operating leases

$

46,935

$

45,942

Future minimum lease payments under non-cancelable leases as of March 31, 2022, were as follows:

Lease Liability Maturity Analysis

    

Operating Leases

2022 (remaining 9 months)

 

140,805

2023

 

189,374

2024

 

155,242

2025

 

81,107

2026

82,324

Thereafter

 

Total lease payments

 

648,852

Less: Imputed Interest

 

(148,341)

Total

$

500,511

Future minimum sublease income under non-cancelable leases as of March 31, 2022, were as follows:

23

Sublease income

Operating Leases

2022 (remaining 9 months)

63,000

2023

84,000

2024

 

56,000

Total

$

203,000

As of March 31, 2022, the Company had no operating leases that had not yet commenced.

15)    Segment Information

The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments.

The Company’s results of operations by reportable segment for the three months ended March 31, 2022 are summarized as follows:

    

Prescription 

    

Medical 

    

    

Medications

Devices

Corporate

Consolidated

Net sales

$

1,524,768

$

940,401

$

$

2,465,169

Cost of goods sold

 

138,181

 

334,159

 

 

472,340

Selling, general and administrative expenses

 

1,711,019

 

663,591

 

1,523,128

 

3,897,738

Gain on settlement with Vivus

(3,389,941)

(3,389,941)

Research and development expenses

 

405,360

 

 

 

405,360

Depreciation and amortization expense

 

1,269,663

 

291,207

 

 

1,560,870

Change in fair value of derivative liability

 

 

 

(460,000)

 

(460,000)

Interest expense

 

 

 

153,026

 

153,026

Income tax (expense)

 

 

 

 

Net income (loss)

$

1,390,486

$

(348,556)

$

(1,216,154)

$

(174,224)

The Company’s results of operations by reportable segment for the three months ended March 31, 2021 are summarized as follows:

    

Prescription 

    

Medical 

    

    

Medications

    

Devices

    

Corporate

    

Consolidated

Net sales

$

3,200,647

$

874,959

$

$

4,075,606

Cost of goods sold

 

389,281

 

254,105

 

 

643,386

Selling, general and administrative expenses

 

1,734,333

 

546,995

 

1,600,389

 

3,881,717

Research and development expense

 

19,181

 

 

 

19,181

Depreciation and amortization expense

 

1,398,270

 

330,559

 

 

1,728,829

Change in fair value of derivative liability

(5,380,000)

(5,380,000)

Interest expense

 

 

 

173,412

 

173,412

Income tax benefit

 

 

 

 

Net income (loss)

$

(340,418)

$

(256,700)

$

3,606,199

$

3,009,081

The following table reflects net sales by geographic region for the three months ended March 31, 2022 and 2021:

For the Three Months Ended

March 31, 

Net sales

    

2022

    

2021

United States

$

2,045,624

$

3,704,523

International

 

419,545

 

371,083

$

2,465,169

$

4,075,606

24

No individual country other than the United States accounted for 10% of total sales for the three months ended March 31, 2022 and 2021.

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of March 31, 2022, are summarized as follows:

Prescription 

    

    

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

17,804,298

$

5,930,536

$

23,734,834

Total segment assets

$

48,240,984

$

7,623,163

$

55,864,147

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2021, are summarized as follows:

Prescription 

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

19,071,407

$

6,221,742

$

25,293,149

Total segment assets

$

59,657,514

$

7,732,544

$

67,390,058

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide a reader of Petros’ financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. In certain instances, parenthetical references are made to relevant sections of the Notes to Consolidated Financial Statements to direct the reader to a further detailed discussion. This section should be read in conjunction with the Consolidated Financial Statements and Supplementary Data included in this Quarterly Report on Form 10-Q. This MD&A contains forward-looking statements reflecting Petros’ current expectations, whose actual outcomes involve risks and uncertainties. Actual results and the timing of events may differ materially from those stated in or implied by these forward-looking statements due to a number of factors, including those discussed in the sections entitled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” contained in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Overview

Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) is a pharmaceutical company focused on men’s health therapeutics, consisting of wholly owned subsidiaries, Metuchen Pharmaceuticals, LLC (“Metuchen”), Timm Medical Technologies, Inc. (“Timm Medical”), Neurotrope, Inc. (“Neurotrope”), and Pos-T-Vac, LLC (“PTV”). On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and development of Stendra® for a one-time fee of $70 million. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. Stendra® is a U.S. Food and Drug Administration (“FDA”) approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”) and is the only patent protected PDE-5 inhibitor on the market. Stendra® offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing). Petros is also currently conducting non-clinical consumer studies in connection with the contemplated pursuit of FDA approval for Stendra® for over-the-counter (“OTC”) use in treating ED

In addition to Stendra®, Petros’ ED portfolio also includes external penile rigidity devices, namely VEDs, which are sold domestically and internationally. In addition to ED products, Petros is committed to identifying and developing other pharmaceuticals to advance men’s health. In March 2020, Petros acquired an exclusive global license (the “Hybrid License”) for the development and commercialization of H100™ from Hybrid Medical LLC (“Hybrid”). H100™ is a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease. Peyronie’s disease is a condition that occurs upon penile tissue disruption often caused by sexual activity or injury, healing into collagen-based scars that may ultimately harden and cause penile deformity. On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months to March 24, 2021. In consideration for the extension, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020. On March 31, 2021, the Company and Hybrid, entered into a second letter agreement, pursuant to which the parties agreed to extend the Second Period (as defined in the Hybrid License) for an additional six (6) months to September 24, 2021. Additionally, the Company agreed to pay Hybrid a one-time, non-creditable and non-refundable payment of $200,000, which was paid within seven calendar days of entering into the agreement. On September 24, 2021, the Company entered into an amendment to the license agreement in which the Company exercised its right not to terminate the Hybrid License even though orphan drug status had not yet been granted by the FDA. Along with this election, the Company paid Hybrid $150,000 on October 1, 2021, $200,000 on October 31, 2021, $200,000 on December 1, 2021, $200,000 on December 23, 2021 and $150,000 on March 24, 2022.

Impact of COVID-19

The World Health Organization (“WHO”) declared the coronavirus COVID-19 (“COVID-19”) a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic, including the emergence of any new variants, such as the Delta and the Omicron variants, will have on its

26

financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2022 and beyond.

During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices. In January 2022, the Company sub-leased its Manalapan office and all administrative employees are working remotely for the foreseeable future. The Company has fully resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. Since the beginning of the COVID-19 pandemic, we have experienced a shift from in-person sales to online, telehealth-based sales. These online sales generally have lower gross margins than in-person sales, which has impacted our net revenues.

Nature of Operations and Basis of Presentation

Petros is a pharmaceutical company focused on men’s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution.

Petros consists of wholly owned subsidiaries, Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). The Company is engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration (“FDA”) approved PDE 5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”), which we have licensed from Vivus, Inc. (“Vivus”). Petros also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, we have acquired an exclusive global license to develop and commercialize H100™, a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease.

The Company was organized as a Delaware corporation on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the “Merger Agreement”), by and between Petros, Neurotrope,, PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen. The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly-owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020.

On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.), a Delaware corporation (“Synaptogenix”), and a wholly-owned subsidiary of Neurotrope.

The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male ED. The Prescription Medications segment consists primarily of Stendra®, which is sold generally in the United States. Expenses related to the development of H100™, which is in the early stages of development and has not yet sought FDA approval to begin Phase 1 clinical trials, will be within the Prescription Medications segment. The Medical Devices segment consists primarily of vacuum erection devices, which are sold domestically and internationally.

Licensing and Distribution

The Company acquired the rights to Stendra® avanafil on September 30, 2016, when it entered into the License Agreement with Vivus to purchase and receive the license for the commercialization and exploitation of Stendra® avanafil for a one-time fee of $70 million. The License Agreement gives the Company the exclusive right to sell avanafil in the U.S. and its territories, as well as Canada, South

27

America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the FDA in April 2012 to treat male ED.

The Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter until the expiration of the applicable patent in a particular country. The last scheduled patent expiration is in April 2025. In consideration for the trademark assignment and the use of the trademarks associated with Stendra® and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the royalty period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of Stendra® in such territory; and (b) following the fourth and fifth years following the end of the royalty period in such territory, pay to Vivus a royalty equal to 1% of the net sales of Stendra® in such territory. After the royalty period, no further royalties shall be owed with respect to net sales of Stendra® in such territory. In addition, the Company will be responsible for a pro-rata portion of a one-time $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra® during any calendar year.

In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement on September 30, 2016, which has since been terminated, effective as of September 30, 2021. Following the termination of the Vivus Supply Agreement, Petros, through its subsidiary Metuchen, entered into a Technology Transfer Service Agreement on January 20, 2022 with Patheon Pharmaceuticals Inc., part of Thermo Fisher Scientific (“Patheon”), pursuant to which the Company and Patheon agreed to collaborate as strategic partners for commercial production of Stendra® tablets at Patheon’s facilities in Cincinnati, Ohio. Under the Agreement, Patheon or one of its affiliates will provide pharmaceutical development and technology transfer services in order to establish and validate its ability to manufacture supply of the Company’s Stendra® product. Any commercial sale of product manufactured during the performance of the Agreement must be subject to a subsequent commercial manufacturing services agreement (with associated quality agreement) between the parties before it can be offered for commercial sale.

The license agreement between MTPC and Vivus contains certain termination rights that will allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra®.

On March 27, 2018, the Company entered into a Sublicense Agreement with Acerus Pharmaceuticals Corporation (“Acerus”) whereby the Company granted to Acerus an exclusive sublicense in Canada for, among other things, the development and commercialization of Stendra® avanafil for a one-time fee of $100,000. The Company was entitled to receive an additional fee of $400,000 if Stendra® is approved by Canadian regulators, as well as commercial milestone payments and royalty fees of 12% of net sales. However, in April 2020 Health Canada issued a Notice of Deficiency (“NOD”) against the New Drug Submission. Metuchen and Acerus are currently renegotiating modified terms to the sub-license agreement and the pathway required to address the deficiency noted by Health Canada.

In March 2020, we entered into the Hybrid License for the development and commercialization of H100™ from Hybrid. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. We paid an initial license fee of $100,000 and additional payments of $250,000, with additional annual milestone payments of $125,000, $150,000, and $200,000 on each of the first, second and third anniversaries of the entry into the Hybrid License and $250,000 annual payments due thereafter. On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months to March 24, 2021. In consideration for the extension, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020. On March 31, 2021, the Company and Hybrid, entered into a second letter agreement, pursuant to which the parties agreed to extend the Second Period (as defined in the License Agreement) for an additional six (6) months to September 24, 2021. Additionally, the Company agreed to pay Hybrid a one-time, non-creditable and non-refundable payment of two hundred thousand U.S. Dollars ($200,000), which was paid within seven calendar days of entering into the agreement. On September 24, 2021, the Company entered into an amendment to the license agreement in which the Company exercised its right not to terminate the Hybrid License even though orphan drug status had not yet been granted by the FDA. Along with this election, the Company paid Hybrid $150,000 on October 1, 2021, $200,000 on October 31, 2021, $200,000 on December 1, 2021, $200,000 on December 23, 2021 and $150,000 on March 24, 2022.

Vivus Settlement Agreement, Promissory Note and the Security Agreement

On January 18, 2022, Petros and Vivus entered into a Settlement Agreement (the “Vivus Settlement Agreement”) related to the minimum purchase requirements under the Vivus Supply Agreement in 2018, 2019 and 2020 and certain reimbursement rights asserted by a third-party retailer in connection with quantities of the Company’s Stendra® product that were delivered to the third-party retailer and later

28

returned. In connection with the Vivus Settlement Agreement, Petros retained approximately $7.3 million of API inventory under the Vivus Supply Agreement. In exchange for the API and reduction of current liabilities, Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the principal amount of $10,201,758, which approximate fair value. The parties also entered into a Security Agreement to secure Petros’ obligations under the Note.

In addition to the payments to be made in accordance with the Note, the Company further agreed in the Vivus Settlement Agreement to (i) grant to Vivus a right of first refusal to provide certain types of debt and convertible equity (but not preferred equity) financing issued by or to Metuchen (including any subsidiaries and intermediaries) until the Note is paid in full, and (ii) undertake to make certain regulatory submissions to effectuate Vivus’ ability to exercise its rights under the License Agreement. On January 18, 2022, the Company made a prepayment of the obligations under the Note in the amount of $900,000, and a payment of $1,542,904 with respect to a purchase order made in 2021 to Vivus. In consideration of these payments and upon the Company’s satisfaction of certain regulatory submissions. Vivus released 50% of the quantity of bulk Stendra® tablets under the Company’s existing open purchase order (the “Open Purchase Order”) being held by Vivus, which represents approximately a six-month supply of inventory. Under the Vivus Settlement Agreement Vivus also agreed to release the remaining 50% of the quantity of bulk Stendra® tablets under the Open Purchase Order upon the Company’s satisfaction of the remaining regulatory submission requirements (not to exceed 180 days from the date of the Vivus Settlement Agreement). The Vivus Settlement Agreement stipulated that Vivus is the sole owner of all API unless or until such time as certain quantities of API are shipped to the Company upon the fulfillment of the aforementioned payment conditions.

As a result of entering into the Vivus Settlement Agreement, the Company decreased the Company’s accrued expenses by $6.5 million and decreased accrued inventory purchases by $14.2 million; which were partially offset by a decrease in API purchase commitments of $6.2 million and an increase to liabilities for the Note of $10.2 million (which is net of the $0.9 million prepayment on the Note). As a result, the Company recorded a $3.4 million gain on settlement for the three months ended March 31, 2022.

Under the terms of the Note, the principal amount of $10,201,758 is payable in consecutive quarterly installments beginning on April 1, 2022 through January 1, 2027. Interest on the principal amount will accrue at a rate of 6% per year until the principal is repaid in full and is due and payable, in arrears, on the first day of each January, April, July, and October of each calendar year, commencing on April 1, 2022. The Company may prepay the Note, in whole or in part, at any time, with no premium or penalty. In the event that the Company defaults under the Security Agreement, all principal outstanding under the Note at the time of the default will bear interest at a rate of 9% per year until the full and final payment of all principal and interest under the Note (regardless of whether any default is waived or cured). If the Note is placed in the hands of any attorney for collection, or if it is collected through any legal proceeding at law or in equity or in bankruptcy, receivership, or other court proceedings, the Company will also be required to pay all costs of collection including, but not limited to, court costs and attorneys’ fees. Pursuant to the Security Agreement, dated January 18, 2022, the Company granted to Vivus a continuing security interest in all of its Stendra® API and products and its rights under the License Agreement. The Security Agreement contains customary events of default.

Critical Accounting Policies and Estimates

The preparation of the consolidated financial statements requires us to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Certain of our more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, we evaluate our judgments, including but not limited to those related to revenue recognition, collectability of accounts receivable, inventory valuation and obsolescence, intangibles, income taxes, litigation, and contingencies. We use historical experience and other assumptions as the basis for our judgments and making these estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in those estimates will be reflected in our consolidated financial statements as they occur. While our significant accounting policies are more fully described in “Part I; Item 1. Financial Statements and Supplementary Data; Notes to Consolidated Financial Statements; Note 2. Summary of Significant Accounting Policies” in this Quarterly Report on Form 10-Q, we believe that the following accounting policies and estimates are most critical to a full understanding and evaluation of our reported financial results. The critical accounting policies addressed below reflect our most significant judgments and estimates used in the preparation of our consolidated financial statements. We have reviewed these critical accounting policies with the Audit Committee of our Board of Directors.

29

Revenue Recognition

The Company recognizes revenue when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide either its prescription medication or medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the prescription medication or medical device, which is typically upon delivery.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers either the prescription medication or medical device to when the customers pay for the product is typically less than one year. The Company records sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

The most significant sales deductions relate to contract returns, contract rebates and coupon redemptions, and distribution service fees (“DSA fees”). Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation are required in developing the foregoing and other relevant assumptions.

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return either the prescription medication or medical device and receive credit for product. The provision for returns is based upon the Company’s estimates for future returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized.

Accounts Receivable

The Company extends credit to its customers in the normal course of business. Accounts receivable are recorded at the invoiced amount, net of chargebacks, distribution service fees, and cash discounts. Management determines each allowance based on historical experience along with the present knowledge of potentially uncollectible accounts.

Inventories

Inventories consist of finished goods held for sale and raw materials. Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out method. Inventories are adjusted for excess and obsolescence. Evaluation of excess inventory includes such factors as expiry date, inventory turnover, and management’s assessment of current product demand.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable markets.

Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

30

In connection with the Mergers in December 2020, each security holder of Metuchen received a liability classified earnout consideration to be paid in the form of Petros Common Stock. The Company estimated their fair value using the Monte Carlo Simulation approach as of March 31, 2022 and December 31, 2021. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.

Intangibles

The Company accounts for recognized intangible assets at cost. Intangible assets with finite useful lives are amortized over the useful life which the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are amortized using an accelerated method based on the pattern in which the economic benefits of the assets are consumed. The Company reviews the carrying value and useful lives of its intangible assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable or the period over which they should be amortized has changed. When indicators of impairment exist, the Company determines whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The Company evaluates the remaining useful life of each intangible asset that is being amortized during each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. If the estimate of the intangible asset’s remaining useful life has changed, the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life. The Company has determined that no impairment exists as of March 31, 2022. As indicators of impairment exist as of March 31, 2022, the Company prepared an undiscounted cash flow analysis. This analysis includes projections of future revenue and expenses, which if not achieved could result in future impairment charges. These projections include continued significant sales growth based in part on the increase in revenue in 2021, along the expectation of higher sales volume resulting from increased product availability as a result of the Vivus settlement. Additionally, we are planning to invest in research and development pursuant to our Non-Prescription / Over-The-Counter (“OTC”) Strategies related to Stendra®, which we anticipate will dramatically increase product sales in the future.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements, which is incorporated herein by reference.

31

Results of Operations

The impact on our results of operations of the COVID-19 pandemic and related changes in economic conditions, including changes to consumer spending resulting from the rapid rise in local and national unemployment rates, are highly uncertain and, in many instances, outside of our control. The duration and severity of the direct and indirect effects of the pandemic continue to evolve and in ways that are difficult to anticipate. There are numerous uncertainties related to the COVID-19 pandemic that have impacted our ability to forecast our future operations as a company. The extent to which the COVID-19 pandemic, and the emergence of any new variants, will affect our business, financial position and operating results in the future cannot be predicted with certainty; however, any such impact could be material. The COVID-19 pandemic could also increase the degree to which our results, including the results of our business segments, fluctuate in the future.

Three Months Ended March 31, 2022 and 2021 (unaudited)

The following table sets forth a summary of our statements of operations for the three months ended March 31, 2022 and 2021:

For the Three Months 

Ended March 31,

    

2022

    

2021

Net sales

$

2,465,169

$

4,075,606

Cost of sales

 

472,340

 

643,386

Gross profit

 

1,992,829

 

3,432,220

Operating expenses:

 

 

Selling, general and administrative

 

3,897,738

 

3,881,717

Gain on settlement with Vivus

(3,389,941)

Research and development

 

405,360

 

19,181

Depreciation and amortization expense

 

1,560,870

 

1,728,829

Total operating expenses

 

2,474,027

 

5,629,727

Loss from operations

 

(481,198)

 

(2,197,507)

Change in fair value of derivative liability

 

460,000

 

5,380,000

Interest expense, senior debt

 

 

(173,412)

Interest expense, promissory note

 

(153,026)

 

Net income (loss)

$

(174,224)

$

3,009,081

Net Sales

Net sales for the three months ended March 31, 2022, were $2,465,169, composed of $1,524,768 of net sales from Prescription Medicines and net sales of $940,401 from Medical Devices.

Net sales for the three months ended March 31, 2021 were $4,075,606, composed of $3,200,647 of net sales from Prescription Medicines and net sales of $874,959 from Medical Devices.

For the three months ended March 31, 2022, gross sales to customers representing 10% or more of the Company’s total gross sales included three customers that represented approximately 30%, 23%, and 22% of total gross sales, respectively.

For the three months ended March 31, 2021, gross sales to customers representing 10% or more of the Company’s total gross sales included one customer that represented approximately 88% of total gross sales.

32

Prescription Medicines sales consist of sales of Stendra® in the U.S. for the treatment of male ED. Stendra® is primarily sold directly to the three main customers as described above, which collectively accounted for approximately 88% of Stendra® net sales for the three months ended March 31, 2022. Individually, sales to the three main customers, accounted for 35%, 27%, and 25%, respectively, of Stendra® gross sales for the three months ended March 31, 2022.

Medical Device sales consist of domestic and international sales of men’s health products for the treatment of ED. The men’s health products do not require a prescription and include Vacuum Erection Devices (“VEDs and related accessories”).

Net sales were $1,610,437, or 40% lower during the three months ended March 31, 2022 than in the same period in 2021 consisting of a $1,675,879 decrease in the net sales of Stendra® offset by a $65,442 increase in Medical Device Sales. The decrease in net sales of Stendra® was primarily due to increased coupon redemptions to support higher wholesale demand as the Company worked to resolve its supply chain challenges and increased wholesaler returns related to the sale of short-dated product. The increase in net sales for Medical Devices included an increase in international sales of VED systems partially offset by a decreased in domestic sales of VED systems.

Cost of Sales

Cost of sales for the three months ended March 31, 2022, were $472,340, composed of $138,181 of cost of sales for our Prescription Medicines segment and $334,159 for our Medical Devices segment.

Cost of sales for the three months ended March 31, 2021 were $643,386, composed of $389,281 of cost of sales for our Prescription Medicines segment and $254,105 for our Medical Devices segment.

Cost of sales for the Prescription Medicine segment for the three months ended March 31, 2022 consisted of 55% royalty expenses, 41% third-party product cost of sales, 2% inventory obsolescence and 2% 3PL order fulfillment and shipping expenses.

Cost of sales for the Medical Device segment for the three months ended March 31, 2022 consisted of 90% raw materials and 10% production labor.

Cost of sales decreased by $171,046 or 27% during the three months ended March 31, 2022 compared to the same period 2021. For the three months ended March 31, 2022 and 2021, cost of sales as a percentage of net sales were 19% and 16%, respectively. The increase in cost of sales as a percentage of net sales was a result of an increased sales order fulfillment costs (on a per unit basis).

Gross Profit

Gross profit for the three months ended March 31, 2022 was $1,992,829, or 81% of net sales, composed of $1,386,587 of gross profit from Prescription Medicines and $606,242 from Medical Devices. Gross profit for the three months ended March 31, 2021 was $3,432,220, or 84% of net sales, composed of $2,811,366 of gross profit from Prescription Medicines and $620,854 from Medical Devices. The decrease in gross profit was driven by the factors noted above.

Operating Expenses

Selling, general and administrative

Selling, general and administrative expenses for the three months ended March 31, 2022, were $3,897,738, composed of $1,711,019 of selling, general and administrative expenses of our Prescription Medicines segment, $663,591 of selling, general and administrative expenses of our Medical Devices segment and $1,523,128 of general corporate expenses.

Selling, general and administrative expenses for the three months ended March 31, 2021 were $3,881,717, composed of $1,734,333 of selling, general and administrative expenses of our Prescription Medicines segment, $546,995 of selling, general and administrative expenses of our Medical Devices segment and $1,600,389 of general corporate expenses.

Selling, general and administrative expenses for both segments include selling, marketing and regulatory expenses. Unallocated general corporate expenses include costs that were not specific to a particular segment but are general to the group, including expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses.

33

Selling, general and administrative expenses were relatively consistent during the three months ended March 31, 2022 compared to the same period of 2021. Increased selling, general and administrative expenses were primarily driven by increased direct selling expenses of $160,724 which were partially offset by decreased direct marketing expenses of $99,491 as management sought to reduce expenses to improve operational efficiencies, as well as lower payroll expenses of $60,115 resulting from decreased headcount.

Gain on settlement with Vivus

As a result of the Vivus Promissory Note, as discussed in Note 8 and Note 13, the Company’s total liabilities were decreased by $3,389,941 in the form of concession of customer returns, which were recognized as a gain on settlement during the three months ended March 31, 2022. There was no such activity in the same period of 2021.

Research and development

Research and development expenses for the three months ended March 31, 2022, were $405,360 in our Prescription Medicines segment.

Research and development expenses for Prescription Medicines segment are composed of $191,565 for consulting fees related to the Company's Non-Prescription / Over-The-Counter (“OTC”) strategies related to Stendra®, $150,000 for upfront licensing fees and $33,421 for clinical development expenses and $30,374 for consulting fees related to the H100 licenses acquired in March 2020.

Research and development expenses for the three months ended March 31, 2021 were $19,181, in our Prescription Medicines segment. Research and development expenses for Prescription Medicines segment are composed entirely of consulting fees.

Research and development expenses increased by $386,179 or 2013% during the three months ended March 31, 2022, compared to the same period in 2021. Increased research and development expenses were primarily driven by increased licensing fees related to the H100 license acquired in March 2020 and increased consulting fees related to the Company’s Non-Prescription / Over-The-Counter (“OTC”) strategies related to Stendra®.

Depreciation and amortization

Depreciation and amortization expenses for the three months ended March 31, 2022, were $1,560,870, composed of $1,269,663 of depreciation and amortization expenses of our Prescription Medicines segment and $291,207 of depreciation and amortization expenses of our Medical Devices segment.

Depreciation and amortization expenses for the three months ended March 31, 2021 were $1,728,829, composed of $1,398,270 of depreciation and amortization expenses of our Prescription Medicines segment and $330,559 of depreciation and amortization expenses of our Medical Devices segment.

Prescription Medicines depreciation and amortization consists primarily of the amortization of the intangible assets related to Stendra® over its estimated useful life of 10 years. Medical Devices depreciation and amortization primarily consists of the amortization of the intangible assets related to Timm Medical and PTV over their estimated useful life of 12 years. The increase in amortization expense was primarily driven by the accelerated method of amortization related to the Stendra® product.

Change in fair value of derivative liability

In connection with the Mergers consummated on December 1, 2020, each security holder of Metuchen received a liability classified earnout consideration to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds from securities offerings that equals or exceeds certain milestones set forth in the Merger Agreement. The earnout contingent consideration met the criteria to be classified as a derivative with fair value remeasurements recorded in earnings each reporting period. As a result, the $460,000 represents the change in fair value of the derivative during the three months ended March 31, 2022, primarily driven by the decline in the Company’s stock price as well as the passage of time, as it became less likely that the earnout would be met.

34

Interest expense, senior debt

Interest expense, senior debt for the three months ended March 31, 2021 was $173,412 consisting of interest payments on our senior debt, with a weighted average balance of $5,597,203. There was no interest expense, senior debt for the three months ended March 31, 2022.

Interest expense, promissory note

In January 2022, the Company executed a promissory note in favor of Vivus with a principal amount of $10,201,758 as part of the settlement. Interest expense, promissory note for the three months ended March 31, 2022 was $153,026 consisting of interest payments on our promissory note. There was no interest expense, promissory note for the three months ended March 31, 2021.

Liquidity and Capital Resources

General

Cash and cash equivalents totaled $17,671,871 at March 31, 2022, compared to $23,847,572 at December 31, 2021.

We have experienced net losses and negative cash flows from operations since our inception. As of March 31, 2022, we had cash of $17.7 million, positive working capital of $16.5 million, and an accumulated deficit of $70.9 million. Our plans include, or may include, utilizing our cash and cash equivalents on hand, as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. In January 2022, the Company executed a promissory note in favor of Vivus in connection with the Vivus Settlement Agreement in the principal amount of $10,201,758. The terms of this promissory note are discussed in the section titled “—Vivus Settlement Agreement, Promissory Note and the Security Agreement” above. The Company believes the cash on hand is sufficient to fund its operations and debt service through at least May 31, 2023, however for periods after May 31, 2023, the Company may need to raise additional funds or curtail certain discretionary expenditures in order to maintain an appropriate level of cash to fund our operations. While we are optimistic that we will be successful in our efforts to achieve our plans, there can be no assurances that we will be successful in doing so.

To date, our principal sources of capital used to fund our operations have been the revenues from product sales, private sales, registered offerings and private placements of equity securities.

In March 2020, the Company acquired the Hybrid License, providing an exclusive license to H100™. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. We paid an initial license fee of $100,000 and an additional payment of $250,000 and additional annual milestone payments of $125,000, $150,000 and $200,000 are due on each of the first, second and third anniversaries of the license agreement and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3 6% of any net sales.

On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the Hybrid License was extended for an additional six months to March 24, 2021. In consideration for the extension, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020. On March 31, 2021, the Company and Hybrid, entered into a second letter agreement, pursuant to which the parties agreed to extend the Second Period (as defined in the Hybrid License) for an additional six (6) months to September 24, 2021. Additionally, the Company agreed to pay Hybrid a one-time, non-creditable and non-refundable payment of two hundred thousand U.S. Dollars ($200,000), which was paid within seven calendar days of entering into the second letter agreement. On September 24, 2021, the Company entered into an amendment to the license agreement in which the Company exercised its right not to terminate the Hybrid License even though orphan drug status had not yet been granted by the FDA. Along with this election, the Company paid Hybrid $150,000 on October 1, 2021, $200,000 on October 31, 2021, $200,000 on December 1, 2021, $200,000 on December 23, 2021 and $150,000 on March 24, 2022.

The Company also expects to incur approximately $14 million of research and development expenses relating to H100™ over the estimated four to six-year period of clinical development prior to FDA approval, including approximately $10 million for clinical trials and $4 million of other expenses. The Company anticipates funding these future expenses through additional capital raises or issuance of debt, until revenues become sufficient to cover these ongoing expenses.

35

October 2021 Financing

On October 13, 2021, we entered into a Securities Purchase Agreement (the “October SPA”) with certain accredited and institutional investors, pursuant to which we sold 3,323,616 shares of our common stock in a registered direct offering (the “October RD”) at an offering price of $1.715 per share and associated October Warrant (as defined below). Also pursuant to the October SPA, in a concurrent private placement (together with the October RD, the “October Offering”), the Company sold to the purchasers warrants to purchase up to an aggregate of 3,323,616 shares of common stock at an exercise price of $1.715 per share (the “October Warrants”). The October Warrants became exercisable immediately upon the closing of the October Offering on October 18, 2021 and will expire five years following that date. In connection with the October Offering, the Company issued warrants to purchase 130,000 shares of common stock to Katalyst as compensation for financial advisory services. The Company received net proceeds from the October Offering, after deducting fees and other offering expenses payable by the Company, of approximately $5.5 million.

The October Warrants and the warrants issued to Katalyst in connection with the October Offering were issued in reliance upon the exemption from the registration requirements in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. Each purchaser represented that it was an “accredited investor” (as defined by Rule 501 under the Securities Act).

November 2021 Financing

On November 29, 2021, we entered into a Securities Purchase Agreement (the “November SPA”) with certain accredited and institutional investors, pursuant to which we sold 2,153,333 shares of our common stock in a registered direct offering (the “November RD) at an offering price of $3.00 per share and associated November Warrant (as defined herein). Also pursuant to the November SPA, in a concurrent private placement (together with the November RD, the “November Offering”), the Company sold to the purchasers (i) 1,180,000 unregistered shares of the Company’s common stock (the “November PIPE Shares) at an offering price of $3.00 per share and associated November Warrant and (ii) the warrants to purchase up to an aggregate of 2,500,000 shares of common stock at an exercise price of $3.50 per share (the “November Warrants”). The November Warrants became exercisable immediately upon the closing of the November Offering on December 2, 2021 and will expire five years following that date. In connection with the November Offering, the Company issued warrants to purchase 150,000 shares of common stock to Katalyst as compensation for financial advisory services. The Company received net proceeds from the November Offering, after deducting fees and other offering expenses payable by the Company, of approximately $9.3 million.

The November PIPE Shares, the November Warrants, and the warrants issued to Katalyst in connection with the November Offering were issued in reliance upon the exemption from the registration requirements in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. Each purchaser represented that it was an “accredited investor” (as defined by Rule 501 under the Securities Act).

December 2021 Financing

On December 22, 2021, we entered into the Securities Purchase Agreement (the “December SPA”) with certain accredited and institutional investors, pursuant to which we sold 1,545,183 shares of our common stock in a registered direct offering (the “December RD) at an offering price of $3.43 per share and associated December Warrant (as defined herein). Also pursuant to the December SPA, in a concurrent private placement (together with the December RD, the “December Offering”), the Company sold to the purchasers (i) 641,406 unregistered shares of the Company’s common stock (the “December PIPE Shares) at an offering price of $3.43 per share and associated December Warrant and (ii) the warrants to purchase up to an aggregate of 1,639,942 shares of common stock at an exercise price of $3.50 per share (the “December Warrants”). The December Warrants became exercisable immediately upon the closing of the December Offering on December 27, 2021 and will expire five years following that date. In connection with the December Offering, the Company issued warrants to purchase 110,000 shares of common stock to Katalyst as compensation for financial advisory services. The Company received net proceeds from the December Offering, after deducting fees and other offering expenses payable by the Company, of approximately $6.9 million.

The December PIPE Shares, the December Warrants, and the warrants issued to Katalyst in connection with the December Offering were issued in reliance upon the exemption from the registration requirements in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. Each purchaser represented that it was an “accredited investor” (as defined by Rule 501 under the Securities Act).

We will require additional financing to further develop and market our products, fund operations, and otherwise implement our business strategy at amounts relatively consistent with the expenditure levels disclosed above. We are exploring additional ways to raise capital,

36

but we cannot assure you that we will be able to raise capital. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition, our ability to meet our obligations, and our ability to pursue our business strategies. We expect to seek additional funds through a variety of sources, which may include additional public or private equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing.

We are focused on expanding our service offering through internal development, collaborations, and through strategic acquisitions. We are continually evaluating potential asset acquisitions and business combinations. To finance such acquisitions, we might raise additional equity capital, incur additional debt, or both.

Debt

Vivus Note

As noted above, in January 2022, the Company executed a promissory note in favor of Vivus with a principal amount of $10,201,758 as part of the settlement. For more information, see the section above titled “—Vivus Settlement Agreement, Promissory Note and the Security Agreement.”

Senior Debt

On September 30, 2016, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), for a $35 million term loan. The Loan Agreement included an additional Payable-In-Kind (“PIK”) interest that increases the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge. The end of term charge was being recognized as interest expense and accreted over the term of the Loan Agreement, as amended, using the effective interest method. We refer to the amounts available under the credit facility with Hercules as Senior Debt.

On November 22, 2017, the Company entered into Amendment No. 1 to the Loan Agreement (the “First Amendment”). A covenant was added, in which the Company must achieve a certain minimum EBITDA, as defined in the First Amendment, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio were reduced from 1:1 to 0.9:1. The Company was also required to prepay $10,000,000 in principal.

On August 13, 2019, the Company entered into a forbearance agreement with Hercules under which Hercules agreed to forbear exercising any remedies under the loan for events of default through the earlier of September 30, 2019 or the occurrence of an event of default under the Loan Agreement, as amended.

Effective April 13, 2020, the Company and Hercules entered into Amendment No. 2 to the Loan Agreement, (the “Second Amendment”), to extend the maturity date to December 1, 2021, if the Company should raise at least $20 million through an equity or debt financing or other transaction. All previously accrued PIK interest was added to principal, and no further PIK interest would accrue. The cash interest accrued at a rate of the greater of (i) the prime rate reported in the Wall Street Journal plus 11.50% minus 4.25% and (ii) 11.50%. The end of term charge of $1,068,750 was partially extended with $534,375 due on October 1, 2020, and $534,375 due on February 1, 2021. The Company incurred a $50,000 amendment fee upon closing of the Second Amendment.

Effective September 30, 2020, the Company and Hercules entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”) to provide for interest only payments commencing on October 1, 2020 and continuing through December 22, 2020. The Third Amendment also amended the minimum cash, minimum net revenue and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P., an affiliate of JCP Investor, Hercules, and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow certain funds in an aggregate amount equal to certain principal payments owed under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated.

The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt had a maturity date of December 1, 2021.

On November 3, 2021, the Company repaid the remaining balance due on the Senior Debt.

37

Cash Flows

The following table summarizes our cash flows for the three months ended March 31, 2022 and 2021:

For the Three Months

Ended March 31,

    

2022

    

2021

Net cash used in operating activities

$

(5,275,701)

$

(446,581)

Net cash used in financing activities

 

(900,000)

 

(2,126,403)

Net decrease in cash

$

(6,175,701)

$

(2,572,984)

Cash Flows from Operating Activities

Net cash used in operating activities for the three months ended March 31, 2022 was $5,275,701, which primarily reflected our net loss of $174,224, in addition to noncash adjustments to reconcile net loss to net cash used in operating activities of $2,087,394 consisting primarily of depreciation and amortization, changes in the fair value of derivative liability and stock compensation, and changes in operating assets and liabilities of $3,014,083.

Net cash used in operating activities for the three months ended March 31, 2021 was $446,581, which primarily reflected our net income of $3,009,081, more than offset by cash adjustments to reconcile net income to net cash used in operating activities of $3,117,296 consisting primarily of depreciation and amortization, inventory obsolescence reserves, changes in the fair value of derivative liability, and changes in operating assets and liabilities of $338,366.

Cash Flows from Investing Activities

No cash was provided by or used in investing activities for the three months ended March 31, 2022 and 2021.

Cash Flows from Financing Activities

Net cash used in financing activities was $900,000 for the three months ended March 31, 2022, consisting of prepayments of promissory note of $900,000.

Net cash used in financing activities was $2,126,403 for the three months ended March 31, 2021, consisting of payments of senior debt of $1,592,028 and a payment for the senior debt end-of-term fee of $534,375.

Off-Balance Sheet Commitments and Arrangements

We have not entered into any off-balance sheet financial guarantees or other off-balance sheet commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholder’s equity or that are not reflected in our financial statements included as Exhibit 99.1 to this Form 10-Q. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us.

Contingencies

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company’s management, in consultation with its legal counsel as appropriate, assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company, in consultation with legal counsel, evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates a potentially material loss contingency is not probable, but is reasonably possible, or is probable, but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

38

Reconciliation of Non-GAAP Financial Measures

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure utilized by management to evaluate the Company’s performance on a comparable basis. The Company believes that Adjusted EBITDA is useful to investors as a supplemental way to evaluate the ongoing operations of the Company’s business as Adjusted EBITDA may enhance investors’ ability to compare historical periods as it adjusts for the impact of financing methods, tax law and strategy changes, and depreciation and amortization and to evaluate the Company’s ability to service debt. In addition, Adjusted EBITDA is a financial measurement that management and the Company’s Board of Directors use in their financial and operational decision-making and in the determination of certain compensation programs. Adjusted EBITDA is a non-GAAP financial measure commonly used in the Company’s industry and should not be construed as an alternative to net income as an indicator of operating performance (as determined in accordance with GAAP). The Company’s presentation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

Adjusted EBITDA is adjusted to exclude certain items that affect comparability. The adjustments are itemized in the tables below. You are encouraged to evaluate these adjustments and the reason the Company considers them appropriate for supplemental analysis. In evaluating adjustments, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments set forth below. The presentation of these adjustments should not be construed as an inference that future results will be unaffected by unusual or recurring items.

The Company defines Adjusted EBITDA as net income (loss) adjusted to exclude (i) interest expense, net, (ii) depreciation and amortization and (iii) income taxes, as further adjusted to eliminate the impact of certain items that the Company does not consider indicative of its ongoing operating performance or that are non-recurring in nature. For example, Adjusted EBITDA:

does not reflect the Company’s capital expenditures, future requirements for capital expenditures or contractual commitments;
does not reflect changes in, or cash requirements for, the Company’s working capital needs;
does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on the Company’s debt; and
does not reflect payments related to income taxes, if applicable.

The following table presents a reconciliation of net income (loss) to Adjusted EBITDA for the three months ended March 31, 2022 and 2021:

For the Three Months Ended 

March 31,

    

2022

    

2021

Net income (loss)

$

(174,224)

$

3,009,081

Interest expense, senior debt

 

 

173,412

Interest expense, promissory note

 

153,026

 

Depreciation and amortization expense

 

1,560,870

 

1,728,829

EBITDA

 

1,539,672

 

4,911,322

Gain on settlement with Vivus

(3,389,941)

Change in fair value of derivative liability

 

(460,000)

 

(5,380,000)

Adjusted EBITDA

$

(2,310,269)

$

(468,678)

Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of the Company’s results as reported under GAAP.

Gross Billings

Gross billings is a non-GAAP financial measure utilized as a key performance metric by management and the Company’s Board of Directors in their financial and operational decision-making as well as for the preparation of the annual budget. The Company believes that gross billings is useful to investors as a supplemental way to provide an alternative measure of the total demand for the products

39

sold by the Company. Gross billings is a non-GAAP financial measure commonly used in the Company’s industry and should not be construed as an alternative to net sales as an indicator of operating performance (as determined in accordance with GAAP). The Company’s presentation of gross billings may not be comparable to similarly titled measures reported by other companies.

Gross billings is adjusted to exclude certain items that affect comparability. The adjustments are itemized in the tables below. You are encouraged to evaluate these adjustments and the reason the Company considers them appropriate for supplemental analysis. In evaluating adjustments, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments set forth below. The presentation of these adjustments should not be construed as an inference that future results will be unaffected by unusual or recurring items.

The Company defines gross billings as the amount of its aggregate sales billed to customers at standard prices before the application of certain adjustments that reduce the net amount received from customers, including product returns, certain rebates and coupon redemptions, discounts and fees.

The following table presents a reconciliation of net sales to gross billings for the three months ended March 31, 2022 and 2021:

For the Three Months Ended 

March 31,

    

2022

    

2021

Net Sales

$

2,465,169

$

4,075,606

Product returns

 

743,753

 

609,705

Contract rebates

 

450,231

 

871,734

Chargebacks

 

36,273

 

237,148

Cash discounts

 

68,233

 

199,874

Distribution service fees

 

396,937

 

595,278

Coupon redemptions

 

2,351,285

 

946,378

Gross billings

$

6,511,881

$

7,535,723

Gross billings has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of the Company’s results as reported under GAAP.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as of the period covered by this report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

A material weakness is a control deficiency (within the meaning of Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 5) or combination of control deficiencies that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. As disclosed in Part II Item 9A Controls and Procedures in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, we identified a material weaknesses in internal control related to (1) Petros has an insufficient level of monitoring and oversight controls and does not enforce the implementation of key controls reflected on its internal control process matrices; (2) the sizes of Petros’ accounting and IT departments make it impracticable to achieve an appropriate segregation of duties; and (3) Petros does not have appropriate IT access related controls.

40

Management plans to expand the scope of its remediation of its internal controls over financial reporting at the consolidated level and has developed a plan to address the remediation of the foregoing deficiencies in 2022. The Company has hired an external consultant to assist in the remediation of the deficiencies.

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Management believes that the financial statements included in this Quarterly Report on Form 10-Q fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than as noted above.

41

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

The information set forth in Note 14 Commitments and Contingencies of the Notes to Consolidated Financial Statements of this Quarterly Report on Form 10-Q is incorporated by reference herein.

ITEM 1A. RISK FACTORS.

There are no additional risk factors other than those previously disclosed in “Item 1A. Risk Factors” of our annual report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 31, 2022. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in our annual report, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results, and stock price.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Issuance of Unregistered Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

42

ITEM 6. EXHIBITS.

Exhibit No.

   

Description

10.1+†*

Settlement Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company.

10.2†*

Promissory Note, dated January 18, 2022, by Metuchen Pharmaceuticals LLC in favor or VIVUS LLC, a Delaware limited liability company.

10.3

Security Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (incorporated by reference to Exhibit 10.3 of the Company’s Form 8-K filed on January 21, 2022).

10.4†*

Amendment No. 1 to License and Commercialization Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company.

10.5*

Technology Transfer Service Agreement, dated January 20, 2022, between Patheon Pharmaceuticals Inc., part of Thermo Fisher Scientific, and Metuchen Pharmaceuticals, Inc.

10.6#

Severance and General Release Agreement, dated March 1, 2022, between Andrew Gesek and Petros Pharmaceuticals, Inc., its affiliates, subsidiaries and successor entities (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on March 4, 2022).

31.1*

Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer.

31.2*

Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer.

32**

Section 1350 Certification – Principal Executive Officer and Principal Financial Officer.

101

The following materials from Petros Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders’ Equity/Members’ Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Consolidated Financial Statements.

104

Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.

*

Filed herewith.

**

Furnished herewith.

+

Certain of the schedules (and similar attachments) to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) of Regulation S-K under the Securities Act of 1933, as amended, because they do not contain information material to an investment or voting decision and that information is not otherwise disclosed in the Exhibit or the disclosure document. The registrant hereby agrees to furnish a copy of all omitted schedules (or similar attachments) to the SEC upon its request.

Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material and (ii) the type that the registrant treats as private or confidential. A copy of the omitted portions will be furnished to the SEC upon its request.

#

Management contract or compensatory plan or arrangement.

43

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Petros Pharmaceuticals, Inc.

Date: May 16, 2022

By:

/s/ Fady Boctor

Fady Boctor

Chief Commercial Officer and Principal Executive Officer

Date: May 16, 2022

By:

/s/ Mitchell Arnold

Mitchell Arnold

Vice President of Finance and Principal Financial Officer

44

EX-10.1 2 tmb-20220331xex10d1.htm EX-10.1

Exhibit 10.1

Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential.

SETTLEMENT AGREEMENT

This SETTLEMENT AGREEMENT, dated as of January 18, 2022, (this “Agreement”) is entered into by and between METUCHEN PHARMACEUTICALS LLC, a Delaware limited liability company (the “Metuchen”) and VIVUS LLC, a Delaware limited liability company and formerly VIVUS, Inc. (“VIVUS”). Metuchen and VIVUS are collectively referred to as the “Parties” and each a “Party.”

WHEREAS, Metuchen and VIVUS are parties to that certain License and Commercialization Agreement, dated September 30, 2016 (as amended, restated, amended and restated, supplemental or otherwise modified, the “License Agreement”), pursuant to which VIVUS granted to Metuchen an exclusive license in the Territory (as defined below) for, among other things, the development and commercialization of the therapeutic drug known as STENDRA® (avanafil) (“STENDRA”);

WHEREAS, Metuchen and VIVUS were parties to that certain Commercial Supply Agreement, dated September 30, 2016 (as amended, restated, amended and restated, supplemental or otherwise modified, the “Supply Agreement”), pursuant to which, among other things, VIVUS supplied to Metuchen, and Metuchen agreed to purchase from VIVUS, the Product (as defined below) in quantities no less than the Minimum Purchase Obligation (as defined in the Supply Agreement);

WHEREAS, the Supply Agreement was terminated on September 30, 2021;

WHEREAS, Metuchen sells its finished product STENDRA tablets to, and VIVUS sells its finished product of a drug known as QSYMIA® (phentermine/topiramate) (“QSYMIA”) tablets to, the retail chain CVS Pharmacy (“CVS”);

WHEREAS, on or about February 2018 and thereafter, CVS [***] deducted monies [***] from its sale of VIVUS’s product QSYMIA in an amount equal to Six Million and Three Hundred Eighty Thousand Three Hundred Forty-Two Dollars and Four Cents ($6,380,342.04) to cover costs owed to CVS by Metuchen for the return of Metuchen’s product STENDRA (the “CVS Principal Amount”);

WHEREAS, on December 2, 2020, Metuchen consummated a merger with Neurotrope, Inc., a Nevada corporation, including its acquisition by a new publicly traded parent holding company, Petros Pharmaceuticals, Inc., a Delaware corporation (“Petros”);

WHEREAS, on March 3, 2021, Metuchen submitted to VIVUS that certain Purchase Order MT 2021-01 dated March 3, 2021 for the Product (the “2021 Purchase Order”) and has agreed to pay, concurrently with the execution and delivery of this Agreement, One Million Five Hundred Forty-Two Thousand Nine Hundred Four Dollars ($1,542,904), representing the full amount payable for the 2021 Purchase Order;

WHEREAS, Metuchen has acknowledged, and hereby reaffirms, that VIVUS is not responsible for the STENDRA products returned by CVS or any costs incurred by CVS in connection with the returned STENDRA products and that Metuchen is obligated to indemnify VIVUS for the total amount of the CVS Principal Amount pursuant to its indemnification obligations under Article 10 of the License Agreement;

1


WHEREAS, Metuchen also has acknowledged, and hereby reaffirms, that VIVUS is not responsible for Metuchen’s failure to fulfil its Minimum Purchase Obligations under the Supply Agreement and that it owes VIVUS an amount equal to Nine Million Two Hundred Twenty-One Thousand Four Hundred and Sixteen Dollars ($9,221,416) less Two Hundred Fifty Thousand Dollars ($250,000) that Metuchen has paid VIVUS and One Million Dollars ($1,000,000) that VIVUS has reduced the indebtedness by (and in consideration for the execution and performance of this Agreement) (the “Vivus Debt Reduction”) with Seven Million Nine Hundred Seventy-One Thousand Four Hundred and Sixteen Dollars ($7,971,416) remaining payable to VIVUS for Metuchen’s failure to fulfil its Minimum Purchase Obligation under the Supply Agreement for the calendar years 2018 and 2019 (the “MPO Principal Amount” and, together with the CVS Principal Amount, the “Principal Amount”) in addition to (and not deductive of) the CVS Principal Amount;

WHEREAS, in order to repay the Principal Amount to VIVUS, the Parties desire to enter into this Agreement and document Metuchen’s obligation to pay such Principal Amount and interest thereon in the form of the promissory note attached hereto as Exhibit A (the “Promissory Note”), which Promissory Note will be secured by certain assets of Metuchen as described and in accordance with the terms of the security agreement attached hereto as Exhibit B (“Security Agreement”);

WHEREAS, in furtherance of the payment and security obligations set forth in the Promissory Note and Security Agreement and to ensure Metuchen’s full and prompt performance of its obligations hereunder and under such documents, the Parties desire to enter into the additional agreements set forth in this Agreement, including certain amendments to the License Agreement, agreements concerning regulatory matters relating to VIVUS’ ability to sell and commercialize STENDRA; and

WHEREAS, the Parties acknowledge and agree that the Vivus Debt Reduction granted and agreed by Vivus constitutes valid and sufficient consideration for the mutual agreements set forth herein and in the Promissory Note and Security Agreement and other documents attached hereto.

NOW THEREFORE, the Parties hereto agree as follows:

1.            Definitions.

(a)            Definitions of Certain Terms Used Herein. The following terms used herein shall have the following meanings:

Affiliate” means, with respect to a Person, any current or future person, firm, trust, corporation, company, partnership, or other entity or combination thereof that directly or indirectly controls, is controlled by or is under common control with such Person. For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means (a) ownership of fifty percent (50%) or more of the voting and equity rights of such person, firm, trust, corporation, company, partnership or other entity or combination thereof, or (b) the power to direct the management of such person, firm, trust, corporation, company, partnership, or other entity or combination thereof.

2


Applicable Law” means any and all laws, statutes, ordinances, regulations, permits, orders, decrees, judgments, directives, rulings or rules of any kind whatsoever that are promulgated by a federal, state, province, or other Governmental Authority, in each case pertaining to any of the activities contemplated by this Agreement, including any regulations promulgated by any Regulatory Authority in the Territory, all as amended from time to time.

Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy,” as amended from time to time, or any successor statute.

Business Day” means each day other than a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to remain closed.

CVS” has the meaning assigned to such term in the preamble.

CVS Principal Amount” has the meaning assigned to such term in the preamble.

Confidential Information” means all confidential and proprietary Information of VIVUS or a Group Member that is disclosed to or accessed without breach of the Settlement Documents.

Debtor Relief Laws” means the Bankruptcy Code, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions from time to time in effect.

Dollars” or “$” means the lawful money of the United States.

Event of Default” has the meaning assigned to such term in the Security Agreement.

FDA” means the United States Food and Drug Administration or its successor.

Fiscal Year” means the twelve-month period ending on December 31st.

Governmental Authority” means any transnational, domestic or foreign federal, provincial, state or local governmental, regulatory or administrative authority (including any Regulatory Authority), department, court, agency or official, including any political subdivision thereof.

Group Member” means Petros, and each of its current and future subsidiaries and affiliates, including Metuchen and Metuchen’s current and future subsidiaries and affiliates.

License Agreement” has the meaning assigned to such term in the preamble.

Settlement Documents” shall mean, collectively, this Agreement, the Promissory Note, the Security Agreement, the License Agreement, and all other documents, instruments, and agreements executed or delivered in connection with, or pursuant to, any of the foregoing, and all exhibits, schedules, annexes, appendices, and other attachments thereto, in each case, as the same may be amended, restated, supplemented, or otherwise modified from time to time.

3


Material Adverse Effect” means (a) a material adverse effect upon the validity, performance, or enforceability of any of the Settlement Documents or any of the transactions contemplated by any of the Settlement Documents; (b) a material adverse effect upon the properties, operations, business, prospects, or condition (financial or otherwise) of Petros and its subsidiaries, taken as a whole, or on Metuchen or any of its subsidiaries, individually or taken as a whole; (c) a material adverse effect upon the ability of any Group Member to fulfill any obligation under any of the Settlement Documents; or (d) a material adverse effect on the Collateral (as defined in the Security Agreement).

Minimum Purchase Obligation” has the meaning assigned to such term in the Supply Agreement.

Person” means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.

Pricing Approval” means the approval, agreement, determination, or governmental decision establishing the price or level of reimbursement for the Product, as required in a given jurisdiction.

Product” means formulated tablets containing Compound (as defined in the License Agreement) in bulk form which, if appropriately packaged and labeled would constitute the pharmaceutical product STENDRA, as described in the FDA-approved New Drug Application (as defined in the United States Federal Food, Drug and Cosmetic Act) for such product (as such New Drug Application may be modified in the future in accordance with the Supply Agreement and/or the License Agreement).

Promissory Note” has the meaning assigned to such term in the preamble.

QSYMIA” has the meaning assigned to such term in the preamble.

Regulatory Approval” means all approvals necessary for the manufacture, marketing, importation and sale of the Product for one or more indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, but which shall exclude any Pricing Approval.

Regulatory Authority” means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, Pricing Approval, including the FDA in the case of the Territory.

4


Responsible Officer” means, with respect to any Person, any of the president, chief executive officer, chief financial officer, treasurer, controller, managing director, managing member or general partner of such Person but, in any event, with respect to financial matters, any such officer that is responsible for preparing or reviewing the financial statements delivered hereunder.

STENDRA” has the meaning assigned to such term as defined in the preamble.

Supply Agreement” has the meaning assigned to such term as defined in the preamble.

Territory” means the United States and its territories and possessions, including Puerto Rico and U.S. military bases abroad, Canada, South America and India.

Third Party” means any legal person, entity or organization other than Metuchen, VIVUS or an Affiliate of either Party, including any Governmental Authority.

VIVUS Exploitation Rights” means VIVUS’ right to Develop, Manufacture, Commercialize (as such terms are defined in the License Agreement) and otherwise exploit STENDRA in the Licensee Territory (as defined in the License Agreement), as to each, without limitation.

2.            Promissory Note; Future Financings.

(a)            Payment. Metuchen shall repay the entire unpaid Principal Amount then outstanding to VIVUS, together with all accrued and unpaid interest thereon, at the times and in accordance with the terms of the Promissory Note.

(b)            Additional Payments. As a condition to the release and shipment of the Product specified in the 2021 Purchase Order, Metuchen shall immediately (i) make an initial payment with respect to the Promissory Note in the amount of Nine Hundred Thousand Dollars ($900,000) and (ii) make the payment with respect to the 2021 Purchase Order in the amount of One Million Five Hundred Forty-Two Thousand Nine Hundred Four Dollars ($1,542,904), which amount represents payment for the Product only and does not include the associated cost, freight and insurance which Metuchen is solely responsible to pay.

(c)            Future Financings. VIVUS is hereby granted a right of first refusal (including in respect of any financing proposal received from a Group Member or Third Party) to provide any debt financing, convertible debt or equity, or debt-linked instrument (e.g. common or preferred equity, or warrants, options or other agreements that act like, may be exercised for, or converted into debt) issued by or to Metuchen (including any subsidiaries and intermediaries) until the Promissory Note is irrevocably paid in full in cash.

3.            Withholding. If any Applicable Law requires the deduction or withholding of any tax from amounts otherwise payable pursuant to this Agreement, the Promissory Note or any other Settlement Document, then Metuchen shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law, and if such tax is imposed, then the sum payable by Metuchen shall be increased as necessary so that after such deduction or withholding has been made (including, such deductions and withholdings applicable to such additional sums payable under this Section 3), VIVUS (or the applicable transferee) receives an amount equal to the sum it would have received had no such deduction or withholding had been made.

5


4.            Termination of Supply Agreement. The Parties hereby agree and acknowledge that the Supply Agreement terminated effective as of September 30, 2021, and except as set forth herein (a) Metuchen has no further obligation to make any further purchases or pay any further amounts to VIVUS under the Supply Agreement and (b) VIVUS has not further obligation to manufacture (or have manufactured) and supply Product or API to Metuchen. For the avoidance of doubt, Metuchen shall not have any Minimum Purchase Obligations under the Supply Agreement for calendar year 2020, 2021 or otherwise.

5.            Amendments to License Agreement. In order to ensure that, upon an Event of Default, VIVUS will already have all of the rights under the License Agreement to exercise the VIVUS Exploitation Rights (regardless of whether the termination of the license is stayed or deemed ipso facto by a bankruptcy court), the License Agreement will be amended in the form of Amendment No. 1 to License Agreement attached hereto as Exhibit C (“First License Amendment”), including to achieve the following:

(a)            VIVUS will retain co-exclusive rights to exercise the VIVUS Exploitation Rights in the Licensee Territory (and otherwise exclusively on a worldwide basis);

(b)            VIVUS will undertake a limited forbearance from exercising the VIVUS Exploitation Rights in the Licensee Territory unless or until an Event of Default occurs;

(c)            Upon an Event of Default, the License Agreement will terminate;

(d)            VIVUS will have such rights to use all Metuchen regulatory documentation, rights of reference to all regulatory submissions to Regulatory Authorities and other rights as may be necessary or appropriate in VIVUS’ discretion in order to enable VIVUS to immediately commence the exercise of the VIVUS Exploitation Rights; and

(e)            Metuchen will agree and stipulate that (i) VIVUS is the sole and exclusive owner of all of the API unless or until such time that certain quantities of API are shipped to Metuchen against payments made under the Promissory Note in accordance with Section 7 below, and (ii) VIVUS’ exercise of the VIVUS Exploitation Rights would not be subject to the automatic stay, any need for a court order (including that of a bankruptcy court) or in any way impact property of a Metuchen bankruptcy estate upon the occurrence of an Event of Default.

6.            Regulatory Matters. Metuchen agrees to the following and to take any and all further actions and to enter into or amend any agreement (including the License Agreement) in each case deemed necessary or appropriate by VIVUS in its sole discretion to effectuate and accomplish the following:

(a)            Labeler Code. VIVUS shall have the right to exercise the VIVUS Exploitation Rights under its own labeler code. VIVUS has the right to take all steps it deems necessary and appropriate to prepare for the immediate exercise of the VIVUS Exploitation Rights, including entering into any agreements with a third party in respect thereof, but will forbear from actually exercising the VIVUS Exploitation Rights only unless or until an Event of Default occurs (the “Limited Forbearance”).

6


(b)            Regulatory Authorities. Metuchen agrees to perform in a timely manner all steps as may be required or as otherwise requested by VIVUS to effectuate VIVUS’ ability to engage in the VIVUS Exploitation Rights, including submitting an NDC Labeler code request SPL to FDA via ESG or CDER Direct Portal, indicating a new labeler and label addition (together, the “Labeler Addition”) and such other documentation as FDA, VIVUS and other third parties may require or request. The Parties acknowledge and agree that Metuchen’s regulatory advisor, OneSource Regulatory (“OneSource”), shall assist Metuchen and VIVUS with respect to the foregoing, and will submit the Labeler Addition documents in form and substance acceptable to VIVUS (estimated to be within 1 business day from the date of this Agreement), with confirmation of receipt estimated to be within three (3) days or less from submission. Any other steps in addition to those stated above deemed necessary or desired by VIVUS to exercise the VIVUS Exploitation Rights will be promptly performed by Metuchen upon request by VIVUS (collectively such requirements in addition to those stated in this Section 6, the “Regulatory Requirements”). The Regulatory Requirements may be performed by OneSource with the prior written consent of VIVUS. The Regulatory Requirements will be performed and completed (i) at Metuchen’s sole cost and expense, (ii)  in accordance with applicable laws, (iii) pursuant to the terms and conditions of the Settlement Documents as well as subject to the additional requirement of VIVUS’s reasonable satisfaction and (iv) in accordance with the time period and other requirements set forth in this Agreement and the other Settlement Documents. A failure to perform the Regulatory Requirements in accordance with this Agreement shall constitute a material breach of this Agreement and accordingly, and Event of Default.

7.            Transfer of Ownership to Active Pharmaceutical Ingredient.

(a)            Initial Transfer. Upon Metuchen’s (i) submission of the Labeler Addition (in accordance with Section 6(b)), and (ii) a nonrefundable payment of $2,442,904 to VIVUS (in accordance with Section 2(b)), VIVUS will agree to promptly (but in any event, within three (3) business days of satisfaction of conditions (i) and (ii) of this Section 7(a)) release to Metuchen 50% of quantity of bulk STENDRA tablets under Metuchen’s existing open purchase order being held by VIVUS (“Open Purchase Order”), which represents approximately a six (6) month supply of inventory. No shipment of STENDRA will occur unless and until the requirements of both Section 7(a)(i) and 7(a)(ii) are performed.

(b)            Upon the timely completion of the remaining Regulatory Requirements (estimated to be within a subsequent 30-60 days of all required submissions by Metuchen or OneSource, VIVUS, or Metuchen in connection therewith, but not to exceed 180 days from the date hereof), VIVUS will release the remaining 50% of the bulk STENDRA tablets covered by the Open Purchase Order to Metuchen. Time is of the essence in respect of the completion of the Regulatory Requirements, and Metuchen shall (and shall cause OneSource) to use its best efforts to do so as quickly as possible. Failure to use such best efforts, complete the Regulatory Requirements within the 180 day time period stated above or achieve the FDA validation of VIVUS’s rights to exercise the VIVUS Exploitation Rights (including specifically the right to manufacture, commercialize, or distribute STENDRA in the Licensed Territory) shall constitute an Event of Default under the Settlement Documents and shall trigger any and all of the rights and remedies available to VIVUS under the Settlement Documents or otherwise.

7


(c)            With respect to all of VIVUS’ inventory of API, the Parties agree that for so long as the Principal Amount remains outstanding, upon the tender of payment by Metuchen on each Payment Date under the Promissory Note, Metuchen shall accrue a Principal Credit Balance (as defined below) against which Metuchen may upon submission of a written API PO (as defined below) to VIVUS request VIVUS to transfer title to the API Quantity (as defined below) to Metuchen against the API Quantity Amount (as defined below) applicable to such API PO. In connection with each API PO submitted in accordance with this Section 7, VIVUS shall convey, assign and transfer to Metuchen title to the applicable API Quantity without any further documentation required to effectuate such transfer; provided that if any other actions are reasonably required in order to effectuate such transfer, VIVUS shall promptly perform any and all such actions. Metuchen shall be the rightful owner of the API Quantity that is the subject of an API PO following tender of payment by Metuchen and transfer of title, including all risks of loss of such API, subject in each case to the security interests granted to VIVUS under the Security Agreement to secure the prompt and full payment of the Principal Amount and all interest accrued in connection therewith under the Promissory Note and such other Obligations (as defined in the Promissory Note).

(d)            For purposes of this Agreement, an “API PO” means a purchase order conforming to the terms and conditions set forth in Exhibit D attached hereto. The Parties agree that any and all terms and conditions included in any API PO and not otherwise set forth in Exhibit D shall be disregarded and not of any force or effect hereunder or under such API PO unless expressly agreed by the Parties in writing and executed by an authorized representative of each Party.

(e)            ALL API TRANSFERRED BY VIVUS TO METUCHEN UNDER THIS SECTION 7 IS TRANSFERRED “AS-IS” AND VIVUS DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES CONCERNING THE API, INCLUDING REPRESENTATIONS AND WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

(f)            For purposes of this Agreement and this Section 7, the follow definitions shall apply:

(i)            The “Principal Credit Balance” means the aggregate amount of all payments of the Principal Balance received by VIVUS under and in accordance with the Promissory Note less the aggregate API Quantity Amount applied by Metuchen to acquire title to each transfer of API Quantity.

8


(ii)            The “API Quantity” means the quantity of API (as defined in the Supply Agreement) in weight equivalent to each API Quantity Amount requested to be applied by Metuchen and as determined using VIVUS’ then current pricing for API.

(iii)            The “API Quantity Amount” means the U.S. dollar amount of the Principal Credit Balance that Metuchen requests VIVUS to apply and release a corresponding API Quantity to Metuchen.

8.            No Duty to Mitigate. Metuchen agrees that VIVUS, its Affiliates and each of their representatives shall have no duty or other obligation to mitigate in respect of any breach, enforcement or action concerning the Settlement Documents, and waives any right, claim, or defense with respect thereto. The Settlement Documents are hereby amended by this Section 8, as applicable.

9.            Intentionally Omitted.

10.            Representations and Warranties. Metuchen represents and warrants the following:

(a)            Metuchen is duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. Metuchen has all requisite power and authority to execute and deliver this Agreement and each of the Settlement Documents and to perform its obligations under this Agreement and each of the Settlement Documents. The execution, delivery and performance of this Agreement and each of the Settlement Documents by Metuchen has been duly authorized and approved by all necessary action in accordance with Applicable Law and no other action on the part of Metuchen is necessary to authorize the execution, delivery and performance of this Agreement and each of the Settlement Documents. This Agreement and each of the Settlement Documents has been duly executed and delivered by Metuchen and constitutes a valid and binding obligation of Metuchen. All documents and financial data (other than any projections or other forward-looking information) that have been or will be provided to VIVUS by Metuchen or any of its Affiliates are, when furnished, true, complete and correct in all material respects.

(b)            Each of the Group Members is solvent and able to pay its obligations as they become due, that this Agreement and the Settlement Documents provide fair consideration and reasonably equivalent value to it (quantitatively and/or qualitatively), and that by entering into and performing the Settlement Documents it is not actually hindering, delaying, or defrauding its creditors.

(c)            Metuchen’s exact legal name is correctly set forth on the signature page hereof. Metuchen will not change its name or identity without giving prior written notice to VIVUS. Metuchen has been duly organized as a Delaware limited liability company. Metuchen’s chief executive office is located at 200 US Hwy 9, Suite 500, Manalapan, NJ 07726. Metuchen will not change the location of its chief executive office, type of organization, business structure or place of incorporation or organization without giving not less than 30 days’ prior written notice to VIVUS.

9


(d)            Metuchen has no knowledge of any Lien held by any third party or other facts or circumstances that would prevent or adversely impact VIVUS obtaining a first priority Lien in and to the Collateral (as defined in the Security Agreement) upon execution of the Settlement Documents (and assuming VIVUS promptly and properly perfects its security interest in and to the Collateral).

11.            Covenants. Metuchen agrees that, from the date of execution of this Agreement until the obligations hereunder and the Obligations (as defined in the Security Agreement) have been fully paid and satisfied, Metuchen will not challenge its obligations to fulfill requirements set forth in the Settlement Documents and in addition to any and all covenants and obligations under the Promissory Note, the Security Agreement and the other Settlement Documents will perform the following:

(a)            Financing Statements and other Information. Metuchen shall deliver to VIVUS each of the following:

(i)            Annual Financial Statements. Upon the earlier of (A) fifteen (15) days following a filing of its annual reports (or the reports of Petros) with the U.S. Securities and Exchange Commission (“SEC”) or (B) one hundred twenty (120) days after the end of each Fiscal Year of Metuchen, Metuchen shall provide VIVUS with its audited consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such year, setting forth in each case in comparative form the figures for the previous fiscal year, accompanied by an audit opinion from an accounting firm (that is not subject to qualification as to the scope of such audit, but that may contain a “going concern” statement) to the effect that such consolidated financial statements present fairly in all material respects the financial condition and results of operations of Metuchen and its subsidiaries on a consolidated basis in accordance with GAAP.

(ii)            Quarterly Financial Statements. Upon the earlier of (A) fifteen (15) days following a filing of its quarterly reports (or the reports of Petros) with the SEC or (B) seventy-five (75) days after the end of each fiscal quarter of Metuchen not corresponding with the fiscal year end, Metuchen shall provide VIVUS with its unaudited consolidated balance sheet and related statements of operations and cash flows as of the end of and for such fiscal quarter and the then elapsed portion of the fiscal year, setting forth in each case in comparative form the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous fiscal year, all certified by a Responsible Officer as presenting fairly in all material respects the financial condition and results of operations of Metuchen and its consolidated subsidiaries on a consolidated basis in accordance with GAAP, subject to normal year-end audit adjustments and the absence of footnotes.

(b)            VIVUS shall have the right to interview and obtain such additional information from Metuchen’s management concerning any financial or business information set forth or otherwise reflected in the annual and quarterly financial statements required to be delivered under Section 11(a) as may be reasonably requested from time to time.

10


(c)            Pay Indebtedness and other Liabilities. Each Group Member will pay and discharge when due all of its and its subsidiaries’ indebtedness and all of its and its subsidiaries’ taxes, assessments, charges, levies and other liabilities imposed upon such Person, such Person’s income, profits, property or business, except those which currently are being contested in good faith by appropriate proceedings and for which Metuchen shall have set aside adequate reserves with respect thereto.

(d)            Compliance with Laws, Etc. Metuchen and each Group Member will comply in all material respects with all Applicable Laws applicable to the Group Members and to the operation of their business (including without limitations any statute, rule or regulation relating to employment practices and pension benefits or to environmental, occupational and health standards and controls) and take all actions necessary to maintain, renew and keep in full force and effect all New Drug Applications, Regulatory Approvals, permits, governmental authorizations, patents, trademarks, copyrights or other rights related to the Product or otherwise necessary to enable it to continue its business.

12.            Acknowledgements; Release of Claims.

(a)            Acknowledgements. Metuchen hereby acknowledges and agrees to the following:

(i)            that VIVUS is not responsible for the STENDRA products returned by CVS or any costs incurred by CVS in connection with the returned STENDRA products and that Metuchen is obligated to indemnify and hold harmless VIVUS for the total amount of the CVS Principal Amount pursuant to its indemnification obligations under Article 10 of the License Agreement; and

(ii)            that VIVUS is not responsible for Metuchen’s failure to fulfil its Minimum Purchase Obligations under the Supply Agreement and that it owes VIVUS the MPO Principal Amount for failure to fulfil its Minimum Purchase Obligation under the Supply Agreement for the calendar years 2018 and 2019.

(b)            Release of Claims. Metuchen, on behalf of itself and each of its former and future subsidiaries, Affiliates and other Group Members and its and their former and future respective predecessors, managing agents, employees, officers, directors, stockholders, managers, representatives, agents, administrators, successors and assigns (each, the applicable Party’s “Releasees”), hereby absolutely and unconditionally, to the fullest extent permitted by Applicable Law, surrenders, relinquishes, releases, holds harmless and forever discharges VIVUS and its Releasees from and against any and all actions, causes of action, setoffs, claims, cross-claims, suits, debts, accounts, demands, proceedings, arbitrations, limitations, covenants, contracts, controversies, agreements, promises, damages, losses, demands, costs and expenses (including attorney’s fees and costs actually incurred), liabilities, obligations, defenses, orders, executions, claims for relief or judgments, of whatsoever kind or character, whether known or unknown, knowable or not knowable, foreseen or unforeseen, suspected or unsuspected, whether or not concealed or hidden, fixed or unfixed, direct or indirect, contingent or otherwise, at law or in equity, that have existed, may have existed, do exist as of the date of this Agreement or which may exist in the future and are based on any facts, events, matters, acts or omissions arising of out of or relating to the subject of the acknowledgments made in Section 12(a).

11


13.            Amendment or Waiver.

(a)            Amendment or Waiver. No change, modification, or amendment of this Agreement shall be valid or binding unless such change, modification or amendment is in writing and shall have been consented to by Metuchen and VIVUS in writing.

(b)            Severability. If any provision of this Agreement, or the application of such provision to any Person or circumstance, shall be held invalid under the Applicable Law of any jurisdiction, the remainder of this Agreement or the application of such provision to other Persons or circumstances or in other jurisdictions shall not be affected thereby. Further, if any provision of this Agreement is invalid or unenforceable under any Applicable Law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such law. Any provision hereof that may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof, and this Agreement shall be amended to give the Parties the benefit of their bargain to the maximum extent possible in that event..

14.            Governing Law; Jurisdiction; Venue; Consent to Service of Process.

(a)            Governing Law. Resolution of all disputes arising out of or related to this Agreement or the validity, construction, interpretation, enforcement, breach, performance, application or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

(b)            JURISDICTION. EACH OF THE PARTIES HERETO AGREES THAT DISPUTES MAY BE RESOLVED BY LITIGATION IN THE FIRST INSTANCE AND HEREBY UNCONDITIONALLY AND IRREVOCABLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE NEW YORK STATE COURT SITTING IN THE BOROUGH OF MANHATTAN, IN THE CITY OF NEW YORK (OR ANY APPELLATE COURT THEREFROM) OVER ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR OTHER SETTLEMENT DOCUMENTS AND AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING SHALL BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT; PROVIDED, HOWEVER, THAT ANY SUIT BY VIVUS SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT VIVUS’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE VIVUS ELECTS TO BRING SUCH ACTION OR WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. THE SETTLEMENT DOCUMENTS ARE HEREBY AMENDED BY THIS SECTION 14(B), AS APPLICABLE.

12


(c)            VENUE. EACH OF THE PARTIES HERETO HEREBY UNCONDITIONALLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY DISPUTE, SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER SETTLEMENT DOCUMENT BROUGHT IN ANY COURT SPECIFIED ABOVE, OR ANY DEFENSE OF INCONVENIENT FORUM FOR THE MAINTENANCE OF SUCH DISPUTE, SUIT, ACTION OR PROCEEDING.

(d)            CONSENT TO SERVICE OF PROCESS. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS UPON THEM WITH RESPECT TO THIS AGREEMENT AND THE OTHER SETTLEMENT DOCUMENTS AND AGREES THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE BY REGISTERED MAIL (OR ANY SUBSTANTIALLY SIMILAR FORM OF MAIL) DIRECTED TO IT AT ITS ADDRESS FOR NOTICES AS PROVIDED IN SECTION 19 OF THIS AGREEMENT. EACH PARTY HERETO HEREBY WAIVES ANY OBJECTION TO SUCH SERVICE OF PROCESS AND FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY ACTION OR PROCEEDING COMMENCED HEREUNDER THAT SUCH SERVICE OF PROCESS WAS INVALID AND INEFFECTIVE. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

(e)            WAIVER OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE SETTLEMENT DOCUMENTS OR THE ACTIONS OR OMISSIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT THEREOF.

15.            Headings. The section headings in this Agreement are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provision hereof.

16.            Other Terms. Whenever in this Agreement the singular number is used, the same shall include the plural where appropriate (and vice versa), and words of any gender shall include each other gender where appropriate. As used in this Agreement, the following words or phrases shall have the meanings indicated: (a) “day” means a calendar day; (b) “include,” “including,” or their derivatives means “including without limitation”; and (c) “laws” means statutes, regulations, rules, judicial orders, and other legal pronouncements having the effect of law. To the extent that the License Agreement (for the avoidance of doubt, including Amendment No. 1 thereto) is in any way inconsistent with the terms of this Agreement, this Agreement shall control and such inconsistent provisions shall be revised to fulfill the agreements set forth in this Agreement.

17.            Counterparts; Electronic Mail Execution. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement. Delivery of an executed counterpart of this Agreement by electronic mail shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by electronic mail also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement.

13


18.            Set Off. Metuchen shall not be entitled to set off, offset or net amounts owed to VIVUS against or in respect of any claim against VIVUS under this Agreement or under any of the Settlement Documents.

19.            Notices. All notices and other communications required or permitted hereunder shall be effective if in writing and (a) delivered personally, (b) sent by electronic mail, (c) sent by nationally recognized overnight courier, or (d) sent by registered or certified mail, postage prepaid, in each case, addressed as follows:

(i)            if to VIVUS, to it at the following address:

VIVUS LLC

900 E. Hamilton Avenue, Suite 550

Campbell, CA 95008

Attention: Chief Financial Officer and General Counsel
Email: CFO@vivus.com and GeneralCounsel@vivus.com

With a copy (which shall not constitute notice) to:

Greenberg Traurig, LLP

MetLife Building

200 Park Avenue

New York, NY 10166

Attention: Oscar N. Pinkas

Email: pinkaso@gtlaw.com

14


(ii)            If to Metuchen, to:

Metuchen Pharmaceuticals LLC

200 US Hwy 9

Suite 500

Manalapan, NJ 07726

Attention: Fady Boctor

Email: fboctor@metuchenpharma.com

With a copy to:

Morgan, Lewis & Bockius LLP

1111 Pennsylvania Avenue, NW

Washington, DC 20004

Attention: Andrew M. Ray, Esq.

Fax: (202) 373-6001

Email: andrew.ray@morganlewis.com

Unless otherwise specified herein, such notices or other communications shall be deemed effective, (a) on the date received, if personally delivered or sent by electronic mail during normal business hours on a Business Day, or (b) if delivered by registered or certified mail or by overnight courier, on the date delivered as established by return receipt or courier service confirmation or the date on which the return receipt or courier service confirms that acceptance of delivery was returned by the addressee. Each of the parties hereto shall be entitled to specify a different address by giving notice as aforesaid to each of the other parties hereto.

20.            Expenses and Indemnification. In addition to VIVUS’s indemnification and other rights under the Security Agreement and other Settlement Documents:

(a)            Metuchen shall reimburse VIVUS on demand for all reasonable and documented out-of-pocket costs, expenses and fees (including reasonable expenses and fees of its external counsel) incurred by VIVUS in connection with the enforcement of VIVUS’s rights hereunder and under the Loan Documents or in any bankruptcy case or insolvency proceeding. Failure by Metuchen to pay VIVUS any amounts due under this Section 20(a) within ten (10) days of demand for payment shall result in such amount being added to the Principal Amount under the Promissory Note.

(b)            Metuchen shall indemnify, defend, protect and hold harmless VIVUS and each of VIVUS’s Affiliates, and their respective officers, directors, members, managers, employees, attorneys, consultants, and agents from and against any and all losses, damages, liabilities, obligations, penalties, fines, fees, costs, and expenses (including, without limitation, attorneys’ and paralegals’ fees, costs and expenses, and fees, costs and expenses for investigations and experts) (collectively “Losses”) incurred by such indemnitees, whether before or from and after the date hereof, arising from or relating to any suit, investigation, action, or proceeding by any Person, whether threatened or initiated, asserting a claim for any legal or equitable remedy against any Person under any statute, regulation, or common law principle, arising from or in connection with the Excluded Liabilities. The obligations of Metuchen under this paragraph shall survive the payment in full of this Agreement. Failure by Metuchen to pay VIVUS any amounts due under this Section 20(b) within ten (10) days of demand for payment shall result in such amount being added to the Principal Amount under the Promissory Note.

15


21.            Confidentiality. Each Party will maintain the Confidential Information in accordance with Article 11 of the License Agreement. The Parties agree not to disclose any financial or otherwise commercially sensitive terms or conditions of this Agreement to any Third Party without the prior written consent of the other Party, except as required by Applicable Law or to the extent necessary in a dispute between the Parties (including between VIVUS and any Group Member). If either Party is required to disclose any financial term or condition of this Agreement due to the reporting obligations under the Securities and Exchange Act of 1934, as amended or other legal obligation, then the Party seeking disclosure shall notify the other Party of such fact prior to any such disclosure and proceed to redact such provisions as the non-disclosing Party reasonably requests pursuant to a confidential treatment request order.

22.            Cleansing. Notwithstanding anything, under any of the Settlement Documents or otherwise, the receipt of Confidential Information shall not in any way limit or restrict VIVUS or any of its affiliates, and does not constitute, and shall not be construed to create, a standstill or any other restriction whatsoever on the ability of VIVUS or any of its affiliates to (i) purchase or sell securities or other instruments, including those of a Group Member, (ii) purchase or sell any such companies substantially in their entirety (whether by merger, asset sale or otherwise), (iii) provide financing to any such companies or (iv) conduct similar activities in the ordinary course of VIVUS or any of its affiliates’ businesses in the same manner as they are presently conducted. In the event that any Confidential Information disclosed to VIVUS constitutes material nonpublic information about Metuchen or any Group Member, within 5 days following the end of each quarterly fiscal period or any material breach or default or a Settlement Document, Petros shall file a document (the “Cleansing Document”) containing such Confidential Information (or an appropriate summary thereof) (the “Disclosure Information”) with the SEC, including appropriate exceptions for information disclosed to VIVUS’s outside advisors and specifically designated as “non-cleansing” or “advisors’ eyes only” information (or other similar designation) with VIVUS’ prior written consent. As promptly as practicable, but in no event less than 48 hours before the filing of the Cleansing Document, Petros will provide VIVUS with a draft of the Cleansing Document and will consider in good faith any timely comments VIVUS has with respect to the Cleansing Document. In the event that Petros fails to timely file the required Cleansing Document or such Cleansing Document does not contain all of the Disclosure Information as determined by VIVUS based on the advice of its legal counsel, then Petros, on behalf of itself and any Group Member, agrees that VIVUS or its representatives (each an “Authorized Cleansing Party”) shall be authorized to make available to the public at any time more than two (2) business days thereafter (and notwithstanding if this Agreement has been terminated) all the Disclosure Information not so disclosed by Petros in a single disclosure; provided that before any such disclosure such Authorized Cleansing Party shall (i) so long as (but only if) the Cleansing Document is delivered by Petros, notify Petros of its intent to disclose any such Disclosure Information within 48 hours after its receipt of the Cleansing Document and (ii) provide Petros with a draft of the documents VIVUS intends to use to publicly disclose such Disclosure Information at least 48 hours prior to any such disclosure. During such periods, such Authorized Cleansing Party and its legal counsel will make a reasonable effort to consult with Petros and its legal counsel regarding the content of any such disclosure and to consider in good faith any comments that Petros has with respect thereto (including, without limitation, as to whether Petros has previously disclosed all Disclosure Information). Petros agrees, on behalf of itself and each Group Member, that none of VIVUS or its affiliates, or any of their representatives, shall have any liability to any Group Member, or any of their representatives in connection with the disclosure of the Disclosure Information in accordance with the foregoing except in the case of an intentional misrepresentation. Petros shall agree to and acknowledge this section on behalf of itself and all of its present and future subsidiaries and affiliates.

23.            Entire Agreement. This Agreement (including its Exhibits) and the other Settlement Documents represent the entire agreement of Metuchen and VIVUS with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by VIVUS related to the subject matter hereof not expressly set forth or referred to herein or in the other Settlement Documents.

[signature pages follow]

16


IN WITNESS WHEREOF, the undersigned have executed and delivered this Agreement on the date first above written.

 

METUCHEN:

 

 

 

METUCHEN PHARMACEUTICALS LLC

 

 

 

By:

/s/ Fady Boctor

 

 

Name: Fady Boctor

 

 

Title: Authorized Person

[SIGNATURE PAGE TO SETTLEMENT AGREEMENT]


 

VIVUS:

 

 

 

VIVUS LLC

 

 

 

By:

/s/ John Amos

 

 

Name: John Amos

 

 

Title: Chief Executive Officer

[SIGNATURE PAGE TO SETTLEMENT AGREEMENT]


 

AGREED AND ACKNOWLEDGED AS TO SECTION 22:

 

 

 

Petros, on behalf of itself and its present and future subsidiaries and affiliates

 

 

 

By:

/s/ Fady Boctor

 

 

Name: Fady Boctor

 

 

Title: President


Exhibit A

Promissory Note

[***]


Exhibit B

Security Agreement

[***]


EXHIBIT C

Amendment No. 1 to License Agreement

[***]


EXHIBIT D

API PO

The following shall constitute the terms of each API PO submitted by Metuchen for API in accordance with Section 5 of the Agreement:

[***]


EX-10.2 3 tmb-20220331xex10d2.htm EX-10.2

Exhibit 10.2

Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential.

PROMISSORY NOTE

$10,201,758.04

 

January 18, 2022

FOR VALUE RECEIVED, the undersigned, METUCHEN PHARMACEUTICALS LLC, a Delaware limited liability company (“Maker”), hereby executes this Promissory Note (this “Note”) and hereby unconditionally promises to pay to the order of VIVUS LLC, a Delaware limited liability company (“VIVUS”; VIVUS, together with its successors and assigns, “Payee”), in accordance with the payment instructions set forth below, the principal sum of TEN MILLION TWO HUNDRED ONE THOUSAND SEVEN HUNDRED FIFTY-EIGHT AND 4/100 DOLLARS ($10,201,758.04), plus interest thereon on the terms provided below.

Capitalized terms which are used, but not defined, herein shall have the meanings given such terms in that certain Settlement Agreement dated as of the date hereof by and among Maker and Vivus (as the same may be amended, restated, supplemented, or otherwise modified from time to time, the “Settlement Agreement”).

1.             Payment of Principal. Maker shall pay the principal amount of this Note in consecutive quarterly installments, each of which shall be due and payable on the “Installment Due Dates” set forth in Schedule A, attached hereto and made a part hereof, in the “Principal Amount” set forth each of such dates in Schedule A (each such installment due on an applicable date in an applicable amount, an “Installment”), with the first Installment due on the first date set forth in Schedule A. In any event, the outstanding principal amount of this Note shall be due and payable in full on January 1, 2027.

2.             Interest. Interest shall accrue on the outstanding principal under this Note from the date hereof until all principal under shall have been repaid. Interest shall be calculated on the basis of a year of 365/6 days based on the actual number of days elapsed. The interest rate under this Note is 6.00% per annum; provided, however, that, upon and at all times after the occurrence of any Event of Default (as defined below), the interest rate otherwise payable under this Note shall be increased by 3.00% per annum, automatically and without notice to any person or entity, to a total rate of 9.00% per annum, and such increased rate shall remain effective until the full and final payment of all principal and interest under this Note (regardless of whether any such Event of Default is waived or cured). All accrued and unpaid interest under this Note shall be due and payable, in arrears, on the first day of each January, April, July, and October of each calendar year, commencing with the first of such dates to occur after the date hereof.

3.             Payments. If any day on which any payment is otherwise due and payable under this Note (whether principal, interest, or otherwise) is not a business day, then such payment shall be made on the immediately following business day (and interest shall accrue for each such day). All payments on this Note shall be applied, first, to all accrued and unpaid interest, next to all costs, fees, and expenses which are, at the time of such payment, due and payable, and, then, to principal. All payments on account of this Note (whether principal, interest, or otherwise) shall be payable in U.S. dollars, in immediately available funds, and in accordance with the following instructions (or such other instructions provided by Payee to Maker in a writing from time to time):

[***]


4.             Occurrence of Event of Default. During the existence of any Event of Default, Payee may (in addition to all rights and remedies of Payee under applicable law or otherwise, all such rights and remedies being cumulative, not exclusive and enforceable alternatively, successively and concurrently), at its option, declare any or all amounts owing under this Note (whether principal, interest, or otherwise), to be due and payable, whereupon the same shall become immediately due and payable; provided, however, that upon the occurrence of any Event of Default of the kind described in Sections 9(e) or 9(f) of the Security Agreement (as defined below), the obligations of Maker hereunder shall automatically become and be due and payable in full, without notice of any kind.

As used herein, “Event of Default” has the meaning given such term in the Security Agreement.

5.             Prepayments. Maker shall have a right to prepay all or any part of the principal of this Note before it is due and any such prepayment shall be without penalty or premium. All prepayments under this Note shall be applied, first, to any accrued and unpaid interest and, secondly, to the then-remaining principal Installments in the inverse order of the maturities thereof.

6.             Security for Payment. The indebtedness evidenced by this Note is secured by that certain Security Agreement dated as of the date hereof, by Maker in favor of Payee (as the same may be amended, restated, supplemented, or otherwise modified from time to time, the “Security Agreement”), which creates legal and valid encumbrances on and an assignment of all of the Collateral (as defined in the Security Agreement).

7.             Legal Fees. If this Note is placed in the hands of any attorney for collection, or if it is collected through any legal proceeding at law or in equity or in bankruptcy, receivership, or other court proceedings, Maker agrees to pay all costs of collection including, but not limited to, court costs and attorneys’ fees.

8.             Waivers. Maker, for itself, its successors and assigns, hereby waives diligence, presentment, protest and demand and notice of protest, demand, dishonor and non-payment of this Note. No waiver by Payee of any of its rights or remedies hereunder or under any other document evidencing or securing this Note or otherwise shall be considered a waiver of any other subsequent right or remedy of Payee; no delay or omission in the exercise or enforcement by Payee of any rights or remedies shall ever be construed as a waiver of any right or remedy of Payee; and no exercise or enforcement of any such rights or remedies shall ever be held to exhaust any right or remedy of Payee.

9.             Choice of Law; Waiver of Jury Trial. This Note shall be governed by and construed in accordance with the laws of the State of New York. MAKER, BY EXECUTION HEREOF, AND PAYEE, BY ACCEPTANCE HEREOF, MUTUALLY AND WILLINGLY WAIVE THE RIGHT TO A TRIAL BY JURY OF ANY AND ALL CLAIMS MADE BETWEEN THEM WHETHER NOW EXISTING OR ARISING IN THE FUTURE, INCLUDING, WITHOUT LIMITATION, ANY AND ALL CLAIMS, DEFENSES, COUNTERCLAIMS, CROSS CLAIMS, THIRD PARTY CLAIMS AND INTERVENOR’S CLAIMS WHETHER ARISING FROM OR RELATED TO THE NEGOTIATION, EXECUTION AND PERFORMANCE OF THE TRANSACTIONS TO WHICH THIS NOTE RELATES.

2


10.           Amendments. This Note may be amended only by an instrument in writing signed by Payee and Maker.

11.           Severability. The unenforceability of any provision of this Note will not affect the enforceability or validity of any other provision herein.

12.           Continuing Obligations. The obligations and liabilities of Maker under this Note shall be binding upon and enforceable against Maker and its successors and assigns. The representations, undertakings, and covenants made by the undersigned under this Note are, and shall be deemed to be, of continuing force and effect until all indebtedness and obligations of the undersigned under this Note have been fully and finally paid and performed.

13.           Authority. Maker hereby represents and warrants to Payee that, by its execution below, Maker has the full power, authority, and legal right to execute and deliver this Note and that the indebtedness evidenced hereby constitutes a valid and binding obligation of Maker without exception or limitation.

14.           Successors-in-Interest; Assignment. This Note binds and may be enforced against the successors-in-interest of Maker, except as otherwise provided. This Note shall inure to the benefit of and may be enforced by Payee and its successors and assigns. This Note may not be assigned by Maker without the prior written consent of Payee.

15.           Time is of the Essence. Time is of the essence to all terms and provisions set forth herein.

[Continued on following page.]

3


IN WITNESS HEREOF, the undersigned has caused this Promissory Note to be duly executed and delivered on the date first given above.

 

METUCHEN PHARMACEUTICALS LLC, as Maker

 

 

 

By:

/s/ Fady Boctor                

 

Name: Fady Boctor

 

Title: Authorized Person

VIVUS—METUCHEN PROMISSORY NOTE


SCHEDULE A

PAYMENT SCHEDULE

Installment

Installment Due Date

Principal Amount

1

4/1/2022

$176,973.63

2

7/1/2022

$179,628.23

3

10/1/2022

$182,322.66

4

1/1/2023

$185,057.50

5

4/1/2023

$357,833.36

6

7/1/2023

$363,200.86

7

10/1/2023

$368,648.87

8

1/1/2024

$374,178.61

9

4/1/2024

$379,791.29

10

7/1/2024

$385,488.15

11

10/1/2024

$391,270.48

12

1/1/2025

$397,139.53

13

4/1/2025

$763,096.63

14

7/1/2025

$774,543.08

15

10/1/2025

$786,161.22

16

1/1/2026

$797,953.64

17

4/1/2026

$809,922.95

18

7/1/2026

$822,071.79

19

10/1/2026

$834,402.87

20

1/1/2027

$872,072.71


EX-10.4 4 tmb-20220331xex10d4.htm EX-10.4

Exhibit 10.4

Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential.

AMENDMENT No. 1 TO

LICENSE AND COMMERCIALIZATION AGREEMENT

This Amendment No. 1 (this “Amendment”) to the License and Commercialization Agreement dated as of September 30, 2016, is hereby entered into and effective as of January 18, 2022 (the “Amendment Effective Date”) by and between VIVUS LLC, a Delaware limited liability company, (“VIVUS”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”). VIVUS and Metuchen are sometimes referred to in this Amendment collectively as the “Parties” and individually as a “Party”.

WHEREAS, VIVUS and Metuchen entered into the License and Commercialization Agreement dated September 30, 2016 (as amended, restated, amended and restated, supplemental or otherwise modified, the “License Agreement”), pursuant to which, among other things, in Section 2.1 of the License Agreement VIVUS granted to Metuchen an exclusive, royalty-bearing license to “(i) to use, distribute, import, Promote, market, sell, offer for sale, and otherwise Commercialize Products in the Field in the Licensee Territory; (ii) make and have made Products in the Manufacturing Territory, where such Product is solely for use or sale in the Field in the Licensee Territory (subject to Section 2.2), and (iii) to conduct certain Development activities on the Product in the Field pursuant to ARTICLE 4 solely in support of Regulatory Approval in the Licensee Territory”;

WHEREAS, in connection with the settlement of certain amounts that Metuchen has agreed are due and payable by Metuchen to VIVUS under that certain Commercial Supply Agreement dated September 30, 2016 (as amended, restated, amended and restated, supplemental or otherwise modified, the “Supply Agreement”), by and between Metuchen and VIVUS and in connection with amounts [***] deducted by CVS Pharmacy (“CVS”) of amounts owed to VIVUS from sale of VIVUS’s product QSYMIA, (i) Metuchen and VIVUS have entered into a Settlement Agreement dated as of even date herewith (“Settlement Agreement”), (ii) Metuchen has executed a promissory note payable to the order of VIVUS, dated as of even date herewith (the “Promissory Note”) and (iii) Metuchen has executed a security agreement to secure the obligations under the Promissory Note, dated as of even date herewith (“Security Agreement”);

WHEREAS the Supply Agreement was terminated on September 30, 2021;

WHEREAS, under the Settlement Agreement, Metuchen has expressly agreed (among other things) that (i) VIVUS will retain co-exclusive rights to exercise the VIVUS Exploitation Rights (as defined in the Settlement Agreement) in the Licensee Territory, (ii) upon an Event of Default (as defined in the Security Agreement), the License Agreement will terminate, (iii)  VIVUS will have and maintain such rights to use all Metuchen regulatory documentation, rights of reference to all regulatory submissions to Regulatory Authorities and other rights as may be necessary or appropriate in VIVUS’ discretion in order to enable VIVUS to immediately commence the exercise of the VIVUS Exploitation Rights; and (iv) Metuchen will agree and stipulate (A) that VIVUS is the sole and exclusive owner of all of the API unless or until such time that certain quantities of API are shipped to Metuchen against payments made under the Promissory Note in accordance with Section 7 of the Settlement Agreement, and (B) VIVUS’ exercise of the VIVUS Exploitation Rights will not be subject to the automatic stay, any need for a court order (including that of a bankruptcy court) or in any way impact property of a Metuchen bankruptcy estate upon the occurrence of an Event of Default;

1


WHEREAS, as a condition to acceptance of the Settlement Agreement, the Promissory Note and Security Agreement by VIVUS, the Parties have agreed to amend the License Agreement as set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the agreements contained herein, Metuchen and VIVUS hereby agree as follows:

1.            Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to them in the License Agreement.

2.            The Article 1 of the License Agreement is hereby amended to add the following definition:

VIVUS Exploitation Rights” means VIVUS’ right to Develop, Commercialize (as such terms are defined in the License Agreement), make and have made and otherwise exploit the Product in the Licensee Territory (as such terms are defined in the License Agreement), as to each, without limitation.

The Article 1 of the License Agreement is hereby amended as follows:

The last sentence of the defined term “Financing Entity” shall be amended to insert (x) the underlined text that follows “(i) … are not Financing Entities” and “(ii) … are not Financing Documents” as the Hercules Loan Agreements and the “Agent” and “Lenders” have been irrevocably satisfied in full and the Hercules Loan Agreements (including the letter agreement dated September 30, 2016 between VIVUS and Hercules Capital, Inc.) have been terminated without further obligation or liability, and (y) just prior to the last sentence, the following: “The Parties acknowledge that the note, security agreement and ancillary or related documents entered into on January 18, 2022 by Metuchen and VIVUS (and as amended from time to time) constitute Financing Documents and that VIVUS is a Financing Entity in its capacity as countersignatory to those documents.

3.            The License Agreement is hereby amended to delete Section 2.1 and replace it with a new Section 2.1 as follows:

2.1            License to Licensee. Subject to the terms and conditions of this Agreement (including VIVUS’ retained rights as set forth in Section 2.4), VIVUS hereby grants to Licensee a co-exclusive, royalty-bearing (subject in all respects to Section 7.2), sublicensable (subject to ARTICLE 6) license under the VIVUS Technology, (i) to use, distribute, import, Promote, market, sell, offer for sale, and otherwise Commercialize Products in the Field in the Licensee Territory; (ii) make and have made Products in the Manufacturing Territory, where such Product is solely for use or sale in the Field in the Licensee Territory (subject to Section 2.2), and (iii) to conduct certain Development activities on the Product in the Field pursuant to ARTICLE 4 solely in support of Regulatory Approval in the Licensee Territory and solely in accordance with the terms of this Agreement (collectively, the “License”).

2


4.            The License Agreement is hereby amended to delete Section 2.3 and replace it with a new Section 2.3 as follows:

2.3            License to VIVUS. Subject to the terms and conditions of this Agreement, Licensee hereby grants to VIVUS (a) a non-exclusive, royalty-free, sublicensable (subject to ARTICLE 6) license under the Licensee Technology, Regulatory Materials (including rights of reference to all of Licensee’s submissions to Regulatory Authorities) and Promotional Materials (i) to the extent necessary or desirable to fulfill obligations under this Agreement, including manufacturing and supply obligations under ARTICLE 6 and (ii) to conduct research, Development, Commercialization and manufacturing activities in the Licensee Territory; (b) an exclusive, royalty-free, sublicensable (subject to ARTICLE 6) license under the Licensee Technology, Regulatory Materials (including rights of reference to all of Licensee’s submissions to Regulatory Authorities) and Promotional Materials to conduct research, Development, Commercialization and manufacturing activities of Products in the VIVUS Territory; and (c) a non-exclusive, royalty-free, sublicensable (subject to ARTICLE 6) license under the Licensee Technology, Regulatory Materials (including rights of reference to all of Licensee’s submissions to Regulatory Authorities) and Promotional Materials to otherwise exercise the VIVUS Exploitation Rights (collectively, the “VIVUS License”).

5.            The License Agreement is hereby amended to delete Section 2.4 and replace it with a new Section 2.4 as follows:

2.4            VIVUS Retained Rights.

(a)            Notwithstanding the rights granted to Licensee under the License, VIVUS retains its rights under the VIVUS Technology within the Field in the Licensee Territory, and retains all rights to conduct Development, Commercialization, manufacturing and all other activities associated with exercise of the VIVUS Exploitation Rights within the Licensee Territory, including all rights as may be necessary or desirable to exercise in connection with the Regulatory Approval, Pricing Approval, or Commercialization of the Product in the Licensee Territory and in the VIVUS Territory (including the right to grant licenses to Affiliates or Third Parties with respect to such activities). VIVUS retains all rights to the VIVUS Technology outside the Field.

(b)            Licensee acknowledges and agrees that VIVUS’ co-exclusive rights as stated in Section 2.1 and its retained rights as set forth in Section 2.4(a) above enable VIVUS, at any time, to exercise the VIVUS Exploitation Rights, without restriction within the Licensee Territory; provided however, that unless or until an Event of Default occurs, VIVUS agrees to forbear from exercising the VIVUS Exploitation Rights in the Licensee Territory; provided further however, that upon the occurrence of an Event of Default, Metuchen shall not have, and waives, any and all rights and defenses under the License Agreement, the Settlement Agreement, the Promissory Note, the Security Agreement or otherwise at law or in equity to challenge, delay, restrict, impede, or otherwise interfere with VIVUS’ immediate and automatic right to exercise any or all of the VIVUS Exploitation Rights and any other rights retained by VIVUS. Neither Licensee nor any of its sublicensees shall (or seek to) challenge, delay, restrict, impede, or otherwise interfere with VIVUS’s retained rights and any such action by Licensee or any of its sublicensees shall constitute a material breach of this Agreement and VIVUS may immediately terminate this Agreement.

3


6.            The License Agreement is hereby amended to delete Section 12.2(a) and replace it with a new Section 12.2(a) as follows:

(a)            Material Breach. Metuchen shall have the right to terminate this Agreement, upon written notice to VIVUS if VIVUS, after receiving written notice from Metuchen identifying a material breach by VIVUS of its obligations under this Agreement, fails to cure (or if not curable within such time period, adopt a plan for cure during such time period) such material breach within [***] from the date of such notice (or, in the case of payment obligations, [***] from the date of such notice); provided, however, that in the event the VIVUS contests any such asserted breach in good faith and diligently pursues the dispute resolution procedures set forth in ARTICLE 13, such [***] cure period shall be tolled or suspended until the final resolution of such dispute pursuant to the terms of, and in accordance with, the terms and provisions of ARTICLE 13, subject to any exercise by MTPC of its right of termination of the MTPC Agreement due to any material breach of the provisions or conditions of the MTPC Agreement by VIVUS arising from the facts or circumstances that resulted in the material breach by VIVUS hereunder. For the avoidance of doubt (and without limiting VIVUS’ remedies for any other breaches by Licensee), Licensee’s failure to pay the amounts set forth in Section 7.1 by the deadlines set forth therein shall each be deemed to be a material breach of this Agreement.

7.            The License Agreement is hereby amended to add a new Section 12.2(e) as follows:

(e)            VIVUS Termination of License Upon Event of Default. Licensee is the maker of that certain Promissory Note dated as of January 18, 2022, payable to the order of VIVUS (the “Promissory Note”), which Promissory Note is secured under the terms of that certain Security Agreement by and between Licensee and VIVUS dated January 18, 2022 (the “Security Agreement”). VIVUS and Licensee agree that, in the event of (i) any Event of Default (as defined in the Security Agreement) or (ii) material breach of this Agreement by Metuchen, this Agreement shall terminate.

8.            Section 14.5 of the License Agreement is amended to insert the following underlined text in the second line thereof: “… except that, subject in each instance to the terms of the Financing Documents entered into with VIVUS as Financing Party and compliance therewith, (a) …”

9.            Section 14.8 of the License agreement is amended to replace the words “Hercules Capital, Inc.” with “VIVUS as Financing Party.”

10.            Further Assurances and Inconsistencies. Licensee acknowledges and agrees that this Amendment is intended to fully vest in VIVUS all of the necessary rights and privileges to practice and exploit the VIVUS Technology and to Develop, manufacture, have manufactured and otherwise Commercialize the Product in the Licensee Territory at such time and in such manner as VIVUS may determine. To the extent that VIVUS deems the execution of any agreement, further amendment to the License Agreement or such other document or any action (including with respect to FDA or any other Regulatory Authority), omission or otherwise as VIVUS may determine as necessary or appropriate in its sole discretion, Metuchen will and will cause any sublicensee or subcontractor to execute such document or perform such action, omission or otherwise in a prompt and timely manner. Any failure of Metuchen or any sublicensee or subcontractor to execute such documents or perform such further action, omission or otherwise in a prompt and timely manner as requested by VIVUS shall constitute a material breach of the License Agreement and VIVUS may immediately terminate the License Agreement.

4


11.            The License Agreement is amended as set forth in this Amendment as of the Amendment Effective Date. To the extent that the License Agreement is in any way inconsistent with the terms of this Amendment, this Amendment shall control and such inconsistent provisions shall be revised to fulfill the agreements set forth in this Amendment. To the extent that the License Agreement, as amended by this Amendment, is in any way inconsistent with the terms of the Financing Documents entered into with VIVUS as Financing Party, such Financing Documents shall control and such inconsistent provisions shall be revised to fulfill the agreements set forth in the Financing Documents entered into with VIVUS as Financing Party.

12.            The defined terms “VIVUS” and “Party” or “Parties” in the License Agreement or this Amendment shall not include VIVUS in its capacity as Financing Party unless expressly provided for therein absent notice from VIVUS provided after the Amendment Effective Date.

13.            Except as specifically provided for in this Amendment (including the resolution of any conflicts between this Amendment and the terms of the License Agreement in favor of the terms of this Amendment), all of the terms and conditions of the License Agreement shall remain in full force and effect as legally binding obligations of the Parties enforceable in accordance with their terms. Metuchen and VIVUS hereby ratify and confirm their respective obligations under the Agreement, as modified pursuant to this Amendment.

14.            This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. All signatures need not be on the same counterpart.

[signature page follows]

5


IN WITNESS WHEREOF, the Parties have executed or caused this Amendment to be executed as of the Amendment Effective Date.

VIVUS, LLC  

 

METUCHEN PHARMACEUTICALS LLC

 

 

 

 

 

 

BY:

/s/ John Amos 

 

BY:

/s/ Fady Boctor

 

 

 

 

 

NAME: John Amos  

 

NAME: Fady Boctor  

 

 

 

TITLE: Chief Executive Officer  

 

TITLE: Authorized Person  

[Amendment to License and Commercialization Agreement]

6


EX-10.5 5 tmb-20220331xex10d5.htm EX-10.5

A picture containing diagram

Description automatically generated


Revision History

Proposal Number

Date Issued

Key Revisions

C-CRC-286511-R0

November 11, 2021

First Issue

C-CRC-286511-R1

November 24, 2021

-

Made Validation stability optional

-

Made Bulk Hold Time Study included in project

-

Updated validation costs

C-CRC-286511-R2

January 7, 2022

-

Updated T&Cs/Signature Box

-

Updated Budget Summary

C-CRC-286511-R3

January 13, 2022

-

Updated T&Cs/Signature Box

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 2 of 31


Contents

Part A: Project Overview

4

1.

Executive Summary of the Opportunity

4

2.

Proposed Site Cincinnati Operations

5

3.

Product Features and Assumptions

6

4.

Key Assumptions to be Finalized

7

Part B: Budget Summary

8

1.

Pricing

8

2.

Costs Included in Grand Total

12

3.

Costs Not Included in Grand Total (Non-Exhaustive)

12

4.

Key Pricing Requisites:

13

5.

Capital Requirements

13

Part C: Technology Transfer & Feasibility Activities

14

1.

Project Start Up

14

2.

Analytical Services

15

3.

Microbiology

15

4.

Feasibility Batch Manufacturing

16

5.

Comparative Dissolution

16

6.

Packaging Line Trial Bottles - Optional

16

7.

Bulk Hold Time Study

16

8.

Stability Bulk Hold Optional

17

9.

Validation Services

18

10.

Stability Validation (Optional)

19

11.

Regulatory Management

20

Part D: Key Technical Parameters

21

1.

Manufacturing Parameters

21

2.

Packaging Parameters

23

3.

Testing Conditions

23

4.

Supply Chain

24

Part E: Legal Terms and Conditions

25

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 3 of 31


Part A: Project Overview

1.

Executive Summary of the Opportunity

Patheon, part of Thermo Fisher Scientific (Patheon), values the opportunity to collaborate with Metuchen Pharmaceutical LLC (Metuchen) as a strategic partner for the manufacturing and packaging of Stendra Tablets. Patheon strives to meet key project milestones such as, the successful technology transfer and subsequent support for commercial manufacturing and packaging.

Certain details of this project require clarification between the parties and therefore a number of assumptions have been made based on Patheons best estimates. Patheon would be pleased to discuss this opportunity further and breakout the activities into executable phases for the convenience of Metuchen. Commercial supply activities and prices are presented in the Commercial Pricing Proposal C-CRC-286512-R0 (or latest revision).

Patheon will be responsible for the following core services:

1.1

Supply of raw materials and packaging components, with the exception of the Drug Substance (DS), which is to be furnished by Metuchen.

1.2

Technology transfer activities per Part B: Budget Summary.

1.3

API identification test and all QC testing requirements for raw materials, packaging components and finished product.

This Project Proposal and the Legal Terms and Conditions herein represent the full agreement regarding the subject matter between the parties identified below (the Contract). The Contract describes the Services to be performed by Patheon in accordance with the Legal Terms and Conditions of the Contract. In the event of a conflict between this Project Proposal and the Legal Terms and Conditions the Legal Terms and Conditions shall control. Unless earlier terminated in accordance with the Contract, the term of the Contract is from the Effective Date until completion by Patheon of these Services.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 4 of 31


2.

Proposed Site Cincinnati Operations

Image1
Image1

Patheons Cincinnati Operations, Ohio USA, offers both commercial manufacturing and fully integrated pharmaceutical development services (PDS). Cincinnati Operations also serves as a Center of Excellence for controlled and sustained release solid oral dosage forms. Development scale soft and hard gel capsules, osmotic release dosage forms, multi-layer tablets, active coating, hot melt extrusion and pelletization are among the dosage forms and technologies offered at the site.

Cincinnati Operations has been registered with the US DEA for more than 30 years. With US DEA manufacturing registrations (schedule II to V), analytical registrations (schedule I to V), and distribution registrations (schedule III to V), the facility is equipped to fully accommodate controlled drug product requirements.

Site Regulatory History

Date of Inspection

Regulatory Authority

Inspection Type

Mar-2021

Russian

PAI

Jan-2021

Russian MIT

PAI

Mar-2020

Health Canada

PAI + General GMP

Feb-2020

Russian MIT

Product Renewal

Jan-2020

US FDA

PAI + General GMP

Dec-2019

US FDA

PAI

Feb-2019

US FDA

PAI

Jul-2018

Russian Inspection

PAI

Feb-2018

FDA (US)

General GMP and PAI

Sep-2017

ANVISA (Brazil)

General GMP

May-2017

FDA (US)

Follow-Up Inspection

Mar-2017

Russian Authority

General GMP

Feb-2017

US FDA

Follow-Up Inspection

Dec-2016

German Inspectorate

PAI

Mar-2016

FDA (US)

PAI and GMP

Mar-2016

ANVISA (Brazil)

PAI and GMP

Aug-2015

FDA (US)

PAI

Jan-2015

EMA (Germany)

PAI and GMP

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 5 of 31


3.

Product Features and Assumptions

3.1

API: Avanafil

·

Indication: Erectile Dysfunction

·

Patheons preliminary categorisation: Category 2

·

Pending Patheons receipt and review of the mechanism of action, therapeutic indication and therapeutic dose, and receipt of the Investigators Brochure or Toxicity Summaries for the API, then it is assumed for the purposes of this project proposal that Patheon can handle the API from a current capability, safety and licensing perspectives.

3.2

Key product parameter overview:

Product

Strength

Solid Form

Packaging Configuration

Stendra Tablets

50mg, 100mg, 200mg

Tablet

Bulk, Optional 30ct Bottle

3.3

Territories U.S.A.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 6 of 31


4.

Key Assumptions to be Finalized:

Certain details of this project require clarification between the parties and therefore a number of assumptions have been made at this point in time. The following key estimations will be discussed and agreed between the parties either during the technology transfer project phase. All technical parameters will be confirmed during the validation phase.

Assumption

Justification/Action

An optimum batch size for the manufacturing area/equipment has been proposed.

To maximize efficiency and reduce cost.

The standard Patheon hold times are suitable for the batch size proposed. Batch size to be further evaluated during the feasibility activities and confirmed on completion of the process validation phase.

Further details on the stability data and hold times for the finished product should be provided by Metuchen.

Defect characteristics and AQL limits are according to Patheon Standard Protocols and within the visual inspection equipments capability.

AQL limits to agreed and defined during the technology transfer phase.

Patheons standard hours for testing have been considered.

Testing costs for raw materials, packaging components and finished product are based on Patheons best estimates. Testing labour may be subject to change after agreement on testing methods and specifications.

The number of PV batches to be manufactured to qualify the process is 3.

The number of PV batches required has been estimated based on Patheons standard approach. Number of PV batches and scope of validation can change based on risk assessment. A process validation strategy should be provided by Metuchen.

The number of feasibility and process validation batches required has been estimated based on Patheons standard approach.

The number of feasibility and process validation batches required is to be agreed between the parties.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 7 of 31


Part B: Budget Summary

1.

Pricing

THE FOLLOWING COSTS ARE ALL QUOTED IN: USD

ACTIVITY

PRICE

Project Start-Up

$

20,000

ACTIVITY

PRICE

Cleaning Residuals Assay (Multiple Surfaces Development and Validation)

$

32,320

Drug Substance Identification by IR (Method Evaluation and Method Transfer)

$

7,046

Drug Substance Potency and Related Substances Assay by HPLC (Method Evaluation and Transfer)

$

17,118

Product Content Uniformity Assay (Method Evaluation and Method Transfer)

$

15,894

IR - Product Dissolution Assay by HPLC - (Method Evaluation and Method Transfer)

$

15,411

Karl Fischer (Method Evaluation and Method Transfer)

$

7,470

Specification Generation (Assumed 3 Specifications)

$

2,615

Total

$

97,874

MICROBIOLOGY

USD

ACTIVITY

ACTIVITY PRICE

PRICE

Preparation

$

1,224

Protocol

$

204

No. of Trials

No. of Materials

Pharmacopeia

One Trial

3

1

$

6,924

Two Trials

3

1

$

10,386

Three Trials

3

1

$

13,848

Four Trials

3

1

$

17,310

SUB TOTAL (Number of Trials Assumed = 4 Trials)

$

18,738

Total

$

18,738

ACTIVITY

ACTIVITY PRICE

PRICE

Protocols

(Assumes 1 protocol(s))

$

3,260

Manufacturing And Analytical

$

92,567

Total Per Batch

$

92,567

1 Batch TOTAL

$

92,567

Back to Back Batch Manufacturing and Analytical

$

92,567

Total Per Batch

$

92,567

2 Back to Back Batch TOTAL

$

185,134

Manufacturing Report

(Assumes 1 report(s))

$

7,824

Total

$

288,785

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 8 of 31


COMPARITIVE DISSOLUTION

USD

ACTIVITY

PRICE

Number of Lots

3

Total Samples

27

Protocol Generation

$

4,708

Pullpoint Months

50mg Tablets

100mg Tablets

200mg Tablets

Microbiology

AET

Samples per pullpoint

Cost per pullpoint (Activity price)

C1

X

X

X

9

$

135

C2

X

X

X

9

$

135

C3

X

X

X

9

$

135

Summary Report Generation

$

4,066

Total

$

9,179

PACKAGING LINE TRIAL-BOTTLES

USD

ACTIVITY

ACTIVITY PRICE

PRICE

Protocols

(Assumes 1 protocol(s))

$

1,630

Bottle Packaging Line Trial, 3 SKU's

$

26,607

Total Per Batch

$

26,607

1 Batch TOTAL

$

26,607

Report

(Assumes 1 report(s))

$

3,912

Total

Optional, not included in the Budget Total:

$

5,363

BULK HOLD TIME STUDY

USD

ACTIVITY

PRICE

Number of Lots

2

Total Samples

12

Protocol Generation

$

3,745

Pullpoint Days

Blend

Core

Microbiology

AET

Samples per pullpoint

Cost per pullpoint (Activity Price)

0 (Initial)

X

2

$

3,422

T = 15

X

2

$

3,542

T = 30

X

M

2

$

4,308

0 (Initial)

X

2

$

3,422

T = 15

X

2

$

3,542

T = 30

X

M

2

$

4,308

Summary Report Generation

$

3,531

Total

$

29,820

STABILITY - BULK HOLD

USD

ACTIVITY

PRICE

Number of Lots

2

Total Samples

22

Protocol Generation

$

3,745

Months

/ 75% RH

/ 65% RH

/ 60% RH

per pullpoint

per pullpoint (Activity Price)

Pullpoint Months

40C / 75% RH

30C / 65% RH

25C / 60% RH

Microbiology

AET

Samples per pullpoint

Cost per pullpoint (Activity Price)

0 (Initial)

R

R

$

0

T = 1

X

C

2

$

3,636

T = 2

X

C

2

$

3,836

T = 3

X

C

X

4

$

5,933

T = 6

X

C

X

4

$

6,833

T = 9

C

X

2

$

5,236

T = 12

C

X

M

2

$

6,482

T = 18

X

2

$

5,222

T = 24

X

M

2

$

6,468

T = 36

X

M

2

$

7,668

Summary Report Generation

$

3,531

Total

Optional cost, not included in the Budget Total: $58,590

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 9 of 31


ACTIVITY

PRICE

Continued Process Verification (CPV) Program Start-up

$

35,000

Cleaning Validation Assessment

$

3,313

Master Validation Plan

$

4,821

Process Validation

(3 Strengths)

$

40,042

Equipment Cleaning Validation

$

42,439

Total

$

125,615

ACTIVITY

PRICE

Number of Lots

9

Total Samples

99

Protocol Generation

$

10,486

Months

/ 65% RH

per pullpoint

per pullpoint (Activity Price)

Pullpoint Months

40C / 75% RH

30C / 65% RH

25C / 60% rh

Microbiology

AET

Samples per pullpoint

Cost per pullpoint (Activity Price)

0 (Initial)

R

R

$

0

T = 1

X

C

9

$

9,994

T = 2

X

C

9

$

10,714

T = 3

X

C

X

18

$

20,270

T = 6

X

C

X

18

$

23,510

T = 9

C

X

9

$

15,754

T = 12

C

X

M

9

$

20,856

T = 18

X

9

$

15,754

T = 24

X

M

9

$

20,856

T = 36

X

M

9

$

25,176

Summary Report Generation

$

7,276

Total

Optional cost, not included in the Budget Total:  $ 180,646

ACTIVITY

ACTIVITY PRICE

PRICE

50mg Tablets Bulk

Manufacturing and Bulk Packaging

Total Per Batch

$

44,600

3 Batch TOTAL

$

133,800

$

133,800

100mg Tablets Bulk

Manufacturing and Bulk Packaging

Total Per Batch

$

100,500

3 Batch TOTAL

$

301,500

200mg Tablets Bulk

$

301,500

Manufacturing and Bulk Packaging

Total Per Batch

$

103,800

3 Batch TOTAL

$

311,400

$

311,400

Total

$

746,700

VALIDATION SERVICES - SUB TOTAL

USD

$

590,011

VALIDATION BATCHES - SUB TOTAL

USD

$

746,700

GRAND TOTAL

USD

$

1,336,711

Optional Items are not included in the Budget Total

USD

$

324,599

**Please note that Patheon reserves the right to check Clients creditworthiness and request additional advance payments or additional financial documentation prior to commencement of any Services.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 10 of 31


STANDARD SHIPMENT SUPPORT

Standard Shipment Support Fee (applies to all shipments originating from a Patheon facility)

$850.00 Per Shipment

Patheon will provide support to Client in preparing the shipment of project material (non-cGMP and cGMP material) for the fixed fee per shipment stated above (Standard Shipment Support Fee). The Standard Shipment Support Fee provides for the following Patheon services (Standard Shipment Support Services):

·

Preparation of internal documentation to support shipment dispatch (e.g. commercial invoice)

·

Assembly of the shipment

·

Tender shipment to selected courier

For budget purposes, a Standard Shipment Support Fee will be applied for each planned shipment whether electing Courier Management through Total Transportation Management or Client Managed Shipping (Client Carrier) as more fully described in the Shipping Options below.

SHIPPING OPTIONS

Service Selection

Description

(A) Courier Management through Total Transportation Management (TTM)

TTM is a service whereby Patheon will manage the couriers for all shipments and lanes, such selection being based on data relating to courier performance across all shipments executed across the Patheon logistics network. The TTM fees will be based on actual shipment characteristics and provides for the following services:

·

Patheon will select the courier from a broad array of vendors managed and qualified through TTMs quality management system

·

Patheon will coordinate the dispatch of the shipment with selected carrier

·

Patheon will support the facilitation and coordination of necessary documentation as required by a receiving country, including the generation and creation of such documents

·

All shipments will be tracked and traced via the Global Logistics Help Desk from origin to final destination

·

Patheon will assist with the resolution of shipment issues arising during transit and will escalate such issues to the Client in accordance when necessary

The TTM fees will be quoted at the time of shipment in a TTM Freight Quote. Client will be responsible for any charges with respect to services that were not contemplated in this quote including, but not limited to, charges for supplementary services such as detention or demurrage. The Terms and Conditions specified in the applicable TTM Freight Quote issued

at the time of shipment will apply.

(B) Client Managed Shipping (Client Carrier)

Client will select the couriers for all shipments and lanes and manage the shipment from origin to destination. All Client carriers will bill any and all freight charges and other costs associated with all Client shipments directly to Client using the Clients account number(s), and Client

shall be solely responsible for the payment of all such charges and other costs.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 11 of 31


2. Costs Included in Grand Total

2.1

Product manufactured, tested and packaged according to the processing instructions.

2.2

Estimated material costs. Material costs included in this proposal are best estimates based on Patheons current standards and specifications and do not include any extraordinary or custom raw materials. Final material costs will be provided after confirmation of Specifications and formal quotations have been received from the suppliers.

2.3

Procurement, storage, inventory control and QC testing of all required raw materials & packaging materials to complete the Services.

2.4

Qualification and auditing of all Common Materials and Supplies suppliers.

2.5

Batch record copies for validation batches.

2.6

Validation Batches and Validation Batch Stability testing.

2.7

API identity test according to Patheon standard incoming process. If Client stipulates a vendor, Client will audit and approve the vendor and ensure cGMP compliance. If Patheon is to release an API or other Client stipulated material based on ID only, Client will ensure the required verification testing by an independent laboratory has been completed.

2.8

First Product Approval Inspection (PAI) and copy of FDA Report. Additional PAI support will be subject to additional fees.

3. Costs Not Included in Grand Total (Non-Exhaustive)

3.1

Items listed as Optional in the Budget Summary

3.2

DS, Client supplied materials and reference standards to be supplied by Client at no cost to Patheon. Reference standards are an Exclusive Item.

3.3

Ongoing annual stability testing program is not included. Patheon can store and test in accordance with an agreed protocol and ICH guidelines.

3.4

Any additional data or report requested by Client beyond the scope of cGMPs and customary FDA or other regulatory agencies requirements will be subject to an additional fee to be agreed upon between Patheon and Client.

3.5

Any specific visual inspection of the bulk or of the finished products outside of standard release testing.

3.6

Regulatory support (such as preparation of Annual Report and Chemistry, Manufacturing, and Controls (CMC) files). Regulatory support work is subject to an additional fee see section 11 below for additional details.

3.7

Label copy change and batch record changes initiated by Client.

3.8

Artworks origination and update costs including one off costs at suppliers.

3.9

Testing required to support OOS results or stability failures, testing required in support of complaint investigations and testing of Products that are not related to Patheons performance.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 12 of 31


3.10

Testing does not include Stage II testing. If Stage II testing is needed, it will be covered under a COS (change of scope).

4. Key Pricing Requisites:

4.1

All stated Values / Invoices are in USD ($).

4.2

The Budget in Part B, Section 1, is based on the assumptions set out in this Project Proposal. Should any of the assumptions prove to be incorrect, Patheon reserves the right to amend the Budget Summary.

4.3

Technology Transfer activities to be invoiced on submission of (as applicable):

First draft of associated deliverable (e.g. protocol, report, or other executed documentation)
Patheon Batch Certificate of Analysis or executed documentation as applicable
For stability studies, invoice will be raised:
oUpon Batch issuance of the protocol first draft
oUpon issuance of the analytical data sheet after every intermediate time point,
Or completion of activity if no deliverable is identified

4.4

Additional services will be agreed under a Change of Scope Agreement.

4.5

The fee for project management is incorporated in the breakdown cost for each activity in the Budget Summary.

5. Capital Requirements

Dedicated equipment, tooling, and change parts will be required to be sourced and purchased at the sole expense of Metuchen to support the manufacture of Stendra Tablets at Patheon. Client will be responsible for the dedicated part requirements listed in this Capital Requirements section. Capital estimates are subject to change pending design of the manufacturing process and would be confirmed at the time of placing an order.

Dedicated Part Requirements - Customer Funded- Patheon Owned

Quantity

Unit cost

Total

Visual Inspection

3

$10,000

$30,000

Compression Tooling

3

$25,000

$75,000

Screens

1

$10,000

$10,000

Contingency

$11,500

Engineering Support

$17,250

Total - Dedicated Part Requirements - Customer Funded - Patheon Owned

$143,750

Prior to expending the capital expenditures, Metuchen will provide confirmation to Patheon to proceed with the purchase of the capital expenditures. Patheon will order the necessary equipment and provide invoices to Metuchen for the costs of the equipment

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 13 of 31


Part C: Technology Transfer & Feasibility Activities

1.

Project Start Up

Scientific review of technical documentation, literature review in preparation for project implementation.
Technical Risk Assessment: Patheon will perform a technical risk assessment based on the key technical parameters, listed in Part D, relating to the manufacturing process for Stendra Tablets. Patheon will perform the specific activities/items as follows:
oIdentify and assess the criticalities of the project
oPerform GAP analysis
oIdentify possible solutions
oRecommend any action/actions to alleviate any identified criticalities
Project team set up: scheduling and attendance of cross functional team meeting with for project kick off.
Creation of detailed project plan with established timelines.
Environmental Health and Safety (EH&S) assessment: EH&S safety categorisation for the API, Safe System of Work report, training of Patheon staff and documentation support for receipt of Metuchen materials.
oProject/Operational Documentation
oBusiness and project management
oTechnology transfer protocols and subsequent reports.
oBill of materials (BOM)
oMaster Batch Records (MBR)
oComponents specifications
oAPI and excipient specification
oProduct specifications
oChange Control Documents
oStandard Operating Procedures (SOP)
oQuality Agreement
oValidation Master Plan (VMP)

A full compliance check of all existing manufacturing equipment/utilities involved in the manufacturing process used for each product will be performed to ensure qualification and compliance. Preparations and review of protocols and reports associated with all the planned qualification/validation activities are included.

Active Blend Combustible Dust Data & Industrial Hygiene

· MIE (Minimum Ignition Energy) and Kst Data for active blend will be required if batch sizes greater than 15kg is planned. If data is unavailable, Patheon can contract third party services to obtain. An approximate 500-600g sample of the active blend will be required for testing. Cost is approximately $3,500 USD for both tests and will be billed back to client. Tests will take approximately 2-3 weeks to complete.

· An air sampling (industrial hygiene) method for the API will be required to be provided by the client upon commercialization. If no method is available, Patheon can contract third party services to obtain. An active ingredient sample will be required for method development. The cost is approximately

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 14 of 31


$15,000 to $16,000 USD per Industrial Hygiene Method and will be billed back to client. Method development will take approximately 2-3 weeks to complete.

2. Analytical Services

For each specific analytical method to be transferred, a protocol with pre-defined acceptance criteria will be prepared and agreed with Metuchen, and only upon the successful completion and approval of the associated protocol and report, the method will be deemed successfully transferred. Successful completion means that Patheons test results must be within the acceptance criteria range of Metuchen QC laboratory test results.

·

Cleaning residuals assay method validation is based on a single surface. If multiple surfaces validation is required, additional bench hours may be necessary and changes to the price will be covered by a Change of Scope Agreement.

It is assumed that a validated cleaning test method is not available and will be developed and validated by Patheon. It is assumed that full cleaning occurs after each campaign OR batch (where applicable).

Patheon will verify the cleaning process when scaling up to the commercial batch size. Protocol, report and execution activities are included.

Analytical Services

Method Validation

Method Evaluation and Method Transfer

·Cleaning Residuals Assay

·API by IR

·Potency and Related Substances

·Content Uniformity

·Dissolution

·Karl Fischer

3. Microbiology

Patheon will validate Microbiological USP/EP test methods required Microbial Limit Tests (MLT) as part of the release and stability testing requirements for cGMP batches. Pricing includes preparation of the appropriate documents to initiate verification, and a summary report upon completion of the suitability study for Client review.

Patheon will perform verification of microbial recovery from pharmacopoeial articles following USP<1227> guideline and USP Harmonized methods (USP<61> and <62>) on Stendra Tablets. A harmonized specification based on USP<1111> will be suggested to meet USP/EP/JP acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use. The verified methods will cover USP, EP and JP compendia for Microbiological Examination of Non-Sterile Products and Antimicrobial Effectiveness Testing (AET).

Each formulation and non proportional dose strength should be verified unless there is justification for matrixing. Adequate trials will be performed with different dilutions targeted to establish recovery. The cost shown applies to three formulations and strengths and four trials. If required, additional costs will be covered by a Change of Scope Agreement.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 15 of 31


4. Feasibility Batch Manufacturing

R0 Standard approach is to present pricing for 1 manufacturing feasibility batch for each of the three strengths for representative pricing purposes. Patheon will confirm scope with the Client for approval before finalizing the proposal. Manufacture of three feasibility batches would be performed to implement and verify the full operational process. Activities include: Documentation preparation including batch records, protocol generation, execution, QC testing, QA review and manufacturing report.

Upon completion of QA review, recommendations will be made to proceed to process validation/pre-validation or to re-evaluate critical processing requirements, experimentation, equipment train, etc. in an additional feasibility batch.

Pricing is for 3 feasibility batches for the entire project. Patheon will finalize strategy with customer before final approval.

5. Comparative Dissolution

Study to be agreed upon before execution to demonstrate the equivalence between the existing Product manufacture by Bayer and the product manufactured by Patheon a Comparative dissolution study will be performed. The study will be performed on the feasibility batches, prepared by Patheon. Dissolution profile (3 time points, n=12) in 3 different media will be done for each.

6. Packaging Line Trial Bottles - Optional

Packaging line trial performed for 3 SKUs. Price is representative of 3 SKUs, scope to be discussed in further revisions. Patheon will finalize strategy with the Client before final approval. Packaging parameters will be established via a dry run of the packaging components prior to packaging validation runs. Patheon will prepare a protocol and summary report for review.

7. Bulk Hold Time Study

To establish holding time parameters prior to commencing process validation. Study conducted for two strengths, for each of the blends (solid of liquid), and cores / or uncoated tablets and on the bulk finished product at T=0, 15 days and 30 days. See Part B: Budget Summary for scope details. Includes protocol and report.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 16 of 31


8. Stability Bulk Hold Optional

The precise strategy to be adopted for the stability studies has to be discussed with Metuchen and therefore several assumptions have been made at this stage. Patheon will make a detailed assessment and supply an accurate revised price for this work on provision of the full testing specification and stability requirements.

Patheon will design a stability program (single strength, single orientation, and single container type) to monitor the stability profiles of two feasibility batches packaged into 2 SKUs.

The following assumptions have been made:

Samples will be placed on store concurrently and also tested concurrently at each test point.
Unless indicated in the stability protocol, analytical data required for the release of each validation batch manufactured at Patheon will be used for the initial time point (T=0) for all conditions.
A stability protocol will be prepared prior to samples being placed on store and a final report will be prepared upon completion of the stability program. Data summaries will be provided upon completion of individual time points.

Testing Matrix:

The following storage conditions and test-points are suggested for testing (to be confirmed):

Storage Conditions

Time Point (Months)

0

1

2

3

6

9

12

18

24

36

60

25°C / 60% RH

R

X

X

X

XM

X

XM

XM

30°C / 65% RH

C

C

C

C

C

C

40°C / 75% RH

X

X

X

X

R: Release testing

X: Physical/Chemical testing (assuming Patheon standard testing regime) M: Microbiology testing

C: Contingency samples testing to be performed only if significant change is observed or at the request of Metuchen. Testing of these samples is not included in budget.

Actual testing requirements can be adapted at a later stage to meet the specific requirements

Stability Testing Requirements

Appearance

Dissolution (profile by HPLC, n=6)

Moisture (KF)

Potency and Related Substances

ID by IR

Uniformity

Patheon will store the stability samples. Should there be insufficient space at Patheon when the project initiates, then samples can be stored off site at a Patheon approved third party supplier. Storage of samples beyond the conclusion of the stability study will be charged back to Metuchen in accordance with the Legal Terms and Conditions/Master Agreement. In the unlikely event that Metuchen requests a stability program to be terminated early, any costs associated with the disposal of any remaining drug product or shipment of any remaining drug

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 17 of 31


product back to Metuchen will be charged back to Metuchen in accordance with the Legal Terms and Conditions/Master Agreement.

Metuchen may instruct Patheon to amend the stability schedule as required. For Minor Changes such as those that increase the number of pull points but maintain the testing and number of batches as outlined above, an invoice will be issued for the new pull points without issuance of a formal Change of Scope Agreement. For Significant Changes that affect the type and number of tests (as mentioned above) to be performed at a given time point, the price per pull point may be re-evaluated. A formal Change of Scope Agreement will be issued to capture the Significant Changes.

Patheon will prepare a stability summary report following completion of the study. The summary report will consist of a high level evaluation of whether the data for each test indicates that a change has occurred on stability and compared to specification. The report will not include any statistical interpretations or shelf life evaluations (these would be agreed between the parties via a Change of Scope Agreement if required).

9. Validation Services

To demonstrate that the manufacturing process is capable of consistently producing a finished product that meets the quality attributes as specified in the established product specification via manufacturing of three consecutive validation batches. Activities include:

Equipment Cleaning Validation
Validation Batches: R0 Standard approach is to present pricing for 3 manufacturing validation batches per strength for representative pricing purposes. Patheon will confirm the scope with Metuchen for approval before finalizing the proposal.
Includes generation of a protocol, execution and reporting.
Validation Batches 3 process validation batches per strength
Continued Process Verification PV Program Start Up - Risk Assessment and Protocol
It is assumed that a Patheon standard testing regime will be performed at the following steps: blend/powder/granulation, cores / or uncoated tablets, and on the bulk finished product. Refer to Part D for the key technical parameters used.

The continued validation approach will be discussed and agreed with Metuchen during the technical transfer project.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 18 of 31


10. Stability Validation (Optional)

The precise strategy to be adopted for the stability studies has to be discussed with Metuchen and therefore several assumptions have been made at this stage. Patheon will make a detailed assessment and supply an accurate revised price for this work on provision of the full testing specification and stability requirements.

Patheon will design a stability program (single strength, single orientation, and single container type) to monitor the stability profiles of three process validation batches per strength packaged into 3 SKUs.

The following assumptions have been made:

Samples will be placed on store concurrently and also tested concurrently at each test point.
Unless indicated in the stability protocol, analytical data required for the release of each validation batch manufactured at Patheon will be used for the initial time point (T=0) for all conditions.
A stability protocol will be prepared prior to samples being placed on store and a final report will be prepared upon completion of the stability program. Data summaries will be provided upon completion of individual time points.

Testing Matrix:

The following storage conditions and test-points are suggested for testing (to be confirmed):

Storage Conditions

Time Point (Months)

0

1

2

3

6

9

12

18

24

36

60

25°C / 60% RH

R

X

X

X

XM

X

XM

XM

30°C / 65% RH

C

C

C

C

C

C

40°C / 75% RH

X

X

X

X

R: Release testing

X: Physical/Chemical testing (assuming Patheon standard testing regime) M: Microbiology testing

C: Contingency samples testing to be performed only if significant change is observed or at the request of Metuchen. Testing of these samples is not included in budget.

Actual testing requirements can be adapted at a later stage to meet the specific requirements

Stability Testing Requirements

Appearance

Dissolution (profile by HPLC, n=6)

Moisture (KF)

Potency and Related Substances

ID by IR

Uniformity

Patheon will store the stability samples. Should there be insufficient space at Patheon when the project initiates, then samples can be stored off site at a Patheon approved third party supplier. Storage of samples beyond the conclusion of the stability study will be charged back to Metuchen in accordance with the Legal Terms and Conditions/Master Agreement. In the unlikely event that Metuchen requests a stability program to be terminated early, any costs associated with the disposal of any remaining drug product or shipment of any remaining drug

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 19 of 31


product back to Metuchen will be charged back to Metuchen in accordance with the Legal Terms and Conditions/Master Agreement.

Metuchen may instruct Patheon to amend the stability schedule as required. For Minor Changes such as those that increase the number of pull points, but maintain the testing and number of batches as outlined above, an invoice will be issued for the new pull points without issuance of a formal Change of Scope Agreement. For Significant Changes that affect the type and number of tests (as mentioned above) to be performed at a given time point, the price per pull point may be re-evaluated. A formal Change of Scope Agreement will be issued to capture the Significant Changes.

Patheon will prepare a stability summary report following completion of the study. The summary report will consist of a high level evaluation of whether the data for each test indicates that a change has occurred on stability and compared to specification. The report will not include any statistical interpretations or shelf life evaluations (these would be agreed between the parties via a Change of Scope Agreement if required).

11. Regulatory Management

Regulatory support may be provided to Client throughout the project by the European Regulatory Affairs network, part of ThermoFisher Scientific Pharmaceutical Services Group.

The wide range of integrated services proposed is built upon successful regulatory support across a wide variety of program, and may typically cover (but is not limited to):

Regulatory guidance, ranging from general guidance to customized regulatory strategies;
Project regulatory liaison and phase-appropriate consultancy;
Common Technical Document (CTD) Quality/Module 3 (Drug Substance/Drug Product) authoring of clinical and commercial applications for major markets (EU/USA/Japan/CA);
Registration support for Rest-of-World (RoW)/International applications (including assistance within GMP compliance certifications);
Documentation review/gap analysis to the latest regulatory standards;
Responses support to authorities questions/deficiencies within registration procedures;
Variations/Post Approval Changes packages preparation;
Regulatory compliance preparedness activities in relation to Client product Pre/Post-Approval Inspections.

For further visibility on our holistic regulatory offerings, please explore our Regulatory Services Menu, which can be provided on a separate basis as required.

As the extent of any regulatory support required can be uncertain at the project conception stages, a combination of fixed prices and hourly rates may be applied depending upon the scope of support requested.

Any regulatory support services requested following contract execution and project initiation can be agreed and documented via the Change of Scope process.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 20 of 31


Part D: Key Technical Parameters

The following technical parameters apply to the production of Stendra Tablets and the materials used therein. Pricing may be adjusted to reflect any technical changes during this project to reflect any specification or process changes.

1.

Manufacturing Parameters

1.1

Batch Size/Yields The core tablet weight, theoretical manufacturing batch size and product yields considered by Patheon are summarized in the following table.

Product

Core Tablet Weight (mg)

Batch Size at Patheon before loss (Tablets)

Batch Size at Patheon (kg)

Manu- facturing Yield (%)

Packaging Yield (%)

Stendra 50mg

97.6

254,752

25

95%

100%

Stendra 100mg

195.2

1,313,037

256

95%

100%

Stendra 200mg

390.4

720,368

281

95%

100%

Product

Core Tablet Weight (mg)

Batch Size at Patheon before loss (Tablets)

Batch Size at Patheon (kg)

Manu- facturing Yield (%)

Packaging Yield (%)

Stendra 50mg

97.6

254,752

25

95%

99%

Stendra 100mg

195.2

1,313,037

256

95%

99%

Stendra 200mg

390.4

720,368

281

95%

99%

1.2

Manufacturing campaign PV batches will not be produced in campaign unless otherwise specified.

1.3

Hold times It is assumed that the process is carried out at room temperature and the holding times throughout the process are suitable for the batch size proposed. It is assumed that only standard light protection is employed and that no special precautions are required during formulation or packaging. Further details on the hold time and stability data for the drug product should be provided by Metuchen.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 21 of 31


1.4

Other Technical Parameters-

Other Technical Parameters

API Storage

Ambient Conditions

Bulk Density assumed

0.5g/mL

Number of Granulation sub-lots

1 per Mannitol Granules 1 per Fumaric Acid Granules

100% Visual Inspection

Included

Finished Product Storage

Room Temperature (15-30°C).

1.5

Manufacturing Equipment Train The following manufacturing equipment train is proposed.

Process Step

Equipment

Mannitol Granules

Fumaric Acid Granules

Final Blend

Compression / Inspection

Screening

Comil

Comil

-

-

Solution Prep

Aqueous Solution Tanks

Aqueous Solution Tanks

-

-

Fluid Bed Granulation

Glatt

Glatt

-

-

Blending

-

-

4 CF In-Bin/40 CF

In-Bin

-

Compression

-

-

-

Fette 2090

Inspection

-

-

-

Viswell

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 22 of 31


2.

Packaging Parameters

2.1

Packaging Components:

Bulk Tablets

30ct. Bottles

7.5-Gal Fibre Drum

60 Cc HDPE, Round, 38 Mm

4 Mil PE Liner

38 Mm CR, Induction Seal

Bubble Pack

Label, 3 Color

Wire Tie Bands

Topsert

Wire Seal

Shrink Wrap

Drum Label

Shipper, (24) 60 Cc Bottles

Pallet

Pallet

Slip Sheet

-

2.2

Secondary packaging Further assessment and discussion will follow once the secondary packaging requirements are fully defined. Patheon assumes that a whole bulk batch will be packed off into a single Stock Keeping Unit (SKU).

2.3

Secondary packaging campaign - It is assumed that PV batches will not be produced in campaign.

2.4

The packaging component specifications assumed in this project proposal have been estimated by Patheon. Changes to the specifications will result in review of the final pricing outlined within this Project Proposal.

3.

Testing Conditions

3.1

Testing for raw materials, packaging components and finished product are based on information provided by Metuchen and Patheons best estimates.

3.2

It is assumed that QC test methods are fully validated and robust at the time of manufacture.

3.3

The analytical tests included in the project proposal are listed below:

Testing Requirements

In-Process Controls

Finished Product Testing

·

Physical - Appearance

·

Physical - Hardness

·

Physical - Friability

·

Physical - Weight variation

·

Physical - Thickness

·

Physical - Appearance

·

Potency (Assay) / ID

·

Related Substances / Impurities

·

Uniformity of Dose

·

Dissolution HPLC (single point)

·

Physical - Karl Fischer/Water

3.4

Microbiological testing has been included.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 23 of 31


3.5

Testing labour may be subject to change after the final agreements on testing specifications and requirements.

4.

Supply Chain

4.1

Patheon will procure Exclusive Items and Common Materials and Supplies for the manufacture of Product from Patheon qualified suppliers. Should Metuchen require Patheon to source any Exclusive Items or Common Materials and Supplies from specified suppliers, then these suppliers will remain under the quality audit control of Metuchen unless an agreement is reached for Patheon to take on this responsibility.

4.2

Patheon recommends review of the Common Materials and Supplies source to reduce the risk of delays and ensure delivery continuity e.g. secondary source suppliers.

4.3

Exclusive Items and Common Materials and Supplies will be supplied by Patheon in accordance with the specifications agreed. Patheon will issue formal Patheon specifications for each material.

4.4

Each lot of incoming components and excipients will be sampled and tested according to the agreed specifications.

4.5

The DS will be provided free issue/released to Patheon by Metuchen or its qualified supplier.

4.6

The DS and all excipients used for the manufacture will be GMP grade and from TSE/BSE certified sources.

4.7

Finished product will be made available at Patheons proposed manufacturing site (supplied EXW according to Incoterms® 2010).

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 24 of 31


Part E: Legal Terms and Conditions

The parties are negotiating an Umbrella Development Services Agreement (the Master Agreement). The parties acknowledge and agree that upon its execution, the terms and conditions in the Master Agreement will govern this Project Proposal and will supersede Part E, Legal Terms & Conditions, of this Project Proposal. Each of the parties agrees to use reasonable, diligent efforts to negotiate and enter into the Master Agreement by January 31, 2021.

LEGAL TERMS AND CONDITIONS

FOR

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY TRANSFER SERVICES

(Certain capitalized terms used herein but not defined are defined elsewhere in this Project Proposal)

1.

Services:

(a)

Patheon agrees to perform the pharmaceutical development or technology transfer services described in this Project Proposal (Services). The term of this Project Proposal will be from the Effective Date until completion by Patheon of the Services.

(b)

Patheon will perform the Services in compliance with cGMP as and where specified and applicable under this Project Proposal. Client acknowledges that certain aspects of the Services may include non-cGMP activities as specified in further detail in this Project Proposal.

(c)

If Patheon manufactures validation batches under this Project Proposal, the validation batches will not be considered commercially saleable and will be subject the Legal Terms and Conditions in this Project Proposal. In order for the validation batches to be commercially saleable, (i) the validation batches must be manufactured and released for commercial sale (i.e. validation must be successfully completed) and (ii) a commercial manufacturing services agreement (with associated quality agreement) must have been entered into between Client and Patheon (the Commercial Agreement). After commercial release, the legal terms and conditions of the Commercial Agreement will apply to the validation batches and their use and will supersede the Legal Terms and Conditions in this Project Proposal.

(d)

The parties must agree on changes, deletions or additions to the Services (Changes) as follows: Minor Changes (i.e. changes that do not affect the timeline or cost of Services) will be confirmed by electronic mail or other written document. Unless otherwise agreed by the parties, the implementation of optional items set forth in this Project Proposal will be considered a Minor Change. Significant Changes (such as a request by Client to change the Project Activities and other changes that impact the timeline or cost of the Services) will be confirmed by a written change of scope agreement.

(e)

Client will have a right of access to the Patheon facility performing the Services (each a Facility) for auditing purposes, limited to one audit every two years after the initial audit unless for cause and as further set forth in the quality agreement between Patheon (including an applicable Affiliate) and Client. Audits performed at Patheon, outside the scope as agreed in the quality agreement, will be charged $2500 per day per auditor.

(f)

Each party will comply with applicable federal, state and local laws in connection with the performance of this Project Proposal.

2.

Advance Payment and Activity Payments:

(a)

Advance Payment. Client will pay Patheon a proportion of the agreed fees in advance as set forth in the Budget Summary of this Project Proposal (the Advance Payment) before the start of the project. Patheon will invoice Client for the Advance Payment immediately upon execution of this Project Proposal. There is no set term for Clients payment of the Advance Payment invoice, but Patheon will not start the Services until the Advance Payment is paid unless otherwise agreed by the parties. The Advance Payment will be automatically applied until exhausted to the first invoices for the project as activities are completed as described below in Section 2(b)(i).

(b)

Activity Payments.

(i)

Client will pay Patheon for the Services as outlined in this Project Proposal and for any Changes which will be invoiced separately for the fees agreed to by Patheon and Client. Patheon may issue an invoice upon completion of each activity set out in the Budget Summary of this Project Proposal and in accordance with the invoicing schedule (if included in this Project Proposal).

(ii)

Client agrees that the fees set out in the Budget Summary are based upon the assumptions contained in this Project Proposal and the fees may require adjustment if these assumptions are incorrect.

(iii)

Each Patheon invoice will be due and payable on or before 30 days of the date of the invoice. Patheon will email the invoice on the date issued to the email address provided by Client.

(iv)

If any portion of an invoice is disputed, Client will pay Patheon the undisputed amount and the parties will use good faith efforts to reconcile the disputed amount as soon as practicable. Interest on undisputed past due accounts will accrue at a rate of 1.5% per month.

(v)

Upon prior written notice to Client, Patheon may suspend all Services until all undisputed outstanding invoices have been paid in full and Patheon will have no liability to Client if this suspension results in delayed performance of any Services or cancellation or rescheduling of any manufacturing slots.

(c)

Currency. All monetary amounts will be invoiced and paid in Euros or US Dollars or such other currency as set forth in the Budget Summary of this Project Proposal, unless otherwise agreed. For amounts expressed in US Dollars herein, an equivalent amount may be charged in the currency as agreed in this Project Proposal.

3.

Supply of Materials:

(a)

Client will, at its expense, supply Patheon with sufficient quantities of any substances, raw materials, intermediates, or active pharmaceutical ingredient (Drug Substance) specified in this Project Proposal to be provided by Client (collectively, the Client- Supplied Materials) for Patheon to perform the Services. All shipments of Client-Supplied Materials from Client or Clients supplier to Patheon will be made DDP (Incoterms 2020) Patheons site unless otherwise agreed. All shipments of Client-Supplied Materials will be accompanied by certificate(s) of analysis from the manufacturer including confirmatory results demonstrating compliance with the manufacturers specifications. Client warrants that the Client-Supplied Materials will be suitable, safe and non-hazardous for use in the Services.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 25 of 31


(b)

Patheon will purchase common materials and supplies required to perform the Services (Common Materials and Supplies). The cost for the Common Materials and Supplies is included within each activity price in the Budget Summary.

(c)

Common Materials and Supplies do not include third party vendor costs and items for which the minimum order cost exceeds $1,500 (collectively Non-Included Items) such as excipients, pre-filled syringes and plungers, vials, packaging components, caps and stoppers (liquid and lyophilisate), compression tooling, blister tooling, specialty laboratory columns, project specific change parts, and reference standards including those under the applicable United States Pharmacopoeia, the National Formulary, the British Pharmacopoeia, the European Pharmacopoeia or the Japanese Pharmacopoeia. The cost of Non-Included Items necessary for Patheon to perform the Services will be billed separately and charged to Client at Patheons cost plus an additional 15% as a handling charge. Client will be invoiced on receipt of any Non-Included Items. For any Non-Included Items purchased by Patheon which have expired or which no longer have any forecasted requirements, Patheon will contact Client regarding instructions to either dispose of or ship these Non-Included Items to Client. If instructions are not received from Client within 30 days, Patheon reserves the right, at Clients cost, to dispose of the Non-Included Items.

(d)

Client is responsible for vendor qualification of Client-Supplied Materials to be used for cGMP purposes and for providing a certificate of compliance consistent with the requirements of cGMP, applicable laws and any applicable quality agreement between the parties. If Client wishes Patheon to use a specific vendor to purchase materials or supply testing or other services and this vendor is not an approved vendor currently used by Patheon, it will be Clients responsibility to audit and approve the vendor. At Clients request and for an additional fee, Patheon will audit the vendor on Clients behalf and provide an audit report to Client.

(e)

If Client-Supplied Materials or materials supplied by Client appointed vendors are not supplied timely or in accordance with the relevant specification, any cancellation, rescheduling or termination of scheduled Services will be subject to applicable batch rescheduling or cancellation fees as set out in Section 4(f) (Cancellation Fees). Client will pay the full fees and costs for any failed or non-conforming Services that are the result of defects or other non-conformities in Client-Supplied Materials that could not have been discovered by Patheon by reasonable inspection or by using the agreed-upon testing methods (if any).

(f)

Unless otherwise agreed in a separate capital equipment and expenditure agreement (Capital Agreement), if any capital equipment expenditures are required to perform the Services, Client hereby directs Patheon to incur, on its behalf, all expenses and costs for the Client capital requirements (the Client Capital Requirements). Patheon will invoice Client for the actual cost of Client Capital Requirements plus any applicable administrative fees as set forth in this Project Proposal. Client acknowledges that advance payments may be required for Client Capital Requirements. Client will pay Patheon for all amounts owing under these invoices. If the Client Capital Requirements will be owned by Client and Patheon purchases the Client Capital Requirements on behalf of Client, Client agrees that Patheon will be the buying agent for Client and Client hereby grants to Patheon a limited power of attorney for this purpose.

(g)

If Patheon is required to buy any marketed drug product to complete the Services, Client acknowledges that the purchases will be made by Patheon on behalf of Client and that Patheon will assume no responsibility or liability whatsoever for the marketed drug product. All marketed drug product purchases will be prepaid by Client and unless otherwise agreed to between the parties, Patheon will only place an order for the marketed drug product once an agreed upon prepayment has been received.

(h)

If applicable, Patheon and Client will reasonably cooperate to permit the import of the Client-Supplied Materials and other materials into the country where the Services will be performed. Client or Clients broker will be the Importer or Importer of Record (or equivalent, as understood under applicable law) for Client-Supplied Materials unless agreed otherwise and Client is responsible for compliance with applicable laws, and the cost of compliance, relating to that role. Clients obligation will include obtaining the proper release of Client- Supplied Materials from the applicable customs agency and regulatory authority.

(i)

To assist Patheon in performing the Services, Client will provide Patheon, in a timely fashion, with all relevant information as Patheon may reasonably request and any delayed or incomplete delivery of information, approvals or other documentation referred to in this Section that causes a cancellation, rescheduling or termination of Services will be subject to applicable Cancellation Fees. Documentation and data supplied to Patheon by or on behalf of Client (as may be set forth in this Project Proposal) will be suitable for use under this Project Proposal, comply with all applicable laws and regulations (including without limitation those relating to the import of these materials), and receive all required governmental and regulatory approvals, including without limitation customs, regulatory and FDA approvals.

(j)

Client will be responsible for disclosing to Patheon all information available to it regarding health risks which may be involved in performing the Services, utilizing specified Client-Supplied Materials, excipients, and other components, including without limitation, industrial hygiene data, industrial hygiene analytical methods, exposure limitations for workers involved in production, toxicology reports, and other health-related data. If reasonable industrial hygiene data is not available, Patheon may develop reasonable data at Clients expense.

4.

Termination:

(a)

Either party may terminate this Project Proposal on written notice if the other party is in material breach of any part of this Project Proposal and fails to remedy the breach on or before 30 days, or such other time period as may be reasonably necessary to remedy the breach, after receiving notice of the breach from the aggrieved party or if the other party is subject to any insolvency event.

(b)

Client may terminate this Project Proposal by giving 30 days notice for any business reason. A termination by Client for any reason other than under Section 4(a), will be subject to Cancellation Fees.

(c)

Patheon may terminate this Project Proposal on written notice to Client:

(i)

if Client requests to reschedule any part of the Services beyond 120 days (it being understood however that Patheon will be under no obligation to accept any rescheduling of Services);

(ii)

after 12 months of inactivity on the project at Clients request; or

(iii)

if Patheon determines that it is unable to perform the Services or manufacture Clients Product in a safe and effective way in accordance with applicable regulatory requirements (including OSHA and FDA regulations, and the equivalent regulations in the relevant territory) and applicable specifications, subject to Section 6(d)(iv).

(d)

If this Project Proposal is completed, expires, or is terminated by either party as provided for herein, Patheon will credit any outstanding balances owed to Client including any un-applied Advance Payment and Client will pay:

·

any fees and expenses due to Patheon for the Services rendered up to the date of completion, expiry or termination;

·

all actual costs and expenses, including any applicable administrative fee, incurred by Patheon to complete wind-down activities as agreed by the parties; and

·

any non-cancellable fees and expenses.

(e)

Client will arrange for the pickup from the Patheon site of all Client-Supplied Materials and any other Client property on or before 30 days after the earlier of the completion, termination or expiration of this Project Proposal. Patheon will charge a storage fee as described in Section 9 for Client property stored at the Patheon site after the 30th day following the completion, termination or expiration of this Project Proposal.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 26 of 31


(f)

The fees in the table below will apply if Client requests or causes the cancellation or rescheduling of the manufacturing of any batch on a cGMP line (the Manufacturing Services) in any project (whether in isolation or through termination of this Project Proposal or as a result of any delay in supplying any Client-Supplied Materials or other breach of this Project Proposal):

Number of days (inclusive) before the date that any Drug Substance is scheduled for introduction into the manufacturing process under this Project Proposal that the cancellation or rescheduling occurs

Percentage of fee quoted for the relevant Service that is payable by Client

31-90 (applies to sterile lyophilisate or sterile liquid projects only)

20%

16-30

40%

6-15

60%

1-5

90%

On or after the date of the start of manufacturing

100%

Client will also pay the fee for the analytical support that is associated with the cancelled or rescheduled Service.

5.

Intellectual Property:

(a)

The term Intellectual Property includes, without limitation, rights in patents, patent applications, formulae, trade-marks, trade-mark applications, trade-names, trade secrets, inventions, copyright, industrial designs, data and know-how.

(b)

For the term of this Project Proposal, Client hereby grants to Patheon, a non-exclusive, paid-up, royalty-free, non-transferable license of Clients Intellectual Property that is reasonably necessary for Patheon to perform the Services .

(c)

All Intellectual Property generated by Patheon as a consequence of performing the Services, to the extent it is specific to Clients Product that is the subject of the Services, will be the exclusive property of Client (Arising Client Intellectual Property). All Intellectual Property generated by Patheon as a consequence of performing the Services which is not Arising Client Intellectual Property will be the exclusive property of Patheon (Patheon Intellectual Property). Patheon hereby grants to Client, a non-exclusive, paid-up, royalty-free, transferable license of the Patheon Intellectual Property which Client may use for the manufacture of Clients Product.

(d)

If Client intends to file a patent application relating to any Arising Client Intellectual Property, Client will give Patheon reasonable time prior to the filing date to review the disclosure for adherence to this Section 5. Patheon will perform this review and make any comments concerning the filing as soon as reasonably practicable and Client will compensate Patheon for all reasonable time devoted and expenses incurred. In instances when Client requires a Patheon employee, who is an inventor on Arising Client Intellectual Property, to opine on the invention before an administrative agency, or participate in an adversarial proceeding in protecting Arising Client Intellectual Property, Client will reimburse Patheon for the time the Patheon employee devotes to this activity.

(e)

Client acknowledges that nothing in this Project Proposal will restrict Patheon from using any Intellectual Property owned or controlled by Patheon in the development or manufacture of products for other Patheon clients or for Patheons own behalf.

6.

Indemnity:

(a)

Indemnification by Client.

Subject to Sections 6(b) and 6(c)(iii), Client will defend and indemnify Patheon, its Affiliates and their respective directors, officers, employees and agents (collectively, the "Patheon Indemnitees") from all third-party (other than Affiliate) actions, causes of action, subpoenas, summonses, costs (including reasonable legal fees), claims, damages, liabilities and expenses (collectively, Losses) relating to or arising from:

(i)

the distribution of Clients Product or the use of Clients Product either as part of or outside of the scope of any clinical trials;

(ii)

personal injury to any employee of Patheon directly or indirectly caused by Clients Product;

(iii)

any misrepresentation, negligence or willful misconduct by Client or any of its Affiliates and their respective directors, officers, employees and agents (collectively, the "Client Indemnitees");

(iv)

any breach by Client of Clients obligations or warranties under this Project Proposal; or

(v)

any claim of infringement (i) of any third party's intellectual property rights in or by Clients Product or process; or (ii) that is related to Patheons use of Clients Intellectual Property (including any Arising Client Intellectual Property) to perform the Services.

This indemnity will not apply to the extent that these Losses are those for which Patheon is obligated to indemnify the Client Indemnitees under Section 6(b).

(b)

Indemnification by Patheon.

Subject to Sections 6(a) and 6(c)(iii), Patheon will defend and indemnify the Client Indemnitees from all Losses relating to or arising from:

(i)

any misrepresentation, negligence or willful misconduct by the Patheon Indemnitees;

(ii)

any failure to manufacture Clients Product in accordance with GMP, where applicable;

(iii)

the breach by Patheon of any of its obligations or warranties under this Project Proposal; or

(iv)

any claim of infringement of any third party's intellectual property rights in or by Patheons Intellectual Property that is used to perform the Services.

This indemnity will not apply to the extent that these Losses are those for which Client is obligated to indemnify the Patheon Indemnitees under Section 6(a).

If a claim occurs under Section 6(a) or 6(b), the indemnified party will: (i) promptly notify the indemnifying party of the claim; (ii) use commercially reasonable efforts to mitigate the effects of the claim; (iii) reasonably cooperate with the indemnifying party in the defense of the claim; and (iv) permit the indemnifying party to control the defense and settlement of the claim, all at the indemnifying party's cost and expense.

(c)

Limitation of Liability.

(i)

If Patheon fails to perform any part of the Services in accordance with this Project Proposal, then Client's sole remedy, whether in contract, tort, equity or otherwise, will be to request Patheon to:

(A)

repeat that part of the Service at Patheons cost except that Client will supply the Client-Supplied Materials; or

(B)

reimburse Client for the price for that part of the Service, excluding the cost of the Client-Supplied Materials.

(ii)

Due to the inherent risk of pharmaceutical development, Patheon accepts no liability for the cost of any lost or replacement Client- Supplied Materials, however that liability arises (including, without limitation, as a result of negligence).

(iii)

Under no circumstances will either party will be liable to the other in contract, tort, negligence, breach of statutory duty, by indemnity or otherwise for (a) any (direct or indirect) delay, penalty, loss of profits, of production, of anticipated savings, of business, of goodwill or of use of Clients Product, or costs of any substitute services or (b) any other liability, damage, cost or expense of any kind incurred by the other party of an indirect or consequential nature, regardless of any notice of the possibility of these damages.

(iv)

Nothing in this Project Proposal is intended to limit either party's liability for: (a) death or personal injury caused by its negligence; or (b) fraud or fraudulent misrepresentation.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 27 of 31


(v)

Notwithstanding any other term of this Project Proposal, if Patheon fails to perform any part of any Clinical Supply Optimization Services in accordance with this Project Proposal, Patheons liability for any and all obligations will not in the aggregate exceed 100% of the fees paid for the Clinical Supply Optimization Services. For the purpose of this Section, Clinical Supply Optimization Services means any project management for the strategic design and initiation phases for coordination of clinical supplies or other early demand planning services that are performed as part of the Services.

(d)

No Warranty.

(i)

The parties recognize that the Services are of a developmental, experimental or research nature and Clients Product is not intended for commercial use. Client acknowledges and agrees that all timelines are good faith estimates. Patheon hereby disclaims any warranties that the Services will be successfully completed, or successfully completed within the contemplated time period, despite Patheons commercially reasonable efforts to do so.

(ii)

PATHEON MAKES NO WARRANTY OR CONDITION OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS PROJECT PROPOSAL. PATHEON MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY FOR CLIENTS PRODUCT, OR FOR ANY PARTICULAR RESULTS FROM THE PERFORMANCE OF THIS PROJECT PROPOSAL.

(iii)

Unless specified in this Project Proposal, Patheon makes no representation or warranty that any product resulting from the performance of the Services will conform to certain specifications.

(iv)

Client acknowledges that due to the uncertain and unpredictable nature of certain aspects of the Services, Patheon may make recommendations before or after the start of the Services to ensure that Clients Product can be manufactured in a safe and effective way in accordance with applicable regulatory requirements (including OSHA and FDA regulations, and the equivalent regulations in the relevant territory) and applicable specifications. The parties will discuss in good faith any Changes required to implement these recommendations. If Client opts to proceed against Patheons recommendation (including by failing to agree a related Change proposed by Patheon), Section 4(c)(iii) will apply.

7.

Regulatory Filings:

If the Services relate to a clinical phase III project or if Patheon is selected to be the site for commercial manufacture of Clients Product, then prior to filing with the relevant regulatory authority any clinical trial application, including any US Investigational New Drug Application or EU Investigational Medicinal Product Dossier or any documentation that is equivalent to these applications, Client will give Patheon a copy of the Quality Module of the Common Technical Document (the CTD) that relates to the application as well as all supporting documents which have been relied upon to prepare the CTD. This disclosure will permit Patheon to verify that the CTD accurately describes the Services that Patheon has performed and the manufacturing and testing processes that Patheon will perform under this Project Proposal. Patheon will have a minimum of 21 days to perform this review or such other time as the parties may agree in writing.

If Client does not provide Patheon with the documentation requested above within the time stipulated and if Patheon reasonably believes that Patheons relationship with the regulatory authority may be jeopardized, Patheon may, in its sole discretion, delay or postpone the regulatory authority inspection which is or is equivalent to the FDAs pre-approval inspection until Patheon has reviewed the requested documentation and is satisfied with its contents.

If Patheon determines that any of the information provided by Client is inaccurate or deficient in any manner whatsoever (the Deficiencies), Patheon will notify Client in writing of the Deficiencies. Until the Deficiencies have been resolved or agreement has been reached with Client for resolution, Patheon reserves the right, in its sole discretion, to not participate in the regulatory authority inspection. If this occurs, Patheons non-participation in the inspection will not be construed as a breach of any of its obligations under this Project Proposal.

8.

Delivery and Shipping:

(a)

Delivery/Shipment. Any delivery by or on behalf of Patheon for Client will be made EXW (Incoterms 2020) the Facility unless otherwise agreed. Risk of loss or damage to shipments will transfer to Client when loaded onto the carriers vehicle by Patheon. Each shipment will be packaged for transport in accordance with Clients instructions and this Project Proposal. Client will be responsible for obtaining insurance covering the shipment after Patheon delivers the shipment to the carrier. Client will obtain any required licenses and authorizations necessary for export, and will otherwise comply with all applicable laws and pay any applicable export or import fees, duties and taxes.

(b)

Carrier Management.

(i)

Carrier Management through TTM. If it is agreed that Patheon will coordinate collection of Clients Product or material using Patheons carriers, as set out in this Project Proposal, then coordination will be provided through Patheons Total Transportation Management Services (TTM), and the following terms will apply:

Client agrees that Patheon is to coordinate the transport of Clients Product or materials, and Patheon will do so as an agent of Client and at Clients sole risk and expense. In addition to the terms and conditions outlined in this Project Proposal, Client agrees to the following: (a) Client will pay, to Patheon, all freight charges as referenced in this Project Proposal and Client will be responsible for all final freight charges based on actual shipping characteristics and all charges with respect to services that were not contemplated in this Project Proposal including but not limited to charges for accessorial services such as detention and demurrage, (b) Client approves and accepts Patheons selection of transportation mode and carrier, (c) Client agrees to grant Patheon the ability to coordinate customs clearance up to, and including, paying duties and taxes on Clients behalf, and (d) Client agrees that shipment will be subject to the terms and conditions of the selected carriers waybill and that Clients sole recovery for loss, damage, destruction or delay will be directly against the underlying carrier, which carrier may limit its liability. In no event will Patheon be considered a freight forwarder or carrier in the provision of TTM.

(ii)

Client Managed Shipping (Client Carrier). If Client expressly elects to provide its own transportation, Client will coordinate collection of Clients Product or material using its own carrier, and (i) Patheon will tender the shipment to Clients carrier as instructed from Patheons location at Clients sole risk and expense, and (ii) Client will ensure that all costs of shipment are billed directly to Client by Clients carrier.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 28 of 31


9.

Storage after Release or Project Completion:

(a)

Unless otherwise agreed between the parties, Client will pay Patheon the following storage fees if manufactured Clients Product, retained samples, stability samples, clinical trial materials, placebo, development, feasibility, scale-up, registration, validation or any other batches, Client-Supplied Materials, Non-Included Items or any other Client property (collectively Materials) are stored at Patheon for more than 30 days after (i) their release for shipment or request for removal by Patheon; or (ii) the issuance of a report by Patheon for the final time point for that given storage condition (according to the agreed stability protocol) or after cancellation of a given program in the case of retained samples or stability samples (Sample Release):

(i)

Non-controlled substances:

(A)

$500 per month, per pallet (one month, one pallet minimum) for storage under room temperature;

(B)

$100 per cubic foot, per month (one cubic foot, one month minimum) for storage under conditions of 2°C 8°C; and

(C)

$200 per cubic foot, per month (one cubic foot, one month minimum) for storage under frozen conditions.

For Materials in subsection (i) stored more than 90 days after their release for shipment or request for removal by Patheon, the stated fees above will double.

(ii)

Controlled-substances: $1,000 per month, per pallet (one month, one pallet minimum).

(iii)

Retained samples or stability samples:

(A)

$500 per 50 liters of walk-in storage volume per month (one month, 50 liter minimum); and

(B)

$100 per liter of reach-in storage volume per month (one month, one liter minimum).

For retained samples or stability samples in subsection (iii) stored more than 90 days after Sample Release, the stated fees above will double.

(iv)

If Client requests storage at conditions different than those stated in Section 9(a), then this will be discussed and agreed between the parties on a separate basis.

(b)

Patheon reserves the right to refuse to store any Materials, at its sole discretion at any time following completion of the Services. Client will assume all risk of loss or damage to the Materials stored for more than 30 days after their release for shipment by Patheon, or in the case of retained samples and stability samples, after Sample Release unless Patheon agrees to the additional storage time, and it will be Clients responsibility to have appropriate insurance coverage in place for this risk. If Client asks Patheon to destroy any Materials, Client will be responsible for the cost of destruction. Patheon will, at Clients cost, destroy all stability samples and retained samples that remain in storage for more than 30 days after Sample Release unless Patheon agrees to the additional storage time.

10.

Miscellaneous:

(a)

Assignment and Subcontracting.

(i)

Neither this Project Proposal, nor any of either partys rights or obligations hereunder, may be assigned, novated or otherwise transferred by either party without the prior written consent of the other party, this consent not to be unreasonably withheld or delayed. But either party may, upon written notification to the other party, assign, in whole or part, its rights and obligations under this Project Proposal to an Affiliate or, in connection with a merger, consolidation or sale of substantially all of the business to which this Project Proposal relates, to an unrelated third party. For purposes of this Project Proposal, Affiliate means an entity controlling, controlled by or under common control with Patheon or Client, where control is defined as ownership, directly or indirectly, of more than 50% of the voting rights in the entity.

(ii)

Patheon may subcontract the Services hereunder to an Affiliate as specified in this Project Proposal or arrange for any of its Affiliates to perform specific Services under this Project Proposal. Client agrees that Patheon will remain exclusively liable to Client for any breach of this Project Proposal or negligence by its Affiliates in the course of performing: (a) subcontracted Services; or (b) obligations under the applicable Quality Agreement (if any).

(iii)

Patheon may also arrange for non-Affiliate third party subcontractors (Third Party Subcontractors) to perform specific Services (such as testing or analysis) under this Project Proposal with Clients consent or at Clients request. Patheons liability for Third Party Subcontractors will remain subject to all limitations on Patheons liability as set out in this Project Proposal.

(iv)

Patheon will have no liability arising from the performance of Services by Third Party Subcontractors: (a) that are chosen or requested by Client; (b) that is a service provider not validated or utilized by Patheon prior to the date of this Project Proposal; or (c) to the extent that the Third Party Subcontractor is following the direct instructions of Client.

(b)

Force Majeure.

Except for payment obligations, neither party will be responsible for delay or failure in performance resulting from acts beyond the reasonable control and without the fault or negligence of the party, including, but not limited to, strikes or other labor disturbances, lockouts, quarantines, communicable disease outbreaks, riots, wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components, or compliance with any order or regulation of any government entity.

(c)

Survival.

Any termination or expiration of this Project Proposal will not affect any outstanding obligations or payments due hereunder prior to the termination or expiration, nor will it prejudice any other remedies that the parties may have under this Project Proposal. The following will survive the expiration or termination of this Project Proposal: the Confidentiality Agreement and Sections 4, 5, 6, 7, 9 and 10 (as applicable) of this Project Proposal.

(d)

Independent Contractors.

The parties are independent contractors and this Project Proposal will not be construed to create between Patheon and Client any other relationship such as, by way of example only, that of employer-employee, principal, agent, joint-venturer, co-partners or any similar relationship.

(e)

Confidentiality.

The Confidentiality Agreement entered into between the parties will apply to all confidential information about the parties and the Services to be conducted under this Project Proposal and the Confidentiality Agreement is incorporated herein by reference. If the Confidentiality Agreement expires or terminates before the expiration or termination of this Project Proposal, then the terms of the Confidentiality Agreement will nonetheless continue to govern the parties obligations of confidentiality for the term of this Project Proposal and for five years thereafter.

(f)

Other Terms.

No terms, provisions or conditions of any purchase order or other business form or written authorization used by Client or Patheon will have any effect on the rights, duties or obligations of the parties, or otherwise modify, this Project Proposal, regardless of any failure of Client or Patheon to object to the terms, provisions, or conditions.

(g)

Insurance.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 29 of 31


Each party will maintain during the term of this Project Proposal commercial general liability and product liability insurance which is sufficient to cover their respective liability under this Project Proposal. Either party will provide evidence of this insurance upon the request of the other party.

(h)

Entire Agreement.

This Project Proposal, together with any quality agreements entered into thereunder, and any other agreements (e.g., a Capital Agreement) that are expressly entered into hereunder, are the complete agreement between the parties with respect to this subject matter and supersedes all other prior agreements, representations and understandings, whether written or oral. Except as otherwise provided in this Project Proposal, any modifications, amendment or supplement to this Project Proposal must be in writing and signed by authorized representatives of both parties.

(i)

Severability.

If any provision of this Project Proposal is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability of the remaining provisions, because each provision is separate, severable, and distinct.

(j)

Execution in Counterparts.

This Project Proposal may be executed in two or more counterparts, by original or electronic (including PDF) signature, each of which will be considered an original, but all of which together will constitute one and the same instrument.

(k)

No Third Party Benefit or Right.

Nothing in this Project Proposal will confer on any third party (except that Patheon Affiliates acting as subcontractors under this Project Proposal may enforce Sections 6(c) and 6(d)) any benefit or the right to enforce any express or implied term of this Project Proposal. The rights of the parties to terminate, rescind or agree on any variation, waiver or settlement under this Project Proposal are not subject to the consent of any other person.

(l)

Choice of Law.

This Project Proposal and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation is governed by the laws of (i) the State of Delaware if it is with a Patheon entity registered in the United States or Canada, or (ii) England if it is with a Patheon entity registered outside the United States or Canada, in each case without regard to any conflicts-of-law principle that directs the application to another jurisdictions law. Both parties hereby submit to the exclusive jurisdiction of the courts in the applicable location. The parties further expressly agree that the UN Convention on Contracts for the International Sale of Goods will not apply to this Project Proposal.

(m)

Patheon Staff.

During the term of this Project Proposal, and for one year after its termination, Client and its Affiliates will not, directly or indirectly, solicit, induce, recruit, encourage or otherwise endeavor to cause or attempt to cause any officer, employee, director or consultant of Patheon or any of its Affiliates who became known to Client or its Affiliates in connection with the Services or who has performed work in connection with the Services, to terminate or discontinue their employment, contract or other relationship with Patheon or any Patheon Affiliate.

(n)

Anti-Bribery.

The parties agree:

(i)

to comply with all applicable laws, statutes and regulations relating to anti-bribery and anti-corruption including but not limited to the

U.S. Foreign Corrupt Practices Act and the UK Bribery Act (collectively, the Relevant Laws);

(ii)

to have and maintain in place throughout the term of this Project Proposal their own policies and procedures to ensure compliance with the Relevant Laws (and to provide a copy to the other party on request) and will appropriately enforce those policies and procedures including providing training; and

(iii)

that no employee, contractor, supplier, agent, broker, or entity will offer or pay anything of value to a public or private official intending to influence or induce an official act or decision or to obtain an improper advantage.

A material breach of this Section 10(n) will be considered a material breach of this Project Proposal. If there is a material breach of this Section 10(n), the aggrieved party will have the right to immediately terminate this Project Proposal, without any liability to the other party.

(o)

Taxes.

(i)

VAT.

(A)

Fees for Services and any other payment due to Patheon under this Project Proposal in consideration for the provision of Services to Client by Patheon is exclusive of value added taxes (VAT), turnover taxes, sales taxes or similar taxes, including any related interest and penalties (together referred to as Transaction Tax) which will be added to the invoice amount and will be reimbursable to Patheon by Client.

(B)

Patheon will use its reasonable commercial efforts to ensure that its invoices to Client are issued in a way to meet the requirements for deduction of input VAT by Client, if Client is permitted by law to do so.

(C)

If Patheon is acting as Clients buying agent, Patheon will always charge to Client Transaction Tax in the relevant territory in addition to the amount paid by Patheon to supplier.

(D)

Reference to the Services in this Section also includes any element (or the entirety) of the Services characterized as a supply of goods by Patheon, its subcontractor or any tax authority for Transaction Tax purposes.

(ii)

Duties. Client will bear the cost of all duties, levies, tariffs and similar charges (and any related interest and penalties) (together Duties) however designated, arising from the performance of the Services by Patheon, including (without limitation) those imposed as a result of the shipping of materials (including Drug Substance, materials, components and finished Clients Product) to, from or between Patheon facilities. If these Duties are incurred by Patheon, then Patheon will be entitled to invoice Client for these Duties at the time that they are incurred.

(iii)

Withholding Tax.

(A)

Where any sum due to be paid to Patheon hereunder is subject to any withholding or similar tax, Client will pay the withholding or similar tax to the appropriate government authority and deduct the amount then due to Patheon, in a timely manner and promptly transmit to Patheon an official certificate or other evidence of the withholding sufficient to enable Patheon to claim payment of these taxes. The parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate or enable the recovery of any tax withholding or similar obligations for royalties, milestone payments, and other payments made by Client to Patheon under a Project Proposal.

(B)

Patheon will provide Client any tax forms that may be reasonably necessary in order for Client not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.

(C)

Each party will provide the other with reasonable assistance to enable the recovery, as permitted by applicable laws, of withholding taxes, or similar obligations resulting from payments made under a Project Proposal, any recovery to be for the benefit of the party bearing the withholding tax.

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 30 of 31


Patheon Pharmaceuticals Inc. (Patheon)

Metuchen Pharmaceuticals LLC (Client)

2110 East Galbraith Road

200 Route 9 North, Ste 500

Cincinnati, OH 45237

Manalapan, NJ 07726

Registered in Delaware

United States

By:

Graphic

By:

Graphic

Name:

Peter Ercoli

Name:

Fady Boctor

Title:

Vice President / General Manager

Title:

President, Chief Commercial Officer

Date:

14 January 2022 | 16:17 PST

Date:

1/13/2022

Proposal # C-CRC-286511-R3

Metuchen Pharmaceutical LLC

January 13, 2022

Stendra Tablets

Confidential

Page 31 of 31


EX-31.1 6 tmb-20220331xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SARBANES–OXLEY ACT OF 2002

I, Fady Boctor, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Petros Pharmaceuticals, Inc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 2022

By:

/s/ Fady Boctor

Fady Boctor

Chief Commercial Officer and Principal Executive Officer


EX-31.2 7 tmb-20220331xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SARBANES–OXLEY ACT OF 2002

I, Mitchell Arnold, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Petros Pharmaceuticals, Inc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 2022

By:

/s/ Mitchell Arnold

Mitchell Arnold

Vice President of Finance and Principal Financial Officer


EX-32 8 tmb-20220331xex32.htm EX-32

Exhibit 32

CERTIFICATION PURSUANT TO SECTION 906

OF THE SARBANES–OXLEY ACT OF 2002

In connection with the Annual Report of Petros Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Petros Pharmaceuticals, Inc.

Date: May 16, 2022

By:

/s/ Fady Boctor

Fady Boctor

Chief Commercial Officer and Principal Executive Officer

Date: May 16, 2022

By:

/s/ Mitchell Arnold

Mitchell Arnold

Vice President of Finance and Principal Financial Officer


GRAPHIC 9 tmb-20220331xex10d5006.jpg GRAPHIC begin 644 tmb-20220331xex10d5006.jpg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tmb-20220331xex10d5005.jpg GRAPHIC begin 644 tmb-20220331xex10d5005.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" ! -$# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*IZQJ] MGX?TF]U/4+A+2PLX7N+B>0X6.-5+,Q]@ :\8T76/BK\:+5=;T34['X:^$[@; M].%UIOV_4[R(_=ED5G5(588(7#-C&2*WITG-.3:275_TV8SJJ#44KM]%_5CW M.D9@JDL0 .I->/?\*P^*_P#T6@_^$O:__%US_P 4?A;\2;SX-_$33;KQI+XZ MNM1T&ZM++2HM(@LG:=E^4AU?D]1@X'/6G.E",6U43_\ O\ (4:DI-)P:^[_ M #/H!'61=R,&7U!R*=7QA9^"?B+X:O=;U'P-X6\1>!O ^H7E@D^A:0+*/4\Q MVLXGN+>*1WAC5YC:JW(9A$QQSDZJ1?M$SP:K%J)UE/$3^&PNGR:6]@NDI=?V M8-QEW R?:/MV_&WY-NW^'-<[T-UJ?7#.J#+,%'3).*4,"2 02.#CM7PS\5?! M/Q2^+^A3WFM>%?$O^CZO.^DZ?+%"VG6R 3VIG0,K3B?$B3+)$22,9XP MOC#XU^+'P:TG6K[4;B]\)#48)7LUT.2TDEFU"/1+-84WW&6FA%RMPIY:5BJX MR*'H'8_02D9@@)8@ =S7QYJ=I^T>G]LZCHM_JD]S=+J4%I97:VGV>&,6=LUK M+&"H82-,;@#>Q&//"_Q\\5?#RQT?4/\ A*=7M[JUF"1006%M.9A? MQ,BW_P"\;*"W5]K1$,3]X XH\A=+GW-N&[&1GKBEKY?^,?AGXF1_M!0:WX+M M];BM;C2M(LOMEF]K]@)34)GNENQ*?,VBWD<@QC.XK[5-^SOXG\=>-EN]3\0: MQJ^JZ5INNCP_87&D_9S!J$=M]H\S4)RP&8I?,B1A'R'@7 P6R+49]-4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[6K-_PH+Q%""0ES/I]I*! M_%'+?6\*_%?C'PKXZ.E2ZUHUKIFI.VDPM&EI] MMCE?[%)N8[I(O*'SC&X2*<"N4Z3W.BO(_P!K7QIJ?P__ &ZXKU#1TNHM)LDOG$EZL""=QT:3:-Q_/- %RFLBOC< MH;!R,C.#2":-F=1(I:/[X!Y7C//I3^M !17GOQV^-OAWX _#C5_%GB"ZA46L M#M9V#3*DVH7 4[+>$'EG=L#@'&<]!6-X5^*?CWQI#IVJVOPU?0O#TLD/G2>( MM42UOC"Q&^6.V5'P$!+;97C<@'Y0<"@#UND50B@* H'8"D61'"E6#!AE2#U' MJ*-Z[2VX;1G)SP* '45XKJ?C#4M5_:]\/^%;+4)X](TKP?=ZQJ%I$Y\J>2XN MHH;<*, M $#)P20#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH \?_:T_Y(3K'_80 MTK_TY6M>P5\W?M=^.M:A^'&O:./AYXDETV.]TQAXB2XTS["^V^MG "F\%QRP M\L9A W$$X3+CO/\ A!/AUHVDZ./$%UJGCO2H?[,>X6!+D1^;<^6SL"%4F 9.#@ \&O._V MF?ASXP^%W[,NI6?A_5G;XE_$/Q=IZZUKEE(T'^D7$R($C?JD,:QQ1+D_=![L M17H'Q9UOXB^/?%OPOU'3_@MXSM;'POXB.LW\=S?Z!OFC^QW,"K$!J9!;=.#\ MQ4 9.<@ ]-\0O$>H_%+PAJ'AGQ'^S[\0+W2;U5$D:ZEH$;JRL&1T==6#(ZL MP92"" :Y3H.>_; \.6?BS0?A=X,U/Q??Z9=ZKXHTVUDM=.O(X);]%<.\A4J6 M.PQ!AC@$@D'BL'X!:-XQM/VTOB[:WGB;6=6\%^%]%TO1[2/6;TSR332PI<^: M> "PW2@OCGK@2*"6QT."1G!Q0!Q":W'\;_VO?B;\-]"OENO"UTVFWWBF_L)^:^OOAYX+@^'?@O2O#=K>W6H6NFQ>1#/>OOE\L, M2BENX52%&><*,YKQ?P2S_#OQ/X@UWP_^SKX[TV[UN*T@N(X+WPXD*16T7E0I M&@U4!%"D\#O7:_\ "Y/%W_1"?B!_X'>'O_EK0!\L_M>?#37;+XX> XM.G/CG MQ+XS\3175I;:UI[-:Z386.+@P"2,,5B\T0.P55+A&WL0^+M9L=(NYX%FE-AI-I-Y+;!!9HX4G<0%,K2.21\U5/BYJ/C[QQJG MA/Q'X=^$'CC0_%OA:[FN=.N;V7P_-_&@N[GXH_#+XD^-+NXMI+>+3[6Y\/6.E6 D1D9X+<:NQ:3#'$LS2,O\.V M@#S;PO\ VIXD_9:C^/%Y=:AIVH^&=(MXO!-K#*42WM[>$6YDD3HPN9BS/D'] MVD8!&,UTGQ;\ :_\*_V>_ /[/'@?7)[SQU\0+R2WU/7KB4F98&S/J=Z%SI(T98H]1\/"1(%C"*0W]J_> .?49K MSBX^$&H:[)9:IXD^&WQIUOQA;.R?\)1'KOARRO&M60QFT @U-42$J3D(JDL2 MV=QS0 []B36I]1^(OBV\UTVZ7>D>%--T2"_5!%'>65EJ.K6R70!Z!Q K'MP. MV*]E_8W\5ZEXX^ >F:YJVJR:W>7FJZPWVV27S=\8U.Z6,*W]U4"JH' 4 #BO M//&/@.R\9SZ&TO[/WQ,TJVTJP&D?8M(UK0;6"\L RN+2X5-6_>0AE!V\=6&< M,P/8_#[6;WX6Z9?Z;X9_9\^(6G:?>ZA<:F]H-4T%XHYIGWR^6K:N1&I8EMBX M4%C@#- 'OU%>5?\ "Y/%W_1"?B!_X'>'O_EK1_PN3Q=_T0GX@?\ @=X>_P#E MK0!ZK17E7_"Y/%W_ $0GX@?^!WA[_P"6M'_"Y/%W_1"?B!_X'>'O_EK0!ZK1 M7E7_ N3Q=_T0GX@?^!WA[_Y:T?\+D\7?]$)^('_ ('>'O\ Y:T >JT5Y5_P MN3Q=_P!$)^('_@=X>_\ EK1_PN3Q=_T0GX@?^!WA[_Y:T >JT5Y5_P +D\7? M]$)^('_@=X>_^6M'_"Y/%W_1"?B!_P"!WA[_ .6M 'JM%>5?\+D\7?\ 1"?B M!_X'>'O_ ):UT/@KQ[KGBK4);?4_AQXG\'0I'O6[UJYTN2*0Y^Z!:7L[Y[\J M![TTK@=I1112 YCXF>!K7XE^ ==\,7$?$ED@A?4);:1].U(*,>?!.BE!N !*,592<8XKW2F2PQS M+MD19%]&&171"K%1]G45UOV:?X_/0PG3DY<\'9_>G^1Y1_PUE\(?^A]TK_OI MO_B:T]&^/'A/QY;ZG;>!=(_!VD>*_#^HZ)J%INT_4(&MKE+=V@9XV^\N]"&&?8BB3HM M/EB[^J_R"*K77-)6]'_F>2:3\;?&/B-_*TK1-"G>"RO+YKB2]F6WOHX)Q$K6 M[^7G:_.&88XR-RD,:$_[45[+I#:]8^'H)M!O$DCTYYKETF$J10R.]PH0A(@) M7)9=Q"Q$X.[ ]!N/@-X1NX+6&>/5I8[>W>S4-K=[E[=B"T+GSP&"18KF:.- 51"T:*X6)RL48+H%;Y%YXKG-SS_1 M?VHK/5[[PKI<%O8WNIZEK$VF7LEG=[K:")))8DN(V8 R+*T8V#'(WG)"Y.?> M?M(>)=#\&:#KFJ:%I0'B+3HK_31:7$\OE%I[:-DF01[CA;H,"F22A7&2*]2@ M^"_@F!-)_P"*=LYI]+N1>6MW<*9;A9M[/O:9R78EW=CN)R6)ZUG6O[/?@BTT MQK!+"^> 01VT)FU6ZD>UB21)42!FD)A >*-OW97E%]!0!R5K\DZ)=[-1MM(LKM;F9(S=RHTS)+E"<1P*K$KU:15'Z?<63B"\O?[ M2E>"XDBE%SD'S4D1@Z,-HP5(P..G% 'E_@O]H35?&_BNWTV'3;.P@V6IF62& M[N'+R*3(%ECB,2A2" 79<\$XS4NB_M#7VG:/H>K>+].T^RT[7='DU73VTVX> M23>C0*+=U=1EW-S&%*G!.0<<$]SIWP8\+Z-J4%[IL6HZ8\,<$0AL=5NH8'6% M=L8>)9 CX P=P.>^:9H/P-\%>'XUCBTI^!_Q;N?BQI5Y=7FGQZ7-&MO<16ZK.K^1/$)(V831(3_$- MRY5MIP000+UG\"/ VGMI0M="2VATQ$CM[6&>5+ GRAPHIC 11 tmb-20220331xex10d5004.jpg GRAPHIC begin 644 tmb-20220331xex10d5004.jpg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end GRAPHIC 12 tmb-20220331xex10d5003.jpg GRAPHIC begin 644 tmb-20220331xex10d5003.jpg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end GRAPHIC 13 tmb-20220331xex10d5002.jpg GRAPHIC begin 644 tmb-20220331xex10d5002.jpg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Ẹ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� E%%% !4D*;FSV%(D9DZ' MCUJR@ '3% "@8I:** "FN^.G)H8X&.]1@%2<\YH ,9Y/6BBB@ HHHH **** M"BBB@ HHHH **** $*@U'4M,9<"@!M%%% !1110 4444 %%%% !1110 4444 M & >M-(YXZ4Z@GB@!E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M,91@FG4$9&* M (J*5EVTE !1110 4444 %%%% !1110 4A!)I:,T ,HIQ7%-H **** "BBB@ M HHHH **** "BBB@!0Q7D'!%:%O,)4ST/I6?2HY1@<__ %Z -2BHH)A*O!Y[ MCTJ6@ HHHH *1NE+2'I0!7FZFJ4_2KLO)JE,,B@"A*,BJ-P,UI.N.*HRKC)H M ;H]P+744!/RR?)C^M==C/&:X.=BKAAP5.179Z;>"^LXYAU(^8>] %RBF;P> M].4Y'K0 CHJJZ-AGNO<&K5>?VEW+ M87'FQ'![CL:[+2]6BU. ,I"R#AD[T 7J0]*6B@!E%.(S3: "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** &N,"F5*1FHV�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�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�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end EX-101.SCH 14 tmb-20220331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Accounts Receivable, net (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Intangible Assets - Future annual amortization (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41404 - Disclosure - Commitments and Contingencies - Supplemental balance sheet (Details) link:presentationLink link:calculationLink link:definitionLink 41406 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 41407 - Disclosure - Commitments and Contingencies - Future Minimum Sublease Income (Details) link:presentationLink link:calculationLink link:definitionLink 41506 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Accounts Receivable, net - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Debt - Promissory Note (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Debt - Senior debt (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Debt - Financial covenant (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Debt - Third Amendment (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Debt - Interest Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stockholders' Equity - Consummation of the Mergers (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stockholders' Equity - Number of shares held (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Stockholders' Equity - Marketing and Consulting Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Stockholders' Equity - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 40905 - Disclosure - Stockholders' Equity - Milestone Earnout Payments (Details) link:presentationLink link:calculationLink link:definitionLink 40906 - Disclosure - Stockholders' Equity - Market Capitalization (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") - Summary of stock options (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Common Stock Warrants - Company's warrants by expiration date (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Marketing, Licensing and Distribution Agreements - Vivus (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Marketing, Licensing and Distribution Agreements - Hybrid (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Commitments and Contingencies - Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Segment Information - Net Sales by Geographic region (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Segment Information - Segment assets (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Accounts Receivable, net link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Basic and Diluted Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Marketing, Licensing and Distribution Agreements link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Accounts Receivable, net (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Inventories - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Common Stock Warrants - Summary of warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Commitments and Contingencies - Lease expense (Details) link:presentationLink link:calculationLink link:definitionLink 41405 - Disclosure - Commitments and Contingencies - Lease term and discount (Details) link:presentationLink link:calculationLink link:definitionLink 41408 - Disclosure - Commitments and Contingencies - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 tmb-20220331_cal.xml EX-101.CAL EX-101.DEF 16 tmb-20220331_def.xml EX-101.DEF EX-101.LAB 17 tmb-20220331_lab.xml EX-101.LAB EX-101.PRE 18 tmb-20220331_pre.xml EX-101.PRE XML 19 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 13, 2022
Document and Entity Information [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Entity File Number 001-39752  
Entity Registrant Name Petros Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1410058  
Entity Address State Or Province NY  
Entity Address, Address Line One 1185 Avenue of the Americas  
Entity Address, Adress Line Two 3rd Floor  
Entity Address, City or Town New York  
Entity Address, Postal Zip Code 10036  
City Area Code 973  
Local Phone Number 242-0005  
Title of 12(b) Security Common stock  
Trading Symbol PTPI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   20,684,723
Entity Central Index Key 0001815903  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash $ 17,671,871 $ 23,847,572
Accounts receivable, net 3,740,775 2,455,386
Inventories 1,942,873 519,649
Prepaid expenses and other current assets 3,482,586 3,720,088
Total current assets 26,838,105 30,542,695
Fixed assets, net 46,842 49,397
Intangible assets, net 23,734,834 25,293,149
API purchase commitment 4,796,771 11,029,260
Other assets 447,595 475,557
Total assets 55,864,147 67,390,058
Current liabilities:    
Accounts payable 3,700,326 4,557,969
Accrued expenses 5,512,006 11,957,384
Accrued inventory purchases   14,203,905
Other current liabilities 352,436 260,818
Current portion of promissory note 723,982  
Total current liabilities 10,288,750 30,980,076
Promissory note 9,477,776  
Derivative liability   460,000
Other long-term liabilities 371,053 405,018
Total liabilities 20,137,579 31,845,094
Stockholders' Equity:    
Preferred stock (par value of $0.0001 per share, 50,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively)
Common stock (par value of $0.0001 per share, 150,000,000 shares authorized, 20,684,723 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively) 2,068 2,068
Additional paid-in capital 106,587,544 106,231,716
Accumulated deficit (70,863,044) (70,688,820)
Total Stockholders' Equity 35,726,568 35,544,964
Total Liabilities and Stockholders' Equity $ 55,864,147 $ 67,390,058
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000,000 50,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 20,684,723 20,684,723
Common stock, shares outstanding 20,684,723 20,684,723
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS    
Net sales $ 2,465,169 $ 4,075,606
Cost of goods sold 472,340 643,386
Gross profit 1,992,829 3,432,220
Operating expenses:    
Selling, general and administrative 3,897,738 3,881,717
Gain on settlement with Vivus (3,389,941)  
Research and development expense 405,360 19,181
Depreciation and amortization expense 1,560,870 1,728,829
Total operating expenses 2,474,027 5,629,727
Loss from operations (481,198) (2,197,507)
Change in fair value of derivative liability 460,000 5,380,000
Interest expense, senior debt   (173,412)
Interest expense, promissory note (153,026)  
Net income (loss) $ (174,224) $ 3,009,081
Net income (loss) per common share    
Basic (in dollars per share) $ (0.01) $ 0.31
Diluted (in dollars per share) $ (0.01) $ 0.31
Weighted average common shares outstanding    
Basic 20,684,723 9,753,086
Effects of common share equivalents   1,600
Diluted 20,684,723 9,754,686
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2020   $ 971 $ 79,170,225 $ (61,702,144) $ 17,469,052
Balance (in shares) at Dec. 31, 2020 500 9,707,655      
Conversion of Preferred Stock to Common Stock   $ 6 (6)    
Conversion of Preferred Stock to Common Stock (in shares) (500) 60,606      
Non-employee stock-based compensation   $ 3 97,797   97,800
Non-employee stock-based compensation (in shares)   30,000      
Stock-based Compensation Expense     347,207   347,207
Net (loss) income       3,009,081 3,009,081
Balance at Mar. 31, 2021   $ 980 79,615,223 (58,693,063) 20,923,140
Balance (in shares) at Mar. 31, 2021   9,798,261      
Balance at Dec. 31, 2021   $ 2,068 106,231,716 (70,688,820) 35,544,964
Balance (in shares) at Dec. 31, 2021   20,684,723      
Stock-based Compensation Expense     355,828   355,828
Net (loss) income       (174,224) (174,224)
Balance at Mar. 31, 2022   $ 2,068 $ 106,587,544 $ (70,863,044) $ 35,726,568
Balance (in shares) at Mar. 31, 2022   20,684,723      
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net income (loss) $ (174,224) $ 3,009,081
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 1,560,870 1,728,829
Bad debt expense (recoveries) (115,364) 2,984
Inventory and sample inventory reserve 3,594 48,228
Amortization of deferred financing costs and debt discount   12,500
Lease expense 27,962 25,156
Derivative liability (460,000) (5,380,000)
Deferred revenue (70,343)  
Gain on settlement with Vivus (3,389,941)  
Employee stock-based compensation 355,828 347,207
Non-employee stock-based compensation   97,800
Changes in operating assets and liabilities:    
Accounts receivable (1,170,025) (1,044,213)
Inventories (1,426,818) 193,987
Prepaid expenses and other current assets 237,502 172,051
Accounts payable (857,643) (333,273)
Accrued expenses 74,905 698,498
Other current liabilities 161,961 74,992
Other long-term liabilities (33,965) (100,408)
Net cash used in operating activities (5,275,701) (446,581)
Cash flows from financing activities:    
Payment of promissory note (900,000)  
Payment of senior debt   (1,592,028)
Payment of portion of senior debt end of term fee   (534,375)
Net cash used in financing activities (900,000) (2,126,403)
Net decrease in cash (6,175,701) (2,572,984)
Cash, beginning of period 23,847,572 17,139,694
Cash, end of period 17,671,871 14,566,710
Supplemental cash flow information:    
Cash paid for interest during the period   $ 176,677
Noncash Items:    
Noncash decrease in accrued expenses related to Vivus settlement (6,520,283)  
Noncash decrease in accrued inventory purchases related to Vivus settlement (14,203,905)  
Noncash increase in promissory note related to Vivus settlement 10,201,758  
Noncash decrease in API purchase commitment related to Vivus settlement $ 6,232,489  
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations, Basis of Presentation, and Liquidity
3 Months Ended
Mar. 31, 2022
Nature of Operations, Basis of Presentation, and Liquidity  
Nature of Operations, Basis of Presentation, and Liquidity

1)    Nature of Operations, Basis of Presentation, and Liquidity

Nature of Operations

Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) is a pharmaceutical company focused on men’s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution.

Petros consists of wholly owned subsidiaries, Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). The Company is engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration (“FDA”) approved PDE 5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”), which we have licensed from Vivus, Inc. (“Vivus”). Petros also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, we have acquired an exclusive global license to develop and commercialize H100™, a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease.

The Company was organized as a Delaware corporation on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Merger Agreement”), by and between Petros, Neurotrope,, PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen. The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly-owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.), a Delaware corporation (“Synaptogenix”), and a wholly-owned subsidiary of Neurotrope.

Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, considered necessary to present fairly our financial position, results of operations and cash flows. However, actual results could differ from those estimates. The unaudited interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission. This Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2021.

All transactions between the consolidated entities have been eliminated in consolidation.

Liquidity

The Company has experienced net losses and negative cash flows from operations since our inception. As of March 31, 2022, the Company had cash of $17.7 million, positive working capital of $16.5 million, an accumulated deficit of $70.9 million and used cash in operations during the three months ended March 31, 2022 of $5.3 million. The Company’s plans include, or may include, utilizing its cash and cash equivalents on hand, as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. In January 2022, the Company executed a promissory note in favor of Vivus in connection with the Vivus Settlement Agreement in the principal amount of $10,201,758. The terms of this promissory note are discussed in Note 8. The Company believes the cash on hand is sufficient to fund operations and debt service through at least May 16, 2023, however for periods after May 16,

XML 26 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2)    Summary of Significant Accounting Policies

Use of Estimates

The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.

Risks and Uncertainties

The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.

The World Health Organization (“WHO”) declared the coronavirus (“COVID-19”) a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic, including the emergence of any new variants, such as the Omicron variants, will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2022 and beyond.

During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices. In January 2022, the Company sub-leased its Manalapan office and all administrative employees are working remotely for the foreseeable future. The Company has fully resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. Since the beginning of the COVID-19 pandemic, we have experienced a shift from in-person sales to online, telehealth-based sales. These online sales generally have lower gross margins than in-person sales, which has impacted our net revenues.

Revenue Recognition

Prescription Medication Sales

The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition (“Topic 606”), the Company recognizes revenue from prescription medication sales when its performance obligations with a customer has been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide Stendra® upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of Stendra®, which is typically upon delivery. The Company invoices its customers after Stendra® has been delivered and invoice payments are generally due within 30 to 75 days of invoice date.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales

net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

As of March 31, 2022 and December 31, 2021, the reserves for sales deductions were $4.7 million and $4.7 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.

Product Returns

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of March 31, 2022 and December 31, 2021, the reserves for product returns were $3.8 million and $3.8 million, respectively, and are included as a component of accrued expenses.

Contract Rebates, Coupon Redemptions and DSA Fees

The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us.

The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. See Note 3 Accounts Receivable, net for further discussion of these reserves.

Medical Device Sales

The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

Product Returns

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of March 31, 2022 and December 31, 2021, the reserves for product returns for medical devices were not significant.

Contract Costs

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at March 31, 2022 and December 31, 2021.

Fair Value of Financial Instruments

Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.

Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities. The Company believes that the carrying values of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to the short-term nature of these instruments.

In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of March 31, 2022 and December 31, 2021 was $0 million and $0.5 million, respectively. See Note 9 Stockholders’ Equity.

Stock-Based Compensation

The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant).

The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 10 Stock Options.

Income Taxes

The Company is a C corporation, which accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of March 31, 2022 and December 31, 2021, no accrued interest or penalties are recorded in the consolidated balance sheet.

Basic and Diluted Net Loss per Common Share

The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of shares of common stocks outstanding during the period, excluding the anti-dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the three months ended March 31, 2022. See Note 13 Basic and Diluted Net Loss per Common Share.

Recent Accounting Pronouncements

Pending Adoption as of March 31, 2022

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13, together with a series of subsequently issued related ASUs, has been codified in Topic 326. Topic 326 establishes new requirements for companies to estimate expected credit losses when measuring certain financial assets, including accounts receivables. The new guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the effect that the new guidance will have on its consolidated financial statements and related disclosures.

XML 27 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Receivable, net
3 Months Ended
Mar. 31, 2022
Accounts Receivable, net  
Accounts Receivable, net

3)    Accounts Receivable, net

Accounts receivable, net is comprised of the following:

    

March 31, 

    

December 31, 

2022

2021

Gross accounts receivables

$

4,528,812

$

3,363,827

Distribution service fees

 

(317,247)

 

(371,310)

Chargebacks accrual

 

(5,880)

 

Cash discount allowances

 

(202,589)

 

(159,446)

Allowance for doubtful accounts

 

(262,321)

 

(377,685)

Total accounts receivable, net

$

3,740,775

$

2,455,386

For the three months ended March 31, 2022, gross sales from customers representing 10% or more of the Company’s total gross sales included three customers which represented approximately 30%, 23% and 22% of total gross sales, respectively. For the three months ended March 31, 2021, gross sales from customers representing 10% or more of the Company’s total gross sales included one customer which represented approximately 88% of total gross sales.

Receivables from customers representing 10% or more of the Company’s gross accounts receivable included two customers at March 31, 2022 equal to 35% and 31%, respectively, of the Company’s total gross accounts receivables. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included three customers at December 31, 2021 equal to 40%, 19% and 15%, respectively, of the Company’s total gross accounts receivables.

XML 28 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories
3 Months Ended
Mar. 31, 2022
Inventories  
Inventories

4)    Inventories

Inventory is comprised of the following:

    

March 31, 2022

    

December 31, 2021

Raw materials

$

1,854,160

$

359,741

Finished goods

 

88,713

 

159,908

Total inventory

$

1,942,873

$

519,649

Finished goods are net of valuation reserves of $386,892 and $383,298 as of March 31, 2022 and December 31, 2021, respectively. Raw materials are net of valuation reserves of $2,872,977 as of March 31, 2022 and December 31, 2021, which is related to bulk inventory that is fully reserved.

XML 29 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses and Other Current Assets
3 Months Ended
Mar. 31, 2022
Prepaid Expenses and Other Current Assets.  
Prepaid Expenses and Other Current Assets

5)    Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets are comprised of the following:

    

March 31, 2022

    

December 31, 2021

Prepaid insurance

$

128,004

$

73,223

Prepaid FDA fees

 

554,120

 

831,179

Prepaid coupon fees

 

71,500

 

71,500

API purchase commitment asset (see Note 13)

 

1,419,538

 

1,419,538

Due from wholesalers

609,059

609,059

Other prepaid expenses

 

624,823

 

605,422

Other current assets

 

75,542

 

110,167

Total prepaid expenses and other current assets

$

3,482,586

$

3,720,088

XML 30 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets
3 Months Ended
Mar. 31, 2022
Intangible Assets  
Intangible Assets

6)    Intangible Assets

Balance at December 31, 2020

    

$

32,160,919

Amortization expense

 

(6,867,770)

Balance at December 31, 2021

25,293,149

Amortization expense

 

(1,558,315)

Balance at March 31, 2022

$

23,734,834

The future annual amortization related to the Company’s intangible assets is as follows as of March 31, 2022:

2022 (remaining 9 months)

    

4,633,426

2023

 

5,445,729

2024

 

4,650,787

2025

 

2,716,011

2026

2,201,720

Thereafter

 

4,087,161

Total

$

23,734,834

The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years, 12 years, and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of March 31, 2022 are $17.8 million, $4.6 million and $1.3 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2021 were $19.1 million, $4.9 million and $1.4 million, respectively. The Company determined that no impairment existed as of March 31, 2022.

XML 31 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses
3 Months Ended
Mar. 31, 2022
Accrued Expenses  
Accrued Expenses

7)    Accrued Expenses

Accrued expenses are comprised of the following:

    

March 31, 2022

    

December 31, 2021

Accrued price protection (see note 13)

$

$

1,853,979

Accrued product returns

 

3,763,211

 

6,192,845

Accrued contract rebates

 

376,937

 

379,242

Due to Vivus (see Note 13)

 

 

2,267,523

Due to third-party logistics provider

 

349,410

 

479,178

Accrued bonuses

532,729

527,563

Accrued professional fees

 

14,957

 

125,392

Other accrued expenses

 

474,762

 

131,662

Total accrued expenses

$

5,512,006

$

11,957,384

XML 32 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Debt
3 Months Ended
Mar. 31, 2022
Debt  
Debt

8)    Debt

Promissory Note

In connection with the Settlement Agreement entered into with Vivus (see Note 13), Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the principal amount of $10,201,758. The parties also entered into a Security Agreement to secure Petros’ obligations under the Note.

Under the terms of the Note, the original principal amount of $10,201,758 is payable in consecutive quarterly installments of principal and interest beginning on April 1, 2022 through January 1, 2027. Interest on the principal amount will accrue at a rate of 6% per year. The Company may prepay the Note, in whole or in part, at any time, with no premium or penalty. In the event that the Company defaults under the Security Agreement, all principal outstanding under the Note at the time of the default will bear interest at a rate of 9% per year until the full and final payment of all principal and interest under the Note (regardless of whether any default is waived or cured). Pursuant to the Security Agreement, dated January 18, 2022, the Company granted to Vivus a continuing security interest in all of its Stendra® API and products and its rights under the License Agreement.

During the three months ended March 31, 2022, the Company recorded $153,026 of interest expense related to the Note.

Senior Debt

The Company did not have any senior indebtedness as of March 31, 2022 and December 31, 2021.

On September 30, 2016, the Company entered into a loan agreement with Hercules, a third party, for a $35 million term loan (“Senior Debt”) with a stated interest rate of the greater of either (i) Prime plus 7.25% or (ii) 10.75%. The Senior Debt included an additional Paid-In-Kind (“PIK”) interest that increased the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge.

On November 22, 2017, the Company amended its loan agreement with Hercules (“First Amendment”). A covenant was added, in which the Company must achieve a certain minimum EBITDA, as defined, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio (1:1 to 0.9:1) were reduced. The Company was also required to prepay $10,000,000 in principal.

Monthly principal payments, including interest, commenced November 1, 2018 with the outstanding balance of the Senior Debt due in full on November 1, 2020. The end of term charge was being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method.

On April 13, 2020, the Company amended its loan agreement with Hercules. The amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The amendment also included the following changes:

Removed the Adjusted EBITDA and Fixed Cost Coverage Ratio Covenants.
Extended the maturity date from October 1, 2020 to April 2021, which was further extendable to December 1, 2021 upon achieving the Financing Milestone, as defined in the agreement.
Increased the cash interest rate from the greater of (a) 10.75% or (b) 10.75% plus the US WSJ Prime minus 4.50% to the greater of (a) 11.50% or (b) 11.50% plus the US WSJ Prime minus 4.25%.
Removed the PIK interest rate.
Removed the prepayment penalty.

The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020 and $534,375 paid on February 1, 2021.

Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to Loan and Security Agreement (“Third Amendment”) to provide for interest only payments commencing on October 1, 2020 and continuing through December 22, 2020 unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated.

The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt had a maturity date of December 1, 2021.

On November 3, 2021, the Company repaid $1,179,651 towards the senior debt. This payment satisfied the remaining balance of the senior debt as of that date.

Interest expense on the Senior Debt was $173,412 for the three months ended March 31, 2021. As of December 31, 2021, there was $0 of accrued and unpaid interest.

XML 33 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2022
Stockholders' Equity  
Stockholders' Equity

9)     Stockholders’ Equity

On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock.

Effective January 1, 2021, the Company entered into a Marketing and Consulting Agreement (the “CorIRAgreement”) with CorProminence, LLC (the “Consultant”) for certain shareholder information and relation services. The term of the CorIRAgreement is for one year with automatic consecutive one-year renewal terms. As consideration for the shareholder information and relation services, the Company will pay the Consultant a monthly retainer of $7,500 and issued 30,000 restricted shares of the Company’s common stock to the Consultant on March 24, 2021 (the “CorIR Grant Date”). The restricted shares vested immediately on the CorIR Grant Date.

Effective April 1, 2021, the Company entered into a Consulting and Advisory Agreement (the “King Agreement”) with Tania King, an employee of Juggernaut Capital Partners LLP, for certain services. The term of the King Agreement is indefinite but may be terminated by either party, with or without cause. As consideration for the consulting and advisory services, the Company will pay Ms. King a monthly fee of $4,000, an additional $12,000 payment included with the first monthly fee for services provided since January 1, 2021, and issue restricted stock units for shares of the Company’s common stock (“RSU’s”) with a cash value of $72,000 as of the date of the grant (the “King Grant Date”). The RSU’s shall vest and settle in full on the one-year anniversary of the King Grant Date. On April 7, 2022, the Company issued an additional grant of 60,505 RSU’s of the Company’s common stock with a value of $72,001 as of the date of the grant. The RSU’s vest and settle in full on the one-year anniversary of the additional grant date.

Effective June 4, 2021, the Company entered into a Service Agreement with IRTH Communications, LLC (“IRTH”) for certain investor relations services (the “IRTH Agreement”). The term of the IRTH Agreement is for one year with an optional one-year renewal term. As consideration for the services, the Company will pay IRTH a fixed fee of $6,750 per month for the term of the IRTH Agreement and issued 28,338 restricted shares of the Company’s common stock with a value of $90,002 as of the date of the grant (the “IRTH Grant Date”). The restricted shares vest immediately on the IRTH Agreement Grant Date.

Contingent Consideration

Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 shares of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period.

Market Capitalization/Gross Proceeds Earnout Payments

In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which was liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment was only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of March 31, 2022, the milestones have not been achieved. The fair value of the derivative liability was $0 and $0.5 million as of March 31, 2022 and December 31, 2021, respectively.

Metuchen equity holders will have the opportunity to receive the following during the period ending December 2022:

a.The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if:
i.Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to $250,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $17.50 on each such trading day; or
ii.Petros receives aggregate gross proceeds of at least $25,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $17.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $250,000,000.
b.The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if:
i.Petros’ Market Capitalization is greater than or equal to $300,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $18.75 on each such trading day; or
ii.Petros receives aggregate gross proceeds of at least $30,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $18.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $300,000,000.
c.The Earnout Payment shall be equal to 3,000,000 shares of Petros Common Stock if:
i.Petros’ Market Capitalization is greater than or equal to $400,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $22.50 on each such trading day; or
ii.Petros receives aggregate gross proceeds of at least $40,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $22.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $400,000,000.
d.The Earnout Payment shall be equal to 3,232,090 shares of Petros Common Stock if:
i.Petros’ Market Capitalization is greater than or equal to $500,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $23.75 on each such trading day; or

Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000.

XML 34 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Restricted Stock Units ("RSU's")
3 Months Ended
Mar. 31, 2022
Stock Options and Restricted Stock Units ("RSU's")  
Stock Options and Restricted Stock Units ("RSU's")

10)    Stock Options and Restricted Stock Units (“RSU’s”)

The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units and other stock-based awards and cash-based awards. On December 22, 2021, our stockholders approved the Second Amendment to the 2020 Plan to increase the total number of shares of common stock issuable under the 2020 Plan by 1,521,654 shares to a total of 2,600,000 shares of common stock. As of March 31, 2022, there were 2,600,000 shares authorized and 1,817,948 shares available for issuance under the 2020 Plan.

The following is a summary of stock options for the three months ended March 31, 2022 and for the year ended December 31, 2021:

    

    

Weighted-Average 

    

Weighted-

Remaining 

Aggregate Intrinsic 

Number of 

Average 

Contractual 

Value 

    

Shares

    

Exercise Price

    

Term (Years)

    

($ in thousands)

Options outstanding at December 31, 2020

 

574,331

$

51.43

 

0.9

$

Options granted

 

615,669

 

3.38

 

9.23

 

Less: options forfeited

 

 

 

 

Less: options expired/cancelled

 

(574,331)

 

51.43

 

 

Less: options exercised

 

 

 

 

Options outstanding at December 31, 2021

615,669

3.38

9.23

Options granted

50,000

3.34

9.76

Less: options forfeited

Less: options expired/cancelled

Less: options exercised

Options outstanding at March 31, 2022

 

665,669

$

3.38

 

9.06

$

Options exercisable at March 31, 2022

 

381,752

$

3.44

 

9.07

$

The following is a summary of RSU’s for the three months ended March 31, 2022 and for the year ended December 31, 2021:

Weighted-Average

Weighted-

Remaining

Aggregate Intrinsic

Number of

Average

Contractual

Value

Shares

Exercise Price

Term (Years)

($ in thousands)

RSU’s outstanding at December 31, 2020

 

$

 

$

RSU’s granted

 

116,383

 

3.29

 

9.84

 

Less: RSU’s forfeited

 

 

 

 

Less: RSU’s expired/cancelled

 

 

 

 

Less: RSU’s exercised

 

 

 

 

RSU’s outstanding at December 31, 2021

 

116,383

 

3.29

 

9.84

 

RSU’s granted

 

 

 

 

Less: RSU’s forfeited

 

 

 

 

Less: RSU’s expired/cancelled

 

 

 

 

Less: RSU’s exercised

 

 

 

 

RSU’s outstanding at March 31, 2022

 

116,383

$

3.29

 

9.60

$

RSU’s exercisable at March 31, 2022

 

$

 

$

On January 4, 2022, pursuant to a consulting agreement, the Company awarded a grant of 50,000 options to purchase shares of common stock of the Company at an exercise price of $3.34 per share. The shares of common stock underlying the options vested 100% upon issuance.

On April 7, 2022, the Company awarded the four Directors grants of 248,742 total RSU’s with a stock price of $1.19 per share. The RSU’s shall vest 100% on one year anniversary of the date of grant. Also on April 7, 2022, Tania King, an employee of Juggernaut Capital Partners LLP, pursuant to her contract, was granted 60,505 RSUs with a stock price of $1.19 per share. The RSU’s shall vest 100% on one year anniversary of the date of grant.

Stock-based compensation expense recognized for the three months ended March 31, 2022 and 2021 was $355,828 and $347,207, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations.

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Common Stock Warrants
3 Months Ended
Mar. 31, 2022
Common Stock Warrants  
Common Stock Warrants

11)    Common Stock Warrants

The following is a summary of warrants for the three months ended March 31, 2022 and for the year ended December 31, 2021:

    

Number of Shares

Warrants outstanding at December 31, 2020

 

4,407,962

Warrants issued

 

7,853,558

Warrants exercised

 

(2,014,586)

Warrants expired

(207,913)

Warrants outstanding at December 31, 2021 and March 31, 2022

 

10,039,021

As of March 31, 2022, the Company’s warrants by expiration date were as follows:

Number of Warrants

    

Exercise Price

    

Expiration Date

2,780

$

1.60

August 23, 2023

22,800

 

35.65

June 1, 2024

74,864

 

21.85

June 17, 2024

20,043

 

31.25

June 19, 2024

22,800

 

26.55

September 1, 2024

10,500

 

12.738

September 16, 2024

22,800

 

4.30

December 1, 2024

28,000

 

5.65

March 2, 2025

28,000

 

7.30

June 1, 2025

28,000

 

5.50

September 1, 2025

28,000

 

4.705

December 1, 2025

2,221,829

 

7.50

December 1, 2025

908,498

 

17.50

December 1, 2025

623,303

 

51.25

December 1, 2025

157,832

 

125.00

December 1, 2025

1,751,311

1.715

October 19, 2026

2,337,719

3.50

December 2, 2026

1,749,942

3.50

December 27, 2026

10,039,021

 

  

  

XML 36 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Common Share
3 Months Ended
Mar. 31, 2022
Basic and Diluted Net Loss per Common Share  
Basic and Diluted Net Loss per Common Share

12)    Basic and Diluted Net Income (Loss) per Common Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share:

For the Three Months Ended

March 31, 

    

2022

    

2021

Numerator

 

  

 

  

Net income (loss)

$

(174,224)

$

3,009,081

Denominator

 

 

Weighted-average common shares for basic net income (loss) per share

 

20,684,723

 

9,753,086

Effect of common share equivalents within common stock warrants

 

 

1,600

Weighted-average common shares for diluted net (loss) income per share

 

20,684,723

 

9,754,686

Basic and diluted net income (loss) per common share

$

(0.01)

$

0.31

The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share because their inclusion would have been antidilutive:

For the Three Months Ended

March 31, 

   

2022

   

2021

Stock Options

 

665,669

 

790,000

RSU’s

116,383

Warrants

 

10,039,021

 

4,405,182

Total

 

10,821,073

 

5,195,182

XML 37 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Marketing, Licensing and Distribution Agreements
3 Months Ended
Mar. 31, 2022
Marketing, Licensing and Distribution Agreements.  
Marketing, Licensing and Distribution Agreements

13)   Marketing, Licensing and Distribution Agreements

(a)    Vivus

On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction.

Under the License Agreement, the Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory.

In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment.

In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement. The License Agreement, was terminated, effective September 30, 2021.

On January 18, 2022, Petros and Vivus entered into a Settlement Agreement (the “Vivus Settlement Agreement”) related to the minimum purchase requirements under the Vivus Supply Agreement in 2018, 2019 and 2020 and certain reimbursement rights asserted by a third-party retailer in connection with quantities of the Company’s Stendra® product that were delivered to the third-party retailer and later returned. In connection with the Vivus Settlement Agreement, Petros retained approximately $7.3 million of API inventory under the Vivus Supply Agreement. In exchange for the API and reduction of current liabilities, Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the original principal amount of $10,201,758, which the Company believes approximates fair value (See Note 8).

In addition to the payments to be made in accordance with the Note, the Company further agreed in the Vivus Settlement Agreement to (i) grant to Vivus a right of first refusal to provide certain types of debt and convertible equity (but not preferred equity) until the Note is paid in full, and (ii) undertake to make certain regulatory submissions to effectuate Vivus’ ability to exercise its rights under the License Agreement. On January 18, 2022, the Company made a prepayment of the obligations under the Note in the amount of $900,000, and a payment of $1,542,904 with respect to a purchase order made in 2021 to Vivus. In consideration of these payment and upon the Company’s satisfaction of certain regulatory submissions Vivus released 50% of the quantity of bulk Stendra® tablets on January 18, 2022 under the Company’s existing open purchase order (the “Open Purchase Order”) being held by Vivus, which represents approximately a six-month supply of inventory. Under the Vivus Settlement Agreement Vivus also agreed to release the remaining 50% of the quantity of bulk Stendra® tablets under the Open Purchase Order upon the Company’s satisfaction of the remaining regulatory submission requirements (not to exceed 180 days from the date of the Vivus Settlement Agreement). The Vivus Settlement Agreement stipulated that Vivus is the sole owner of all API unless or until such time as certain quantities of API are shipped to the Company upon the fulfillment of the aforementioned payment conditions.

As a result of entering into the Vivus Settlement Agreement, the Company decreased accrued expenses by $6.5 million and decreased accrued inventory purchases by $14.2 million; which were partially offset by a decrease in API purchase commitments of $6.2 million and an increase to liabilities for the Note of $10.2 million (which is net of the $0.9 million prepayment on the Note). As a result, the Company recorded a $3.4 million gain on settlement for the three months ended March 31, 2022.

As of March 31, 2022 and December 31, 2021, the Company has $0 and $14.2 million, respectively, of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of March 31, 2022 and December 31, 2021, there was $1.4 million and

$1.4 million, respectively, included in other current assets (see Note 5 Prepaid and Other Current Assets). As of March 31, 2022 and December 31, 2021, there was $4.8 million and $11.0 million included as non-current on the accompanying consolidated balance sheets, respectively. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. The Company did not record any reserve for the three months ended March 31, 2022 and 2021.

During the three months ended March 31, 2022 and 2021, the Company incurred royalties to MTPC for Stendra® of $76,238 and $160,032, respectively. Royalties incurred were included in cost of goods sold in the consolidated statements of operations. As of March 31, 2022 and December 31, 2021, the Company had a receivable for royalties of $4,897 and $81,136, respectively, which is included in other current assets in prepaid expenses and other current assets (see Note 5 Prepaid and Other Current Assets).

The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra®.

(b)     Patheon

Following the termination of the Vivus Supply Agreement, Petros, through its subsidiary Metuchen, entered into a Technology Transfer Service Agreement on January 20, 2022 with Patheon Pharmaceuticals Inc., part of Thermo Fisher Scientific (“Patheon”), pursuant to which the Company and Patheon agreed to collaborate as strategic partners for commercial production of Stendra® tablets at Patheon’s facilities in Cincinnati, Ohio. Under the Agreement, Patheon or one of its affiliates will provide pharmaceutical development and technology transfer services in order to establish and validate its ability to manufacture supply of the Company’s Stendra® product. Any

commercial sale of product manufactured during the performance of the Agreement must be subject to a subsequent commercial manufacturing services agreement (with associated quality agreement) between the parties before it can be offered for commercial sale.

(c)    Hybrid

In March 2020, the Company acquired the exclusive license to H100™ from Hybrid. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. The Company paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000 and $200,000 due on each of the first, second and third anniversaries of the license agreement and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon ninety (90) days’ notice.

The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired and the upfront payment should be expensed as it was considered an IPR&D asset with no alternative future uses.

On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months to March 24, 2021. In consideration for the extension, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020. On March 31, 2021, the Company and Hybrid, entered into a second letter agreement, pursuant to which the parties agreed to extend the Second Period (as defined in the Hybrid License) for an additional six (6) months to September 24, 2021. Additionally, the Company agreed to pay Hybrid a one-time, non-creditable and non-refundable payment of $200,000, which was paid within seven calendar days of entering into the agreement. On September 24, 2021, the Company entered into an amendment to the license agreement in which the Company exercised its right not to terminate the Hybrid License even though orphan drug status had not yet been granted by the FDA. Along with this election, the Company paid Hybrid $150,000 on October 1, 2021, $200,000 on October 31, 2021, $200,000 on December 1, 2021, $200,000 on December 23, 2021 and $150,000 on March 24, 2022.

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies  
Commitments and Contingencies

14)  Commitments and Contingencies

(a)    Employment Agreements

The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary and performance bonuses.

In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021 and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company.

(b)    Legal Proceedings

On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome.

The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows.

(c)    Operating Leases

The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 2.4 years to 4.8 years.

On November 30, 2021, the Company entered into a sublease with respect to its entire headquarters facility. The sublessor delivered a $14,000 security deposit to the Company on the lease commencement date and also agreed to pay $7,000 per month for the term beginning January 10, 2022 and continuing until the expiration of the head lease on August 30, 2024. The Company will account for this sublease as an operating lease in accordance with the lessor accounting guidance within ASC 842.

The components of lease expense were consisted entirely of fixed lease costs related to operating leases. These costs were $44,812 for the three months ended March 31, 2022 and 2021, respectively. Fixed lease costs for the three months ended March 31, 2022 were offset by sublease income of $21,000.

Supplemental balance sheet information related to leases was as follows:

    

As of March 31, 2022

    

As of December 31, 2021

Operating lease ROU asset:

 

  

 

  

Other assets

$

447,595

$

475,557

Operating lease liability:

 

 

Other current liabilities

$

129,458

$

125,579

Other long-term liabilities

 

371,053

 

405,018

Total operating lease liability

$

500,511

$

530,597

Supplemental lease term and discount rate information related to leases was as follows:

    

As of March 31, 2022

As of December 31, 2021

Weighted-average remaining lease terms - operating leases

 

3.4 years

 

3.7 years

Weighted-average discount rate - operating leases

 

12.6

%  

12.6

%

Supplemental cash flow information related to leases was as follows:

For the Three Months 

Ended March 31,

    

2022

    

2021

Cash paid for amounts included in the measurement of lease liabilities:

 

  

 

  

Operating cash flows from operating leases

$

46,935

$

45,942

Future minimum lease payments under non-cancelable leases as of March 31, 2022, were as follows:

Lease Liability Maturity Analysis

    

Operating Leases

2022 (remaining 9 months)

 

140,805

2023

 

189,374

2024

 

155,242

2025

 

81,107

2026

82,324

Thereafter

 

Total lease payments

 

648,852

Less: Imputed Interest

 

(148,341)

Total

$

500,511

Future minimum sublease income under non-cancelable leases as of March 31, 2022, were as follows:

Sublease income

Operating Leases

2022 (remaining 9 months)

63,000

2023

84,000

2024

 

56,000

Total

$

203,000

As of March 31, 2022, the Company had no operating leases that had not yet commenced.

XML 39 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information
3 Months Ended
Mar. 31, 2022
Segment Information  
Segment Information

15)    Segment Information

The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments.

The Company’s results of operations by reportable segment for the three months ended March 31, 2022 are summarized as follows:

    

Prescription 

    

Medical 

    

    

Medications

Devices

Corporate

Consolidated

Net sales

$

1,524,768

$

940,401

$

$

2,465,169

Cost of goods sold

 

138,181

 

334,159

 

 

472,340

Selling, general and administrative expenses

 

1,711,019

 

663,591

 

1,523,128

 

3,897,738

Gain on settlement with Vivus

(3,389,941)

(3,389,941)

Research and development expenses

 

405,360

 

 

 

405,360

Depreciation and amortization expense

 

1,269,663

 

291,207

 

 

1,560,870

Change in fair value of derivative liability

 

 

 

(460,000)

 

(460,000)

Interest expense

 

 

 

153,026

 

153,026

Income tax (expense)

 

 

 

 

Net income (loss)

$

1,390,486

$

(348,556)

$

(1,216,154)

$

(174,224)

The Company’s results of operations by reportable segment for the three months ended March 31, 2021 are summarized as follows:

    

Prescription 

    

Medical 

    

    

Medications

    

Devices

    

Corporate

    

Consolidated

Net sales

$

3,200,647

$

874,959

$

$

4,075,606

Cost of goods sold

 

389,281

 

254,105

 

 

643,386

Selling, general and administrative expenses

 

1,734,333

 

546,995

 

1,600,389

 

3,881,717

Research and development expense

 

19,181

 

 

 

19,181

Depreciation and amortization expense

 

1,398,270

 

330,559

 

 

1,728,829

Change in fair value of derivative liability

(5,380,000)

(5,380,000)

Interest expense

 

 

 

173,412

 

173,412

Income tax benefit

 

 

 

 

Net income (loss)

$

(340,418)

$

(256,700)

$

3,606,199

$

3,009,081

The following table reflects net sales by geographic region for the three months ended March 31, 2022 and 2021:

For the Three Months Ended

March 31, 

Net sales

    

2022

    

2021

United States

$

2,045,624

$

3,704,523

International

 

419,545

 

371,083

$

2,465,169

$

4,075,606

No individual country other than the United States accounted for 10% of total sales for the three months ended March 31, 2022 and 2021.

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of March 31, 2022, are summarized as follows:

Prescription 

    

    

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

17,804,298

$

5,930,536

$

23,734,834

Total segment assets

$

48,240,984

$

7,623,163

$

55,864,147

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2021, are summarized as follows:

Prescription 

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

19,071,407

$

6,221,742

$

25,293,149

Total segment assets

$

59,657,514

$

7,732,544

$

67,390,058

XML 40 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Summary of Significant Accounting Policies  
Use of Estimates

Use of Estimates

The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.

Concentration of Credit Risk

Risks and Uncertainties

The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.

The World Health Organization (“WHO”) declared the coronavirus (“COVID-19”) a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic, including the emergence of any new variants, such as the Omicron variants, will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2022 and beyond.

Revenue Recognition

Revenue Recognition

Prescription Medication Sales

The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition (“Topic 606”), the Company recognizes revenue from prescription medication sales when its performance obligations with a customer has been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide Stendra® upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of Stendra®, which is typically upon delivery. The Company invoices its customers after Stendra® has been delivered and invoice payments are generally due within 30 to 75 days of invoice date.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales

net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

As of March 31, 2022 and December 31, 2021, the reserves for sales deductions were $4.7 million and $4.7 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.

Product Returns

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of March 31, 2022 and December 31, 2021, the reserves for product returns were $3.8 million and $3.8 million, respectively, and are included as a component of accrued expenses.

Contract Rebates, Coupon Redemptions and DSA Fees

The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us.

The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. See Note 3 Accounts Receivable, net for further discussion of these reserves.

Medical Device Sales

The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers.

In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

Product Returns

Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of March 31, 2022 and December 31, 2021, the reserves for product returns for medical devices were not significant.

Contract Costs

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at March 31, 2022 and December 31, 2021.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.

Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities. The Company believes that the carrying values of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to the short-term nature of these instruments.

In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of March 31, 2022 and December 31, 2021 was $0 million and $0.5 million, respectively. See Note 9 Stockholders’ Equity.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant).

The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 10 Stock Options.

Income Taxes

Income Taxes

The Company is a C corporation, which accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of March 31, 2022 and December 31, 2021, no accrued interest or penalties are recorded in the consolidated balance sheet.

Basic and Diluted Net Loss per Common Share

Basic and Diluted Net Loss per Common Share

The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of shares of common stocks outstanding during the period, excluding the anti-dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the three months ended March 31, 2022. See Note 13 Basic and Diluted Net Loss per Common Share.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Pending Adoption as of March 31, 2022

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13, together with a series of subsequently issued related ASUs, has been codified in Topic 326. Topic 326 establishes new requirements for companies to estimate expected credit losses when measuring certain financial assets, including accounts receivables. The new guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the effect that the new guidance will have on its consolidated financial statements and related disclosures.

XML 41 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Receivable, net (Tables)
3 Months Ended
Mar. 31, 2022
Accounts Receivable, net  
Summary of accounts receivable

    

March 31, 

    

December 31, 

2022

2021

Gross accounts receivables

$

4,528,812

$

3,363,827

Distribution service fees

 

(317,247)

 

(371,310)

Chargebacks accrual

 

(5,880)

 

Cash discount allowances

 

(202,589)

 

(159,446)

Allowance for doubtful accounts

 

(262,321)

 

(377,685)

Total accounts receivable, net

$

3,740,775

$

2,455,386

XML 42 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2022
Inventories  
Schedule of Inventories

    

March 31, 2022

    

December 31, 2021

Raw materials

$

1,854,160

$

359,741

Finished goods

 

88,713

 

159,908

Total inventory

$

1,942,873

$

519,649

XML 43 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses and Other Current Assets (Tables)
3 Months Ended
Mar. 31, 2022
Prepaid Expenses and Other Current Assets.  
Schedule of Prepaid Expenses and Other Current Assets

    

March 31, 2022

    

December 31, 2021

Prepaid insurance

$

128,004

$

73,223

Prepaid FDA fees

 

554,120

 

831,179

Prepaid coupon fees

 

71,500

 

71,500

API purchase commitment asset (see Note 13)

 

1,419,538

 

1,419,538

Due from wholesalers

609,059

609,059

Other prepaid expenses

 

624,823

 

605,422

Other current assets

 

75,542

 

110,167

Total prepaid expenses and other current assets

$

3,482,586

$

3,720,088

XML 44 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2022
Intangible Assets  
Schedule of intangible assets

Balance at December 31, 2020

    

$

32,160,919

Amortization expense

 

(6,867,770)

Balance at December 31, 2021

25,293,149

Amortization expense

 

(1,558,315)

Balance at March 31, 2022

$

23,734,834

Schedule of future annual amortization of intangible assets

2022 (remaining 9 months)

    

4,633,426

2023

 

5,445,729

2024

 

4,650,787

2025

 

2,716,011

2026

2,201,720

Thereafter

 

4,087,161

Total

$

23,734,834

XML 45 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2022
Accrued Expenses  
Summary of accrued expenses

    

March 31, 2022

    

December 31, 2021

Accrued price protection (see note 13)

$

$

1,853,979

Accrued product returns

 

3,763,211

 

6,192,845

Accrued contract rebates

 

376,937

 

379,242

Due to Vivus (see Note 13)

 

 

2,267,523

Due to third-party logistics provider

 

349,410

 

479,178

Accrued bonuses

532,729

527,563

Accrued professional fees

 

14,957

 

125,392

Other accrued expenses

 

474,762

 

131,662

Total accrued expenses

$

5,512,006

$

11,957,384

XML 46 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Restricted Stock Units ("RSU's") (Tables)
3 Months Ended
Mar. 31, 2022
Stock Options and Restricted Stock Units ("RSU's")  
Summary of stock options

    

    

Weighted-Average 

    

Weighted-

Remaining 

Aggregate Intrinsic 

Number of 

Average 

Contractual 

Value 

    

Shares

    

Exercise Price

    

Term (Years)

    

($ in thousands)

Options outstanding at December 31, 2020

 

574,331

$

51.43

 

0.9

$

Options granted

 

615,669

 

3.38

 

9.23

 

Less: options forfeited

 

 

 

 

Less: options expired/cancelled

 

(574,331)

 

51.43

 

 

Less: options exercised

 

 

 

 

Options outstanding at December 31, 2021

615,669

3.38

9.23

Options granted

50,000

3.34

9.76

Less: options forfeited

Less: options expired/cancelled

Less: options exercised

Options outstanding at March 31, 2022

 

665,669

$

3.38

 

9.06

$

Options exercisable at March 31, 2022

 

381,752

$

3.44

 

9.07

$

Weighted-Average

Weighted-

Remaining

Aggregate Intrinsic

Number of

Average

Contractual

Value

Shares

Exercise Price

Term (Years)

($ in thousands)

RSU’s outstanding at December 31, 2020

 

$

 

$

RSU’s granted

 

116,383

 

3.29

 

9.84

 

Less: RSU’s forfeited

 

 

 

 

Less: RSU’s expired/cancelled

 

 

 

 

Less: RSU’s exercised

 

 

 

 

RSU’s outstanding at December 31, 2021

 

116,383

 

3.29

 

9.84

 

RSU’s granted

 

 

 

 

Less: RSU’s forfeited

 

 

 

 

Less: RSU’s expired/cancelled

 

 

 

 

Less: RSU’s exercised

 

 

 

 

RSU’s outstanding at March 31, 2022

 

116,383

$

3.29

 

9.60

$

RSU’s exercisable at March 31, 2022

 

$

 

$

XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Common Stock Warrants (Tables)
3 Months Ended
Mar. 31, 2022
Common Stock Warrants  
Summary of warrants

    

Number of Shares

Warrants outstanding at December 31, 2020

 

4,407,962

Warrants issued

 

7,853,558

Warrants exercised

 

(2,014,586)

Warrants expired

(207,913)

Warrants outstanding at December 31, 2021 and March 31, 2022

 

10,039,021

Summary of warrants by expiration date

Number of Warrants

    

Exercise Price

    

Expiration Date

2,780

$

1.60

August 23, 2023

22,800

 

35.65

June 1, 2024

74,864

 

21.85

June 17, 2024

20,043

 

31.25

June 19, 2024

22,800

 

26.55

September 1, 2024

10,500

 

12.738

September 16, 2024

22,800

 

4.30

December 1, 2024

28,000

 

5.65

March 2, 2025

28,000

 

7.30

June 1, 2025

28,000

 

5.50

September 1, 2025

28,000

 

4.705

December 1, 2025

2,221,829

 

7.50

December 1, 2025

908,498

 

17.50

December 1, 2025

623,303

 

51.25

December 1, 2025

157,832

 

125.00

December 1, 2025

1,751,311

1.715

October 19, 2026

2,337,719

3.50

December 2, 2026

1,749,942

3.50

December 27, 2026

10,039,021

 

  

  

XML 48 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Common Share (Tables)
3 Months Ended
Mar. 31, 2022
Basic and Diluted Net Loss per Common Share  
Summary of Computation of Basic and Diluted Net Loss per Share

For the Three Months Ended

March 31, 

    

2022

    

2021

Numerator

 

  

 

  

Net income (loss)

$

(174,224)

$

3,009,081

Denominator

 

 

Weighted-average common shares for basic net income (loss) per share

 

20,684,723

 

9,753,086

Effect of common share equivalents within common stock warrants

 

 

1,600

Weighted-average common shares for diluted net (loss) income per share

 

20,684,723

 

9,754,686

Basic and diluted net income (loss) per common share

$

(0.01)

$

0.31

Summary of Computation of Basic and Diluted Net Loss per Share

For the Three Months Ended

March 31, 

   

2022

   

2021

Stock Options

 

665,669

 

790,000

RSU’s

116,383

Warrants

 

10,039,021

 

4,405,182

Total

 

10,821,073

 

5,195,182

XML 49 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies  
Summary of supplemental balance sheet information related to leases

Supplemental balance sheet information related to leases was as follows:

    

As of March 31, 2022

    

As of December 31, 2021

Operating lease ROU asset:

 

  

 

  

Other assets

$

447,595

$

475,557

Operating lease liability:

 

 

Other current liabilities

$

129,458

$

125,579

Other long-term liabilities

 

371,053

 

405,018

Total operating lease liability

$

500,511

$

530,597

Summary of supplemental lease term and discount rate information related to leases

Supplemental lease term and discount rate information related to leases was as follows:

    

As of March 31, 2022

As of December 31, 2021

Weighted-average remaining lease terms - operating leases

 

3.4 years

 

3.7 years

Weighted-average discount rate - operating leases

 

12.6

%  

12.6

%

Summary of supplemental cash flow information related to leases

Supplemental cash flow information related to leases was as follows:

For the Three Months 

Ended March 31,

    

2022

    

2021

Cash paid for amounts included in the measurement of lease liabilities:

 

  

 

  

Operating cash flows from operating leases

$

46,935

$

45,942

Summary of future minimum lease payments under non-cancelable leases

Future minimum lease payments under non-cancelable leases as of March 31, 2022, were as follows:

Lease Liability Maturity Analysis

    

Operating Leases

2022 (remaining 9 months)

 

140,805

2023

 

189,374

2024

 

155,242

2025

 

81,107

2026

82,324

Thereafter

 

Total lease payments

 

648,852

Less: Imputed Interest

 

(148,341)

Total

$

500,511

XML 50 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2022
Segment Information  
Summary of results of operations by reportable segment

The Company’s results of operations by reportable segment for the three months ended March 31, 2022 are summarized as follows:

    

Prescription 

    

Medical 

    

    

Medications

Devices

Corporate

Consolidated

Net sales

$

1,524,768

$

940,401

$

$

2,465,169

Cost of goods sold

 

138,181

 

334,159

 

 

472,340

Selling, general and administrative expenses

 

1,711,019

 

663,591

 

1,523,128

 

3,897,738

Gain on settlement with Vivus

(3,389,941)

(3,389,941)

Research and development expenses

 

405,360

 

 

 

405,360

Depreciation and amortization expense

 

1,269,663

 

291,207

 

 

1,560,870

Change in fair value of derivative liability

 

 

 

(460,000)

 

(460,000)

Interest expense

 

 

 

153,026

 

153,026

Income tax (expense)

 

 

 

 

Net income (loss)

$

1,390,486

$

(348,556)

$

(1,216,154)

$

(174,224)

The Company’s results of operations by reportable segment for the three months ended March 31, 2021 are summarized as follows:

    

Prescription 

    

Medical 

    

    

Medications

    

Devices

    

Corporate

    

Consolidated

Net sales

$

3,200,647

$

874,959

$

$

4,075,606

Cost of goods sold

 

389,281

 

254,105

 

 

643,386

Selling, general and administrative expenses

 

1,734,333

 

546,995

 

1,600,389

 

3,881,717

Research and development expense

 

19,181

 

 

 

19,181

Depreciation and amortization expense

 

1,398,270

 

330,559

 

 

1,728,829

Change in fair value of derivative liability

(5,380,000)

(5,380,000)

Interest expense

 

 

 

173,412

 

173,412

Income tax benefit

 

 

 

 

Net income (loss)

$

(340,418)

$

(256,700)

$

3,606,199

$

3,009,081

Summary of net sales by geographic region

For the Three Months Ended

March 31, 

Net sales

    

2022

    

2021

United States

$

2,045,624

$

3,704,523

International

 

419,545

 

371,083

$

2,465,169

$

4,075,606

Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of March 31, 2022, are summarized as follows:

Prescription 

    

    

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

17,804,298

$

5,930,536

$

23,734,834

Total segment assets

$

48,240,984

$

7,623,163

$

55,864,147

The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2021, are summarized as follows:

Prescription 

    

Medications

    

Medical Devices

    

Consolidated

Intangible assets, net

$

19,071,407

$

6,221,742

$

25,293,149

Total segment assets

$

59,657,514

$

7,732,544

$

67,390,058

XML 51 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations, Basis of Presentation, and Liquidity (Details)
Dec. 07, 2020
USD ($)
Nature of Operations, Basis of Presentation, and Liquidity  
Cash in excess of certain limit, subject to adjustment as provided in the Merger Agreement $ 20,000,000
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details) - USD ($)
1 Months Ended 3 Months Ended
Jan. 31, 2022
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Nature of Operations, Basis of Presentation, and Liquidity        
Cash   $ 17,671,871   $ 23,847,572
Negative working capital   16,500,000    
Sustained cumulative losses attributable to common stockholders   (70,863,044)   $ (70,688,820)
Number of shares issued $ 10,201,758      
Cash in operations   $ (5,275,701) $ (446,581)  
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Reserves for product returns $ 3.8 $ 3.8
Revenue, Practical Expedient, Financing Component [true false] true  
Prescription Medication Sales    
Disaggregation of Revenue [Line Items]    
Reserves for sales deductions $ 4.7 $ 4.7
Medical Device Sales    
Disaggregation of Revenue [Line Items]    
Right to return and receive credit for product 90 days  
Minimum | Prescription Medication Sales    
Disaggregation of Revenue [Line Items]    
Due period for invoice payments 30 days  
Right to return and receive credit for product 6 months  
Minimum | Medical Device Sales | Domestic customers    
Disaggregation of Revenue [Line Items]    
Due period for invoice payments 30 days  
Maximum | Prescription Medication Sales    
Disaggregation of Revenue [Line Items]    
Due period for invoice payments 75 days  
Right to return and receive credit for product 1 year  
Maximum | Medical Device Sales | International Customers [Member]    
Disaggregation of Revenue [Line Items]    
Due period for invoice payments 90 days  
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Additional information (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Fair Value of Financial Instruments    
Fair value of the derivative liability $ 0 $ 500,000
Income Taxes    
Accrued interest or penalties $ 0 $ 0
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Receivable, net (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Accounts Receivable, net    
Gross accounts receivables $ 4,528,812 $ 3,363,827
Distribution service fees (317,247) (371,310)
Chargebacks accrual (5,880)  
Cash discount allowances (202,589) (159,446)
Allowance for doubtful accounts (262,321) (377,685)
Total accounts receivable, net $ 3,740,775 $ 2,455,386
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Accounts Receivable, net - Additional information (Details) - customer
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Gross sales from customers | Customer concentration risk      
Concentration Risk [Line Items]      
Number of customers 3 1  
Gross sales from customers | Customer concentration risk | One customers      
Concentration Risk [Line Items]      
Concentration risk percentage 30.00% 88.00%  
Gross sales from customers | Customer concentration risk | Two customers      
Concentration Risk [Line Items]      
Concentration risk percentage   23.00%  
Gross sales from customers | Customer concentration risk | Three customers      
Concentration Risk [Line Items]      
Concentration risk percentage 22.00%    
Receivables from customers | Credit concentration risk      
Concentration Risk [Line Items]      
Number of customers     3
Receivables from customers | Credit concentration risk | One customers      
Concentration Risk [Line Items]      
Concentration risk percentage 35.00%   40.00%
Receivables from customers | Credit concentration risk | Two customers      
Concentration Risk [Line Items]      
Concentration risk percentage 31.00%   19.00%
Number of customers 2    
Receivables from customers | Credit concentration risk | Three customers      
Concentration Risk [Line Items]      
Concentration risk percentage     15.00%
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Inventories    
Raw materials $ 1,854,160 $ 359,741
Finished goods 88,713 159,908
Total inventory $ 1,942,873 $ 519,649
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories - Additional Information (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Inventories    
Finished goods are net of valuation reserves $ 386,892 $ 383,298
Raw materials are net of valuation reserves $ 2,872,977 $ 2,872,977
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Prepaid Expenses and Other Current Assets (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Prepaid Expenses and Other Current Assets.    
Prepaid insurance $ 128,004 $ 73,223
Prepaid FDA fees 554,120 831,179
Prepaid coupon fees 71,500 71,500
API purchase commitment asset (see Note 13) 1,419,538 1,419,538
Due from wholesalers 609,059 609,059
Other prepaid expenses 624,823 605,422
Other current assets 75,542 110,167
Total prepaid expenses and other current assets $ 3,482,586 $ 3,720,088
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Finite-lived Intangible Assets [Roll Forward]    
Amortization expense $ (1,558,315) $ (6,867,770)
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets - Future annual amortization (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Intangible Assets      
2022 (remaining 9 months) $ 4,633,426    
2023 5,445,729    
2024 4,650,787    
2025 2,716,011    
2026 2,201,720    
Thereafter 4,087,161    
Total $ 23,734,834 $ 25,293,149 $ 32,160,919
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]      
Carrying value of intangible assets $ 23,734,834 $ 25,293,149 $ 32,160,919
Stendra Product      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives of intangible assets 10 years    
Carrying value of intangible assets $ 17,800,000 19,100,000  
Timm Medical product      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives of intangible assets 12 years    
Carrying value of intangible assets $ 4,600,000 4,900,000  
PTV product      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful lives of intangible assets 12 years    
Carrying value of intangible assets $ 1,300,000 $ 1,400,000  
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Accrued Expenses    
Accrued price protection (see note 13)   $ 1,853,979
Accrued product returns $ 3,763,211 6,192,845
Accrued contract rebates 376,937 379,242
Due to Vivus (see Note 13)   2,267,523
Due to third-party logistic provider 349,410 479,178
Accrued bonuses 532,729 527,563
Accrued professional fees 14,957 125,392
Other accrued expenses 474,762 131,662
Total accrued expenses $ 5,512,006 $ 11,957,384
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Promissory Note (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
Debt Instrument [Line Items]  
Interest expense $ 153,026
Note  
Debt Instrument [Line Items]  
Principal amount $ 10,201,758
Interest rate (in percent) 6.00%
Interest rate at the time of default (in percent) 9.00%
Interest expense $ 153,026
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Senior debt (Details) - Senior debt
Apr. 13, 2020
Mar. 31, 2020
Nov. 22, 2017
USD ($)
Sep. 30, 2016
USD ($)
Debt Instrument [Line Items]        
Face amount of debt     $ 1,068,750 $ 35,000,000
Stated interest rate 11.50% 10.75%   10.75%
Paid-In-Kind ("PIK") interest rate       1.35%
End of term charge     1,068,750 $ 787,500
Amount of principal prepaid     $ 10,000,000  
Percentage added to variable rate 11.50% 10.75%   10.75%
Minimum        
Debt Instrument [Line Items]        
Fixed charge coverage ratio     0.9  
Maximum        
Debt Instrument [Line Items]        
Fixed charge coverage ratio     1  
Prime rate        
Debt Instrument [Line Items]        
Spread on variable rate 4.25% 4.50%    
Stated interest rate       7.25%
Percentage added to variable rate       7.25%
Debt Instrument, Basis Spread on Variable Rate 4.25% 4.50%    
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Financial covenant (Details) - Senior debt - USD ($)
Feb. 01, 2021
Oct. 01, 2020
Apr. 13, 2020
Mar. 31, 2020
Nov. 22, 2017
Sep. 30, 2016
Debt Instrument [Line Items]            
Stated interest rate     11.50% 10.75%   10.75%
End of term fee paid $ 534,375 $ 534,375        
End of term charge         $ 1,068,750 $ 787,500
Prime rate            
Debt Instrument [Line Items]            
Stated interest rate           7.25%
Spread on variable rate     4.25% 4.50%    
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Third Amendment (Details) - USD ($)
Nov. 03, 2021
Sep. 30, 2020
Debt Instrument [Line Items]    
Repayment of senior debt $ 1,179,651  
Senior debt    
Debt Instrument [Line Items]    
Required cash proceeds through an equity or debt financing or other transaction   $ 25,000,000
Escrow fund   $ 1,500,000
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Interest Expenses (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Dec. 31, 2021
Debt    
Interest expense, senior debt $ 173,412  
Accrued and unpaid interest   $ 0
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Consummation of the Mergers (Details) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Stockholders' Equity    
Common stock, par value $ 0.0001 $ 0.0001
Preferred stock, par value $ 0.0001 $ 0.0001
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Number of shares held (Details)
Jan. 26, 2021
shares
Common Stock  
Class of Stock [Line Items]  
Number of common stock issued upon conversion 60,606
Preferred Stock  
Class of Stock [Line Items]  
Number of preferred stock converted 500
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Marketing and Consulting Agreement (Details) - USD ($)
Apr. 07, 2022
Jun. 04, 2021
Apr. 01, 2021
Jan. 01, 2021
Marketing and Consulting Agreement | CorProminence, LLC        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Term of agreement       1 year
Renewal term of agreement       1 year
Monthly retainer amount       $ 7,500,000
Number of restricted shares issued       30,000
Consulting and Advisory Agreement | Tania King        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Monthly retainer amount     $ 4,000,000  
Additional payment included with the first monthly fee     12,000,000  
Restricted share cash value     $ 72,000,000  
Vesting period     1 year  
Consulting and Advisory Agreement | Tania King | Subsequent event        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Issued additional grants 60,505      
Amount of additional grant $ 72,001      
Service Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Term of agreement   1 year    
Renewal term of agreement   1 year    
Monthly retainer amount   $ 6,750    
Number of restricted shares issued   28,338    
Restricted share cash value   $ 90,002    
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Contingent Consideration (Details)
3 Months Ended
Mar. 31, 2022
shares
Stockholders' Equity  
Common Stock potentially issuable upon the achievement of certain milestones 14,232,090
Milestones term for achievement of stock price and market capitalization 2 years
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Market Capitalization (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
D
$ / shares
shares
Dec. 31, 2021
USD ($)
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Fair value of the derivative liability $ 0 $ 500,000
Market Capitalization/Gross Proceeds Earnout Payments | Metuchen    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Milestone earnout payments (in shares) | shares 0 500,000
Market Capitalization/Gross Proceeds Earnout Payments | Maximum | Metuchen    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Milestone earnout payments (in shares) | shares 10,232,090  
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $250,000,000 | Metuchen    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Milestone earnout payments (in shares) | shares 2,000,000  
Market Capitalization $ 250,000,000  
Number of trading days for stock price trigger | D 20  
Number of consecutive trading days for stock price trigger | D 30  
Stock price | $ / shares $ 17.50  
Aggregate gross proceeds $ 25,000,000  
Term to receive gross proceeds 60 days  
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $300,000,000 | Metuchen    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Milestone earnout payments (in shares) | shares 2,000,000  
Market Capitalization $ 300,000,000  
Number of trading days for stock price trigger | D 20  
Number of consecutive trading days for stock price trigger | D 30  
Stock price | $ / shares $ 18.75  
Aggregate gross proceeds $ 30,000,000  
Term to receive gross proceeds 60 days  
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $400,000,000 | Metuchen    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Milestone earnout payments (in shares) | shares 3,000,000  
Market Capitalization $ 400,000,000  
Number of trading days for stock price trigger | D 20  
Number of consecutive trading days for stock price trigger | D 30  
Stock price | $ / shares $ 22.50  
Aggregate gross proceeds $ 40,000,000  
Term to receive gross proceeds 60 days  
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $500,000,000 | Metuchen    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Milestone earnout payments (in shares) | shares 3,232,090  
Market Capitalization $ 500,000,000  
Number of trading days for stock price trigger | D 20  
Number of consecutive trading days for stock price trigger | D 30  
Stock price | $ / shares $ 23.75  
Aggregate gross proceeds $ 50,000,000  
Term to receive gross proceeds 60 days  
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Restricted Stock Units ("RSU's") (Details) - shares
Dec. 22, 2021
Jan. 31, 2022
Stock Options and Restricted Stock Units ("RSU's")    
Number of shares authorized   2,600,000
Number of shares available for issuance 2,600,000 1,817,948
Number of shares increased for issuance 1,521,654  
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Restricted Stock Units ("RSU's") - Summary of stock options (Details) - $ / shares
3 Months Ended 12 Months Ended
Jan. 04, 2022
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Number of Shares        
Options outstanding and exercisable on beginning   615,669 574,331  
Options granted 50,000 50,000 615,669  
Less: options and RSU's expired/cancelled     (574,331)  
Options and RSU's outstanding at the end   665,669 615,669 574,331
Options and RSU's exercisable at the end   381,752    
Weighted-Average Exercise Price        
Options outstanding and exercisable at the beginning (in dollars per share)   $ 3.38 $ 51.43  
Options granted (in dollars per share) $ 3.34 3.34 3.38  
Less: options expired/cancelled (in dollars per share)     51.43  
Options outstanding at the end (in dollars per share)   3.38 $ 3.38 $ 51.43
Options exercisable at the end (in dollars per share)   $ 3.44    
Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value        
Options outstanding and exercisable at the beginning (in years)   9 years 21 days 9 years 2 months 23 days 10 months 24 days
Options granted (in years)   9 years 9 months 3 days 9 years 2 months 23 days  
Options outstanding at the end (in years)   9 years 21 days 9 years 2 months 23 days 10 months 24 days
Options exercisable at the end (in years)   9 years 25 days    
Restricted Stock Units        
Number of Shares        
Options outstanding and exercisable on beginning   116,383 0  
Options granted     116,383  
Options and RSU's outstanding at the end   116,383 116,383 0
Weighted-Average Exercise Price        
Options outstanding and exercisable at the beginning (in dollars per share)   $ 3.29 $ 0  
Options granted (in dollars per share)     3.29  
Options outstanding at the end (in dollars per share)   $ 3.29 $ 3.29 $ 0
Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value        
Options outstanding and exercisable at the beginning (in years)   9 years 7 months 6 days 9 years 10 months 2 days 0 years
Options granted (in years)     9 years 10 months 2 days  
Options outstanding at the end (in years)   9 years 7 months 6 days 9 years 10 months 2 days 0 years
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Options and Restricted Stock Units ("RSU's") - Additional Information (Details)
3 Months Ended 12 Months Ended
Apr. 07, 2022
director
$ / shares
shares
Jan. 04, 2022
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2021
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of options granted | shares   50,000 50,000   615,669
Exercise price | $ / shares   $ 3.34 $ 3.34   $ 3.38
Vesting percentage   100.00%      
Stock-based compensation expense | $     $ 355,828 $ 347,207  
Restricted Stock Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of options granted | shares         116,383
Exercise price | $ / shares         $ 3.29
Subsequent event          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage 100.00%        
Subsequent event | Restricted Stock Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of directors to whom option is granted | director 4        
Number of options granted | shares 248,742        
Exercise price | $ / shares $ 1.19        
Vesting period 1 year        
Tania King | Subsequent event | Restricted Stock Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Exercise price | $ / shares $ 1.19        
Vesting percentage 100.00%        
Vesting period 1 year        
Option grants | shares 60,505        
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Common Stock Warrants - Summary of warrants (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Common Stock Warrants    
Warrants outstanding at the beginning 10,039,021 4,407,962
Warrants issued 0 7,853,558
Warrants exercised 0 (2,014,586)
Warrants expired 0 (207,913)
Warrants outstanding at the end 10,039,021 10,039,021
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Common Stock Warrants - Company's warrants by expiration date (Details) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Class of Warrant or Right [Line Items]      
Number of Warrants 10,039,021 10,039,021 4,407,962
Expiration Date of August 23, 2023      
Class of Warrant or Right [Line Items]      
Number of Warrants 2,780    
Exercise Price $ 1.60    
Expiration Date of June 1, 2024      
Class of Warrant or Right [Line Items]      
Number of Warrants 22,800    
Exercise Price $ 35.65    
Expiration Date of June 17, 2024      
Class of Warrant or Right [Line Items]      
Number of Warrants 74,864    
Exercise Price $ 21.85    
Expiration Date of June 19, 2024      
Class of Warrant or Right [Line Items]      
Number of Warrants 20,043    
Exercise Price $ 31.25    
Expiration Date of September 1, 2024      
Class of Warrant or Right [Line Items]      
Number of Warrants 22,800    
Exercise Price $ 26.55    
Expiration Date of September 16, 2024      
Class of Warrant or Right [Line Items]      
Number of Warrants 10,500    
Exercise Price $ 12.738    
Expiration Date of December 1, 2024      
Class of Warrant or Right [Line Items]      
Number of Warrants 22,800    
Exercise Price $ 4.30    
Expiration Date of March 2, 2025      
Class of Warrant or Right [Line Items]      
Number of Warrants 28,000    
Exercise Price $ 5.65    
Expiration Date of June 1, 2025      
Class of Warrant or Right [Line Items]      
Number of Warrants 28,000    
Exercise Price $ 7.30    
Expiration Date of September 1, 2025      
Class of Warrant or Right [Line Items]      
Number of Warrants 28,000    
Exercise Price $ 5.50    
Expiration Date of December 1, 2025, One      
Class of Warrant or Right [Line Items]      
Number of Warrants 28,000    
Exercise Price $ 4.705    
Expiration Date of December 1, 2025, Two      
Class of Warrant or Right [Line Items]      
Number of Warrants 2,221,829    
Exercise Price $ 7.50    
Expiration Date of December 1, 2025, Three      
Class of Warrant or Right [Line Items]      
Number of Warrants 908,498    
Exercise Price $ 17.50    
Expiration Date of December 1, 2025, Four      
Class of Warrant or Right [Line Items]      
Number of Warrants 623,303    
Exercise Price $ 51.25    
Expiration Date of December 1, 2025, Five      
Class of Warrant or Right [Line Items]      
Number of Warrants 157,832    
Exercise Price $ 125.00    
Expiration Date Of October 19 2026      
Class of Warrant or Right [Line Items]      
Number of Warrants 1,751,311    
Exercise Price $ 1.715    
Expiration Date of December 2, 2026      
Class of Warrant or Right [Line Items]      
Number of Warrants 2,337,719    
Exercise Price $ 3.50    
Expiration Date of December 27, 2026      
Class of Warrant or Right [Line Items]      
Number of Warrants 1,749,942    
Exercise Price $ 3.50    
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator    
Net (loss) income $ (174,224) $ 3,009,081
Weighted average common shares outstanding    
Weighted-average common shares for basic net loss per unit 20,684,723 9,753,086
Effect of common share equivalents within common stock warrants   1,600
Weighted-average common shares for diluted net loss per unit 20,684,723 9,754,686
Basic net loss per common share $ (0.01) $ 0.31
Diluted net loss per common share $ (0.01) $ 0.31
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details) - shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 10,821,073 5,195,182
Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 665,669 790,000
RSUs    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 116,383  
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 10,039,021 4,405,182
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Marketing, Licensing and Distribution Agreements - Vivus (Details)
3 Months Ended
Jan. 18, 2022
USD ($)
Sep. 30, 2016
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Noncash decrease in accrued expenses related to Vivus settlement     $ (6,520,283)    
Noncash decrease in accrued inventory purchases related to Vivus settlement     (14,203,905)    
Gain on settlement with Vivus     3,389,941    
API purchase commitment asset     1,419,538   $ 1,419,538
License Agreement | Royalty on the first $500 million of net sales          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Threshold net sales     500,000,000    
License Agreement | Milestone payment to be paid once $250 million in sales has been reached          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Threshold net sales     250,000,000    
Milestone payment     6,000,000    
License Agreement | Milestone payment to be paid after $250 million in sales has been reached          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Threshold net sales     250,000,000    
Milestone payment     $ 3,200,000    
License Agreement | Vivus, Inc          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
One-time fee to purchase and receive the license for the commercialization and exploitation of Stendra   $ 70,000,000      
License Agreement | Vivus, Inc | Royalty during the first, second, and third years following the expiration of the Royalty Period          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty percentage     2.00%    
License Agreement | Vivus, Inc | Royalty following the fourth and fifth years following the end of the Royalty Period          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty percentage     1.00%    
License Agreement | MTPC          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty incurred     $ 76,238 $ 160,032  
Royalty receivable     $ 4,897   81,136
License Agreement | MTPC | Royalty on the first $500 million of net sales          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty percentage     5.00%    
License Agreement | MTPC | Royalty on net sales after $500 million          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty percentage     6.00%    
Settlement Agreement | Vivus, Inc          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Inventory amount retained - API $ 7,300,000        
Payment made for purchase order $ 1,542,904        
Percentage of stendra tablets released 50        
Threshold number of days to release remaining percentage of stendra Tablets upon satisfaction 180 days        
Noncash decrease in accrued expenses related to Vivus settlement     $ 6,500,000    
Noncash decrease in accrued inventory purchases related to Vivus settlement     14,200,000    
Gain on settlement with Vivus     3,400,000    
Decrease in API purchase commitment     6,200,000    
Accrued inventory purchases     0   14,200,000
Settlement Agreement | Vivus, Inc | Other Current Assets [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
API purchase commitment asset     1,400,000   1,400,000
Settlement Agreement | Vivus, Inc | Other Noncurrent Assets [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accrued inventory purchases, non-current     4,800,000   $ 11,000,000.0
Settlement Agreement | Vivus, Inc | Promissory Note          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Principal amount of notes payable $ 10,201,758   $ 10,200,000    
Prepayment amount $ 900,000        
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Marketing, Licensing and Distribution Agreements - Hybrid (Details) - Hybrid - USD ($)
1 Months Ended
Mar. 24, 2022
Dec. 23, 2021
Dec. 01, 2021
Oct. 31, 2021
Oct. 01, 2021
Mar. 31, 2021
Sep. 24, 2020
Dec. 31, 2020
Oct. 31, 2020
Mar. 31, 2020
Exclusive license to H100                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Initial license fee                   $ 100,000
Additional payment due upon obtainment of orphan indication for H100                   900,000
Annual payments due on first anniversary of the license agreement                   125,000
Annual payments due on second anniversary of the license agreement                   150,000
Annual payments due on third anniversary of the license agreement                   200,000
Annual payments due after third anniversary of the license agreement                   250,000
Payments upon first commercial sale and a sliding scale of percentage payments on net sales                   $ 1,000,000
Threshold period of notice required to terminate agreement at any time after first anniversary                   90 days
Extension payment of license agreement               $ 100,000 $ 50,000  
Extension term of license agreement           6 months 6 months      
One-time, non-creditable and non-refundable payment           $ 200,000        
Threshold period for payments of one-time, non-creditable and non-refundable payment           7 days        
Exclusive license to H100 | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Royalty percentage                   3.00%
Exclusive license to H100 | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Royalty percentage                   6.00%
Amended license agreement of H100                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Payment of License Fees $ 150,000 $ 200,000 $ 200,000 $ 200,000 $ 150,000          
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details) - Separation Agreement - Mr. Keith Lavan
Dec. 31, 2020
USD ($)
Commitments And Contingencies [Line Items]  
Stay-on bonus $ 50,000
Percentage of base salary to be paid as an advisor 50.00%
Percentage of fees as an advisor paid 70.00%
Percentage of fees as an advisor to be paid in equal installments 30.00%
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Operating Leases (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Jan. 10, 2022
Lessee, Lease, Description [Line Items]    
Security deposit received for sublease   $ 14,000
Operating lease expense per month $ 7,000  
Minimum    
Lessee, Lease, Description [Line Items]    
Remaining lease terms 2 years 4 months 24 days  
Maximum    
Lessee, Lease, Description [Line Items]    
Remaining lease terms 4 years 9 months 18 days  
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Lease expense (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Lease Cost:    
Fixed lease cost $ 44,812 $ 44,812
Amount of fixed lease cost which are offset by sublease income $ 21,000  
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Supplemental balance sheet (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Supplemental balance sheet information related to leases    
Operating lease ROU asset: Other assets $ 447,595 $ 475,557
Operating lease ROU asset Other assets  
Operating lease liability:    
Operating lease liability, current $ 129,458 125,579
Other current liabilities Other current liabilities  
Operating lease liability, noncurrent $ 371,053 405,018
Other long-term liabilities Other long-term liabilities  
Total operating lease liability $ 500,511 $ 530,597
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Lease term and discount (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Commitments and Contingencies      
Weighted-average remaining lease terms - operating leases 3 years 4 months 24 days   3 years 8 months 12 days
Weighted-average discount rate - operating leases 12.60%   12.60%
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash flows from operating leases $ 46,935 $ 45,942  
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Minimum lease payments (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Future minimum lease payments under non-cancelable leases    
2022 (remaining 9 months) $ 140,805  
2023 189,374  
2024 155,242  
2025 81,107  
2026 82,324  
Total lease payments 648,852  
Less: Imputed Interest (148,341)  
Total operating lease liability $ 500,511 $ 530,597
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Future Minimum Sublease Income (Details)
Mar. 31, 2022
USD ($)
Operating Leases, Future Minimum Payments Receivable, Sub-lease [Abstract]  
2022 (remaining 9 months) $ 63,000
2023 84,000
2024 56,000
Total $ 203,000
XML 90 R72.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Additional information (Details)
Mar. 31, 2022
USD ($)
Commitments and Contingencies  
Operating leases that had not yet commenced $ 0
XML 91 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
segment
Mar. 31, 2021
USD ($)
Results of operations by reportable segment    
Net sales $ 2,465,169 $ 4,075,606
Cost of goods sold 472,340 643,386
Selling, general and administrative expenses 3,897,738 3,881,717
Gain on settlement with Vivus (3,389,941)  
Research and development expenses 405,360 19,181
Depreciation and amortization expense 1,560,870 1,728,829
Change in fair value of derivative liability (460,000) (5,380,000)
Interest expense 153,026 173,412
Net income (loss) $ (174,224) 3,009,081
Operating segments    
Segment Reporting Information [Line Items]    
Number of Operating Segments | segment 2  
Corporate    
Results of operations by reportable segment    
Selling, general and administrative expenses $ 1,523,128 1,600,389
Change in fair value of derivative liability (460,000) (5,380,000)
Interest expense 153,026 173,412
Net income (loss) (1,216,154) 3,606,199
Prescription Medication Sales    
Results of operations by reportable segment    
Net sales 1,524,768 3,200,647
Cost of goods sold 138,181 389,281
Selling, general and administrative expenses 1,711,019 1,734,333
Gain on settlement with Vivus (3,389,941)  
Research and development expenses 405,360 19,181
Depreciation and amortization expense 1,269,663 1,398,270
Net income (loss) 1,390,486 (340,418)
Medical Device Sales    
Results of operations by reportable segment    
Net sales 940,401 874,959
Cost of goods sold 334,159 254,105
Selling, general and administrative expenses 663,591 546,995
Depreciation and amortization expense 291,207 330,559
Net income (loss) $ (348,556) $ (256,700)
XML 92 R74.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information - Net Sales by Geographic region (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]    
Net sales $ 2,465,169 $ 4,075,606
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Net sales 2,045,624 3,704,523
International    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Net sales $ 419,545 $ 371,083
XML 93 R75.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information - Segment assets (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]    
Intangible assets, net $ 23,734,834 $ 25,293,149
Total segment assets 55,864,147 67,390,058
Prescription Medication Sales    
Segment Reporting, Asset Reconciling Item [Line Items]    
Intangible assets, net 17,804,298 19,071,407
Total segment assets 48,240,984 59,657,514
Medical Device Sales    
Segment Reporting, Asset Reconciling Item [Line Items]    
Intangible assets, net 5,930,536 6,221,742
Total segment assets $ 7,623,163 $ 7,732,544
XML 94 tmb-20220331x10q_htm.xml IDEA: XBRL DOCUMENT 0001815903 2022-01-01 2022-01-31 0001815903 us-gaap:CommonStockMember 2021-01-26 2021-01-26 0001815903 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001815903 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001815903 us-gaap:RetainedEarningsMember 2022-03-31 0001815903 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001815903 us-gaap:RetainedEarningsMember 2021-12-31 0001815903 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001815903 us-gaap:RetainedEarningsMember 2021-03-31 0001815903 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001815903 us-gaap:RetainedEarningsMember 2020-12-31 0001815903 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001815903 us-gaap:CommonStockMember 2022-03-31 0001815903 us-gaap:CommonStockMember 2021-12-31 0001815903 us-gaap:CommonStockMember 2021-03-31 0001815903 us-gaap:PreferredStockMember 2020-12-31 0001815903 us-gaap:CommonStockMember 2020-12-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001815903 2020-01-01 2020-12-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001815903 2021-12-22 2021-12-22 0001815903 2021-12-22 0001815903 2022-01-31 0001815903 us-gaap:SubsequentEventMember 2022-04-07 2022-04-07 0001815903 2022-01-04 2022-01-04 0001815903 ptpi:TaniaKingMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2022-04-07 2022-04-07 0001815903 ptpi:MitsubishiTanabePharmaCorporationMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:MitsubishiTanabePharmaCorporationMember ptpi:LicenseAgreementMember 2021-01-01 2021-03-31 0001815903 us-gaap:NonUsMember 2022-01-01 2022-03-31 0001815903 country:US 2022-01-01 2022-03-31 0001815903 us-gaap:NonUsMember 2021-01-01 2021-03-31 0001815903 country:US 2021-01-01 2021-03-31 0001815903 2021-11-03 2021-11-03 0001815903 us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0001815903 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001815903 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001815903 srt:MinimumMember 2022-03-31 0001815903 srt:MaximumMember 2022-03-31 0001815903 ptpi:TimmMedicalProductMember 2022-01-01 2022-03-31 0001815903 ptpi:StendraProductMember 2022-01-01 2022-03-31 0001815903 ptpi:PtvProductMember 2022-01-01 2022-03-31 0001815903 ptpi:TimmMedicalProductMember 2022-03-31 0001815903 ptpi:StendraProductMember 2022-03-31 0001815903 ptpi:PtvProductMember 2022-03-31 0001815903 ptpi:TimmMedicalProductMember 2021-12-31 0001815903 ptpi:StendraProductMember 2021-12-31 0001815903 ptpi:PtvProductMember 2021-12-31 0001815903 us-gaap:SeniorDebtObligationsMember 2020-09-30 0001815903 us-gaap:SeniorDebtObligationsMember 2017-11-22 2017-11-22 0001815903 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0001815903 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0001815903 us-gaap:SeniorDebtObligationsMember 2020-04-13 0001815903 us-gaap:SeniorDebtObligationsMember 2020-03-31 0001815903 us-gaap:SeniorDebtObligationsMember us-gaap:PrimeRateMember 2016-09-30 0001815903 ptpi:VivusIncMember ptpi:PromissoryNoteMember ptpi:SettlementAgreementMember 2022-03-31 0001815903 us-gaap:NotesPayableOtherPayablesMember 2022-03-31 0001815903 us-gaap:SeniorDebtObligationsMember us-gaap:PrimeRateMember 2020-04-13 2020-04-13 0001815903 us-gaap:SeniorDebtObligationsMember us-gaap:PrimeRateMember 2020-03-31 2020-03-31 0001815903 ptpi:PrescriptionMedicationSalesMember 2021-01-01 2021-03-31 0001815903 ptpi:MedicalDeviceSalesMember 2021-01-01 2021-03-31 0001815903 us-gaap:PreferredStockMember 2021-01-26 2021-01-26 0001815903 ptpi:ThreeCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001815903 ptpi:OneCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001815903 ptpi:OneCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-03-31 0001815903 ptpi:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0001815903 ptpi:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0001815903 ptpi:OneCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0001815903 ptpi:TwoCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001815903 ptpi:OneCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001815903 ptpi:ExpirationDateOfSeptember162024Member 2022-03-31 0001815903 ptpi:ExpirationDateOfSeptember12025Member 2022-03-31 0001815903 ptpi:ExpirationDateOfSeptember12024Member 2022-03-31 0001815903 ptpi:ExpirationDateOfOctober192026Member 2022-03-31 0001815903 ptpi:ExpirationDateOfMarch22025Member 2022-03-31 0001815903 ptpi:ExpirationDateOfJune192024Member 2022-03-31 0001815903 ptpi:ExpirationDateOfJune172024Member 2022-03-31 0001815903 ptpi:ExpirationDateOfJune12025Member 2022-03-31 0001815903 ptpi:ExpirationDateOfJune12024Member 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember272026Member 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember22026Member 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember12025TwoMember 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember12025ThreeMember 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember12025OneMember 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember12025FourMember 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember12025FiveMember 2022-03-31 0001815903 ptpi:ExpirationDateOfDecember12024Member 2022-03-31 0001815903 ptpi:ExpirationDateOfAugust232023Member 2022-03-31 0001815903 2021-03-31 0001815903 2020-12-31 0001815903 ptpi:MedicalDeviceSalesMember 2022-03-31 0001815903 ptpi:MedicalDeviceSalesMember 2021-12-31 0001815903 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001815903 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001815903 ptpi:RestrictedStockUnitsMember 2022-01-01 2022-03-31 0001815903 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001815903 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001815903 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001815903 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001815903 ptpi:VivusIncMember ptpi:SettlementAgreementMember 2022-01-18 2022-01-18 0001815903 ptpi:TaniaKingMember us-gaap:SubsequentEventMember ptpi:ConsultingAndAdvisoryAgreementMember 2022-04-07 2022-04-07 0001815903 srt:MaximumMember ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-01-01 2022-03-31 0001815903 ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-01-01 2022-03-31 0001815903 ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2021-01-01 2021-12-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001815903 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2022-04-07 2022-04-07 0001815903 ptpi:TaniaKingMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2022-04-07 0001815903 2022-01-10 0001815903 ptpi:MitsubishiTanabePharmaCorporationMember ptpi:LicenseAgreementMember 2022-03-31 0001815903 ptpi:MitsubishiTanabePharmaCorporationMember ptpi:LicenseAgreementMember 2021-12-31 0001815903 us-gaap:SeniorDebtObligationsMember 2020-09-30 2020-09-30 0001815903 ptpi:VivusIncMember ptpi:PromissoryNoteMember ptpi:SettlementAgreementMember 2022-01-18 0001815903 ptpi:VivusIncMember us-gaap:OtherCurrentAssetsMember ptpi:SettlementAgreementMember 2022-03-31 0001815903 ptpi:VivusIncMember us-gaap:OtherCurrentAssetsMember ptpi:SettlementAgreementMember 2021-12-31 0001815903 ptpi:Mr.KeithLavanMember ptpi:SeparationAgreementMember 2020-12-31 2020-12-31 0001815903 ptpi:HybridMember ptpi:AmendedLicenseAgreementOfH100Member 2022-03-24 2022-03-24 0001815903 ptpi:HybridMember ptpi:AmendedLicenseAgreementOfH100Member 2021-12-23 2021-12-23 0001815903 ptpi:HybridMember ptpi:AmendedLicenseAgreementOfH100Member 2021-12-01 2021-12-01 0001815903 ptpi:HybridMember ptpi:AmendedLicenseAgreementOfH100Member 2021-10-31 2021-10-31 0001815903 ptpi:HybridMember ptpi:AmendedLicenseAgreementOfH100Member 2021-10-01 2021-10-01 0001815903 ptpi:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-03-31 0001815903 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001815903 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0001815903 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo500000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-01-01 2022-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo400000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-01-01 2022-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo300000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-01-01 2022-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo250000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-01-01 2022-03-31 0001815903 ptpi:ServiceAgreementWithIrthCommunicationsLlcMember 2021-06-04 2021-06-04 0001815903 ptpi:CorprominenceLlcMember ptpi:MarketingAndConsultingAgreementMember 2021-01-01 2021-01-01 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo500000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo400000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo300000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-03-31 0001815903 ptpi:MarketCapitalizationIsGreaterThanOrEqualTo250000000Member ptpi:MetuchenPharmaceuticalsLlcMember ptpi:MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember 2022-03-31 0001815903 2021-01-01 2021-03-31 0001815903 ptpi:VivusIncMember ptpi:SettlementAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:PrescriptionMedicationSalesMember 2022-01-01 2022-03-31 0001815903 ptpi:InternationalCustomersMember srt:MaximumMember ptpi:MedicalDeviceSalesMember 2022-01-01 2022-03-31 0001815903 ptpi:DomesticCustomersMember srt:MinimumMember ptpi:MedicalDeviceSalesMember 2022-01-01 2022-03-31 0001815903 us-gaap:SeniorDebtObligationsMember 2016-09-30 2016-09-30 0001815903 srt:MinimumMember us-gaap:SeniorDebtObligationsMember 2017-11-22 0001815903 srt:MaximumMember us-gaap:SeniorDebtObligationsMember 2017-11-22 0001815903 us-gaap:SeniorDebtObligationsMember 2021-02-01 2021-02-01 0001815903 us-gaap:SeniorDebtObligationsMember 2020-10-01 2020-10-01 0001815903 us-gaap:SeniorDebtObligationsMember 2017-11-22 0001815903 us-gaap:SeniorDebtObligationsMember 2016-09-30 0001815903 us-gaap:NotesPayableOtherPayablesMember 2022-01-01 2022-03-31 0001815903 ptpi:PrescriptionMedicationSalesMember 2022-03-31 0001815903 ptpi:PrescriptionMedicationSalesMember 2021-12-31 0001815903 srt:MinimumMember ptpi:PrescriptionMedicationSalesMember 2022-01-01 2022-03-31 0001815903 srt:MaximumMember ptpi:PrescriptionMedicationSalesMember 2022-01-01 2022-03-31 0001815903 ptpi:MedicalDeviceSalesMember 2022-01-01 2022-03-31 0001815903 ptpi:ScenarioSixMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:ScenarioOneMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:ScenarioFiveMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:VivusIncMember ptpi:ScenarioThreeMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:VivusIncMember ptpi:ScenarioFourMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:MitsubishiTanabePharmaCorporationMember ptpi:ScenarioTwoMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:MitsubishiTanabePharmaCorporationMember ptpi:ScenarioOneMember ptpi:LicenseAgreementMember 2022-01-01 2022-03-31 0001815903 ptpi:HybridMember srt:MinimumMember ptpi:ExclusiveLicenseToH100Member 2020-03-01 2020-03-31 0001815903 ptpi:HybridMember srt:MaximumMember ptpi:ExclusiveLicenseToH100Member 2020-03-01 2020-03-31 0001815903 ptpi:HybridMember ptpi:ExclusiveLicenseToH100Member 2020-03-31 0001815903 ptpi:HybridMember ptpi:ExclusiveLicenseToH100Member 2020-12-01 2020-12-31 0001815903 ptpi:HybridMember ptpi:ExclusiveLicenseToH100Member 2020-10-01 2020-10-31 0001815903 ptpi:VivusIncMember ptpi:LicenseAgreementMember 2016-09-30 2016-09-30 0001815903 ptpi:ScenarioSixMember ptpi:LicenseAgreementMember 2022-03-31 0001815903 ptpi:ScenarioFiveMember ptpi:LicenseAgreementMember 2022-03-31 0001815903 ptpi:HybridMember ptpi:ExclusiveLicenseToH100Member 2021-03-31 2021-03-31 0001815903 ptpi:HybridMember ptpi:ExclusiveLicenseToH100Member 2020-09-24 2020-09-24 0001815903 ptpi:HybridMember ptpi:ExclusiveLicenseToH100Member 2020-03-01 2020-03-31 0001815903 ptpi:VivusIncMember us-gaap:OtherNoncurrentAssetsMember ptpi:SettlementAgreementMember 2022-03-31 0001815903 ptpi:VivusIncMember us-gaap:OtherNoncurrentAssetsMember ptpi:SettlementAgreementMember 2021-12-31 0001815903 ptpi:VivusIncMember ptpi:SettlementAgreementMember 2022-03-31 0001815903 ptpi:VivusIncMember ptpi:SettlementAgreementMember 2021-12-31 0001815903 2021-01-01 2021-12-31 0001815903 2020-12-07 0001815903 ptpi:VivusIncMember ptpi:SettlementAgreementMember 2022-01-18 0001815903 ptpi:TaniaKingMember ptpi:ConsultingAndAdvisoryAgreementMember 2021-04-01 2021-04-01 0001815903 2022-03-31 0001815903 2021-12-31 0001815903 2022-05-13 0001815903 2022-01-01 2022-03-31 shares iso4217:USD pure ptpi:D ptpi:customer ptpi:director iso4217:USD shares ptpi:segment -0.01 0.31 10039021 0 0 0 10039021 0 0 20684723 20684723 0001815903 --12-31 2022 Q1 true P60D P60D P60D P60D P0Y -0.01 0.31 P90D P6M P7D http://fasb.org/us-gaap/2021-01-31#OtherAssets http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent false 10-Q true 2022-03-31 false 001-39752 Petros Pharmaceuticals, Inc. DE 85-1410058 1185 Avenue of the Americas 3rd Floor New York NY 10036 973 242-0005 Common stock PTPI NASDAQ Yes Yes Non-accelerated Filer true true false false 20684723 17671871 23847572 3740775 2455386 1942873 519649 3482586 3720088 26838105 30542695 46842 49397 23734834 25293149 4796771 11029260 447595 475557 55864147 67390058 3700326 4557969 5512006 11957384 14203905 352436 260818 723982 10288750 30980076 9477776 460000 371053 405018 20137579 31845094 0.0001 0.0001 50000000 50000000 0 0 0.0001 0.0001 150000000 150000000 20684723 20684723 2068 2068 106587544 106231716 -70863044 -70688820 35726568 35544964 55864147 67390058 2465169 4075606 472340 643386 1992829 3432220 3897738 3881717 3389941 405360 19181 1560870 1728829 2474027 5629727 -481198 -2197507 460000 5380000 173412 153026 -174224 3009081 -0.01 0.31 20684723 9753086 1600 20684723 9754686 20684723 2068 106231716 -70688820 35544964 355828 355828 -174224 -174224 20684723 2068 106587544 -70863044 35726568 500 9707655 971 79170225 -61702144 17469052 -500 60606 6 -6 30000 3 97797 97800 347207 347207 3009081 3009081 9798261 980 79615223 -58693063 20923140 -174224 3009081 1560870 1728829 -115364 2984 3594 48228 12500 27962 25156 460000 5380000 -70343 3389941 355828 347207 97800 1170025 1044213 1426818 -193987 -237502 -172051 -857643 -333273 74905 698498 161961 74992 -33965 -100408 -5275701 -446581 -900000 1592028 -534375 -900000 -2126403 -6175701 -2572984 23847572 17139694 17671871 14566710 176677 -6520283 -14203905 10201758 6232489 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1)    Nature of Operations, Basis of Presentation, and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) is a pharmaceutical company focused on men’s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Petros consists of wholly owned subsidiaries, Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). The Company is engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration (“FDA”) approved PDE 5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”), which we have licensed from Vivus, Inc. (“Vivus”). Petros also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, we have acquired an exclusive global license to develop and commercialize H100™, a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was organized as a Delaware corporation on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Merger Agreement”), by and between Petros, Neurotrope,, PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen. The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly-owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.), a Delaware corporation (“Synaptogenix”), and a wholly-owned subsidiary of Neurotrope.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP. In the opinion of management, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, considered necessary to present fairly our financial position, results of operations and cash flows. However, actual results could differ from those estimates. The unaudited interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission. This Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All transactions between the consolidated entities have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has experienced net losses and negative cash flows from operations since our inception. As of March 31, 2022, the Company had cash of $17.7 million, positive working capital of $16.5 million, an accumulated deficit of $70.9 million and used cash in operations during the three months ended March 31, 2022 of $5.3 million. The Company’s plans include, or may include, utilizing its cash and cash equivalents on hand, as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. In January 2022, the Company executed a promissory note in favor of Vivus in connection with the Vivus Settlement Agreement in the principal amount of $10,201,758. The terms of this promissory note are discussed in Note 8. The Company believes the cash on hand is sufficient to fund operations and debt service through at least May 16, 2023, however for periods after May 16, </p> 20000000 17700000 16500000 -70900000 -5300000 10201758 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2)    Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The World Health Organization (“WHO”) declared the coronavirus (“COVID-19”) a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic, including the emergence of any new variants, such as the Omicron variants, will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2022 and beyond.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices. In January 2022, the Company sub-leased its Manalapan office and all administrative employees are working remotely for the foreseeable future. The Company has fully resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. Since the beginning of the COVID-19 pandemic, we have experienced a shift from in-person sales to online, telehealth-based sales. These online sales generally have lower gross margins than in-person sales, which has impacted our net revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Prescription Medication Sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition (“Topic 606”), the Company recognizes revenue from prescription medication sales when its performance obligations with a customer has been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide Stendra® upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of Stendra®, which is typically upon delivery. The Company invoices its customers after Stendra® has been delivered and invoice payments are generally due within 30 to 75 days of invoice date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022 and December 31, 2021, the reserves for sales deductions were $4.7 million and $4.7 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Product Returns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of March 31, 2022 and December 31, 2021, the reserves for product returns were $3.8 million and $3.8 million, respectively, and are included as a component of accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contract Rebates, Coupon Redemptions and DSA Fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. See Note 3 Accounts Receivable, net for further discussion of these reserves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Medical Device Sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In determining the transaction price, a significant <span style="-sec-ix-hidden:Hidden_vVnMxk33qE6bnVOnfvObfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financing component</span></span> does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Product Returns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of March 31, 2022 and December 31, 2021, the reserves for product returns for medical devices were not significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at March 31, 2022 and December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level 1 — Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities. The Company believes that the carrying values of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to the short-term nature of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of March 31, 2022 and December 31, 2021 was $0 million and $0.5 million, respectively. See Note 9 Stockholders’ Equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 10 Stock Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a C corporation, which accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of March 31, 2022 and December 31, 2021, no accrued interest or penalties are recorded in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of shares of common stocks outstanding during the period, excluding the anti-dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the three months ended March 31, 2022. See Note 13 Basic and Diluted Net Loss per Common Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Pending Adoption as of March 31, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13, together with a series of subsequently issued related ASUs, has been codified in Topic 326. Topic 326 establishes new requirements for companies to estimate expected credit losses when measuring certain financial assets, including accounts receivables. The new guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the effect that the new guidance will have on its consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The World Health Organization (“WHO”) declared the coronavirus (“COVID-19”) a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic, including the emergence of any new variants, such as the Omicron variants, will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2022 and beyond.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Prescription Medication Sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition (“Topic 606”), the Company recognizes revenue from prescription medication sales when its performance obligations with a customer has been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide Stendra® upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of Stendra®, which is typically upon delivery. The Company invoices its customers after Stendra® has been delivered and invoice payments are generally due within 30 to 75 days of invoice date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022 and December 31, 2021, the reserves for sales deductions were $4.7 million and $4.7 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Product Returns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of March 31, 2022 and December 31, 2021, the reserves for product returns were $3.8 million and $3.8 million, respectively, and are included as a component of accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contract Rebates, Coupon Redemptions and DSA Fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. See Note 3 Accounts Receivable, net for further discussion of these reserves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Medical Device Sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In determining the transaction price, a significant <span style="-sec-ix-hidden:Hidden_vVnMxk33qE6bnVOnfvObfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financing component</span></span> does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Product Returns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of March 31, 2022 and December 31, 2021, the reserves for product returns for medical devices were not significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at March 31, 2022 and December 31, 2021.</p> P30D P75D 4700000 4700000 P6M P1Y 3800000 3800000 P30D P90D P90D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level 1 — Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities. The Company believes that the carrying values of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to the short-term nature of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of March 31, 2022 and December 31, 2021 was $0 million and $0.5 million, respectively. See Note 9 Stockholders’ Equity.</p> 0 500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 10 Stock Options.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a C corporation, which accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of March 31, 2022 and December 31, 2021, no accrued interest or penalties are recorded in the consolidated balance sheet.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of shares of common stocks outstanding during the period, excluding the anti-dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the three months ended March 31, 2022. See Note 13 Basic and Diluted Net Loss per Common Share.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Pending Adoption as of March 31, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13, together with a series of subsequently issued related ASUs, has been codified in Topic 326. Topic 326 establishes new requirements for companies to estimate expected credit losses when measuring certain financial assets, including accounts receivables. The new guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the effect that the new guidance will have on its consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3)    Accounts Receivable, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts receivable, net is comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross accounts receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,528,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,363,827</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Distribution service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (317,247)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (371,310)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chargebacks accrual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash discount allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (202,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (159,446)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (262,321)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (377,685)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,740,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,455,386</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2022, gross sales from customers representing 10% or more of the Company’s total gross sales included three customers which represented approximately 30%, 23% and 22% of total gross sales, respectively. For the three months ended March 31, 2021, gross sales from customers representing 10% or more of the Company’s total gross sales included one customer which represented approximately 88% of total gross sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Receivables from customers representing 10% or more of the Company’s gross accounts receivable included two customers at March 31, 2022 equal to 35% and 31%, respectively, of the Company’s total gross accounts receivables. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included three customers at December 31, 2021 equal to 40%, 19% and 15%, respectively, of the Company’s total gross accounts receivables.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross accounts receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,528,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,363,827</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Distribution service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (317,247)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (371,310)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chargebacks accrual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash discount allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (202,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (159,446)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (262,321)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (377,685)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,740,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,455,386</p></td></tr></table> 4528812 3363827 317247 371310 5880 202589 159446 262321 377685 3740775 2455386 3 0.30 0.23 0.22 1 0.88 2 0.35 0.31 3 0.40 0.19 0.15 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4)    Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inventory is comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,854,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 359,741</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159,908</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,942,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519,649</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Finished goods are net of valuation reserves of $386,892 and $383,298 as of March 31, 2022 and December 31, 2021, respectively. Raw materials are net of valuation reserves of $2,872,977 as of March 31, 2022 and December 31, 2021, which is related to bulk inventory that is fully reserved.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,854,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 359,741</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159,908</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,942,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 519,649</p></td></tr></table> 1854160 359741 88713 159908 1942873 519649 386892 383298 2872977 2872977 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5)    Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prepaid expenses and other current assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,223</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid FDA fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 554,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 831,179</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid coupon fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,500</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">API purchase commitment asset (see Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,419,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,419,538</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due from wholesalers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 609,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 609,059</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 605,422</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110,167</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,482,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,720,088</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,223</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid FDA fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 554,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 831,179</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid coupon fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,500</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">API purchase commitment asset (see Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,419,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,419,538</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due from wholesalers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 609,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 609,059</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 605,422</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110,167</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,482,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,720,088</p></td></tr></table> 128004 73223 554120 831179 71500 71500 1419538 1419538 609059 609059 624823 605422 75542 110167 3482586 3720088 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">6)    Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,160,919</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,867,770)</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,293,149</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,558,315)</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,734,834</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The future annual amortization related to the Company’s intangible assets is as follows as of March 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining 9 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,633,426</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,445,729</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,650,787</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,716,011</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,201,720</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,087,161</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,734,834</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years, 12 years, and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of March 31, 2022 are $17.8 million, $4.6 million and $1.3 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2021 were $19.1 million, $4.9 million and $1.4 million, respectively. The Company determined that no impairment existed as of March 31, 2022.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,160,919</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,867,770)</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,293,149</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,558,315)</p></td></tr><tr><td style="vertical-align:bottom;width:84.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,734,834</p></td></tr></table> 32160919 -6867770 25293149 -1558315 23734834 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining 9 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,633,426</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,445,729</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,650,787</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,716,011</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,201,720</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,087,161</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,734,834</p></td></tr></table> 4633426 5445729 4650787 2716011 2201720 4087161 23734834 P10Y P12Y P12Y 17800000 4600000 1300000 19100000 4900000 1400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7)    Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued price protection (see note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,853,979</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued product returns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,763,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,192,845</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued contract rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 376,937</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379,242</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due to Vivus (see Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,267,523</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due to third-party logistics provider</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479,178</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 532,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527,563</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,392</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 474,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,662</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,512,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,957,384</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued price protection (see note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,853,979</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued product returns</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,763,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,192,845</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued contract rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 376,937</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379,242</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due to Vivus (see Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,267,523</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due to third-party logistics provider</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479,178</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 532,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527,563</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,392</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 474,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,662</p></td></tr><tr><td style="vertical-align:bottom;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,512,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,957,384</p></td></tr></table> 1853979 3763211 6192845 376937 379242 2267523 349410 479178 532729 527563 14957 125392 474762 131662 5512006 11957384 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8)    Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Promissory Note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Settlement Agreement entered into with Vivus (see Note 13), Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the principal amount of $10,201,758. The parties also entered into a Security Agreement to secure Petros’ obligations under the Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the terms of the Note, the original principal amount of $10,201,758 is payable in consecutive quarterly installments of principal and interest beginning on April 1, 2022 through January 1, 2027. Interest on the principal amount will accrue at a rate of 6% per year. The Company may prepay the Note, in whole or in part, at any time, with no premium or penalty. In the event that the Company defaults under the Security Agreement, all principal outstanding under the Note at the time of the default will bear interest at a rate of 9% per year until the full and final payment of all principal and interest under the Note (regardless of whether any default is waived or cured). Pursuant to the Security Agreement, dated January 18, 2022, the Company granted to Vivus a continuing security interest in all of its Stendra® API and products and its rights under the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the three months ended March 31, 2022, the Company recorded $153,026 of interest expense related to the Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Senior Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company did not have any senior indebtedness as of March 31, 2022 and December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2016, the Company entered into a loan agreement with Hercules, a third party, for a $35 million term loan (“Senior Debt”) with a stated interest rate of the greater of either (i) Prime plus 7.25% or (ii) 10.75%. The Senior Debt included an additional Paid-In-Kind (“PIK”) interest that increased the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 22, 2017, the Company amended its loan agreement with Hercules (“First Amendment”). A covenant was added, in which the Company must achieve a certain minimum EBITDA, as defined, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio (1:1 to 0.9:1) were reduced. The Company was also required to prepay $10,000,000 in principal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Monthly principal payments, including interest, commenced November 1, 2018 with the outstanding balance of the Senior Debt due in full on November 1, 2020. The end of term charge was being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 13, 2020, the Company amended its loan agreement with Hercules. The amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The amendment also included the following changes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Removed the Adjusted EBITDA and Fixed Cost Coverage Ratio Covenants.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Extended the maturity date from October 1, 2020 to April 2021, which was further extendable to December 1, 2021 upon achieving the Financing Milestone, as defined in the agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Increased the cash interest rate from the greater of (a) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.75%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or (b) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.75%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> plus the US WSJ Prime minus </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.50%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to the greater of (a) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.50%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or (b) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.50%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> plus the US WSJ Prime minus </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.25%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Removed the PIK interest rate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Removed the prepayment penalty.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020 and $534,375 paid on February 1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to Loan and Security Agreement (“Third Amendment”) to provide for interest only payments commencing on October 1, 2020 and continuing through December 22, 2020 unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt had a maturity date of December 1, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 3, 2021, the Company repaid $1,179,651 towards the senior debt. This payment satisfied the remaining balance of the senior debt as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expense on the Senior Debt was $173,412 for the three months ended March 31, 2021. As of December 31, 2021, there was $0 of accrued and unpaid interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 10201758 10201758 0.06 0.09 153026 35000000 0.0725 0.1075 0.0135 787500 787500 1068750 1 0.9 10000000 0.1075 0.1075 0.0450 0.1150 0.1150 0.0425 1068750 534375 534375 25000000 1500000 1179651 173412 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9)     Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective January 1, 2021, the Company entered into a Marketing and Consulting Agreement (the “CorIRAgreement”) with CorProminence, LLC (the “Consultant”) for certain shareholder information and relation services. The term of the CorIRAgreement is for one year with automatic consecutive one-year renewal terms. As consideration for the shareholder information and relation services, the Company will pay the Consultant a monthly retainer of $7,500 and issued 30,000 restricted shares of the Company’s common stock to the Consultant on March 24, 2021 (the “CorIR Grant Date”). The restricted shares vested immediately on the CorIR Grant Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective April 1, 2021, the Company entered into a Consulting and Advisory Agreement (the “King Agreement”) with Tania King, an employee of Juggernaut Capital Partners LLP, for certain services. The term of the King Agreement is indefinite but may be terminated by either party, with or without cause. As consideration for the consulting and advisory services, the Company will pay Ms. King a monthly fee of $4,000, an additional $12,000 payment included with the first monthly fee for services provided since January 1, 2021, and issue restricted stock units for shares of the Company’s common stock (“RSU’s”) with a cash value of $72,000 as of the date of the grant (the “King Grant Date”). The RSU’s shall vest and settle in full on the one-year anniversary of the King Grant Date. On April 7, 2022, the Company issued an additional grant of 60,505 RSU’s of the Company’s common stock with a value of $72,001 as of the date of the grant. The RSU’s vest and settle in full on the one-year anniversary of the additional grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective June 4, 2021, the Company entered into a Service Agreement with IRTH Communications, LLC (“IRTH”) for certain investor relations services (the “IRTH Agreement”). The term of the IRTH Agreement is for one year with an optional one-year renewal term. As consideration for the services, the Company will pay IRTH a fixed fee of $6,750 per month for the term of the IRTH Agreement and issued 28,338 restricted shares of the Company’s common stock with a value of $90,002 as of the date of the grant (the “IRTH Grant Date”). The restricted shares vest immediately on the IRTH Agreement Grant Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 shares of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Market Capitalization/Gross Proceeds Earnout Payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which was liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment was only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of March 31, 2022, the milestones have not been achieved. The fair value of the derivative liability was $0 and $0.5 million as of March 31, 2022 and December 31, 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Metuchen equity holders will have the opportunity to receive the following during the period ending December 2022:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Earnout Payment shall be equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Petros Common Stock if:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$250,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for a period of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (20) trading days during any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (30) consecutive trading day period with a Closing Price of no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$17.50</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> on each such trading day; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros receives aggregate gross proceeds of at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in an offering (or series of offerings within a </span><span style="-sec-ix-hidden:Hidden_4OoRHP5YyUKGODlQk8kX6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sixty</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$17.50</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$250,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Earnout Payment shall be equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Petros Common Stock if:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros’ Market Capitalization is greater than or equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$300,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for a period of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (20) trading days during any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (30) consecutive trading day period with a Closing Price of no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$18.75</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> on each such trading day; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros receives aggregate gross proceeds of at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$30,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in an offering (or series of offerings within a </span><span style="-sec-ix-hidden:Hidden_ETLMNGHSf0C4-mGjhulBmw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sixty</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$18.75</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$300,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Earnout Payment shall be equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Petros Common Stock if:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros’ Market Capitalization is greater than or equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$400,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for a period of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (20) trading days during any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (30) consecutive trading day period with a Closing Price of no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$22.50</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> on each such trading day; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">ii.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros receives aggregate gross proceeds of at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in an offering (or series of offerings within a </span><span style="-sec-ix-hidden:Hidden_kRg4wwiczkaX9hYTkRih9g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sixty</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$22.50</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$400,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Earnout Payment shall be equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3,232,090</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Petros Common Stock if:</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Petros’ Market Capitalization is greater than or equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$500,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for a period of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (20) trading days during any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (30) consecutive trading day period with a Closing Price of no less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$23.75</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> on each such trading day; or</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a <span style="-sec-ix-hidden:Hidden_-8QhznyOS06Md-9sQbdhig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sixty</span></span> (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000.</p> 500 60606 P1Y P1Y 7500000 30000 4000000 12000000 72000000 P1Y 60505 72001 P1Y P1Y 6750 28338 90002 14232090 P2Y 10232090 0 500000 2000000 250000000 20 30 17.50 25000000 17.50 250000000 2000000 300000000 20 30 18.75 30000000 18.75 300000000 3000000 400000000 20 30 22.50 40000000 22.50 400000000 3232090 500000000 20 30 23.75 50000000 23.75 500000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">10)    Stock Options and Restricted Stock Units (“RSU’s”)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units and other stock-based awards and cash-based awards. On December 22, 2021, our stockholders approved the Second Amendment to the 2020 Plan to increase the total number of shares of common stock issuable under the 2020 Plan by 1,521,654 shares to a total of 2,600,000 shares of common stock. As of March 31, 2022, there were 2,600,000 shares authorized and 1,817,948 shares available for issuance under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a summary of stock options for the three months ended March 31, 2022 and for the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate Intrinsic </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b> </p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 574,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 615,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (574,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 615,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 665,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a summary of RSU’s for the three months ended March 31, 2022 and for the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FoYzmlZ-q0Kd1MCYvn0Plw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s outstanding at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s exercisable at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 4, 2022, pursuant to a consulting agreement, the Company awarded a grant of 50,000 options to purchase shares of common stock of the Company at an exercise price of $3.34 per share. The shares of common stock underlying the options vested 100% upon issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2022, the Company awarded the four Directors grants of 248,742 total RSU’s with a stock price of $1.19 per share. The RSU’s shall vest 100% on one year anniversary of the date of grant. Also on April 7, 2022, Tania King, an employee of Juggernaut Capital Partners LLP, pursuant to her contract, was granted 60,505 RSUs with a stock price of $1.19 per share. The RSU’s shall vest 100% on one year anniversary of the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recognized for the three months ended March 31, 2022 and 2021 was $355,828 and $347,207, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations.</p> 1521654 2600000 2600000 1817948 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate Intrinsic </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b> </p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 574,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 615,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (574,331)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 615,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 665,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FoYzmlZ-q0Kd1MCYvn0Plw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s expired/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: RSU’s exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s outstanding at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:54.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU’s exercisable at March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table> 574331 51.43 P0Y10M24D 615669 3.38 P9Y2M23D 574331 51.43 615669 3.38 P9Y2M23D 50000 3.34 P9Y9M3D 665669 3.38 P9Y21D 381752 3.44 P9Y25D 0 0 116383 3.29 P9Y10M2D 116383 3.29 P9Y10M2D 116383 3.29 P9Y7M6D 50000 3.34 1 4 248742 1.19 1 P1Y 60505 1.19 1 P1Y 355828 347207 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11)    Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of warrants for the three months ended March 31, 2022 and for the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,407,962</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,853,558</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,014,586)</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207,913)</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at December 31, 2021 and March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,039,021</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022, the Company’s warrants by expiration date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">August 23, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 1, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">74,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 17, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">September 1, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">September 16, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">March 2, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">September 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,221,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">908,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">623,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">157,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,751,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">October 19, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,337,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 2, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,749,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 27, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,039,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,407,962</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,853,558</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,014,586)</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207,913)</p></td></tr><tr><td style="vertical-align:bottom;width:83.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at December 31, 2021 and March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,039,021</p></td></tr></table> 4407962 7853558 -2014586 -207913 10039021 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">August 23, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 1, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">74,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 17, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">September 1, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">September 16, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">March 2, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">June 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">September 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">28,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,221,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">908,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">623,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">157,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 1, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,751,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">October 19, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,337,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 2, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,749,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">December 27, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:41.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,039,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr></table> 2780 1.60 22800 35.65 74864 21.85 20043 31.25 22800 26.55 10500 12.738 22800 4.30 28000 5.65 28000 7.30 28000 5.50 28000 4.705 2221829 7.50 908498 17.50 623303 51.25 157832 125.00 1751311 1.715 2337719 3.50 1749942 3.50 10039021 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12)    Basic and Diluted Net Income (Loss) per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,009,081</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares for basic net income (loss) per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,684,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,753,086</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of common share equivalents within common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares for diluted net (loss) income per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,684,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,754,686</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net income (loss) per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1P9nnPQ1qk-nulHA7OeKdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.01)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_4Ox6qCIx_kCqABJX7KkowA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share because their inclusion would have been antidilutive: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 790,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU’s</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,039,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,405,182</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,821,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,195,182</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,009,081</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares for basic net income (loss) per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,684,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,753,086</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of common share equivalents within common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares for diluted net (loss) income per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,684,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,754,686</p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net income (loss) per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1P9nnPQ1qk-nulHA7OeKdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.01)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_4Ox6qCIx_kCqABJX7KkowA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.31</p></td></tr></table> -174224 3009081 20684723 9753086 1600 20684723 9754686 -0.01 0.31 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 790,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU’s</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,039,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,405,182</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,821,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,195,182</p></td></tr></table> 665669 790000 116383 10039021 4405182 10821073 5195182 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13)   Marketing, Licensing and Distribution Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;">(a)    Vivus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the License Agreement, the Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement. The License Agreement, was terminated, effective September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 18, 2022, Petros and Vivus entered into a Settlement Agreement (the “Vivus Settlement Agreement”) related to the minimum purchase requirements under the Vivus Supply Agreement in 2018, 2019 and 2020 and certain reimbursement rights asserted by a third-party retailer in connection with quantities of the Company’s Stendra® product that were delivered to the third-party retailer and later returned. In connection with the Vivus Settlement Agreement, Petros retained approximately $7.3 million of API inventory under the Vivus Supply Agreement. In exchange for the API and reduction of current liabilities, Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the original principal amount of $10,201,758, which the Company believes approximates fair value (See Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the payments to be made in accordance with the Note, the Company further agreed in the Vivus Settlement Agreement to (i) grant to Vivus a right of first refusal to provide certain types of debt and convertible equity (but not preferred equity) until the Note is paid in full, and (ii) undertake to make certain regulatory submissions to effectuate Vivus’ ability to exercise its rights under the License Agreement. On January 18, 2022, the Company made a prepayment of the obligations under the Note in the amount of $900,000, and a payment of $1,542,904 with respect to a purchase order made in 2021 to Vivus. In consideration of these payment and upon the Company’s satisfaction of certain regulatory submissions Vivus released 50% of the quantity of bulk Stendra® tablets on January 18, 2022 under the Company’s existing open purchase order (the “Open Purchase Order”) being held by Vivus, which represents approximately a six-month supply of inventory. Under the Vivus Settlement Agreement Vivus also agreed to release the remaining 50% of the quantity of bulk Stendra® tablets under the Open Purchase Order upon the Company’s satisfaction of the remaining regulatory submission requirements (not to exceed 180 days from the date of the Vivus Settlement Agreement). The Vivus Settlement Agreement stipulated that Vivus is the sole owner of all API unless or until such time as certain quantities of API are shipped to the Company upon the fulfillment of the aforementioned payment conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of entering into the Vivus Settlement Agreement, the Company decreased accrued expenses by $6.5 million and decreased accrued inventory purchases by $14.2 million; which were partially offset by a decrease in API purchase commitments of $6.2 million and an increase to liabilities for the Note of $10.2 million (which is net of the $0.9 million prepayment on the Note). As a result, the Company recorded a $3.4 million gain on settlement for the three months ended March 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#212121;">As of March 31, 2022 and December 31, 2021, the Company has</span> $0 and $14.2 million, respectively, of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of March 31, 2022 and December 31, 2021, there was $1.4 million and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$1.4 million, respectively, included in other current assets (see Note 5 Prepaid and Other Current Assets). As of March 31, 2022 and December 31, 2021, there was $4.8 million and $11.0 million included as non-current on the accompanying consolidated balance sheets, respectively. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. The Company did not record any reserve for the three months ended March 31, 2022 and 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2022 and 2021, the Company incurred royalties to MTPC for Stendra® of $76,238 and $160,032, respectively. Royalties incurred were included in cost of goods sold in the consolidated statements of operations. As of March 31, 2022 and December 31, 2021, the Company had a receivable for royalties of $4,897 and $81,136, respectively, which is included in other current assets in prepaid expenses and other current assets (see Note 5 Prepaid and Other Current Assets). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell <span style="color:#212121;">Stendra</span>®.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;">(b)     Patheon</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Following the termination of the Vivus Supply Agreement, Petros, through its subsidiary Metuchen, entered into a Technology Transfer Service Agreement on January 20, 2022 with Patheon Pharmaceuticals Inc., part of Thermo Fisher Scientific (“Patheon”), pursuant to which the Company and Patheon agreed to collaborate as strategic partners for commercial production of Stendra® tablets at Patheon’s facilities in Cincinnati, Ohio. Under the Agreement, Patheon or one of its affiliates will provide pharmaceutical development and technology transfer services in order to establish and validate its ability to manufacture supply of the Company’s Stendra® product. Any </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercial sale of product manufactured during the performance of the Agreement must be subject to a subsequent commercial manufacturing services agreement (with associated quality agreement) between the parties before it can be offered for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;">(c)    Hybrid</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2020, the Company acquired the exclusive license to H100™ from Hybrid. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. The Company paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000 and $200,000 due on each of the first, second and third anniversaries of the license agreement and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon <span style="-sec-ix-hidden:Hidden_JVqQUuVdr0OGpr7sjsiTgQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ninety</span></span> (90) days’ notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired and the upfront payment should be expensed as it was considered an IPR&amp;D asset with no alternative future uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months to March 24, 2021. In consideration for the extension, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020. On March 31, 2021, the Company and Hybrid, entered into a second letter agreement, pursuant to which the parties agreed to extend the Second Period (as defined in the Hybrid License) for an additional <span style="-sec-ix-hidden:Hidden_Ng9hod-MRkKfENDDqDzyiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span></span> (6) months to September 24, 2021. Additionally, the Company agreed to pay Hybrid a one-time, non-creditable and non-refundable payment of $200,000, which was paid within <span style="-sec-ix-hidden:Hidden_aL4a6YcU0kKVkRqbC1IMWw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seven</span></span> calendar days of entering into the agreement. On September 24, 2021, the Company entered into an amendment to the license agreement in which the Company exercised its right not to terminate the Hybrid License even though orphan drug status had not yet been granted by the FDA. Along with this election, the Company paid Hybrid $150,000 on October 1, 2021, $200,000 on October 31, 2021, $200,000 on December 1, 2021, $200,000 on December 23, 2021 and $150,000 on March 24, 2022.</p> 70000000 0.05 500000000 0.06 0.02 0.01 6000000 250000000 250000000 3200000 7300000 10201758 900000 1542904 50 50 P180D 6500000 14200000 6200000 10200000 900000 3400000 0 14200000 1400000 1400000 4800000 11000000.0 76238 160032 4897 81136 100000 900000 125000 150000 200000 250000 1000000 0.03 0.06 P6M 50000 100000 200000 150000 200000 200000 200000 150000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14)  Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;">(a)    Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary and performance bonuses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021 and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;">(b)    Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;">(c)    Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 2.4 years to 4.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 30, 2021, the Company entered into a sublease with respect to its entire headquarters facility. The sublessor delivered a $14,000 security deposit to the Company on the lease commencement date and also agreed to pay $7,000 per month for the term beginning January 10, 2022 and continuing until the expiration of the head lease on August 30, 2024. The Company will account for this sublease as an operating lease in accordance with the lessor accounting guidance within ASC 842.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of lease expense were consisted entirely of fixed lease costs related to operating leases. These costs were $44,812 for the three months ended March 31, 2022 and 2021, respectively. Fixed lease costs for the three months ended March 31, 2022 were offset by sublease income of $21,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental balance sheet information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease ROU asset:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_8g-NuZN_xkmJmK2ck9KkRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 447,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475,557</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_prGNWlH4B0C5tvDgfUHD7g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 129,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125,579</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_5Osd-4Kafkit1DuArN3alw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other long-term liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405,018</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530,597</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Supplemental lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease terms - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Supplemental cash flow information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,942</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum lease payments under non-cancelable leases as of March 31, 2022, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Lease Liability Maturity Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining 9 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,805</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189,374</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155,242</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,107</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,324</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648,852</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (148,341)</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,511</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Future minimum sublease income under non-cancelable leases as of March 31, 2022, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Sublease income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining 9 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,000</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,000</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,000</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 31, 2022, the Company had no operating leases that had not yet commenced.</p> 50000 0.50 0.70 0.30 P2Y4M24D P4Y9M18D 14000 7000 44812 44812 21000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplemental balance sheet information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease ROU asset:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_8g-NuZN_xkmJmK2ck9KkRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 447,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475,557</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_prGNWlH4B0C5tvDgfUHD7g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 129,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125,579</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_5Osd-4Kafkit1DuArN3alw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other long-term liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405,018</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530,597</p></td></tr></table> 447595 475557 129458 125579 371053 405018 500511 530597 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Supplemental lease term and discount rate information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease terms - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> P3Y4M24D P3Y8M12D 0.126 0.126 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Supplemental cash flow information related to leases was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended March 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,942</p></td></tr></table> 46935 45942 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum lease payments under non-cancelable leases as of March 31, 2022, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Lease Liability Maturity Analysis</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining 9 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,805</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 189,374</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155,242</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,107</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,324</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648,852</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (148,341)</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,511</p></td></tr></table> 140805 189374 155242 81107 82324 648852 148341 500511 63000 84000 56000 203000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15)    Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s results of operations by reportable segment for the three months ended March 31, 2022 are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prescription </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,524,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 940,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,465,169</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472,340</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,711,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 663,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,523,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,897,738</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain on settlement with Vivus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,389,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,389,941)</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405,360</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,269,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,560,870</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (460,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (460,000)</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,026</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,390,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (348,556)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,216,154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,224)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s results of operations by reportable segment for the three months ended March 31, 2021 are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.06944656%;padding-left:0pt;padding-right:0pt;width:100.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prescription </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,200,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 874,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,075,606</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 389,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 643,386</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,734,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,881,717</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,181</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,398,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 330,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,728,829</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,380,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,380,000)</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,412</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (340,418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,606,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,009,081</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table reflects net sales by geographic region for the three months ended March 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Net sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,045,624</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,704,523</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">International</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371,083</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,465,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,075,606</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No individual country other than the United States accounted for 10% of total sales for the three months ended March 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of March 31, 2022, are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prescription</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,804,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,930,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,734,834</p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,240,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,623,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,864,147</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2021, are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prescription</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Medical Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,071,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,221,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,293,149</p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,657,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,732,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,390,058</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">​</span></p> 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s results of operations by reportable segment for the three months ended March 31, 2022 are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prescription </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,524,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 940,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,465,169</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 472,340</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,711,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 663,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,523,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,897,738</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain on settlement with Vivus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,389,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,389,941)</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405,360</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,269,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,560,870</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (460,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (460,000)</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,026</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:55.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,390,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (348,556)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,216,154)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (174,224)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s results of operations by reportable segment for the three months ended March 31, 2021 are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.06944656%;padding-left:0pt;padding-right:0pt;width:100.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prescription </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,200,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 874,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,075,606</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 389,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 643,386</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,734,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,881,717</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,181</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,398,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 330,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,728,829</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,380,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,380,000)</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,412</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (340,418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,606,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,009,081</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1524768 940401 2465169 138181 334159 472340 1711019 663591 1523128 3897738 3389941 3389941 405360 405360 1269663 291207 1560870 460000 460000 153026 153026 1390486 -348556 -1216154 -174224 3200647 874959 4075606 389281 254105 643386 1734333 546995 1600389 3881717 19181 19181 1398270 330559 1728829 5380000 5380000 173412 173412 -340418 -256700 3606199 3009081 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Net sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,045,624</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,704,523</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">International</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371,083</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,465,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,075,606</p></td></tr></table> 2045624 3704523 419545 371083 2465169 4075606 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of March 31, 2022, are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prescription</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Medical Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,804,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,930,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,734,834</p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,240,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,623,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,864,147</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2021, are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prescription</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Medications</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Medical Devices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,071,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,221,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,293,149</p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total segment assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,657,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,732,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,390,058</p></td></tr></table> 17804298 5930536 23734834 48240984 7623163 55864147 19071407 6221742 25293149 59657514 7732544 67390058 EXCEL 95 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 96 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 97 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 184 321 1 false 81 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity Sheet http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidity Nature of Operations, Basis of Presentation, and Liquidity Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Accounts Receivable, net Sheet http://www.petrospharma.com/role/DisclosureAccountsReceivableNet Accounts Receivable, net Notes 9 false false R10.htm 10401 - Disclosure - Inventories Sheet http://www.petrospharma.com/role/DisclosureInventories Inventories Notes 10 false false R11.htm 10501 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 10601 - Disclosure - Intangible Assets Sheet http://www.petrospharma.com/role/DisclosureIntangibleAssets Intangible Assets Notes 12 false false R13.htm 10701 - Disclosure - Accrued Expenses Sheet http://www.petrospharma.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 10801 - Disclosure - Debt Sheet http://www.petrospharma.com/role/DisclosureDebt Debt Notes 14 false false R15.htm 10901 - Disclosure - Stockholders' Equity Sheet http://www.petrospharma.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 11001 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") Sheet http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuS Stock Options and Restricted Stock Units ("RSU's") Notes 16 false false R17.htm 11101 - Disclosure - Common Stock Warrants Sheet http://www.petrospharma.com/role/DisclosureCommonStockWarrants Common Stock Warrants Notes 17 false false R18.htm 11201 - Disclosure - Basic and Diluted Net Loss per Common Share Sheet http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare Basic and Diluted Net Loss per Common Share Notes 18 false false R19.htm 11301 - Disclosure - Marketing, Licensing and Distribution Agreements Sheet http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements Marketing, Licensing and Distribution Agreements Notes 19 false false R20.htm 11401 - Disclosure - Commitments and Contingencies Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 11501 - Disclosure - Segment Information Sheet http://www.petrospharma.com/role/DisclosureSegmentInformation Segment Information Notes 21 false false R22.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30303 - Disclosure - Accounts Receivable, net (Tables) Sheet http://www.petrospharma.com/role/DisclosureAccountsReceivableNetTables Accounts Receivable, net (Tables) Tables http://www.petrospharma.com/role/DisclosureAccountsReceivableNet 23 false false R24.htm 30403 - Disclosure - Inventories (Tables) Sheet http://www.petrospharma.com/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.petrospharma.com/role/DisclosureInventories 24 false false R25.htm 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 25 false false R26.htm 30603 - Disclosure - Intangible Assets (Tables) Sheet http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.petrospharma.com/role/DisclosureIntangibleAssets 26 false false R27.htm 30703 - Disclosure - Accrued Expenses (Tables) Sheet http://www.petrospharma.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.petrospharma.com/role/DisclosureAccruedExpenses 27 false false R28.htm 31003 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") (Tables) Sheet http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables Stock Options and Restricted Stock Units ("RSU's") (Tables) Tables http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuS 28 false false R29.htm 31103 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables Common Stock Warrants (Tables) Tables http://www.petrospharma.com/role/DisclosureCommonStockWarrants 29 false false R30.htm 31203 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables) Sheet http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables Basic and Diluted Net Loss per Common Share (Tables) Tables http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare 30 false false R31.htm 31403 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.petrospharma.com/role/DisclosureCommitmentsAndContingencies 31 false false R32.htm 31503 - Disclosure - Segment Information (Tables) Sheet http://www.petrospharma.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.petrospharma.com/role/DisclosureSegmentInformation 32 false false R33.htm 40101 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity (Details) Sheet http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityDetails Nature of Operations, Basis of Presentation, and Liquidity (Details) Details http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidity 33 false false R34.htm 40102 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details) Sheet http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details) Details 34 false false R35.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 35 false false R36.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Additional information (Details) Sheet http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional information (Details) Details 36 false false R37.htm 40301 - Disclosure - Accounts Receivable, net (Details) Sheet http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails Accounts Receivable, net (Details) Details http://www.petrospharma.com/role/DisclosureAccountsReceivableNetTables 37 false false R38.htm 40302 - Disclosure - Accounts Receivable, net - Additional information (Details) Sheet http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails Accounts Receivable, net - Additional information (Details) Details 38 false false R39.htm 40401 - Disclosure - Inventories (Details) Sheet http://www.petrospharma.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.petrospharma.com/role/DisclosureInventoriesTables 39 false false R40.htm 40402 - Disclosure - Inventories - Additional Information (Details) Sheet http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails Inventories - Additional Information (Details) Details 40 false false R41.htm 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 41 false false R42.htm 40601 - Disclosure - Intangible Assets (Details) Sheet http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) Details http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables 42 false false R43.htm 40602 - Disclosure - Intangible Assets - Future annual amortization (Details) Sheet http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails Intangible Assets - Future annual amortization (Details) Details 43 false false R44.htm 40603 - Disclosure - Intangible Assets - Additional Information (Details) Sheet http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails Intangible Assets - Additional Information (Details) Details 44 false false R45.htm 40701 - Disclosure - Accrued Expenses (Details) Sheet http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.petrospharma.com/role/DisclosureAccruedExpensesTables 45 false false R46.htm 40801 - Disclosure - Debt - Promissory Note (Details) Sheet http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails Debt - Promissory Note (Details) Details 46 false false R47.htm 40802 - Disclosure - Debt - Senior debt (Details) Sheet http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails Debt - Senior debt (Details) Details 47 false false R48.htm 40803 - Disclosure - Debt - Financial covenant (Details) Sheet http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails Debt - Financial covenant (Details) Details 48 false false R49.htm 40804 - Disclosure - Debt - Third Amendment (Details) Sheet http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails Debt - Third Amendment (Details) Details 49 false false R50.htm 40805 - Disclosure - Debt - Interest Expenses (Details) Sheet http://www.petrospharma.com/role/DisclosureDebtInterestExpensesDetails Debt - Interest Expenses (Details) Details 50 false false R51.htm 40901 - Disclosure - Stockholders' Equity - Consummation of the Mergers (Details) Sheet http://www.petrospharma.com/role/DisclosureStockholdersEquityConsummationOfMergersDetails Stockholders' Equity - Consummation of the Mergers (Details) Details 51 false false R52.htm 40902 - Disclosure - Stockholders' Equity - Number of shares held (Details) Sheet http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails Stockholders' Equity - Number of shares held (Details) Details 52 false false R53.htm 40903 - Disclosure - Stockholders' Equity - Marketing and Consulting Agreement (Details) Sheet http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails Stockholders' Equity - Marketing and Consulting Agreement (Details) Details 53 false false R54.htm 40904 - Disclosure - Stockholders' Equity - Contingent Consideration (Details) Sheet http://www.petrospharma.com/role/DisclosureStockholdersEquityContingentConsiderationDetails Stockholders' Equity - Contingent Consideration (Details) Details 54 false false R55.htm 40906 - Disclosure - Stockholders' Equity - Market Capitalization (Details) Sheet http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails Stockholders' Equity - Market Capitalization (Details) Details 55 false false R56.htm 41001 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") (Details) Sheet http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails Stock Options and Restricted Stock Units ("RSU's") (Details) Details http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables 56 false false R57.htm 41002 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") - Summary of stock options (Details) Sheet http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails Stock Options and Restricted Stock Units ("RSU's") - Summary of stock options (Details) Details http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables 57 false false R58.htm 41003 - Disclosure - Stock Options and Restricted Stock Units ("RSU's") - Additional Information (Details) Sheet http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails Stock Options and Restricted Stock Units ("RSU's") - Additional Information (Details) Details http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables 58 false false R59.htm 41101 - Disclosure - Common Stock Warrants - Summary of warrants (Details) Sheet http://www.petrospharma.com/role/DisclosureCommonStockWarrantsSummaryOfWarrantsDetails Common Stock Warrants - Summary of warrants (Details) Details 59 false false R60.htm 41102 - Disclosure - Common Stock Warrants - Company's warrants by expiration date (Details) Sheet http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails Common Stock Warrants - Company's warrants by expiration date (Details) Details 60 false false R61.htm 41201 - Disclosure - Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) Sheet http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) Details 61 false false R62.htm 41202 - Disclosure - Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details) Sheet http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details) Details 62 false false R63.htm 41301 - Disclosure - Marketing, Licensing and Distribution Agreements - Vivus (Details) Sheet http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails Marketing, Licensing and Distribution Agreements - Vivus (Details) Details http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements 63 false false R64.htm 41302 - Disclosure - Marketing, Licensing and Distribution Agreements - Hybrid (Details) Sheet http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails Marketing, Licensing and Distribution Agreements - Hybrid (Details) Details http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements 64 false false R65.htm 41401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables 65 false false R66.htm 41402 - Disclosure - Commitments and Contingencies - Operating Leases (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails Commitments and Contingencies - Operating Leases (Details) Details 66 false false R67.htm 41403 - Disclosure - Commitments and Contingencies - Lease expense (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails Commitments and Contingencies - Lease expense (Details) Details 67 false false R68.htm 41404 - Disclosure - Commitments and Contingencies - Supplemental balance sheet (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails Commitments and Contingencies - Supplemental balance sheet (Details) Details 68 false false R69.htm 41405 - Disclosure - Commitments and Contingencies - Lease term and discount (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails Commitments and Contingencies - Lease term and discount (Details) Details 69 false false R70.htm 41406 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails Commitments and Contingencies - Minimum lease payments (Details) Details 70 false false R71.htm 41407 - Disclosure - Commitments and Contingencies - Future Minimum Sublease Income (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails Commitments and Contingencies - Future Minimum Sublease Income (Details) Details 71 false false R72.htm 41408 - Disclosure - Commitments and Contingencies - Additional information (Details) Sheet http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional information (Details) Details 72 false false R73.htm 41501 - Disclosure - Segment Information (Details) Sheet http://www.petrospharma.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.petrospharma.com/role/DisclosureSegmentInformationTables 73 false false R74.htm 41502 - Disclosure - Segment Information - Net Sales by Geographic region (Details) Sheet http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails Segment Information - Net Sales by Geographic region (Details) Details 74 false false R75.htm 41503 - Disclosure - Segment Information - Segment assets (Details) Sheet http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails Segment Information - Segment assets (Details) Details 75 false false All Reports Book All Reports tmb-20220331x10q.htm tmb-20220331.xsd tmb-20220331_cal.xml tmb-20220331_def.xml tmb-20220331_lab.xml tmb-20220331_pre.xml tmb-20220331xex10d1.htm tmb-20220331xex10d2.htm tmb-20220331xex10d4.htm tmb-20220331xex10d5.htm tmb-20220331xex31d1.htm tmb-20220331xex31d2.htm tmb-20220331xex32.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 101 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tmb-20220331x10q.htm": { "axisCustom": 1, "axisStandard": 23, "contextCount": 184, "dts": { "calculationLink": { "local": [ "tmb-20220331_cal.xml" ] }, "definitionLink": { "local": [ "tmb-20220331_def.xml" ] }, "inline": { "local": [ "tmb-20220331x10q.htm" ] }, "labelLink": { "local": [ "tmb-20220331_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20220331_pre.xml" ] }, "schema": { "local": [ "tmb-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 527, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 17, "http://www.petrospharma.com/20220331": 10, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 32 }, "keyCustom": 102, "keyStandard": 219, "memberCustom": 56, "memberStandard": 23, "nsprefix": "ptpi", "nsuri": "http://www.petrospharma.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Inventories", "role": "http://www.petrospharma.com/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Intangible Assets", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:AccruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Accrued Expenses", "role": "http://www.petrospharma.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:AccruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Debt", "role": "http://www.petrospharma.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stockholders' Equity", "role": "http://www.petrospharma.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\")", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuS", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\")", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Common Stock Warrants", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrants", "shortName": "Common Stock Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Basic and Diluted Net Loss per Common Share", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare", "shortName": "Basic and Diluted Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Marketing, Licensing and Distribution Agreements", "role": "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements", "shortName": "Marketing, Licensing and Distribution Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Commitments and Contingencies", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Segment Information", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Accounts Receivable, net (Tables)", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetTables", "shortName": "Accounts Receivable, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Inventories (Tables)", "role": "http://www.petrospharma.com/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:ScheduleOfPrepaidExpensesAndOthercurrentAssetsTabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:ScheduleOfPrepaidExpensesAndOthercurrentAssetsTabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Intangible Assets (Tables)", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.petrospharma.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") (Tables)", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Common Stock Warrants (Tables)", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables", "shortName": "Common Stock Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_XXnp-bv4V0OeA1tIYmt7zA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables", "shortName": "Basic and Diluted Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Segment Information (Tables)", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_7_2020_jNNHU2UuL0KnRnx7-VMt9g", "decimals": "0", "first": true, "lang": null, "name": "ptpi:CashInExcessOfCertainLimitSubjectToAdjustmentAsProvidedInMergerAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity (Details)", "role": "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityDetails", "shortName": "Nature of Operations, Basis of Presentation, and Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_7_2020_jNNHU2UuL0KnRnx7-VMt9g", "decimals": "0", "first": true, "lang": null, "name": "ptpi:CashInExcessOfCertainLimitSubjectToAdjustmentAsProvidedInMergerAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40102 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details)", "role": "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails", "shortName": "Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "-5", "lang": null, "name": "ptpi:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Additional information (Details)", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Accounts Receivable, net (Details)", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails", "shortName": "Accounts Receivable, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6xdL6EeWz0mj4AMK-_noaA", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_Bc9dMTVV40-ZcWT6dVxr4w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Accounts Receivable, net - Additional information (Details)", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails", "shortName": "Accounts Receivable, net - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6xdL6EeWz0mj4AMK-_noaA", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_Bc9dMTVV40-ZcWT6dVxr4w", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Inventories (Details)", "role": "http://www.petrospharma.com/role/DisclosureInventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Inventories - Additional Information (Details)", "role": "http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails", "shortName": "Inventories - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfPrepaidExpensesAndOthercurrentAssetsTabletextblock", "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfPrepaidExpensesAndOthercurrentAssetsTabletextblock", "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Intangible Assets (Details)", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Intangible Assets - Future annual amortization (Details)", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails", "shortName": "Intangible Assets - Future annual amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Intangible Assets - Additional Information (Details)", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "shortName": "Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ptpi_StendraProductMember_rIrKUP0pgki2d47ISpNOfw", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_3YucAbEmDkOFevzQF_mbmg", "decimals": "0", "first": true, "lang": null, "name": "ptpi:AccruedPriceProtection", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Accrued Expenses (Details)", "role": "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_3YucAbEmDkOFevzQF_mbmg", "decimals": "0", "first": true, "lang": null, "name": "ptpi:AccruedPriceProtection", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "ptpi:InterestExpenseOnPromissoryNotes", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Debt - Promissory Note (Details)", "role": "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "shortName": "Debt - Promissory Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember_yJe1QHzFI0miiG6dFSBYTQ", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_11_22_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorDebtObligationsMember_W4M5Tn2uqU2qn5JcRhGKJQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Debt - Senior debt (Details)", "role": "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "shortName": "Debt - Senior debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_11_22_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorDebtObligationsMember_W4M5Tn2uqU2qn5JcRhGKJQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_4_13_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorDebtObligationsMember_VJaulwZYl06I1stuHOQrKQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Unit_Standard_pure_RseNWXzhV02m4NOCZYQGCA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Debt - Financial covenant (Details)", "role": "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "shortName": "Debt - Financial covenant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_2_1_2021_To_2_1_2021_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorDebtObligationsMember_RJyJOXuu00OIDP9Bvc6ElQ", "decimals": "0", "lang": null, "name": "ptpi:DebtInstrumentEndOfTermChargePaid", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_11_3_2021_To_11_3_2021_28YWJWywL0eFArwZfEev0g", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Debt - Third Amendment (Details)", "role": "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails", "shortName": "Debt - Third Amendment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_11_3_2021_To_11_3_2021_28YWJWywL0eFArwZfEev0g", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yWLDVypMtEu4EH06r_exEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yWLDVypMtEu4EH06r_exEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_jI4RZ4X0oEmhNAiUOFuaVQ", "decimals": "0", "first": true, "lang": null, "name": "ptpi:InterestExpenseSeniorDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40805 - Disclosure - Debt - Interest Expenses (Details)", "role": "http://www.petrospharma.com/role/DisclosureDebtInterestExpensesDetails", "shortName": "Debt - Interest Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_3YucAbEmDkOFevzQF_mbmg", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_XXnp-bv4V0OeA1tIYmt7zA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stockholders' Equity - Consummation of the Mergers (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockholdersEquityConsummationOfMergersDetails", "shortName": "Stockholders' Equity - Consummation of the Mergers (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_26_2021_To_1_26_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_oxfqTEymm067-BkFZSk1xg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Stockholders' Equity - Number of shares held (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails", "shortName": "Stockholders' Equity - Number of shares held (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_26_2021_To_1_26_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_oxfqTEymm067-BkFZSk1xg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_1_1_2021_srt_CounterpartyNameAxis_ptpi_CorprominenceLlcMember_us-gaap_TypeOfArrangementAxis_ptpi_MarketingAndConsultingAgreementMember_Nuk26up1oUudjQ_WuimymQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:TermOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Stockholders' Equity - Marketing and Consulting Agreement (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails", "shortName": "Stockholders' Equity - Marketing and Consulting Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_1_1_2021_srt_CounterpartyNameAxis_ptpi_CorprominenceLlcMember_us-gaap_TypeOfArrangementAxis_ptpi_MarketingAndConsultingAgreementMember_Nuk26up1oUudjQ_WuimymQ", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:TermOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:CommonStockPotentiallyIssuableUponAchievementOfCertainMilestones", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Stockholders' Equity - Contingent Consideration (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockholdersEquityContingentConsiderationDetails", "shortName": "Stockholders' Equity - Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:CommonStockPotentiallyIssuableUponAchievementOfCertainMilestones", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40906 - Disclosure - Stockholders' Equity - Market Capitalization (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "shortName": "Stockholders' Equity - Market Capitalization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_ptpi_EarnoutPaymentsMethodAxis_ptpi_MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember_us-gaap_BusinessAcquisitionAxis_ptpi_MetuchenPharmaceuticalsLlcMember_7I9tvUW3jEq4OWiJ1VXc5w", "decimals": "-5", "lang": null, "name": "ptpi:SharesToBeIssuedAsPartOfMilestoneEarnoutPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_1_31_2022_MGil12NfMkat75n75Fo5Hw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_1_31_2022_MGil12NfMkat75n75Fo5Hw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_3YucAbEmDkOFevzQF_mbmg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") - Summary of stock options (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") - Summary of stock options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_lWNt8vw9QUShAGBcpgRjpA", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_4_2022_To_1_4_2022_GxiZ3QCxG0-81L8YGCVIFA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") - Additional Information (Details)", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_4_2022_To_1_4_2022_GxiZ3QCxG0-81L8YGCVIFA", "decimals": "2", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_RseNWXzhV02m4NOCZYQGCA", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_RmtiilvAkE-h8_jgcbRgiw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Common Stock Warrants - Summary of warrants (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsSummaryOfWarrantsDetails", "shortName": "Common Stock Warrants - Summary of warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_lWNt8vw9QUShAGBcpgRjpA", "decimals": "INF", "lang": null, "name": "ptpi:ClassOfWarrantOrRightIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_RmtiilvAkE-h8_jgcbRgiw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Common Stock Warrants - Company's warrants by expiration date (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails", "shortName": "Common Stock Warrants - Company's warrants by expiration date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_ClassOfWarrantOrRightAxis_ptpi_ExpirationDateOfAugust232023Member_K8SFlfKi5k-W6lzAgKJr2A", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details)", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_jI4RZ4X0oEmhNAiUOFuaVQ", "decimals": "INF", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details)", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails", "shortName": "Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_24il2yBjy0yAb5GCqwpVDg", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "ptpi:NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Marketing, Licensing and Distribution Agreements - Vivus (Details)", "role": "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "shortName": "Marketing, Licensing and Distribution Agreements - Vivus (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_StatementScenarioAxis_ptpi_ScenarioOneMember_us-gaap_TypeOfArrangementAxis_ptpi_LicenseAgreementMember_3Zspw_HOmEqt1Cc97YSI8w", "decimals": "-6", "lang": null, "name": "ptpi:CollaborativeArrangementThresholdNetSales", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_3_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_ptpi_HybridMember_us-gaap_TypeOfArrangementAxis_ptpi_ExclusiveLicenseToH100Member_E63veVg3yUGCFl60wAW1nA", "decimals": "0", "first": true, "lang": null, "name": "ptpi:CollaborativeArrangementInitialLicenseFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Marketing, Licensing and Distribution Agreements - Hybrid (Details)", "role": "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "shortName": "Marketing, Licensing and Distribution Agreements - Hybrid (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_3_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_ptpi_HybridMember_us-gaap_TypeOfArrangementAxis_ptpi_ExclusiveLicenseToH100Member_E63veVg3yUGCFl60wAW1nA", "decimals": "0", "first": true, "lang": null, "name": "ptpi:CollaborativeArrangementInitialLicenseFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_12_31_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ptpi_Mr.KeithLavanMember_us-gaap_TypeOfArrangementAxis_ptpi_SeparationAgreementMember_uaRM923Nc0ev28FYVAhZMw", "decimals": "0", "first": true, "lang": null, "name": "ptpi:StayOnBonus", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_12_31_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ptpi_Mr.KeithLavanMember_us-gaap_TypeOfArrangementAxis_ptpi_SeparationAgreementMember_uaRM923Nc0ev28FYVAhZMw", "decimals": "0", "first": true, "lang": null, "name": "ptpi:StayOnBonus", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_1_10_2022_s_hwZk8S3Eyqpk_oO0Ea6A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:SecurityDepositForSubLeaseReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Commitments and Contingencies - Operating Leases (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails", "shortName": "Commitments and Contingencies - Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_1_10_2022_s_hwZk8S3Eyqpk_oO0Ea6A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:SecurityDepositForSubLeaseReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "us-gaap:OperatingLeaseCost", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Commitments and Contingencies - Lease expense (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails", "shortName": "Commitments and Contingencies - Lease expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:OperatingLeaseCost", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41404 - Disclosure - Commitments and Contingencies - Supplemental balance sheet (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails", "shortName": "Commitments and Contingencies - Supplemental balance sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41405 - Disclosure - Commitments and Contingencies - Lease term and discount (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails", "shortName": "Commitments and Contingencies - Lease term and discount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Operations, Basis of Presentation, and Liquidity", "role": "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidity", "shortName": "Nature of Operations, Basis of Presentation, and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41406 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails", "shortName": "Commitments and Contingencies - Minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41407 - Disclosure - Commitments and Contingencies - Future Minimum Sublease Income (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails", "shortName": "Commitments and Contingencies - Future Minimum Sublease Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:LesseeOperatingLeaseLeaseNotYetCommencedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41408 - Disclosure - Commitments and Contingencies - Additional information (Details)", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:LesseeOperatingLeaseLeaseNotYetCommencedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Segment Information (Details)", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Segment Information - Net Sales by Geographic region (Details)", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails", "shortName": "Segment Information - Net Sales by Geographic region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_country_US_mT1s6w2l1UCm1zxI3ypC8A", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7yatVEE55UWuXVV3JwgF_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Segment Information - Segment assets (Details)", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "shortName": "Segment Information - Segment assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_StatementBusinessSegmentsAxis_ptpi_PrescriptionMedicationSalesMember_OlYiYQ4-HEKOmKfgjKlT0Q", "decimals": "0", "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HHgNV4l4_kCwEOlx9xeuIA", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Accounts Receivable, net", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNet", "shortName": "Accounts Receivable, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_Q8hscXnWHEO8m1N_T9pHoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 81, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ptpi_AccountsReceivableCashDiscountAllowances": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash discount allowances on accounts receivable.", "label": "Accounts Receivable, Cash Discount Allowances", "negatedLabel": "Cash discount allowances" } } }, "localname": "AccountsReceivableCashDiscountAllowances", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccountsReceivableChargebacksAccruals": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for chargebacks accruals on accounts receivable.", "label": "Accounts Receivable, Chargebacks Accruals", "negatedLabel": "Chargebacks accrual" } } }, "localname": "AccountsReceivableChargebacksAccruals", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccountsReceivableDistributionServiceFees": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for distribution service fees on accounts receivable.", "label": "Accounts Receivable, Distribution Service Fees", "negatedLabel": "Distribution service fees" } } }, "localname": "AccountsReceivableDistributionServiceFees", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccruedContractRebates": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contract rebates Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Contract Rebates", "terseLabel": "Accrued contract rebates" } } }, "localname": "AccruedContractRebates", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccruedInventoryPurchases": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued inventory purchases.", "label": "Accrued Inventory Purchases", "terseLabel": "Accrued inventory purchases" } } }, "localname": "AccruedInventoryPurchases", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ptpi_AccruedLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on accrued liabilities.", "label": "Accrued Liabilities [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesTextBlock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "ptpi_AccruedPriceProtection": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for price protection. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Price Protection", "terseLabel": "Accrued price protection (see note 13)" } } }, "localname": "AccruedPriceProtection", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccruedProductReturns": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Product Returns", "terseLabel": "Accrued product returns" } } }, "localname": "AccruedProductReturns", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AdditionalPaymentIncludedWithFirstMonthlyFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the additional payment included with the first monthly fee.", "label": "Additional Payment Included With The First Monthly Fee", "terseLabel": "Additional payment included with the first monthly fee" } } }, "localname": "AdditionalPaymentIncludedWithFirstMonthlyFee", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AdjustmentsForDeferredRevenue": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of adjustments charged against deferred revenue during the period.", "label": "Adjustments for Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "AdjustmentsForDeferredRevenue", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_AmendedLicenseAgreementOfH100Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amended license agreement of H100.", "label": "Amended license agreement of H100" } } }, "localname": "AmendedLicenseAgreementOfH100Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "domainItemType" }, "ptpi_ApiInventoryRetained": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount due under agreement. The amount of API inventory retained.", "label": "API Inventory Retained", "terseLabel": "Inventory amount retained - API" } } }, "localname": "ApiInventoryRetained", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CashInExcessOfCertainLimitSubjectToAdjustmentAsProvidedInMergerAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the cash in excess of certain limit is subject to adjustment as provided in the Merger Agreement", "label": "Cash In Excess Of Certain Limit, Subject To Adjustment As Provided In Merger Agreement", "terseLabel": "Cash in excess of certain limit, subject to adjustment as provided in the Merger Agreement" } } }, "localname": "CashInExcessOfCertainLimitSubjectToAdjustmentAsProvidedInMergerAgreement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_ClassOfWarrantOrRightExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period.", "label": "Class of Warrant or Right, Exercised", "verboseLabel": "Warrants exercised" } } }, "localname": "ClassOfWarrantOrRightExercised", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsSummaryOfWarrantsDetails" ], "xbrltype": "sharesItemType" }, "ptpi_ClassOfWarrantOrRightExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights expired during the period.", "label": "Class Of Warrant Or Right Expired", "terseLabel": "Warrants expired" } } }, "localname": "ClassOfWarrantOrRightExpired", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsSummaryOfWarrantsDetails" ], "xbrltype": "sharesItemType" }, "ptpi_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued during the period.", "label": "Class of Warrant or Right, Issued", "verboseLabel": "Warrants issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsSummaryOfWarrantsDetails" ], "xbrltype": "sharesItemType" }, "ptpi_CollaborativeArrangementAccruedInventoryPurchases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued inventory purchases as of balance sheet date.", "label": "Collaborative Arrangement, Accrued Inventory Purchases", "terseLabel": "Accrued inventory purchases" } } }, "localname": "CollaborativeArrangementAccruedInventoryPurchases", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementAccruedInventoryPurchasesNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued inventory purchases as of balance sheet date, classified as non-current.", "label": "Collaborative Arrangement, Accrued Inventory Purchases, Non-current", "terseLabel": "Accrued inventory purchases, non-current" } } }, "localname": "CollaborativeArrangementAccruedInventoryPurchasesNonCurrent", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementAdditionalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of additional fee to purchase and receive the license for the commercialization and exploitation of Stendra", "label": "Collaborative Arrangement, Additional Fees", "terseLabel": "Additional fee to purchase and receive the license for the commercialization and exploitation of Stendra", "verboseLabel": "Additional payment due upon obtainment of orphan indication for H100" } } }, "localname": "CollaborativeArrangementAdditionalFees", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the extension term of license agreement.", "label": "Collaborative Arrangement, Extension Term", "terseLabel": "Extension term of license agreement" } } }, "localname": "CollaborativeArrangementExtensionTerm", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "durationItemType" }, "ptpi_CollaborativeArrangementInitialLicenseFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of initial license fee.", "label": "Collaborative Arrangement, Initial License Fees", "terseLabel": "Initial license fee" } } }, "localname": "CollaborativeArrangementInitialLicenseFees", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementMilestonePaymentPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment payable.", "label": "Collaborative Arrangement, Milestone Payment Payable", "terseLabel": "Milestone payment" } } }, "localname": "CollaborativeArrangementMilestonePaymentPayable", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementOneTimeFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of one-time fee to purchase and receive the license for the commercialization and exploitation of Stendra", "label": "Collaborative Arrangement, One Time Fees", "terseLabel": "One-time fee to purchase and receive the license for the commercialization and exploitation of Stendra" } } }, "localname": "CollaborativeArrangementOneTimeFees", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementOneTimeNonCreditableAndNonRefundablePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of one-time, non-creditable and non-refundable payment.", "label": "Collaborative Arrangement, One-Time, Non-Creditable And Non-Refundable Payment", "terseLabel": "One-time, non-creditable and non-refundable payment" } } }, "localname": "CollaborativeArrangementOneTimeNonCreditableAndNonRefundablePayment", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementPaymentForExtension": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of extension payment of license agreement.", "label": "Collaborative Arrangement, Payment For Extension", "terseLabel": "Extension payment of license agreement" } } }, "localname": "CollaborativeArrangementPaymentForExtension", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementPaymentsDueAfterThirdAnniversary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the annual payments due after third anniversary of the license agreement.", "label": "Collaborative Arrangement, Payments Due after Third Anniversary", "terseLabel": "Annual payments due after third anniversary of the license agreement" } } }, "localname": "CollaborativeArrangementPaymentsDueAfterThirdAnniversary", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementPaymentsDueOnFirstAnniversary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the annual payments due on first anniversary of the license agreement.", "label": "Collaborative Arrangement, Payments Due On First Anniversary", "terseLabel": "Annual payments due on first anniversary of the license agreement" } } }, "localname": "CollaborativeArrangementPaymentsDueOnFirstAnniversary", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementPaymentsDueOnSecondAnniversary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the annual payments due on second anniversary of the license agreement.", "label": "Collaborative Arrangement, Payments Due On Second Anniversary", "terseLabel": "Annual payments due on second anniversary of the license agreement" } } }, "localname": "CollaborativeArrangementPaymentsDueOnSecondAnniversary", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementPaymentsDueOnThirdAnniversary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the annual payments due on third anniversary of the license agreement.", "label": "Collaborative Arrangement, Payments Due On Third Anniversary", "terseLabel": "Annual payments due on third anniversary of the license agreement" } } }, "localname": "CollaborativeArrangementPaymentsDueOnThirdAnniversary", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementPaymentsUponFirstCommercialSaleAndSlidingScaleOfPercentagePaymentsOnNetSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the payments upon first commercial sale and a sliding scale of percentage payments on net sales", "label": "Collaborative Arrangement, Payments Upon First Commercial Sale And A Sliding Scale Of Percentage Payments On Net Sales", "terseLabel": "Payments upon first commercial sale and a sliding scale of percentage payments on net sales" } } }, "localname": "CollaborativeArrangementPaymentsUponFirstCommercialSaleAndSlidingScaleOfPercentagePaymentsOnNetSales", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementRoyaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalty.", "label": "Collaborative Arrangement, Royalty Percentage", "terseLabel": "Royalty percentage" } } }, "localname": "CollaborativeArrangementRoyaltyPercentage", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "percentItemType" }, "ptpi_CollaborativeArrangementThresholdNetSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the threshold net sales.", "label": "Collaborative Arrangement, Threshold Net Sales", "terseLabel": "Threshold net sales" } } }, "localname": "CollaborativeArrangementThresholdNetSales", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementThresholdPeriodForOneTimeNonCreditableAndNonRefundablePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period for payments of one-time, non-creditable and non-refundable payment.", "label": "Collaborative Arrangement, Threshold Period for One-Time, Non-Creditable And Non-Refundable Payment", "terseLabel": "Threshold period for payments of one-time, non-creditable and non-refundable payment" } } }, "localname": "CollaborativeArrangementThresholdPeriodForOneTimeNonCreditableAndNonRefundablePayment", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "durationItemType" }, "ptpi_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "ptpi_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about commitments and contingencies", "label": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "ptpi_CommonStockPotentiallyIssuableUponAchievementOfCertainMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the common stock potentially issuable upon the achievement of certain milestones.", "label": "Common Stock Potentially Issuable Upon The Achievement Of Certain Milestones", "terseLabel": "Common Stock potentially issuable upon the achievement of certain milestones" } } }, "localname": "CommonStockPotentiallyIssuableUponAchievementOfCertainMilestones", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityContingentConsiderationDetails" ], "xbrltype": "sharesItemType" }, "ptpi_ConsultingAndAdvisoryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to consulting and advisory agreement.", "label": "Consulting and Advisory Agreement" } } }, "localname": "ConsultingAndAdvisoryAgreementMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "ptpi_ContractWithCustomerRightToReturnAndReceiveCreditForProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the right to return and receive credit for product.", "label": "Contract With Customer, Right to Return and Receive Credit for Product", "terseLabel": "Right to return and receive credit for product" } } }, "localname": "ContractWithCustomerRightToReturnAndReceiveCreditForProduct", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "ptpi_ContractWithCustomerSalesDeduction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the reserves for sales deductions.", "label": "Contract With Customer, Sales Deduction", "terseLabel": "Reserves for sales deductions" } } }, "localname": "ContractWithCustomerSalesDeduction", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CorprominenceLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to CorProminence, LLC.", "label": "CorProminence, LLC" } } }, "localname": "CorprominenceLlcMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "ptpi_DebtInstrumentDebtDefaultInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the interest rate at the time of default.", "label": "Debt Instrument, Debt Default, Interest Rate", "terseLabel": "Interest rate at the time of default (in percent)" } } }, "localname": "DebtInstrumentDebtDefaultInterestRate", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "percentItemType" }, "ptpi_DebtInstrumentEndOfTermCharge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the end of term charge that increases the outstanding principal on a monthly basis.", "label": "Debt Instrument, End of Term Charge", "verboseLabel": "End of term charge" } } }, "localname": "DebtInstrumentEndOfTermCharge", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_DebtInstrumentEndOfTermChargePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow from payments of end of term fee.", "label": "Debt Instrument, End of Term Charge Paid", "terseLabel": "End of term fee paid" } } }, "localname": "DebtInstrumentEndOfTermChargePaid", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_DebtInstrumentFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the fixed charge coverage ratio.", "label": "Debt Instrument, Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage ratio" } } }, "localname": "DebtInstrumentFixedChargeCoverageRatio", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "pureItemType" }, "ptpi_DebtInstrumentPaidInKindInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the paid in kind (\"PIK\") interest rate.", "label": "Debt Instrument, Paid-In-Kind Interest Rate", "terseLabel": "Paid-In-Kind (\"PIK\") interest rate" } } }, "localname": "DebtInstrumentPaidInKindInterestRate", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "percentItemType" }, "ptpi_DomesticCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to domestic customers.", "label": "Domestic customers" } } }, "localname": "DomesticCustomersMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_DueFromWholesalersCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration due from wholesalers that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Due From Wholesalers Current", "terseLabel": "Due from wholesalers" } } }, "localname": "DueFromWholesalersCurrent", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_DuePeriodForInvoicePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the due period for invoice payments.", "label": "Due Period for Invoice Payments", "terseLabel": "Due period for invoice payments" } } }, "localname": "DuePeriodForInvoicePayments", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "ptpi_DueToThirdPartyLogisticProvider": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for third-party logistic provider. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Third-party Logistic Provider", "terseLabel": "Due to third-party logistic provider" } } }, "localname": "DueToThirdPartyLogisticProvider", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_DueUnderLicenseAgreement": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for license agreement. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due under License Agreement", "terseLabel": "Due to Vivus (see Note 13)" } } }, "localname": "DueUnderLicenseAgreement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_EarnoutPaymentsMethodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to method of earnout payments.", "label": "Earnout Payments Method [Axis]" } } }, "localname": "EarnoutPaymentsMethodAxis", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "stringItemType" }, "ptpi_EarnoutPaymentsMethodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Method of earnout payments.", "label": "Earnout Payments Method [Domain]" } } }, "localname": "EarnoutPaymentsMethodDomain", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExclusiveLicenseToH100Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive license to H100.", "label": "Exclusive license to H100" } } }, "localname": "ExclusiveLicenseToH100Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfAugust232023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of August 23, 2023.", "label": "Expiration Date of August 23, 2023" } } }, "localname": "ExpirationDateOfAugust232023Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2024.", "label": "Expiration Date of December 1, 2024" } } }, "localname": "ExpirationDateOfDecember12024Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025FiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Five.", "label": "Expiration Date of December 1, 2025, Five" } } }, "localname": "ExpirationDateOfDecember12025FiveMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025FourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Four.", "label": "Expiration Date of December 1, 2025, Four" } } }, "localname": "ExpirationDateOfDecember12025FourMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025OneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, One.", "label": "Expiration Date of December 1, 2025, One" } } }, "localname": "ExpirationDateOfDecember12025OneMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025ThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Three.", "label": "Expiration Date of December 1, 2025, Three" } } }, "localname": "ExpirationDateOfDecember12025ThreeMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025TwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Two.", "label": "Expiration Date of December 1, 2025, Two" } } }, "localname": "ExpirationDateOfDecember12025TwoMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember22026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 2, 2026.", "label": "Expiration Date of December 2, 2026" } } }, "localname": "ExpirationDateOfDecember22026Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember272026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 27, 2026.", "label": "Expiration Date of December 27, 2026" } } }, "localname": "ExpirationDateOfDecember272026Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 1, 2024.", "label": "Expiration Date of June 1, 2024" } } }, "localname": "ExpirationDateOfJune12024Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune12025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 1, 2025.", "label": "Expiration Date of June 1, 2025" } } }, "localname": "ExpirationDateOfJune12025Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune172024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 17, 2024.", "label": "Expiration Date of June 17, 2024" } } }, "localname": "ExpirationDateOfJune172024Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune192024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 19, 2024.", "label": "Expiration Date of June 19, 2024" } } }, "localname": "ExpirationDateOfJune192024Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfMarch22025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of March 2, 2025.", "label": "Expiration Date of March 2, 2025" } } }, "localname": "ExpirationDateOfMarch22025Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfOctober192026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents for expiration date of October 19 2026.", "label": "Expiration Date Of October 19 2026" } } }, "localname": "ExpirationDateOfOctober192026Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfSeptember12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of September 1, 2024.", "label": "Expiration Date of September 1, 2024" } } }, "localname": "ExpirationDateOfSeptember12024Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfSeptember12025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of September 1, 2025.", "label": "Expiration Date of September 1, 2025" } } }, "localname": "ExpirationDateOfSeptember12025Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfSeptember162024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of September 16, 2024.", "label": "Expiration Date of September 16, 2024" } } }, "localname": "ExpirationDateOfSeptember162024Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after four fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_GainLossOnSettlementWithVivus": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) on settlement with Vivus.", "label": "Gain Loss on Settlement with Vivus", "negatedLabel": "Gain on settlement with Vivus", "terseLabel": "Gain on settlement with Vivus" } } }, "localname": "GainLossOnSettlementWithVivus", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ptpi_HybridMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hybrid.", "label": "Hybrid" } } }, "localname": "HybridMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "domainItemType" }, "ptpi_InterestExpenseOnPromissoryNotes": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of promissory notes accounted for as interest expense for debt.", "label": "Interest Expense on Promissory Notes", "negatedLabel": "Interest expense, promissory note", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOnPromissoryNotes", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ptpi_InterestExpenseSeniorDebt": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of senior debt funds accounted for as interest expense for debt.", "label": "Interest Expense Senior Debt", "negatedLabel": "Interest expense, senior debt", "terseLabel": "Interest expense, senior debt" } } }, "localname": "InterestExpenseSeniorDebt", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtInterestExpensesDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ptpi_InternationalCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to international customers.", "label": "International Customers [Member]" } } }, "localname": "InternationalCustomersMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_InventoryAndSampleInventoryReserve": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory and sample inventory reserve.", "label": "Inventory and Sample Inventory Reserve", "verboseLabel": "Inventory and sample inventory reserve" } } }, "localname": "InventoryAndSampleInventoryReserve", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_LesseeOperatingLeaseLeaseNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of operating leases that had not yet commenced.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount", "terseLabel": "Operating leases that had not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental balance sheet information related to leases.", "label": "Lessee, Operating Lease, Supplemental Balance Sheet Information [Table Text Block]", "terseLabel": "Summary of supplemental balance sheet information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental cash flow information related to leases.", "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Summary of supplemental cash flow information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental lease term and discount rate information related to leases.", "label": "Lessee, Operating Lease, Supplemental Lease Term And Discount Rate Information [Table Text Block]", "terseLabel": "Summary of supplemental lease term and discount rate information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreement.", "label": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketCapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value of entity that is traded on the stock market, calculated by multiplying the total number of shares by the present share price.", "label": "Market Capitalization", "terseLabel": "Market Capitalization" } } }, "localname": "MarketCapitalization", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_MarketCapitalizationIsGreaterThanOrEqualTo250000000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of market Capitalization is greater than or equal to $250,000,000.", "label": "Market Capitalization is greater than or equal to $250,000,000" } } }, "localname": "MarketCapitalizationIsGreaterThanOrEqualTo250000000Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketCapitalizationIsGreaterThanOrEqualTo300000000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of market Capitalization is greater than or equal to $300,000,000.", "label": "Market Capitalization is greater than or equal to $300,000,000" } } }, "localname": "MarketCapitalizationIsGreaterThanOrEqualTo300000000Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketCapitalizationIsGreaterThanOrEqualTo400000000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of market Capitalization is greater than or equal to $400,000,000.", "label": "Market Capitalization is greater than or equal to $400,000,000" } } }, "localname": "MarketCapitalizationIsGreaterThanOrEqualTo400000000Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketCapitalizationIsGreaterThanOrEqualTo500000000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of market Capitalization is greater than or equal to $500,000,000.", "label": "Market Capitalization is greater than or equal to $500,000,000" } } }, "localname": "MarketCapitalizationIsGreaterThanOrEqualTo500000000Member", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Market Capitalization or Gross Proceeds Earnout Payments.", "label": "Market Capitalization/Gross Proceeds Earnout Payments" } } }, "localname": "MarketCapitalizationOrGrossProceedsEarnoutPaymentsMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketingAndConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to marketing and consulting agreement.", "label": "Marketing and Consulting Agreement" } } }, "localname": "MarketingAndConsultingAgreementMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketingLicensingAndDistributionAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Marketing, Licensing and Distribution Agreements." } } }, "localname": "MarketingLicensingAndDistributionAgreementsAbstract", "nsuri": "http://www.petrospharma.com/20220331", "xbrltype": "stringItemType" }, "ptpi_MedicalDeviceSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Medical Device Sales.", "label": "Medical Device Sales" } } }, "localname": "MedicalDeviceSalesMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_MetuchenPharmaceuticalsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Metuchen Pharmaceuticals LLC.", "label": "Metuchen" } } }, "localname": "MetuchenPharmaceuticalsLlcMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "domainItemType" }, "ptpi_MilestonesTermForAchievementOfStockPriceAndMarketCapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the milestones term for achievement of stock price and market capitalization.", "label": "Milestones Term For Achievement Of Stock Price And Market Capitalization", "terseLabel": "Milestones term for achievement of stock price and market capitalization" } } }, "localname": "MilestonesTermForAchievementOfStockPriceAndMarketCapitalization", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityContingentConsiderationDetails" ], "xbrltype": "durationItemType" }, "ptpi_MitsubishiTanabePharmaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Mitsubishi Tanabe Pharma Corporation.", "label": "MTPC" } } }, "localname": "MitsubishiTanabePharmaCorporationMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_MonthlyFeeUnderAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the monthly retainer amount under the agreement.", "label": "Monthly Fee Under Agreement", "terseLabel": "Monthly retainer amount" } } }, "localname": "MonthlyFeeUnderAgreement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_Mr.KeithLavanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Mr. Keith Lavan.", "label": "Mr. Keith Lavan" } } }, "localname": "Mr.KeithLavanMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_NonEmployeeStockBasedCompensation": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under non-employee share-based payment arrangement.", "label": "Non-employee Stock Based Compensation", "verboseLabel": "Non-employee stock-based compensation" } } }, "localname": "NonEmployeeStockBasedCompensation", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash decrease in accrued expenses related to Vivus settlement.", "label": "Noncash Decrease In Accrued Expenses Related To Vivus Settlement", "terseLabel": "Noncash decrease in accrued expenses related to Vivus settlement" } } }, "localname": "NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash decrease in accrued inventory purchases related to Vivus settlement .", "label": "Noncash Decrease In Accrued Inventory Purchases Related To Vivus Settlement", "terseLabel": "Noncash decrease in accrued inventory purchases related to Vivus settlement" } } }, "localname": "NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInApiPurchaseCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of Noncash decrease in API purchase commitment.", "label": "Noncash Decrease In Api Purchase Commitment", "terseLabel": "Decrease in API purchase commitment" } } }, "localname": "NoncashDecreaseInApiPurchaseCommitment", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash decrease in API purchase commitment related to Vivus settlement", "label": "Noncash Decrease In API Purchase Commitment Related To Vivus Settlement", "terseLabel": "Noncash decrease in API purchase commitment related to Vivus settlement" } } }, "localname": "NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash increase in promissory note related to Vivus settlement.", "label": "Noncash Increase In Promissory Note Related To Vivus Settlement", "terseLabel": "Noncash increase in promissory note related to Vivus settlement" } } }, "localname": "NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NumberOfConsecutiveTradingDaysForStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of consecutive trading days for stock price trigger.", "label": "Number of Consecutive Trading Days for Stock Price Trigger", "terseLabel": "Number of consecutive trading days for stock price trigger" } } }, "localname": "NumberOfConsecutiveTradingDaysForStockPriceTrigger", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "integerItemType" }, "ptpi_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of customers.", "label": "Number Of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ptpi_NumberOfTradingDaysForStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of trading days for stock price trigger.", "label": "Number of Trading Days for Stock Price Trigger", "terseLabel": "Number of trading days for stock price trigger" } } }, "localname": "NumberOfTradingDaysForStockPriceTrigger", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "integerItemType" }, "ptpi_NumeratorForCalculationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition.", "label": "Numerator For Calculation Of Earnings Per Share Abstract", "terseLabel": "Numerator" } } }, "localname": "NumeratorForCalculationOfEarningsPerShareAbstract", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "ptpi_OneCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to one customers.", "label": "One customers" } } }, "localname": "OneCustomersMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_OperatingLeaseExpensePerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of operating lease expense per month.", "label": "Operating Lease Expense Per Month", "terseLabel": "Operating lease expense per month" } } }, "localname": "OperatingLeaseExpensePerMonth", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future minimum rental payment for sub-lease in aggregate as of the balance sheet date under operating leases.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseAbstract", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails" ], "xbrltype": "stringItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails": { "order": 2.0, "parentTag": "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable for sub-lease within one year of the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease, Current", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseCurrent", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInTwoYears": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails": { "order": 3.0, "parentTag": "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable for sub-lease within the second year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease, in Two Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInTwoYears", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails": { "order": 1.0, "parentTag": "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable for sub-lease within remainder of fiscal year of the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease, Remainder of Fiscal Year", "terseLabel": "2022 (remaining 9 months)" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PaymentMadeForPurchaseOrder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of payment made for purchase order.", "label": "Payment Made For Purchase Order", "terseLabel": "Payment made for purchase order" } } }, "localname": "PaymentMadeForPurchaseOrder", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PaymentOfLicenseFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for license fees.", "label": "Payment of License Fees", "terseLabel": "Payment of License Fees" } } }, "localname": "PaymentOfLicenseFees", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PaymentOfSeniorDebtEndOfTermFee": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the payment of portion of senior debt end of term fee.", "label": "Payment of Senior Debt End of Term Fee", "verboseLabel": "Payment of portion of senior debt end of term fee" } } }, "localname": "PaymentOfSeniorDebtEndOfTermFee", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_PercentageOfBaseSalaryToBePaidAsAdvisor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of base salary to be paid as an advisor.", "label": "Percentage Of Base Salary To Be Paid As An Advisor", "terseLabel": "Percentage of base salary to be paid as an advisor" } } }, "localname": "PercentageOfBaseSalaryToBePaidAsAdvisor", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfFeesAsAdvisorPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of fees as an advisor paid.", "label": "Percentage Of Fees As An Advisor Paid", "terseLabel": "Percentage of fees as an advisor paid" } } }, "localname": "PercentageOfFeesAsAdvisorPaid", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfFeesAsAdvisorToBePaidInEqualInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of fees as an advisor to be paid in equal installments.", "label": "Percentage Of Fees As An Advisor To Be Paid In Equal Installments", "terseLabel": "Percentage of fees as an advisor to be paid in equal installments" } } }, "localname": "PercentageOfFeesAsAdvisorToBePaidInEqualInstallments", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfStendraTabletsReleased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of stendra tablets released.", "label": "Percentage Of Stendra Tablets Released", "terseLabel": "Percentage of stendra tablets released" } } }, "localname": "PercentageOfStendraTabletsReleased", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "pureItemType" }, "ptpi_PrepaidCouponFeeCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of coupon fee paid in advance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Coupon Fee Current", "terseLabel": "Prepaid coupon fees" } } }, "localname": "PrepaidCouponFeeCurrent", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrepaidFoodAndDrugAdministrationFeeCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of fee paid in advance for FDA that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Food And Drug Administration Fee Current", "terseLabel": "Prepaid FDA fees" } } }, "localname": "PrepaidFoodAndDrugAdministrationFeeCurrent", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrepaidPurchaseCommitmentAssetCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for API purchase commitments that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Purchase Commitment Asset Current", "terseLabel": "API purchase commitment asset (see Note 13)", "verboseLabel": "API purchase commitment asset" } } }, "localname": "PrepaidPurchaseCommitmentAssetCurrent", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrepaymentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of prepayment amount.", "label": "Prepayment Amount", "terseLabel": "Prepayment amount" } } }, "localname": "PrepaymentAmount", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrescriptionMedicationSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prescription Medication Sales.", "label": "Prescription Medication Sales" } } }, "localname": "PrescriptionMedicationSalesMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for promissory note.", "label": "Promissory Note" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_PtvProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PTV product .", "label": "PTV product" } } }, "localname": "PtvProductMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_RenewalTermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the renewal term of agreement.", "label": "Renewal Term of Agreement", "terseLabel": "Renewal term of agreement" } } }, "localname": "RenewalTermOfAgreement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "durationItemType" }, "ptpi_RequiredCashProceedsThroughEquityOrDebtFinancingOrOtherTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of required cash proceeds through an equity or debt financing or other transaction.", "label": "Required Cash Proceeds Through An Equity Or Debt Financing Or Other Transaction", "terseLabel": "Required cash proceeds through an equity or debt financing or other transaction" } } }, "localname": "RequiredCashProceedsThroughEquityOrDebtFinancingOrOtherTransaction", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "RSUs" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "ptpi_RoyaltyReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of royalty receivable as of balance sheet date.", "label": "Royalty Receivable", "terseLabel": "Royalty receivable" } } }, "localname": "RoyaltyReceivable", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_ScenarioFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of milestone payment to be paid once $250 million in sales has been reached.", "label": "Milestone payment to be paid once $250 million in sales has been reached" } } }, "localname": "ScenarioFiveMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty following the fourth and fifth years following the end of the Royalty Period.", "label": "Royalty following the fourth and fifth years following the end of the Royalty Period" } } }, "localname": "ScenarioFourMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty on the first $500 million of net sales.", "label": "Royalty on the first $500 million of net sales" } } }, "localname": "ScenarioOneMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of milestone payment to be paid after $250 million in sales has been reached.", "label": "Milestone payment to be paid after $250 million in sales has been reached" } } }, "localname": "ScenarioSixMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty during the first, second, and third years following the expiration of the Royalty Period.", "label": "Royalty during the first, second, and third years following the expiration of the Royalty Period" } } }, "localname": "ScenarioThreeMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty on net sales after $500 million.", "label": "Royalty on net sales after $500 million" } } }, "localname": "ScenarioTwoMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScheduleOfPrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition.", "label": "Prepaid Expenses and Other Current Assets." } } }, "localname": "ScheduleOfPrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://www.petrospharma.com/20220331", "xbrltype": "stringItemType" }, "ptpi_ScheduleOfPrepaidExpensesAndOthercurrentAssetsTabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for prepaid costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet.", "label": "Schedule of Prepaid Expenses and OtherCurrent Assets TableTextBlock", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOthercurrentAssetsTabletextblock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ptpi_ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of warrants by expiration date.", "label": "Schedule of Warrants And Rights by Expiration Date [Table Text Block]", "verboseLabel": "Summary of warrants by expiration date" } } }, "localname": "ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "ptpi_SecurityDepositForSubLeaseReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of security deposit received for sublease from sub lessor.", "label": "Security Deposit For Sub Lease Received", "terseLabel": "Security deposit received for sublease" } } }, "localname": "SecurityDepositForSubLeaseReceived", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_SeparationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Separation Agreement.", "label": "Separation Agreement" } } }, "localname": "SeparationAgreementMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_ServiceAgreementWithIrthCommunicationsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service agreement with IRTH Communications, LLC.", "label": "Service Agreement" } } }, "localname": "ServiceAgreementWithIrthCommunicationsLlcMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "ptpi_SettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Settlement Agreement.", "label": "Settlement Agreement" } } }, "localname": "SettlementAgreementMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesRequired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares required, which is authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Required", "terseLabel": "Option grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesRequired", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ptpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of directors to whom option is granted in share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Directors to Whom Option is Granted", "verboseLabel": "Number of directors to whom option is granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ptpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for options granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Remaining Contractual Term", "verboseLabel": "Options granted (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "ptpi_SharesToBeIssuedAsPartOfMilestoneEarnoutPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares to be issued as part of milestone earnout payments.", "label": "Shares to Be Issued As Part of Milestone Earnout Payments", "terseLabel": "Milestone earnout payments (in shares)" } } }, "localname": "SharesToBeIssuedAsPartOfMilestoneEarnoutPayments", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "sharesItemType" }, "ptpi_StayOnBonus": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of stay-on bonus.", "label": "Stay-On Bonus", "terseLabel": "Stay-on bonus" } } }, "localname": "StayOnBonus", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_StendraProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Stendra product.", "label": "Stendra Product" } } }, "localname": "StendraProductMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_StockIssuedDuringPeriodSharesRestrictedStockAwardAdditionalGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents for stock issued during period shares restricted stock award additional grants.", "label": "Stock Issued During Period Shares Restricted Stock Award Additional Grants", "terseLabel": "Issued additional grants" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardAdditionalGrants", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "sharesItemType" }, "ptpi_StockIssuedDuringPeriodValueRestrictedStockAwardAdditionalGrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents for stock issued during period value restricted stock award additional grants.", "label": "Stock Issued During Period Value Restricted Stock Award Additional Grants", "terseLabel": "Amount of additional grant" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardAdditionalGrants", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure information about prepaid expenses and other current assets", "label": "Summary of Prepaid Expenses And Other Current Assets TextBlock", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextblock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ptpi_TaniaKingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tania King.", "label": "Tania King" } } }, "localname": "TaniaKingMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "ptpi_TermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term of agreement.", "label": "Term of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "TermOfAgreement", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "durationItemType" }, "ptpi_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to three customers.", "label": "Three customers" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_ThresholdAggregateGrossProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the threshold amount of aggregate gross proceeds in offering.", "label": "Threshold Aggregate Gross Proceeds", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "ThresholdAggregateGrossProceeds", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_ThresholdNumberOfDaysToSatisfyConditionForReleasingRemainingPercentOfStendraTablets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days to satisfy the condition to release remaining percentage of stendra tablets.", "label": "Threshold Number Of Days To Satisfy The Condition For Releasing Remaining Percent Of Stendra Tablets", "terseLabel": "Threshold number of days to release remaining percentage of stendra Tablets upon satisfaction" } } }, "localname": "ThresholdNumberOfDaysToSatisfyConditionForReleasingRemainingPercentOfStendraTablets", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "durationItemType" }, "ptpi_ThresholdPeriodOfNoticeRequiredToTerminateAgreementAtAnyTimeAfterFirstAnniversary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period of notice required to terminate agreement at any time after first anniversary", "label": "Threshold Period Of Notice Required To Terminate Agreement At Any Time After First Anniversary", "terseLabel": "Threshold period of notice required to terminate agreement at any time after first anniversary" } } }, "localname": "ThresholdPeriodOfNoticeRequiredToTerminateAgreementAtAnyTimeAfterFirstAnniversary", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails" ], "xbrltype": "durationItemType" }, "ptpi_ThresholdTermToReceiveGrossProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold term to receive aggregate gross proceeds in offering.", "label": "Threshold Term to Receive Gross Proceeds", "terseLabel": "Term to receive gross proceeds" } } }, "localname": "ThresholdTermToReceiveGrossProceeds", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "durationItemType" }, "ptpi_TimmMedicalProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Timm Medical product.", "label": "Timm Medical product" } } }, "localname": "TimmMedicalProductMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to two customers.", "label": "Two customers" } } }, "localname": "TwoCustomersMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_VivusIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Vivus, Inc.", "label": "Vivus, Inc" } } }, "localname": "VivusIncMember", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_WarrantsAndRightsNoteDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclsoure on warrants and rights.", "label": "Warrants And Rights Note Disclosure [Text Block]", "verboseLabel": "Common Stock Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureTextBlock", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrants" ], "xbrltype": "textBlockItemType" }, "ptpi_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net current assets (current liabilities).", "label": "Working Capital", "terseLabel": "Negative working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.petrospharma.com/20220331", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r104", "r159", "r172", "r173", "r174", "r175", "r177", "r179", "r183", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r238", "r240", "r241" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r104", "r159", "r172", "r173", "r174", "r175", "r177", "r179", "r183", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r238", "r240", "r241" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r60", "r62", "r102", "r103", "r247", "r283" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r191", "r316", "r320", "r487" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r246", "r282", "r329", "r332", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r485", "r488", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r246", "r282", "r329", "r332", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r485", "r488", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r191", "r316", "r320", "r487" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r246", "r282", "r326", "r329", "r332", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r485", "r488", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r246", "r282", "r326", "r329", "r332", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r485", "r488", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r61", "r62", "r102", "r103", "r247", "r283" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r114", "r119", "r330" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r187", "r188", "r316", "r319", "r486", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r187", "r188", "r316", "r319", "r486", "r495", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r114", "r119", "r225", "r330", "r433" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable, net" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r465", "r480" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r193" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Gross accounts receivables" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Receivables from customers" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r26", "r474", "r496" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "totalLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r26", "r193", "r194" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "auth_ref": [ "r465", "r480" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.", "label": "Accrued Bonuses", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13", "r14", "r42" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27", "r354", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r106", "r107", "r108", "r351", "r352", "r353", "r389" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r333", "r335", "r355", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r195", "r200", "r201", "r203" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r87", "r266", "r274", "r275", "r409" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "verboseLabel": "Amortization of deferred financing costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r101", "r167", "r174", "r181", "r198", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r375", "r379", "r398", "r429", "r431", "r460", "r476" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Total segment assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental balance sheet information related to leases" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r11", "r56", "r101", "r198", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r375", "r379", "r398", "r429", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r336", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r384", "r387" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r328", "r331" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r328", "r331", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r39", "r89" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r83", "r89", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r399" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r98", "r101", "r122", "r123", "r126", "r128", "r130", "r138", "r139", "r140", "r198", "r228", "r233", "r234", "r235", "r241", "r242", "r280", "r281", "r285", "r289", "r398", "r517" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r304", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise Price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding at the end", "periodStartLabel": "Warrants outstanding at the beginning", "terseLabel": "Number of Warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails", "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsSummaryOfWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r304", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r370", "r371", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Marketing, Licensing and Distribution Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r222", "r223", "r224", "r226", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r106", "r107", "r389" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityConsummationOfMergersDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock (par value of $0.0001 per share, 150,000,000 shares authorized, 20,684,723 shares issued and outstanding as of March 31, 2022, and December 31, 2021, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r148", "r149", "r191", "r395", "r396", "r497" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r148", "r149", "r191", "r395", "r396", "r494", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r148", "r149", "r191", "r395", "r396", "r494", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r143", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r148", "r149", "r191", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r146", "r148", "r149", "r150", "r395", "r397", "r497" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r148", "r149", "r191", "r395", "r396", "r497" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Reserves for product returns" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r91", "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Number of preferred stock converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r172", "r173", "r174", "r175", "r177", "r183", "r185" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r76", "r443" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit concentration risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r147", "r191" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r97", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r260", "r267", "r268", "r270", "r276" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r21", "r22", "r100", "r104", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275", "r410", "r461", "r462", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r243", "r272", "r273", "r408", "r410", "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "positiveLabel": "Principal amount", "terseLabel": "Face amount of debt", "verboseLabel": "Principal amount of notes payable" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44", "r244" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "positiveLabel": "Interest rate (in percent)", "terseLabel": "Stated interest rate", "verboseLabel": "Percentage added to variable rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45", "r100", "r104", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275", "r410" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r100", "r104", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r272", "r273", "r274", "r275", "r297", "r300", "r301", "r302", "r407", "r408", "r410", "r411", "r471" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r87", "r162" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r57", "r62", "r63", "r386", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Fair value of the derivative liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r385" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in Fair Value of Derivative Liability", "negatedLabel": "Derivative liability", "negatedTerseLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r58", "r59", "r62", "r394" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r316", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock Options and Restricted Stock Units (\"RSU's\")" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options and Restricted Stock Units (\"RSU's\")" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarlyRepaymentOfSeniorDebt": { "auth_ref": [ "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.", "label": "Early Repayment of Senior Debt", "terseLabel": "Amount of principal prepaid" } } }, "localname": "EarlyRepaymentOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r111", "r112", "r113", "r114", "r115", "r120", "r122", "r128", "r129", "r130", "r134", "r135", "r390", "r391", "r468", "r482" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income (loss) per common share" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r73", "r111", "r112", "r113", "r114", "r115", "r122", "r128", "r129", "r130", "r134", "r135", "r390", "r391", "r468", "r482" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r67", "r68", "r69", "r106", "r107", "r108", "r110", "r116", "r118", "r137", "r199", "r296", "r303", "r351", "r352", "r353", "r366", "r367", "r389", "r400", "r401", "r402", "r403", "r404", "r405", "r489", "r490", "r491", "r520" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r464", "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow fund" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments" } } }, "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful lives of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r215" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2022 (remaining 9 months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r215" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r215" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r215" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r210", "r211", "r214", "r216", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r210", "r213" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r214", "r444" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Carrying value of intangible assets", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Finite-lived Intangible Assets [Roll Forward]" } } }, "localname": "FiniteLivedIntangibleAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r75", "r101", "r167", "r173", "r177", "r180", "r183", "r198", "r228", "r229", "r230", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r398" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r167", "r173", "r177", "r180", "r183", "r458", "r466", "r469", "r483" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r66", "r359", "r360", "r362", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "verboseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r124", "r125", "r130" ], "calculation": { "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "terseLabel": "Effect of common share equivalents within common stock warrants" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r209", "r212" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r79", "r264", "r271", "r274", "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r81", "r84", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest during the period" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r14", "r15", "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued and unpaid interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r51" ], "calculation": { "http://www.petrospharma.com/role/DisclosureInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r32", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods are net of valuation reserves" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r53" ], "calculation": { "http://www.petrospharma.com/role/DisclosureInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total inventory" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r53", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "API purchase commitment" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r52" ], "calculation": { "http://www.petrospharma.com/role/DisclosureInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials are net of valuation reserves" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of future minimum lease payments under non-cancelable leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (remaining 9 months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r424" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41", "r101", "r175", "r198", "r228", "r229", "r230", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r376", "r379", "r380", "r398", "r429", "r430" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r101", "r198", "r398", "r431", "r463", "r478" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43", "r101", "r198", "r228", "r229", "r230", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r376", "r379", "r380", "r398", "r429", "r430", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables.", "label": "Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]", "terseLabel": "Accounts Receivable, net" } } }, "localname": "LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r45" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Promissory note" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r227" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r85", "r88" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash in operations", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r64", "r65", "r69", "r72", "r88", "r101", "r109", "r111", "r112", "r113", "r114", "r117", "r118", "r127", "r167", "r173", "r177", "r180", "r183", "r198", "r228", "r229", "r230", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r391", "r398", "r467", "r481" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net (loss) income", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash Items:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Current portion of promissory note" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Note" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r173", "r177", "r180", "r183" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r419", "r425" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Fixed lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r415" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "verboseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Future minimum lease payments under non-cancelable leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r413" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails", "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease liability:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r413" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r413" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r416", "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU asset: Other assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Operating lease ROU asset" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseTermAndDiscountDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r172", "r173", "r174", "r175", "r177", "r183" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Operations, Basis of Presentation, and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Operations, Basis of Presentation, and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r42" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r19", "r459", "r475" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r55", "r431" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r384", "r388" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r42", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r7", "r10", "r207" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r280" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityConsummationOfMergersDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24", "r280" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock (par value of $0.0001 per share, 50,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r37", "r38" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r8", "r10", "r206", "r207" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds from (Repayments of) Notes Payable", "terseLabel": "Payment of promissory note" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r64", "r65", "r69", "r82", "r101", "r109", "r117", "r118", "r167", "r173", "r177", "r180", "r183", "r198", "r228", "r229", "r230", "r233", "r234", "r235", "r237", "r239", "r241", "r242", "r374", "r377", "r378", "r381", "r382", "r391", "r398", "r469" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r218", "r431", "r470", "r479" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r74", "r202" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense (recoveries)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r174", "r177" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r174", "r177" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r327", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r327", "r426", "r428", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayment of senior debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSeniorDebt": { "auth_ref": [ "r80" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.", "label": "Repayments of Senior Debt", "negatedLabel": "Payment of senior debt" } } }, "localname": "RepaymentsOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r358", "r442", "r511" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r303", "r354", "r431", "r477", "r492", "r493" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Sustained cumulative losses attributable to common stockholders", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r106", "r107", "r108", "r110", "r116", "r118", "r199", "r351", "r352", "r353", "r366", "r367", "r389", "r489", "r491" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r158", "r159", "r172", "r178", "r179", "r186", "r187", "r191", "r315", "r316", "r443" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r148", "r191" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Gross sales from customers" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Summary of net sales by geographic region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePracticalExpedientFinancingComponent": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.", "label": "Revenue, Practical Expedient, Financing Component [true false]" } } }, "localname": "RevenuePracticalExpedientFinancingComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty incurred" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Computation of Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Computation of Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r210", "r213", "r444" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r210", "r213" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r70", "r190" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r167", "r170", "r176", "r208" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r167", "r170", "r176", "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of results of operations by reportable segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r336", "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r341", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r47", "r98", "r138", "r139", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r285", "r289", "r294", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r304", "r334" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Summary of warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future annual amortization of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r154", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r183", "r191", "r220", "r221", "r484" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r154", "r156", "r157", "r167", "r171", "r177", "r181", "r182", "r183", "r184", "r186", "r190", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Results of operations by reportable segment" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorDebtObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing with the highest claim on the assets of the entity in event of bankruptcy or liquidation.", "label": "Senior debt" } } }, "localname": "SeniorDebtObligationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails", "http://www.petrospharma.com/role/DisclosureDebtThirdAmendmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Employee stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Options and RSU's exercisable at the end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Options exercisable at the end (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Less: options and RSU's expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options granted", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r343", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options and RSU's outstanding at the end", "periodStartLabel": "Options outstanding and exercisable on beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding at the end (in dollars per share)", "periodStartLabel": "Options outstanding and exercisable at the beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r334", "r339" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Less: options expired/cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price", "verboseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r336", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price trigger", "verboseLabel": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketCapitalizationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMilestoneEarnoutPaymentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "verboseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Options exercisable at the end (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) of non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)", "terseLabel": "Number of shares increased for issuance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding at the end (in years)", "verboseLabel": "Options outstanding and exercisable at the beginning (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r154", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r183", "r191", "r208", "r219", "r220", "r221", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r98", "r101", "r122", "r123", "r126", "r128", "r130", "r138", "r139", "r140", "r198", "r228", "r233", "r234", "r235", "r241", "r242", "r280", "r281", "r285", "r289", "r296", "r398", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r49", "r67", "r68", "r69", "r106", "r107", "r108", "r110", "r116", "r118", "r137", "r199", "r296", "r303", "r351", "r352", "r353", "r366", "r367", "r389", "r400", "r401", "r402", "r403", "r404", "r405", "r489", "r490", "r491", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r106", "r107", "r108", "r137", "r443" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r48", "r261", "r296", "r297", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Preferred Stock to Common Stock (in shares)", "verboseLabel": "Number of common stock issued upon conversion" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityNumberOfSharesHeldDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r24", "r25", "r296", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Number of restricted shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Non-employee stock-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r49", "r296", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of Preferred Stock to Common Stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r296", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationAndLiquidityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r296", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted share cash value" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Non-employee stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r101", "r196", "r198", "r398", "r431" ], "calculation": { "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r99", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r420", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Amount of fixed lease cost which are offset by sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r406", "r432" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r406", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r406", "r432" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsHybridDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockholdersEquityMarketingAndConsultingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r141", "r142", "r144", "r145", "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFinancialCovenantDetails", "http://www.petrospharma.com/role/DisclosureDebtSeniorDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfPotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effects of common share equivalents" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r121", "r130" ], "calculation": { "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average common shares for diluted net loss per unit", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r120", "r130" ], "calculation": { "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares for basic net loss per unit", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130569-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r515": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r516": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r517": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r518": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r519": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 102 0001410578-22-001669-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-22-001669-xbrl.zip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�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

! M/PJ_FO,P4ECN@,S]2-%-[6S[@S4PO5#(3@1^/(EP!4VO /3JML1+AQS,T_'M M&7R98J4J'WX -%10$5 S()F$(;.K!(:\RREB'P":F-S>W$.27[+]&2G2!VXH MH)BRWV>RN>].JN#BVDD+<0783U+LSI?9A]4C,# 3!A+?*L3I+ #T Q*E4LD- MZS6JU7%)MU?=08$16!=Q+0LB2=6&2T)8DL)YH\4TAX3-J2 *.%.[)4T#,0BNQGIV M:[\@D)?LLGORW ]N;_ZZ>$"&#>W1CO[&-),?@9=FEU8@RJ2?BZ!RVT+E()0[ M[!6V$NC@!@RS\4(AYYS\+F#Q?E? N\^VG!GR$1N[:K\PKB*T^ !DW,\\^9_P M?&P6C7SIJU86-RU.UK7'%K\K5'/-HVK.W?J=F MU"S<>H-&?I3K]G-RSQ:$ME5^?&_=K("KOUR/[8J8:S\@YGAQ/ 59WNW72Z0MOS%;@)_8"'F-"' MU^.J$IR_Y ]YT\SMGM,H1Y+M.:K4P*%HZ\@RVN9>,]KYG(=*)R\E/98^@DG, M4(/*:AI\[@MG2Q8\*^<>^LY"_C6*)N,/_P%02P,$% @ EH*P5)>%.D8* M2@ ,P " !< !T;6(M,C R,C S,S%X97@Q,&0Q+FAT;>U]:W/;R)7V7^EW M-MF54I LR=>QO5.A*<[[_[>UU8LO_7BL _5I>'2H@F1<3'6V?[YU=;6[^\AZ&ZK:WL[>G=G?>OGS^=N^EZARIC?-A=Y.NWC_I#G\[[?%33\\_'/:[ZJ>M9\\^ M/^\^>[8_W. M/!N>/;O,I]&+9U&29'H[R(.??GF/W\!_M1_\\GZJ?P/_9CH-)__UCJ[.PG]K&!I>+]=?\RT_"B]@<)SK.W[_M_+JH\I# MKC6]SBB) OBQ]_4R'(4Y[/KV[OMG(UBGV0/,:@PDJM/:M/!R\Z"K,(-I1&$^ M?WL9!H&.X8+__(\W>SO/W[U_AA:+.]$41\86#K;][JI_KJ7JUL[LQVMS8W=G<"*\V MU21-IBJ_##.U;P[T2(_](M,*]@:^1H)2<9(K>"2\DQ\I/P[PA_Q2JWP^@_]< M^CE]2O5%F.4I/1T/>*9@>K,TO(([59*J<1)/0ECA'$;97F_Y[5L^Z V'A[VC MWO%0=3Z>]>BO>UZWQ[=*_RRR/)S,JS,;(H6V+8>G I(D0&G)1/W-CPL_G?_G M?^R^VGFW^\93*%<\M4$$CI/?VWGWOC SIH<&>IRD=$BVQDF4I&__8X?^]Z[^ M:Q3&^FT1!SK%OQH_TYAOLR0*<>)K>/RMHU?9VWVWBJ2$2@/F&,1S0 MT9P.TTCGUWB(CWK#\^ZGWK$Z_=0Y.^IT>^?#?K=S.%"'AUU/^6H?V/>UGVH5 MA=,07SH*?=XA.%I3D+MS?%.]U!<]TGDQOM1QY3WQI7[M_WK^+3/'>Y"QP5/G M?+/'V]B/Q]MJ8YGO1$]W7VA;F==T7@U?!QX:Z3&*5)ATJB>@]L#+P<[ZS!^7 M.>M3/\U#G3GSILEJ?WP).[#LFIN,H73, 9A&?Z;I;CE*H;K#?0,9/I(IWQ4GN\@Q]M]I3: M_GRX$#0"#^@RR_%JSWQ%HY??9L5L%M&P(-Q!3(/ U^EU"+.8)D$X"?&:91.S M68=6/NI5M)SKRQ HG)?V I4//H'.PK-VE,$I!;[#X\)2XRL-T4[)DW1.*Q;H M"Z MR,.Q"M+B0GV)D^L8&<1@V#O>/^O UKU^\0XF<.7'_B2,-I?+[&06[OJNSVOE MO%[K&PYL>4C5 ,_1?(4.:?V%;SFC[8>)UYA>+ZR>7(^6H-P0? Q= ".#>0ZO M3L8+ZPKT\J=I$A3CO.TPPU;]"V<3TB[&B8ITAC+:9T9P%,;AM)BJ4S/TR0B( MA0^R.YKPC?J;K_21:5L0=8T:D$ZG82R.GO9CL%8.B+8S'449&-R9 C(+LTLT MY(66A3^KW!]%.D<&Y#F\Z88;0?[X-8GS/X/?COI6X,PNR1B!+=+/\F06ICZ: M^$L6/SREBO7@OBF[%8#31NB10W[[ZT"=7OKIU!_/ESM3>/):2#+=HG:3*G^4 M%+DZT*.TM+E!L+TA\D0>K_T)T)='>_:/O_SE+_\';!1)$X@4! 'R8?Z6V#C2 M<.9'&NF6:!M?<_?UN\P2-),*LF!@VB!*"E@F#4P]0IDP"+\"$X\B9-CX_.$E M<"+U"387+;(>>E7F\&529,U?#Q*P5[:&UXG:!WO.3S,:X2 I4M6%(Y*IC3^] M\IZ_V?&>O]C;WGFQB<\;)U<:/5H9_)Q)A'=)VX43YUJ>&AF>"39'7Z4U>9@_3'. M+);+37F::TJSE';D@^8IJA%K1JY^4(RF82Z6+4O^BA52JJTI++\Z&M( 6SN[ M8H(T![?,R>K,R^8\-(OJQ!M.1(QO.'J_#_0-)VY?] M#.( C;<96&H8V("3B-.9%%%D1!3,&A4:N^ M[[W*I&]IG/9ZC+IJI(,+LH21 M D"-&*%OU9],PG1*WA<@?#X#84:1*5C[&?#AT%UE(U!%P&8BA-$@G).@1@4F MGHL$#YFF[(\AL.W]C#D MI_#_;_C?[R3%1N2\$N.F0#O\G2=3CK4[(>^'"'"WA>]V']/)Y>7B_UZFYN81 M'*J+%$@HJ'%O9S&K/UQR$'(/)H)\?$L^[[2MN7SEY"[(-V[J0CTI8N9?Z*T1 MG.DO6V0BO/6C:W^>R0:^>;.]]^+/[T8)LD;)8]BI)3O\F"D4=W5-1EERC^RR M891,P-PN4F1-*,@F8'LCO[G!16883JLGR++&,$=+*3-1D*8-1^+6R&84Q$;T M#J]AH/D6BFXKFTD_%[JM-]O:Y0QZ$$]<@+&_: M>[GCP2'8K+%S7.Z9']H8#MSC:A*N7@!W.R/P]7A[BL:O)M.8F/<()$.,\QIA M^"$.1.ID(2PELW0C(ZK:S4RGE $2CW53P=EQOJJ>@!Z/Z9=0MJRC?#XG?1.%FF\#0 MTG'@IVJN<8+6%P)__/P'1.9/3VZR['%FP!V2"TWN>*OCM.D>RP\MW.22( \0 M,'?:%MA .CO(V-B[A#I],ME<^#*KK&R'Z+@C.D[0:/'G8@+65$US=B2J(J&O M0&JJ&+.@6$[OFP^GYDA)LID.7L2D]B$7I#U M&4T6U.]IF&48OX7]U\K/B"=UR6BJ)@V3@-1\*0\;(QS"8@2609 M"(84,K-#-#2F^?@EB3R&3?K F[34:*E9BM9XZ8ISI4F14J*$U6DPXCZW+,62 MD6OD H4B-P"R$]90IV_2&AJKS@HI,K$,-8"F:D"^FY@":5,P7VOJ%NH)[BR0 MBEDWP'OX+^)JA@UF=^*BVHHT] :8N39>LNK+*MW&]MQB\@#?*<,VK'W/'1Z] M:3HEQ2GE;&%(Y"-#!CK?R$U8X5)V]UY MQUJC!:-M*+.GV]1HF]!DKRBK9"'>9'#V%>*<[KL&1?9_3;JT<&QR>?U1!)X>#DK%KMTB[VRR2?_]_ER+&]S$3B!@U1:]6D*HW_,VGNF,HP$T=S9#TU/,, M"]J([=%VJB'9&'@82?#1144F7 QNRRY]$'B7_I46<\1<.M4^RM%5/,)+K:P M\1:%?L7"H;4'/8ML$'1OZC$9L;XZ!34FH4Q"L&TX;(B1GPG(0$SJE%_150KL M.85W\ZJ!>1M6Q_S/&"Z_#&>>S;]$%8ZT4LP$F8XPUXUL6[)8)RS: ]#VQABK M3%#7LY] -N=I$L&DP\Q\B%BZXX7&HXI*51*;"_@%V6:FJ6]CU)*UY0)FG>G, M>@0#2_4L>*[!4#,&J0QG5F_#ZI&RA+ $QL]MR-IS;+OJ*#QK,Q9,1WXN'68M M+V%].;1SRK*4Y%H6&=]C0CY:V"2,O*B-ESM_WL3QITEJC82KA/13*G3X5X%[ M0?Y^6@9:I^_;XCON,%'"QDCF3MN07+-WA3>:%2X_]B]83?I]L[HKX3V,3%J) M>-[>8V+>ZWC>CQC/6ZJPQ*SZ,<5##OWKAL14IO .59K(OP9IA/4&:%$BKX'U M1J]'YAG? *I0'C*O:9CS%<"8/! U8[!BX(]_%L&%N#R8_\'"XMU%A(H1$%5R"Y MM,,6/V)69BQ5$ITBOTS03B4/$]7!C3&H,V,%4/P:. <1)CY.F L$4%;IZ2PR M3U_L><'[G>5I3!M^/BL]*W9.C0HDCS:A+ F1RFP@-?+DP+\K:&HL\ZQ\\.,O M:3'+QW/538*F>JF&B/R@=G<-N9S'5,HZ0&K,Z!X6RZ@0R<3+,3T;=KMAASV3 ME01* IR[+$G->5SO_+2&,C<$T.:N/M'FTB@P_GX$6- 5YN]ZB M/[)L8;UGCW'/'/@7U2]1;%K44M"$7+ 8$XZ;I:'.?5"CG+MMO1#)3O41+*.9 M.J*B#4D[RT 9S9AQXO;C921=!;,*BYC0=@&B$,$^T'G.M;86%"=;T\8#^VA' MH 2#IAR%>H*V2M:D"MR:FI+F6>N%)6\4@N ,K LEAA>_0L6;O2>C4AL3AE!) MWQKI6$]"I'U^($0 6CL8Z QX]C.%EKG2, MHZ@H M#A)X201>PI!ODFIXG]*++.[CT'J4\:HH09*Z4"HMEB,ADR=[\K %2- MY-1O&W=-&G\82-W: _4(-ZS-L>/N&>=VX8YY%6A/KQ'_:TF-]18H[M["-.R* MZ\))%P]C$"_F@\W\Y:1:+@7D,(' '.B@I5Z=? Y.R;CG!CI1%EXDE-5C)J&Y M.@(CP)BSBV%:_#&&Y^$?LQDJ3F,M$Q+/!"7X2K8Y)[160ZV>P4'-_"GFPAVRPJ'KD26R_/'Q&;662[K+)??6>EJD.D[ 7ICM>J1$[2I MK=DT0]]!LY=[V'&JBAEKUEQ10-P8>Q-C4PDL=R0^S 1/4-(BP: M*;XX<>N))K<,]:Y,-[S#.V#(1%.] 4Q\)H4@\/=(PMUD!%&V+&7SX&2DK'9C M0KD_80UL=!/G)@A35"1"[HY2_P19YW_A6D%?75\FD23GQ*5:6ZY%\V;,C[T* M@P($$ME#]<'@[<=W?_O:!E4C0Z;N.^+9U.N\;]T&3/P,;IV+S*2+_N(.>&\FY.%[?C@J/4KVJ]+MT^K> MR=;^G64A38SQ<'=FZ!#THW97LB^_.L6SZ,LS",Z. F!=@)02>W84-GI!Y MKVU=)IKP8RF%(4UEC*FY'#IU JFNYF+@B9#%^-$HD#;RN^JUI=6FTNC",[S'54+N=<8$)DW"I4'5P,G?G>7F=5IS WU MBKIE6"85I\GQLF5AZRC'=T8*-22C]("@8%R MS@'!L,B).J/J"D^-+S$172!F"3N3QC8_.($ \P,V]T7LM-0KD2M2CW$.D*]Q M[6_B?C5EMSNZ2'1,QJ&XSRPD D\2Y36+ )@KP<(V7ZF"4>:9F\M+,T59^ MU+&.9XAZF5(&(#+MJU!?6\Q^.RR%I3ER4X;8+<[;6DM83:_$V@;Y MH]L KK?N<6^=53/ODOMN KZYW&3R#4'^9F!1VJ0@+*N.E-8N+%/=_7!GO375/"P5' 9 MIH&R79N; ;5(7SCAM!)[R(V,N<7Q90?/LC(S5A:Y"V6^#NER>F@]W;G=?%L3 MP<,W/5>]K[,H"<7GCF]#"J]+LBC/!ZGA0129@CR M,I!(_T8H:SCUO^"C%"%ZDO.$L?'KKI$VQ&YY=MEAKM)[IZ4#TL^F?Q%^O1%6 MYN "\[<]O.4-FQ-XB!:,'..19]A^C)F=;+W=91)'<^E6HKDME@D]T5PE_TL' MU"#04Y.4_*QR_K.".Q7P0]V6?T!-N'&NVXD[G:PB!Q@_+0[0KC>4O=.DMYJ% MY!?5EX!JTPRI;@(T&[F%H&%L#XAD(4_,Z)2#U B,B)2XU"!L@6\<\H];3 M5+@J(4Q$$RG')'\LU2HCX=%OF*].P+@>5PR-] MI!--_3"=>Z\)^X0RQ6<*;^-4F"/,\C-JY8:9">+.K M!".%:3Q-9_1/A^N*MRI"=BR+RNP/342 MU@!-YVPYF+G_50X@R9#,,3E-2SFW ^L="@)MJ0.=D98R H^UU9H",')@).%! M)':YHB[9<64;8KZ;"P?I9AT%KC)SA2^V,'#>T'BK2\U5 M@:&$D,L!B:A<3#GGSQ>&88VP)N:N;J)(EPE81] J<^\$@7VKQZ'S,.Y\[,S2 P[FFG*0],/K.S-^#FX9*:5PVXM%.P*I#H M-XUS;4,T&W?V6&$$'%SK32-=LK:&FV9/PESR1ZFM@95'ESZFUMRZWD&YWNML MA>_.5GCYF*3..EOA1\Q6>/&TI/RP+*Y (=T69N1V+6Y/I='<]%3"PG:GXY;M ML]5("C=%'*CN4MD>X;J0*V>@9[D+$K3CD84K>!]?Q_ S7MEHH&5=;Y7^P7%B M^MS5.F&*>3^W/\_$@B8=&Z6Y^Z-14&R'VUN:+UM/3-F*&.W=15.QSGN2+"01 MG"^#3>DR1@^RUG2J.J=]5V4O.Y/X5TD8F.YY05*,\H;/ Z=##\+7_-X^TVCA M5SKPXE;)AE6*6%=0OW_YM$Y^I]+%L!5F!71^IY>M]'+$,^YQ 3!H.W4P/J,P M4=M3/P*A$*,\"=U(N3\W&!_P4%"M9Z #XQ%,N!=""67**%*;"U!&;(]7@SE? MZZ)K5QHL%J&1W=8U?QQM6[O+;]MZ0+X=NQYFO:K]=9V<7E@93)RKMP=;P:Y@ M]QA_<@XN$!\!X2=;E,J?H;"60WOW@WE3T+@6;99G1 3I[V,;K2BX1O?;R,_" M;!7[]MYC9,?95SJ/.2E"''YG9^$(!#DI#^2;D>TU*9O?L\%%S.PX%2=ABZ!0 MR7AS/%TKA&P255<57<>V#ASA6I-^0!Z=DDD7&*H_5PIWJ%0-# M)C7M93<]"@EH/(DHXH@1VYNR8H2.3T8M2-J@+XVCGGVA,BJH$!(?*%U]2>I6 M.^,YKF0;(9(_2 \Z6%%_R._%[\W?':#J-2 A>9]608BC,ZUD(.L:./J#7UO M1&BIB_5M:Y3#4V=4,,\FN8UQVS@;>2632!LC6X0\M88TM8"R?6ATUADZNZ ) M* ['-YW1_X6>>R9$U'OA1LP^P]#]C!WM)?#FA8^Q,1,ZSMB37%H$+0'VNG>\ MXJY]#10.2J!7BZ=7Z/K.="F.6K281X3]^4\G^NX7>8)=,<9D0'!91*Q9D'(I M9IK+H=EPR]!\#D\VK0IN6DKC7&-UYG2&H3V!E6)DI7+=G+L9V:^$8B*!RMR# MPBT-J;""-OFKIV63.TS]B,MN:HE:=,(S0XIE7V2D>OS2^+@,XJ1U9SGA&&+E M.>6,2*<6M+<$+L=H"AO5"LIV&(VRW9]8T M%#-C3PGIBAB1#UN/(&9P3N04+ MO)K=B@@"A( N:QOOB>48'A)<2FH[_)GTCEI7;YO4?$=[DH4#4@](*<%DP1R' M0)L'F$(8.S*?APBKS?0LPQ <$JH;]212%P0Q>_.%ALE9-W= M.%,;.-QRT9[9*#THC5+7";0.?7YWZ//58^*;Z]#GCQCZ?&K9R.TF]$*-2R!J M&3M#DH"FB-Z=.B*F-+T"R-&X MW>XD?,AID.>L(JKC_:XZ=.2FF8H:G![B Q GXRKT56_P$6?=W>^=J7VJ,U>G M"%(3>19Z!@<$,7IMY;#%2;/I/" ]I!B W5%+E2,R*Y-P[@H1B:UB(7ON@L(+ M!D^&RV#"6*4[I131:-WB'LL&FUZRL([52+D;&+< \VP(-EI.N%@[ 3!13. \ MB?4 #$0PYQQ"76I8QLZ@&HAA/0ZKC+.\VDK#^,2:.>LU-'Q29I@XV;ZH[5>) MU$^)HWCL>-=&6',RUM1=C,-# NV#A[4C6]#*P7+77'>O%H^@W".U)DS]XJR2:=YP86& MRU?6K3RQMF )S K,Y0/1DNN8NV6RIDU+>?,C[";99^ 9(+-8XUI:KUX;1R$+ M&^LJQ,,W0_O=;Z:F*N*<7B&4G=CJW,:@5H!\YZK8EQ M-%QJ90*H0TAVE1PNZ6<)>Z$KV&7L\[N2B2XJ'4-OI30H<[SD[H*7*4:&3*M) M/N1E6Y1HG,&Q5A,_C"A)HE07\AMVN'6JE<A;F.N/"XPW&C. M+'?M#?SE]=/R!@XEPYC*N:X-##:05H?3YTZKR+/]^ ([ZIK6UY=JA&&V#=UIX[9@R2NPU#;KH1)0YY,8RZOB@ LQI*@/ MGO*G/>\%%P$ZRM9M#]GCA[CI8*P )Z76L8&.K28055.=(K"B.DXJE;MF]8@>R,EHW)%<'FXJRBIB&9<^:03\ M8.X;>7C50&0??)636891>7EA&?AE*ZL8)XQR-^+"L99#6$WN1@K 6+V, M":>$@KO5>E<"-6WLR()]\"H-+T6YW"A+V\8^IJW8%=TTB2P8=!FA#:@GJ!^3 M.RQ(L&0,E'D8?OP%F4)&*%58%KNM#DI%& <@(]$=P;-VS(T*LI4&VFQ/18^O MF,CH9W.R0LF9A?VEK 5?,R:^-9_1"8D*Z,"8HB^5B%,%YGGLXO)P;3 VM0U' MJ,BW8^L$91;=9HORWQ*J<;+U6ZVNLFX1)GDA;9=L6\1*0C9^BRL?D/OJ"K:P MZF"YY5$/G_^_$I&:UX])6JTC-4\Q4G.O)^;)9<5^KL/S,J.KA%6LBBJ):E)< M;ESWI:N>6J@D*DH(6%-RTVIX2*P"9"XDDE?F9>6:V"8\QYA4%0U&TF@$#T?M M4T[7HCRX1E47HRN!'E5.JHM>@%Q]\".RS%R$-LJ1V[3)=S5H%71ITJRK-J9O MW9>8T'=ZTC:B%1'&66P=TJ9,6E&UO?'XX4C_8TRK]O$:J8*-^V3UVUZP663. M*IEH77UY_>3<)F.D%"%1_2"GZ:[3-O$H2#2%[S#V!>F7GI%UH9^TJB^ZL M2F4=#2"?6_]8#8I9/;P:J.0L4'GN.X.9$O#!"2<.,(/-/TMUZ<6=*Q?MO\PS M7O" Z@K4(Q<5M89A!?B9#9BSD9-^-"FB,N>U06 &X)I+^-EES:F50BUE M[- MA[RR/_@DW)8*(B<:%6'VA93]*.%2-D.WGGUX)>?.8 N8SI8&52VSZ#FMBEN] M#R:=$/Q6@*=H76G&A&SAN(%:>9]9%EA>-^3XUN*R;DEJ"\QD[>Y5 M["QUC]4,!]S)',%$LF9$ >W&I8;G^'RU .7676D8I4VPGN7BQKA4);*S_)+* M?2JIK%5WUK(%2I7#Y62M;R,H:H%QG0HWDBX]3JI)Y;6K,RJ9(=BD7$(K 48: M0H"TL )A7A;F@1F'REKDK M@NG,C/GUF(KS;QV4_D=?FB8852E=2:3B>ZP;Z1P>TJ8-SSK'@X/>V5EO7WWX M3:3%\$0=]8;GW4^]8W5^C$E PT_]@1KTNL/^R;'H) J^<>\6[M 9;/4'YLQV MCO=ER/W^H'O8Z1\-X+O?Z'N'D -[DK/L)/G8^] _[P]_4R9DZZ ^/ M>X.!.H"_.^JT&P$,EYS*L\CR7=!D^.("I5WN8J7ZI9Z;-15=8TA;R"X;LS-M M[!?"%=JK]MF.I-%6,OY(G %SFRTUB.)7=> <0=;NWJ_V]7[ MYC$QFK6K=^WJ79*L>;K"QF5\[0+&S1C!JUM<%W58+2JFO&;P:_2(72'"5FX9 M;QOG+HL(.)[>QLG)AL2',^(#_%I0C5C%$9[CE5PXC$7'W$ASPEACJZ@(AS\( M<0JA+.@YA6VB L)X=]2@JMI3"R-4ZA8,^66EGY\49XD@"VJ_@FDR2#OY.*NN M52?18?6H[,W32D0]3M1^(9L&<@S5R0554D@DDH6#.2.V&Q6[L,IT91VF->]. MYI8'QXD*"FE_U8:?*)-H@7[GG&CLGT6^*W9=F_@#^M#&.HU-H6Q;%H/4I_@" MYSOG.(&GQI$?3@7??4*U\-4R%]>GUYZ(D6H+GBDX<>07JZ+\6VPY374'P+I...[W_MEH%7.G=W>>%DLZE'%!+#VB-&+8(K?1.W4!2:0DS]E>A'VPV:)@:&DU2Z[%,>-;?'U.]!L7 M$FB4IL-M[DE'3"W.J7,+@M%KU(*?^\T#L_20+M&(#":39+U*'F=0?K]GXJYU M8#'\:;N+_2C)BL(H6Y^D23?D$5";- M; R>V ,M""[XMZ]B=>5L^,JAJA9#K,SBQ"@F'0GZ?A0R^3L:CK,RVZH#JQ]4 M**_LH1WXN:\VG)Z@J*_ QOU32[J%U9]@G8#K!5M1DGQA+!)[D#99:R.]B]Z* M>@_8\E#)Z#"9!+7D:^EV7M?U,/GU&B^9%*!M99?4H"(MM)/URVN2II+6@$1F M"]M$JV'AC33&GBAQ2QS^!#ZMO2323="6)]OYR-UL*J:C1%35'CGTNB!"^@<7G-L%!1 NFP_D$K(]>8AZ3*S@< MA8'8&V[R&)CF!9'(9TD=QK"#,U'L&SVN:PN/$Z.T$I)PS[E& MQW@O;]Z5=6#J>P-3/S\F)K8.3#W%P-02DQ?K#6!*W!WQ"AZ&^*/4VU(C.@=P MKU220=*0SCP.4U (&&E&G)J,"#M+]97Q* :@YV>HC A@*^O'R2B7:D!?.E82 MBT(.3Y,(8XO5"5RVBRYX(!1L:-D2)FKDZFYR?KXUB&XT4S8X_I,54QOT*;.F M22$BB%E)H49]FZ$YZ_G$"^>\BBFWN[M/RT_6!2L^]FV?Y3:'O==$1*H16$73 M+XNT73NAS PUEL MZ=MMQ%W:H)AZ+HU#*2N,/[I3>F=DPY)F9]E<8+X[JH5IH.[B]6OYP ?1QC5] #Z\$K MR6&;4O8LU@(H;%'(N78;'7G)20A*)39JWGVY*4@%)0"X0N\;=]H-B;CH2:F> M4;V^Z5]J/L-5ISI/DVRS3%:DI !A3J:51.^KV(3=9&I* I>*5#+H=2O8C? > M&Q\,HDNLU:5TK<^O81'GL#1[.[(VW,>6UA(/FM0.'(098B7]AB#*CI^U45=I M7%8.HB$M:Q&$W+ ^IAF2^3V2%(GL4NO3ML% KJ\2H# LT MU)1K*$KQ$5X4V+;9H%RC:ALF!7S!*\0#,PH[V.9.>09FA20S4'*!%AB'FF,! MJ!C@'$)XPH8IG4,![:"]D<=N$HXMUJ8I8ALG[$?@RCU\!D-TT#A8F HK3BTF M?)-10VB2)J)O4ESL@F^:D:5RA<:AP2M;5_K2G:V28"&Y*Z/Y0N^T+*,9P-;G M" 5D153?]DK,@]2+/*OV6:?V5S7BRL)6H+B/G<[I"BK@]YD\N!0.]C\%6)ED M9K6Q?0?SZS[8_K_LP[Z%\P.3K3#6C*S<^=8$.<;&ZYQ/_1T-'P8A,C =09S8)@?M0)>8$) MWUJ8)KWE4OAFA0!^#Q/U7 $5HR+.;[]%75%(W/D!\B(G^(^5%:/,]-J9)$D. MM*Y7,O9SWXT*%W4)(7?45:BOQ=XF;8#5A1(^UHEKLV[2B*; ._L7;%P[V8!4 M[&I)$HZ5C6"X(SK1IK0"Z#Y!..32MR'*-\ZS9,BMJH8+K("EN#9]@'T(RZ^1 MV]T%VYHU;OSHPME74!LX]YP=1]0&+*%_UR&7[PZY[.X\)N:QCKG\D#&7^PO4 M+Z>T$WA/'ZX= ;.)#4HH^\P.)7)NLSTIW<7-4\!?@C FVKTJXS*M\'(TH)JI0" MQH20!SK-,+#N?+ 2#:/I4^VARCP)\2%EZ\!2CGF$ZGY.GRSX"T$SX8[,JLHU."E'D*/@]#'K!V0U" \< M -7%%'/L6]/H'Q,K?'+AT"4%EK [7ZE)'U*_@%X^K@>:3$9E\VA2+N -=@*W M)("?JIFE60W>JYG?YD0KK1%1UIU8UP(M'.M:3D&/,U,_G*DR3F&"V M(H_@D&>^*+)XVZ7V(\15Q@QI/PTL# Q8[U'&;6QL@SL#L%5)HT54.E238?HZ M%L7YB]8SZJE2<#NYL;2 93<9#H4TO9\6%V;9Q6/I=DNB[& _0EZ#I87(="X0 MW%;>Q>;OFGOAM9C_Y2DP *#[+P0 .YN;UL=IM6FQL=YE$T_3)"C&>57KKKRI M]"8.R5+ )0KC0F!K9;=7D*7L[CVM6'6G;)A$XO(=T!R7$L+9[6+]5;;N;/ D M=[(F$TP97'E55G;(:G:W70<2\:-.H9LUIDP7F1QNST MZ_XZ,,G^V%&(5$Y4'>V/81-4DWW.,D9C=)NI[9: 2 X%\WW4NJ][?([7(U5/ [+/ \-GZ'3U8GSB8A\CL(XG!93!\*_-0>H#O90TC[& M4:^UK:&':X].3YIDBU/ZYAG<- $;4L!""] LR=N=J;V=W3<@ Q5B>+@ I6#*"'4H(-Z"&DTQ0DY8/++=!(>VNSJJ- M>8SJ-(+KBEQJH>"PVR@:UBQY5H4"(X^:;GS-R2HE8TV@-JM&-:X+.H,"64R8 M(1;37FK^A%.!OW#=LU(.B^-'8VZ:]:\9?F;(PKZ(218)+**WFTXI!JS'/4BX M \R8JTDRG0,I9(+!@/^F299MF4]9008H.NDRSV2BT!= '0'[PXRO"GY/1V%N MTW <>]\K,SH]MK(Q'5S^1.,V"YFL3/-V&G@:TL($_M1GOUZ2\1?FX:PP.3T8 M*WX'/P>BC'5)8A.MC9U/]YDJ-*-Q;7JNI]!S=1;/(%/@UREOI$WDM:M'W!_W M5V/1COIG$5S(V\"*7X-8RA+:SR]A3/%EW%28!<)O7U]2-U]*KX\9 9;^].@; MHB3X$B6J^>P1>61255K$YA-N&C$$;H]? PWJIR+_FBR7KRG.J8*E.'0?%T%?UFR#AOYT@ M>GL7667]H3@(WR/106&)1/CH=O71U9MP\>Z$:8[R+XB]P6E-B:K%2V*[( %_ MSB3Q QU75()5\4;50,N)L5F#R_0P#2@!H1H!W -K?80\,BPQ<^(K92N/7E/>N>PL2.GAH.42@+K1*'2>+^\J2$7+>P\ M0V!@B#(T #"D5'*2;LO0U9'#!HZ\$V^D&B)IMBW)-34X#G$ V!%6D12?F+T[ M0+U4RN69!OL3@WB""]M6K4;DZ-AT)A)(1%;>)Z5='%BO5X!Z)WZ+6,#V: %,$6#3P*1LV=H+E4TH<&A< M6PG87MG0KMBNQF,FM0 3&%K2!3A,;!E .1@S#S[_TB>$?=,T"; ME6G\J8, M%%'6'! &TEU>%:V)A MY$F:YAJ4\,MQ9B?D#><>TR5E24&1(;^A<0M(UTXV4.#=R?S87D&6N/OB:>E5 M'RGHC@(03M@[]3?GP+]3O^JXT.]4E\4@[OT $V@Y9?D4?2+9.I[Z!/>99=^9 M)@^@,&BJ$@VS&<.+&== U2]@\BG:Q([A4Q[CE"%H"TDM2KJ>I3H7Y>( M%'55H@A2""07)PV2T&])^H72X8P/+BXE"DO4RT1."?+U2N;/C(,SD> A3RDY MO9()SCVI[!*R0'87L6492F^-.WN6$$U1OHKG]8FIJG\[/^L/]OO4+TFR4SO= M3]B."!L94<>AWD!]ZIWUAB>J\_&L!Y^&GSI#[)-T>CZ$3T>=WWB^'WKJK#X0%?,QRHT[.3T][9\#G)\-U: _'&*3)IGHAY.S MD_./M I'G6-X6YBP9W[L4F^F@W*@#6S.A+VB3D][AX?EH$-\N8.SDZ--=?)K MCZ\9G/>'GNK(C,YP\MU>CQI$=6"N^._)^1"'AQ_/>CC:/K]7?\#+?]0['N*/ M)SB\&O2&PT/^;O^D>XY_<&LI=ZNP@97TM()W@#TZ[77I&3PCV.[6"0T^X8VP MJY]ZG;-]&G6_-^R='?6/85(P$MW:MI[O<)A?^_N]?4]].OG<@[?W9"JR!F4+ MKT&O]W=\6N\8]K;+K]+YV$$JH:N[)[2F9YW#\JW-EE=H[P/M&:[NL-(W8*!. M3O'M;$[JA[!4U&?LPQFM276U^%+Z\L[S/#@Y/][? MIDFT[]Y9SQR+#GRSSZ>IV==L]\7&ATUXVP$2WF$?#\H#]0-;#6?XWF,25FMG M^(_H#']J12V_]H[/>[=J!7>4X9\[()('5DH?G!\>]H#']_YWB/SO%.7*<,C, MKF1HZK#SV2,6??+A;SW#G_LP%Y AP%75\&P3QS3%12+9R"84FBS32.D ,=P_Z,,K=SZ @N"9 M8?9[![WC V:]]WF#:PL' .8UX#'^K'<+F@<.3-< CZ0[FMC:5@=7YZ0FI M1D?J MGPSA\0/4FHR*BH=R60!!CO;V,V7/$D=U5_>&O97]K#)#))(%"XN;< ",!G>I MA2Z;.^LA&A8(KBR2GI6>?*--G M*@4S[A@5A*O3MN=2-1P"L-.!"?!(VP,XC,OK0&0#MP&D 'CT\@SM1G3DK[?'/ M_4%O\_MTAX/%%J%(?)XH?3PYZ@\&_*'E*(B)>]S["-RNPV_7V0>S'1CKF7R& MDX"\D]6'LXKU37Z+DX,5/!N[+Y]64.63]BE7E,\#=F3)I+#E4G[A0%G5DYUR M[< XB:]T'!ID&'((\X=888\&SJ$!(Z6LDBDK5/D%"4P@0\YE]:9EQG:0,((4D=4$YX+5!N6* 9BZ_ M-\;>5AV>6?,]W);K5&S-STO5[#+%O/(ZY(^0/15HA=3AX*UR(G:4@Q_X\VI; M2[\L9X'?WBDG9$ WR*MXYJ[*U]C3P_S $;$0&WRDX157$\@SZO>TE(W+*%2G MI1S/!-V((:GJK*6^G)+L34UYQM7F\,\_X2D"2,3IW Y:].8 MZ,IT-Y%Z;HYA 1=KYE*TUI>I#5,Z,RJ&6#61DN1#BS MC%FKP8"FU[+I^W44:/>IJ\A'7S\M/MK%*@\0B7Z*A>(]!.""PQ".U9$?1JIG MZAZ,$*_0E$!:V5K4K4%&XL#][YBR'V5)#5[[VROZ8>/XZ4O4C1JIVGUC?[P%H2">326M/ C%@J5E:Q&(+ M%:ID,J'"7?H;C!8$_J(R]@QKW9U&DJ8&E!.6:UV\J5317L(WM'95I9QSE-Y@DPBXFMPQ1F$;38Z!DGTVD1&TBJ$CR589"EM+GL M1%-J)585"2?UJA%K6);8JS-*KN=":FM&9NUZA%<:>>:*V#=UV###<7+!_?\X M@Q/3!4$'2$/4UQ!R.ZC=#&8@&C7R5B7T,C\+>%<.#!=KZ+$WCE>!DL92]P . M4L;=!MG>SGY \)R'0LH!XC#LR9/&HV(G.X#KO,0_^JHRRST\[#[4 W[>V5&] M;?4)Q\K!D.I<8;9ZM7/ERP=#Q.WZT]E(1W"BNAWU\\N=G3ET\TNF%&J8^ M2,D+#WC0Z4,]#33:PW"BU8*CG8&_>4S_](DSNH1Y3UC8<_Z9V=W9? MO5H"4SO)QGZJCK?5:1A_\;.'>J+PJ!D])/GK18Y>[8?B$*OA[WCQF'C)VM_Q M%/T=#X;1UR=-O$0R^R$EWVT&O'6XG"+@EC_6!:@!?I3=LUI^VS3D%GH=#?1UFPJ?!@GZ'U/DE++)[5M)O]6S" M_]2ICN-L'EWY<>A;[\'QYV62A9]=@IC.L2YZOZN 3^[@A#TTS&>-EMRT8:D[V>GJ"]:5[I>M< MFE<&W-=EK.'7@(!D2D^ZT]H,FRHN",H'!07VI0F?;=1QF12IM/7[8+[;!THG M#[IQT,/CRF?>95R.$QGR')_%"$BJHR.T.;\MC.*0\D0*A.0 M#804"$WG.$FJ8JS(6) A2XCT.XR3<=:6/\8N/C8ORZ157/M5Q'9*=9)H@);> M2!(>,]DKG*SE!$G<2![1"G9[++->9#@<_2*\XFU"TL'%\0G8TP_I9K+')8U)4@+F%(S\^$M:S/+Q7%KJXB]P3$#A M',\=9.EM,-#V;G!HW;Y*M58#Y8*<$K1UAMV>CI/\ M@?IZ/NY3=W^8,[539UN;"&)W0$CB.?7?6M#KQ(7MKQ)V"=!O,.,P=]W!VV]% MT9\R=K\+H.\ [QM4942MJ^X2._A7H@;;) MA_D]S;--M0'R-^(U!W5WF:T"#FFYW3X!%:8I^?)$[R3KFK1" 52C*ZK 8U3G[PBI/H 9WD\B]]/N%F&43)\U]QVM#1SR2]!/ "C M8W4]A*DB40?9)E;V]+,E M%QXKWM,I7(C(6Q;FJ_GF"X1/C^#$8/).7U(N'G.["KE]S!WVCS1ZD?HS$__- M"E#]I1C&L';3LJ\E.?H^)<]H-23/:H3X7CXFJ;T.\3W%$-^MENWNT[)LN^A- M"=#7X9H58_W)C6]$WE5G+.'6#V$M(E\7ZT$,;PF*!L@EMMY;:[L(T; M2P8#V4LU:93T@^4C83:.L$4SM0.QR6*5UJV>&5Q MU2J+UK)F*#3E-5(]2U@=:;8+=!P:IKDWZ 4$9:\ZG-V^^_/S%QZYS 3#V?I= M19NQ@PI@MED0W&C]!9\K[T&]NDRZ&#KK:AMDX<.QIXQLJ]76X&MG&-*364/# M2V"]\)8J5'>&D\9'Q'"FY%Z<#3_+FO9S6G*-VK/;;M%G-Z8Y1CGJ>K2RX"D2/SH!;5@J6+>B,8:'+S)9[PR6+. M6V9).F7&9 FR;9+E*:+#BT_+SH*:U-7,Y2#162W?TFO"-)18PP@E3X8*7*7H MM>&N*+)/82^GS( LA+*EEL06' #XFV>(#[/I[3/3XY'")V@DE(S&\I"0IBG] MO$KN"=R=^P3Z%9;IJ3)GIS&\Y1/8I=V/\3$6GU@ZDHFO 38W>M->K9].#*90!NF[)J5E0E@N">\DIN07V-3\ SV'?$1 MT-J\XO40R0T\!09,YQ12X06X><&-A\ $GLJAJ'(6SGN,-$U\<$Z0'])S,"($ M:9R.#L@W3@+ORM;:X],64K.12TYQ5$F,V*0+)!3> XQW5H!X&,.DRKO]$4IN M:_?)JU6W68RYEXH,N+*8@;VF 2X$.9?^50 S!S: XC$;([X /#D)S*!V)@S\ MC5\'>N*CQ8=7M)UP#\SO/$U,&!$66J/0EU_5!LY@F:X2R[[L#"MN$X09 +T/ M?R?26[AG&[0D%6R-K)A.J1L]^TPVE_]R^Z5$=^9:>4'KKQCTNBZ'<%^$]3H2 M^>SSNHE4K1\2J###,^P'(%]-Z^\B"?X2U36$^:'B">23\*N_N3KI=UR4@$^SL.,NYD'V&_0]9I?6H MX!N.4IS(\28?+9SQ6+UX(W%J\:I1W1 P%N[11Y9$@_CL\2"SP[!!Y@'#5_K+?M)X6JAU>J45+;>617:Q M3&;0*4#JIU1Z6"XS*>L5AE#VE"FOA]V<^E\0 @8VERPYH0P1/R+0<,?5E$D= M7BZ_!FUE3X2S3=T@B4,LD3W+A$ 4U[3&L&%P(6U2$R_3/T('FT0*-] !4DV6 M.#QJ-#=42J8FK@"\2VGWO%M.E9,<:RYU(FH1#M%FBM'GQ7LG^V6U0GC?*$'^ M#53&:!^HF8'P6< MPJR:)&.H7DQ(62XY)H@Y%C>=$C3%!7L@FH;EA;SI?"BL M7G\#)]MHZ(2603:Y86#-"!,7AOD&Q(V*C(B6"19ECWF!FR:/;6'!CLW+Z=]D M-6^K?K M"CR[*ND% Z>=L&;^;7 2%\I0EN6XTO(,M:#QO,0BS6ZLHF/HB;5X[9$7H!3A MK6#$;*7'^242R*2MP6>;?FN:8G-S[5K# M/4(U3-'+Z71WIS7(_2_<0;YZ0,@K<>VG*3I&=%;JGY6>6PN>2CJ+_HKC9>3* M-XATY,::Z%1PO\#.W_,&!O[D? $/@ERQ\N=/[MO+@.;57B E14EC(Y^'M T826R MF0_+MO?3HYSR^U%ES&O>H%$2!0TM\!Y5R*/>\+S[J7?\_MGHIAG\],M;NL(N MZ#/:_#4!/."4UTM\_^@S0NWJ]%/G[*C3[9T/^]W.88FZM5[X-6TO6.([3//Y MDF?Y8?[V6Z?XXK55'T57W=U&W8KD@3(B9:EO\2Q[UL!=6!/)'SQ+I).E3O/8 MG^HF_L::#E:-#H98$/W6C>9P,4F-')Z1U6-,^D=BFRW%L?*/0?_C<6=X?H;M M2S_V>%NI9YQMN&5[TR>'137B_Q MO4^YBLJ]7N4U(3\=E?_'\0_\+;F,L6PY6Y/(8YCE'^0=6%/!HYKE'^4;X*8. MTF[P2INF#FL/P8_G(?A#,US662=K+\?:R_$8IGRCFX%XV;[J',/_NW\_/OE\ MV-O_B%\,%#&][K!_M@[3KX 0I6;BM&6TX? M 2KP9);7P9+0QU2^\N.LG][Z?^A_Z0F?1]-AA^&DQC.:!\"/I-9?[' MB<#[["*^2P,@?LVWUWQ[S;?7?/M;^?;^RC&-Y?#MT[XZ/?GAF7(K$-V04 0- M9#C# );XY 16(XU'!$6<%PN#^%.$K DJ?:D041HO:($K7):)5/:[>DF0K(*K M:&7O?788O6UQ'\6VWRR+UX+O[H+O]TJYJP2(]!8A]VR4!'/XYS*?1K_\?U!+ M P04 " "6@K!4%#.JGQP4 -L@ %P '1M8BTR,#(R,#,S,7AE>#$P M9#(N:'1M[5U[<^+&LO\JBN MD#AZF.5\^MO=,WJ!83<)]MI>I1+;H-%,3T__^BWE[7^52H8[YZXI+'8YN;YB MEF=&"^&&S/0%#^';E1W.V<1;+KG+KH7OVX[#WONV=2<8:^O5$[VBMQNETKNW M,%5/W>.Y'79:KC;*M4JMQJJ5SFF]4VNQ[C4[NIWTCFGT^; W^71CR%5O;M]? M]7OL3:E<_ECOEC\CQ<."=EQ_,"H5NA]>;=6_P&?@INO7N[$"%GYIS[@0A_>W,[N2BU M8$1HAXYX][8<_Y9CIYZU?O?6LN]9$*X=\=N;!??O;+<4>LM.O;(,S^#.,ES> M&/.EM+*M<-ZI5BH_GRVY9=GN7^?3=/OO/DUCJ^<'AHWPN< M.S.KZ0CN=Z9>.#_;7."A.Y?Q?3//#4LSOK"==>>7B;T0 1N(%1MY"^[^HLEO MX'<@?'OVRQF-#NS_")@:MA>*+V&)._8=3(ZTGLG]=]36I[E%5H*V,_4<"RX: M7^;VU [AU/7:V_(4^+1\(JIP=+S.O1T %8X=KCMSV[*$"P/^^5.K5JF?O2WC MP$>BRP3H"/]/L*LG_)#;+K/=F>#P6C@8L/I=[1IT%$A("D_(:$0G, MZT/\)J/><&$?_K,2^@$JMLD=Q7<0X=!;J#M.X8;,SM7$,1<>@;/_J%:T6J6J M-4];>N6$&%<.K6\EM_K$U/[SIVJCT9MY-^KWLU9E=7/8UQ=@Z.PXK[@CGVPD;' MS;&YW"%H]05X?&MVA#NL@>Q$\;:(,DN8GD]&"#6!YW=^JM _9YM7'=L5'2(* M_]JZ3'-V L^Q43->\\_"?UN.B*VUZMFQQN;"%],U6$)A1J$(I%&[ ?-F!X$' MDC'PP H=T;=/22DNFR64S*>B-7)!X5G*7W768"N16J3=8TN^QE]X4J1'F3=C M'_H?;I_MD1!QF9V>27)!V+P[ =OP98!@@UL01*8I\%0"X@8/4 P#[4G/Y8:O MAT ME^ C!=$"#VP"B+KN7UWUAP,V^3ADE[>#\Y%QSH8#@TTNA[?C[N"QN=0R)5?T+=\WRU8H\O[1"N_P?8(KFTFMOFG"&@P/D%E3B- M0O)[+3&S24T$L7@CN@JT+V!W$52Z*]EQ-:+O2-3:5XSX6 M(42.)$K=.U_(ORP*@\%/!FG!Z? SK02?04,0/!:>>\=(X]'G#_8]'/D1ERYX MP!= !"B+J8"1 J0?2$59P(DUH&>YE(OB)W#"/121%6@9MO L>V;#ZC(& ':2 MPH'?4IJ?$HT/\28+SD)HD;*J+MVS0_U\*D5+YPH"?1/K1SQ:78FTQ!.9NYP* M!;&/Y&UDL\E\ XK 8@9HX0%M[-_@\@'6P'*B;H9I<"&P(X(#".%&"6FY ,## MB@0!"-:B.$4I227G_70*=@XCSP% @9*_C+H'$IX&$>9<6!%0V45F@<$/0XY? MD7( G.)&%MR"'<%^_%#I#$UJG613"<=9E]BYO9^85Z2X4/L$WVF+[(A((3HR MQTFG!B?%X5]091"!X-&1FK0WOY4BH^&W3ZF\,I*3=R@2%V)F^V"<^]N[2B_2 MCKZWF.E (T//48 M"Z49\*(0R'8QH/L*.G<"#38SB^ 2;#B)TRA,:Q9Z'2FK MO42]WE<^9RPWR@.50@!^M)]*^,,B1 MEQ$>E(O,^$ B9#=.AA=BX,>.'40K4 M%TMN6UN4@#B:W#$Q$4KU!EIAR@.;7"[.UH)3;%5OG)8;L/0ZP*OI4&Z&$:SI M1HNI#,)HB*!,%JPVF8O4^_:1\,UMP>^&7JG\S);DO\%$9XE'#DZEMP*L^1JY MBAJ+EJ3JP.D+:=,A21J?A30E<-(T(]\7&)\@]8!4XUX9UW,QXY$3DF.H?%;I M\!]+'.>I3-W &*2;="?L [;[@E@"#FD]OQ70M5'H83;:I @624>MYTGGV3;) MIT0ZX98 Q.?80(X7&MT 7Z 2E0DS5A[:W:83UF$F @:*XGSQ0(=:S&;"9,< M BDMI%11W^#=P CN)#$<,BTG2Y3,CCFSR8(C7]QQWW(@5I7NA(QC<3M$U!;O MX<85!T(L2G='OK".==9-\E@ @ M'Y8>X\08=W.(P ,@&K '-) .4^%U3$$"%/*#%2!L$&++!GD$;33S'-!_*-#9 MJ4!#9D&?,U@SU$^)&PJ#%7[5DH%<90NIY(.B.B>\2-6V'_4:<^$LXH&F%V#< M,A,BD% 57Y;"Q4Q@DI7 "$#F=#!0CQ&IZ-*V=05\D#PC:A*V;V\'4UY;KMR? M.:^$"QEW[U8?Z\S"@@_J*JQ:9HZ%WW/;H9$SD!.UXQW)M_0(<^FW(R"!&$!T MY*^EZ:XUHRP?,D#&FK@(6_EVB!-NI3V..S^:[GJH(OD_O_[ZZ_\^2IF1X7\M M^?LO2WXG2%&SUYQ*9R0YW5N XJGI9JZ773GX^4Q52^5UE MHYWC=3:)/(B%DY=H+8$WM'?>Z.V^C;89T:H>XD\+=1\JZ 16-5(GH M:0N9#VF>.,T[5T4B5:3:K%'%R>)M&2N.%2D[?8EVZ0838=E +EMFH709ER9 MQ@4XF#2PYZOPSD]459HFR04'4P&&(.X/C'5&DA19)NNGD4&L/R"H QHH>*1E.;=Z9"'@BQ8=%]JA8*@0&"7A2,S3A1!0514DKFC?$8RDZ /8FS8 M+FC[(-.$07CB(0+&IC:3(NV14-9XB8!)M!\&_RH'(I$CD[N6F(;"HNR!0"> M6N"GZWR*%VN2?OQ]KNB_9;[WE/PUO#\)56?\WO-3'^^U5?PW&;-1.Z/$AWRV M(&".N%/)VGL0/_1%P5>=^I@KD$D,TD"JDRB;Z54\[F$J I0"3)+UGG;:OZ+A M@"AKOD0\7Y&L7 B1)C)S4%TZW$S/?@ZB$\0>+8>HWW>%5 78KRP]F ML-'"S.UEBE98(P(SG,X6:'$#$$IHTB"8Y YQ RF]6"UQ(KPO;6.*NP1#3U.S MRQMEL4ENF]H=JLTS2D06"$#*6B\1 1\YB53&_=-(HB$&%P[VB.SIP52MJ53& M D4)YW"'%D]#'RT S2C3S2"9H7*P0)DNI/JU,O&A&J"IJ_#;#N:>Z_EJG%O* ME.02>.KP4R[MI]E;A4UO1G2K[ 5,E"0OTA 7OE69$+R!D)0\IJ9L-T(3D\>D M\BDW$ZN&G*E,B\<03<.-:-MY3%I,$2T01-, X(U+2+K^ M;.IH-PESX:"*@K<3[+6^-$;&\$*C!NJ;[B?#H.O=7L^XF70'/2,9<'T[N>U>77VBD1^Q M4WOP.WSZV.U_P YM@XVH$7LR9%TV&?6[5SC/'[>C3VQX ??(^V "UKOJ]J_' M0,RYP=X;DX^&,<#[K]G'2P-^C]A@^!$([(\GL (;CEAWU!_CGWT:QRZ D!&0 MV1_TKF[/X8(&Y&"+^(1=]:_[DR[N2WM@28V=&Q?&8&S 7[WA[6!BC.(+O=%P M/$Z&32[[(^3&:/(IIA9GZN,='XS!<*2,?WQ'0GE,Z<5H>(V4CXRK[L0X1Z8@ MY0/C]^&DK^A+CX!8;XPNAJ-KXCCP"T=/1MW!N-O#(6.-EOW>)M(WI$3K9JFKEGY][DLIBK2CAO=H27K5R #OV)+:KBRF33'HT-5'Y MG KS7"R0H)%2_07J*:"D@4 ^/)?Z:6C-R-O^,;375T7B$(\K/%$N"EP2]?!< MFOF+W*3B*1^K4YXPU0+)@<]EQ5?XO@MJ7*)V1.G:;TS@R_159C)/E37C*64% MJ1 @$J!#]$4_C3\,&[/=")7","W"IJ*4K;3PQO M$2L[U+!;-^E>Q4RJ):OQFLQ/)4PB\N56)%C2-N]MU MV@.,S]=B<8@*W,+'EVB(HGPM@7:(=M6G,=Y1./?\1$VG+0X@HHE<2[E9<=\G M$08)5&V U&(/(Q$A\CEQ5+GJ 5XUERJR4/_XTEMAZHS'BTH)EYG>I(2J'CA7 MJ3"'(N$,+EPK?4'*CEJ2HI\"83NDA]>YJG-08X:"?PJ$5&?$A57QQ11+>QA%)U'8)(I'X298SUDWJ6IL^*PI'H!X&).]5V08K,0Q4 M,LS-FY3'8S'2E/Q043)],$3U/&UG<4"+^R*NID^%*V:VRA-NDY'SCO>;IJP? MCHX4^N)!ZF3G)5[U)X"XHSL>"O5DJ'K0M,@O)L)_B":6)Q%^W">S$R-O! &J M1R7P^6M"7HM;(^7S]F388T=^2E?5_TZ=GJ;=)/D0H>T_Y%$++'T,5%^_7 M^UYOK -.!$L.;*N]>98D?^5M:P%3KS?+O<*N.(+')/D%LO@;R*P_,97OUYT_ M_>K(9F*ZE9]0U=%]HZB Q2[&D^ZB')39!;?6[+UGAIY_V/Z,!X*KERR$SQWG M [X0G>QI%MQ^1)(G^&[T#E-96GRWW@V]]N.'?!OK V^II3=B4I]-[2QU C;? M\OP\@_ B6GR)T>+CY&$>,S>Q-WX= V+.;Z\,?%W9=WM__!9=+X9]-]U/U\9@ MPF(VOD FOK2@>&Z'H@1&VQ0=UUOY?*DFJ;7T=OM;7%\U@JC:K+49.YEBM\<2NSB\DGE3[#X%;(P>9/I 7A9K_Z O-Q\@>I? M"1^^OPKXCDQ]P NN/A]@/R_&G)2KY?S_O.)[@_5Y\>J/."B#^ M?7X>0M!>)1";!1"_!L2VU@#8U H@'H*?]0*(.UR%2H'$KR"Q5=/JM9K>:!1( M/(0+5B!Q!Q(E$ ^AJ5XK$$^URFE3/ZT40#P /T\+(.X-$@L@[@)B_;2IM>IU MO5Y8Q$/PLU$ <6^06 !Q)Q ;=:U6J>BM H@'D;<"B/N#Q *)NY'8TAHG+;W5 M+)!X 'ZV"B3N#1(/$42_4B V3[1JLZ4WJ@40#\#/=@'$O4%B <3=0&QKS795 MK[4+(![$!2N0N#=*+)"X$XFM4^VDU=*KIP42#X'$HKOF*V%B <6=4&Q7M5JS MHI^T"B@>0N"*_IK]<>(A:CRO%8E-K5IOZZ=%?\U!Y*UHL-D?*!9(W(7$9J.N M5=J-HN7T0$@L&FSV!XH%$GBB:;_8%B@<1=2&Q5 MVEJ[5M/;11WC($@LFFSV!XH%$GL1[S[:^]G;$\M2SUO!K'BZ<=_\/4$L#!!0 ( ):"L%1*$U5^^A8 M .>2 7 =&UB+3(P,C(P,S,Q>&5X,3!D-"YH=&WM7?]3V\:V_U?VI=-; MZ @; TE30S/C@'/+?4#RP&FG[\[]82VM[;V1)5^+Y_S9=='_[6STT\F/ E%Q'X=G)^Q* V+J4AR%F:"YW!U+O,) M&Z2S&4_8N<@R&'OG[KAX]OSTZ/V8N==OOW_>-V M^V1PHC^ X3MLD/%$R5RF"8_;[?[%"_9BDN>S;KL]G\];\_U6FHW;@\OV))_& M!^TX395H17GTXLT17H&?@D=OCJ8BYRR<\$R)_)<7'P?O=E[#';G,8_'FJ&W_ MU?<.TVCQYBB2UTSEBUC\\F+*L[%,=O)TUMW?G>6'\&0;/J[=\WEG+J-\TNWL M[GY_..-1))/Q3BQ&>?=EZ_7K\E(FQQ-W+=53ZV8BYKF\%CBV-VH8"YYUAVD^ M.:R_H.G)F7UNE";YSHA/9;SH_C"04Z'8A9BSRW3*DQ\"?07^52*3HQ\.Z6XE M_R-@:)A>+C[G.SR68Q@<:3W4\^^:J0\K+YD+FLXPC2/XL/]Y(HO]W;W#X_:>.-=DN$Q)P1- M$=D7<.=89#F7"9/)*,VF')>/3;AB0R$2)CZ'<1&!_LR*3!4G[%*,BUC? M>+7SWP$[S<64O=KM; VWMSJ[VUOR>IN-LG3*\HE4[,2J[U"$O%""P4K 910? MEJ0Y@U?"G'C,>!+A!_E$L'PQ@Q\3GM-?F1A+E6?T=E1GQ8"\62:OX4F69BQ, MDY$$#NL+W#OO7YS _P-VD;;^]EWGU>XA&+#W=\RHVU (AK9_<=5G MO8L3=OS^_+Q_>7S:.SO]W][@]/T%Z_W]LM]'^K_YI?UWH7(Y6E0I&Z 2]4"# M(M(B;PVW2+^0L+W=P_4B8!]'%M(#G<-M5&54KS,)"P9ZB?IWG$ZG(@M!D>1_ MM(;WQID0].:('"FH7CIB5V(&2C\4F:9E?S=@>[N=5P$J\$1D8KA@) 3P@$S@ M/3BV&(U$B$[!C/$/GA0\6YC9O,81P#5O(4E?-"?6=P.? (F5*0(=^.JAR.=H MSGX[_>WC%3L[.PX89R?@H^8\$RR64XE3BR77JPX690K@8A&PK4THH5']UP;T MTG.1%^$$WOH!//R4AZ+(9X'IMNBH?>)9+H3Q:M%U/ #_(J."Q'HYO/-C"&ZKU M]+1_+7]^_[5_V>]=!0QYU+#@%17\1L"Q<0)45$ 8B1RO'NP%ZBP83&4Z0IC09ZW>B MA"=C%:"P7Z%HIXF>UUZK@^;(YT_)" [JL1X(GS,RVY+9^'UP"&!2P"$&-'!8Y_"ZGLS3+ _8!8%.*%T (/@FX MH$0Z"H#?,84CX4V+R4C_944.$14A "22*D%>R=%'-D_S 0%&V#[1R,]HB'>4&S=*,$P'"!Y@5X8Y]!7Z#2& T( M4H[0STQ@0]+8EBJ&_X:E0B[6EFS/&%D@WN,K($%ZBWN7@]/BLKX<_L).!VU&H8;U0; P81G)[LUF67H.8KYR1 MD=7#9SNVVHX!\V 9$[W<.M9'9D*(G&L[@ERW"PSZ722YTK&"4TT,7SBJ<$0^ M+RJT5,_X@@]!^@ 4N%MAE;6*%V"[,CV.';S4*W:%5FSQ\"UDG:%@ R^9__OCCC_]B, 50&Y@'C'?\VY7%-QO"%7BB M%@->WPZ5S;6$T+ MA9!D+N 6NH3/='XZQ.!/:^[_7/UQ?MH#F&9M0,.4R)95P2BLFQ.F9GP+=B.A M"X1FB0<;3:YIX.H:E-:V(J[BLP@+>C].;BJ50HL"\;%P8FM\>)JAH%J6!#>2 MO3%R*U][D=9@=,W2KJ)SNUOM[DHU:+(= M :OIV@S\AHH7UKUM+0/<;>W$G$G45G".2?),D%\+TQV'7!DE4Q7J*2@R.#NE M-54_U?\\BU.9Z_#@4M^)OBT2(YD(!]V:*-]>C8)\(UC,4H+2_6OCV4_$B!=Q MWOR:NDIO!RM@.TW7"6?@&R_F,81\ QJW*?"%>$, MN0)@E:(6BSR29II@.KPO1T5F#'E"_#< M#/PR2 "'!P J<$291)Q4EB>!'"@N/*P4?::^ J)^1,-!,P] >,$^$ M,:4=IIIN8*H3!Q,;K92(0^,>KNO>@5A,@DIW@)K,<+*";?4L9$=)U0.;S"]B M;)TMAU-P(#%P MD X$'&>NDPMU%%<7\BFC>X?T0/4AYD M(F>S>D0WAOM5C@X7UU7I"&BEGT*V\C $SF*Q2@.E2I3RDZ6V6;.):V]]+;5+ MMS'K-8LQBS[$V,L%2_@0+_(4T_DA,)XO\'6 )]!F8##&8:T+#&!(++9D@FE^ MC.B(=%"W[N-G,8IPSASD$4(62&D0K0R TXO]$..E][3&N@R MTG0" 2&HL=8/?&99]Q^4OUBJJ56J7U2"@]^!U;H*YQ7#_HK25S6UO@>?,OQ_ MW_P"[^QX5.N?D\Q2,>3AIW$&6#O:"=,XS;K?[=)_A]Z#!*83X;U,GE.\U56]>/][P :XM._>7_;] M#(F2H!/:&9@%!3Z*<8I6G!N6NSA,X1/H#F%1-*.#IO#?E&Z,SU8P8ARG<]5] M>HO2,56VV_\\YC-PVIB:C0B1*@25$1L6.3GN"L:MEA%N(BFLY%3Q!? _K M$F9RJ+4+/IC6@':I7T]0E_;N;-D&B#+!HH$CL/76E46"LNAI,WQH^*+(:"7J M$&HE+;7V'4]O938NI#;A7+^)W,@&PB&:KC^&S+5T9KP3AIF?J(&J&$)!M M?79AO0F;8S/LYUP'EH;W2R51_'M_]Y"4XJBPS*#Y1 (B;!+V6LQ2_Q3?U75O M7?J8QNRJ-)9H:<#S'K6+-ZPV2\"O?M>"(_,!T6G;Z4I"=>+D5S!W10SRTEIJW9'!49I=3* M(@1F-%S3C4G(+,Q2HP9ADV&:V81*176"JF_O6C8.O$@(HNTDG<<"&Y-=,V-" M%8Z&2@F^'=7-$MIOT?BN+&D:-"E;EM*_ MVQ14@!(4N6B2-[/4?L*.U_6'BN,2HPT^XR'-#R./ NE68)=TII/XF8*E=C-[ M@GYL_TZ1ZH:8-!*@?V*Y_447I& V4A-5SN1ZEG3I&DDX6/!M.;K7 =2I#B>;-SLS6N$D6OZ3.!:W9(URJY4<.) M[O#3R(?VM%9>73IWW1>2HR95^E BH61FFQ1'13S"MH2F9K_J&I23FE8P#;EH MW6ZV/$B5K1:!+ ,00)9@X#!OZD&0H&';@^[_J;R_Q"GK0-O02DCC3H G(AYW MSG&@LHYX+9)WK*=%#Y\5U*Z 7Y/8K(GOZZ"LV3_WP 'M_7B]EP\'JAQL#E4. MGCI4.;B7!(Y6E$N;7]%:]^WO36_DN4-2M_]YD>8HVBH'>;<5!6-NO2UZSFHO M&7*;O]*)+T6I:O/\ZKP1:=-FZ9+ **(>G?);KI78>LGUOC%H@$+D.:ATX;E) MKE0:RO(\E"_I&773:9I!Z<@\^E?T'U=PGZ-@Q0ZNAC0-9MLDE0_**S#L,F(P MD[JYRFXV,#6@AGHERC4-D.18YT]+U1L!@$7>4G?Q8"*SR!5U:#HF:TF[6S#= M5JZ+VWG=+ 2-\I46.39SE0+V!+VI ]-W%B8*O_ZF(T(JMBFOB&43X4T[(C 9 M3COT&C<,DYRA]?C"%'H95@Y3VI=6=N.#\AUU^P(VWF&"7=OK.8=E5[I#WMI;NYSP9P0HGBS#DCNI]\UN MW%%K;U]JJ:UL_X0YQGQNVN[%GP7>BHX$IR"2,=8O1(RM_7;=J8@A(A%4QY&8 M4<5(1!NOBN2[[1]ZYF[/@+..3@:1.[ASH-R$L7I1=2U[4=W#XE3%]@VWP'Y( MNL.M?H)O2&@S 6J7B]U0Q/32;6$!0XA/0-OVG;*B09?-+)R)APD"[8[8&VGU M"NJ\/.<(<\$PX')]H2S63VE_1;DQQW4SU!YY4([BL=41]I_K"-]L'>'50PG. M.WNMO=+G;Q:E5Y]YRN'Z'8:.ZX]0LK;Y+=EFC--;=;@ MVW-X',"&#,NJ!9-NZS[I,4A$*"!Z *14>X* E*-"GW W6E!DMN1-K$^UWNCF MY/N(2Y.^Q=WYZ%:!, 1&\#>!4H,@RVV5,WACBL=81"D84UT1Q>B)P(/C-(V0G:C-B!=!>[#)$OPV=3(( MW: 9235#) ()8T+ A- 3"B ;Z(6-%02TYW]0+]9SX]XK5E;]N+FF,V-J+>C M@,B4#)(&\-2E*#%A[+W7065A,%6VA,S$DL!2BB[*!?Z52HJ\@+6RQ=ZD.(?AU*B.['2]*BV&N M6S0K3?X-'5L("H72FW@=PM;O@\L>/-T.EFL-J/-T%D>**J3I,&>OK(Y:?X)P M=[@PC>(\0G3CWY[K_61&&/6\\4ZD%%\TW C\/B@D>S_.[:?_#XR"NY)600[Q M##D (UX7GS:MZ%[!]J56;_7#2M)W_+XT;7 MGR?DG[=94D#;:)'^H(HO8%:NJP*-^%<>?H)>R>\OM$.T3 M-,>O[\P<5RWK0>OEVAUJR_NHJKM&ZQNIC#R Q@"H8?B!=L'IR&U"L=N4Q&?< M\T\2>"^[E4JHAPE+C8XU8*HC2U/K6-YD4MGB4N;HT'25M].YL*;':SJ+)3=G MUNCSP0+:,>6%CL0,HZE/3ZY__LOD^G5=KOD*N;8Y#[QW#H[%;0!DH5F8Z 4/U@H? @"H5;XLRISQY"65M_ MJQUV(!7EYJW$X-["!;N&T-N=:^57'LHBM)>JQV\$D+$8ZVK4+,.,?6@/DRIW M:B^57VE?F[=WO"S B\!NPW!7HK4;/S:L4>=>EL1$V"9)DN!15UQY98!(:*NU4Z$H9B@C2T:7[ A83AJ6P >3$WG6ZWNU3A_O+SN\#.JP>#I8>7!9U[=3Y]% M1O$U%F;HBRAT3L=5;?2LAYCR0=G1&S_-Z98F7^(Q8B8R_+X,OSBT:CZ80*%3 M/6>ZQH/K'B_,:K=8#\BP@3FLFB/9,/"K*%1+)+K5_WI2<04R\6 +11R>NAGVWRV"I?!\^5KV^V\M6YNY.+5J:5O-,T*FG#FD_G#NFO^JZ. M1I^V,E+R#Q\L@4>^?6E0)\Q9K#Q+8[/;@((5;U O@>S2[)F 2PZ@T":' MO'K*UAIV;#[7P-^G3YG7ZFR^D!6W#;1,^:%ID'MCY&WG\*#XNW6Q=JTU>X)"=G?'6/1UL@I]"H01H84\$U/]=7SZ@!V8M@UB2=B001#D$F^&4K?!^\5^VREMVI5%0@-0 M9K]YN[O,-)FMIE-C3 $)LWTCFW%+1C*;FB=-S$?'-#>>[5]U:O8++6H5YXJ; M?()*=)>[GBNR;7KVW5@D:G-PM6GCI4<\\KYM26C\ MDD19>8M.KM/AH2%\^D_'/H81D5YP4ZC]UU%;WB>A3R!(?OD<)#_:(+DBK*<7 M[/?3P47_ZHK1&=GOWS4<6.U,)';Z<#JAMX83="M+^6TW-P>W#\E^X8J0Y/_R M A<4OV::,($5:"T8N"N8SY3HVE]\.E[!RXW8XDI2:UR25^5$2Z(O)O6[M[W_M<,"^Q'/DKN'QC]T: W^1) MWX]C*BAD,/*(IG?3E/9;/^_?\XP:J/S21;AODM=W[?8''X]_[5^P#[_V+L][ MQ_V/@]/CWMF5799RIFV2N<J^S:*LV^TK1BO;-5':>I>,KI>,= MCQ;L;8HU[D>CFU\A(F8!'CJ9S_KV3:WX8P(^%[WS?K=T%L^1UE_+:,_N+K'Z M,8G-LY@\VY(EV@>G@S.0\>.)%"/6UYV2UX*]'XUD*);E_5EF[I;OIO$3OP?M M@\A4FC1;F#8E)FW._8&D3Q]"^:>2BG8M]TG4<%R6J[J6=:''5GYY=:_EE]O6 M6G S[TVEEO8PC1;PSR2?QF_^#U!+ P04 " "6@K!4^A,0,T;I RT0\ M%P '1M8BTR,#(R,#,S,7AE>#$P9#4N:'1M[+UY=]O(L0?Z5?II)KGR>R1, M$"1%TK'.D25[K,2+(LES;_YL@DT1,0@@6"0KG_[U I#@BH786>,SM@2"0'=U M;;^JZNJ__3_M]D=CC@V53-'GQZ]?T-14O04Q7*3:!+OTZHOFSM&C:5G80%^) M;6NZCC[8VO2)(#22Y)[4D4:#=OOR;_11U_YW3&.,^F_EP=MNI]M%H[/VV[?_JUR_?7OS>",^H(^7 MT:.-#4=S-=/ ^MNW'[^=H;.YZUKCMV]?7EZD%T4R[:>WC_=OY^Y"[[W53=,A MTM2=GEW^C5VA?Q,\O?S;@K@8J7-L.\1]?_;C\5-[2.]P-5%P='7JJJA-LCR>F.W^W M^8*M;R[H$.>$/_QBU!7###W*_XB-?_N[H0?O_)9XX/)[>.*8NN>2=_Y>._92"S9_VWK1E3\FO<[*'IK^/_>=06Q$'?R NZ-Q?8^)^6N$+_=8BMS?[G';_;T?Y+Z+O9 ]D+ ML*X]&6.5OH38X8407!>\4%L\(<=6WY^YBTF;259'4>1?Y)?)2:= MLHIU_14]$8/83)+/@CE.-M8,W3-(.V);JH_WV6X0%061KY868%H;?^= M#D-?_UM2 G][F]OV8UB>%4;1K XAFF0 M=WQ]0I*^_S5I1\\>%7.(X<6;V\&+)UC]^62;GC%MJZ9NVN/?.OR_=R%=M_Z! M/Q_.9^'Y^;,+>$U933BL=OTK8:V[J<\M_$2YFIJOGVT\HU(XQOH+?G5\_AP. MI6[O+^\FICTEMJ^".QL*I7SMGYE.6F>9R7(L8DEZD]ZT-PE_IR?UZ:W\PHM8 MF(FI3^EW[PGC$ZI>/FN.:]JO?WL[*4:"0C?*\;F5LZF+)SI9="?F6-1\*JTUY*+Q]-FPJWZ?E?"MMI MQ T'71EN.9@W8V_:-T$;=[K4+<3F6MZW.50 _"=V^U)OM&9R_-$$]-UA/.D' M)GW@3#=? L(&O[=?;&R-A42]4"I& 0?2$H7 M"%X^%QHT@,WL"78]?%^+LG+[_??2,T)8L/Q_]UE@6<7[,\N@WMG MFY3+L(Z^>8L)L9?V-J%.@A7);$5N*(Q"MX[CD6GBU? 5%JQ&9JOQ#_** J?4 M65^/W?I,Z4G=8_39C/]WRNO%/D6A_^DKK]O7]]?M[G#0E^7V?>=8#04TWD'C M;]1-828 R7(+=3M=^5C- U3>0>5/FNVX0KW'T"2]8S3)=,3^ /T/:))D/+Y# MDP"-#VF2;B\;35(#*C/4)K[\_JQSAE2BZ_X=R]\="ZO![QMQ6!ZTV0!_:Y^U M;?/EX.?L!3X!^Y+2WQ[@5O)IQ_:2-AL_&1LF0[$! !U*G1WO MRA*/AK,"H1BL>%,[A#0/3ZVL$7[%4X+^I/2<8IXV<>B8.'9&IB7RDWOR%\!0 M>2^7)%>?I7:/D3/5!T__B3Y3E(+8$]&#ZTU?D6:HNCXR!.7C\*UY8[Z[WEX-/M!%PKSFZ(/Y"[P4\%)2>"D?O.D3<=&#MZ"W MO*;Q42#"EJN#HD"$+4<'15:R\5!J0.1*68+F>2CK2M8O?ZZR'?"'6+)_LC(M M;SDU*E9WO+5T:]6A6X6P>505A=0:UPK'3XI-QR]C9'KH++L*S*3EE3/M%YEN M4.V8@DI%4@9_V=+"_966)%.EH_2@(&UU(]./6V4;>98$*E)W!&M4Z352J!SU M8(W*6R,?:Z50>L(O3+)21Y-HN$6AR=HC]]1+_H:V@$[28KTU55+"S)/:YXRX M)944E\08$=0YQ"E?B>NI7P-:2=:]-8Z:Q;;H:J\$ MFT6V][A)X+XLFX1 M:?W&;C#]0T]#Y@PI\@[>KS#JASVT==Y#&U[VG5OI-_L,^'(Y\(.1@AM2,$_% M-@1?B]", QN!DVX$SFO;;^\$-Z$J?O9%66TAVL,S\5DF361C.)#Z,A"_'.*/ M)+D/M,]O8S!?!*HF'0M35=4]BUZ0CC3,UPF-(,5A!]1VT=48W8DJ7/2=3N-9 M(R^)H484V^6+-!+.NI<>'T;9E:+G*4N)EBE2->?,C!]_$=5C:B,HAF&8Q9T3 M]-VR3-OU#"J6M>:[7C/8JELOMA+Q;C)%#YI+ ?6QZ74YL 3H6C-4S3"HI:,< MRGJ'B0W6-6;0?C,85*D=@TX]:E\_$5ZKX2!L3-&5XW@+J_XL-6@&2_7JQ5*L MYT.(@Y!KH@E!GS2##O2_K"M'C3GJ8C='-*@QNLM,]!*>[-..CL8K3 M6K/6L!F<4S._^IKMJ42WH>VZ?]C,$WY2>XV@Z%JY@<+AOIFNON8 M"IU_,XWVQU]S[#DL3O & 9M58!XU](U]JX?NR7\\S=% MNL:6QA03YR.;+$2>MX%\U"QT=3U&CT2=&Z9N/KV*HS9FQ$9\ PX+PP1)('2E M4CNCN1IQFHV_9,AZE!C]X]FU!Y=QY@^KUDPF0XJC#!ZZ,K#^*FJS'UB.5B4U MMT*0B"B#C;YJJFU.-&X5@7\J,(^:(:NPY_0!N^H-::8!K%2!>0SJQ4IW6/V)GUC4YXMF$(KZ-.HN?3!= M5Z?/;Z/O:\U,@;7*S?'6B[5V-3(%/JK /(;UXJ.'96OE#,O45LS9#!6WI_ZC M;JPYJA=KAAJ -R/$T)"B ;E3+S[*1<6%F/,\4')U3PZ/&L*?-0O'WY,G3\?L MX%86O,!//*=7:T[J=G9S4K-2>C=CQ!+[/*W' ^'T*EX0E]@-3]UU=VWJKZNR MJ)>N6(MNKC%A^)O1#[!\/RWVCW MMU^OGE;0R1HZ6=>XF\H.3EG=")VL88TVUP@Z69>\1M#)&CI90R=KZ&0-+8'C MR5J"3-72RWGAJ*9VL0\S^;]9K8/8:X@0>GF*'MVW% MI_PE\]VAU3.[O5UJ($:'31%,B7]HX*8!\!6$--A6"A':)?I 8_/X M.7DA=HU+=5G9UY*;Y9EW&YE:3B=>X\R]^K(,D=EM+>6.),YLOL-T^*;10A:3 M$#J;QSFQ%R;ZI#GT!_2@:LQ7F&DJ.M_5*'YM(E'59#M>S_1XM_-N[Z-W#C:W M@J2;!+T(OFSM$!3%0%J@;#JP!9$780 MIC I_0FS3K+TB3D+_>H4URB".'1TCHM8VG]!^3/$7B^FIT]9WT>+NE!L MV)3/IIJC>HXC:!;6$#//9L3@5.%>H.FYG%QXV0(#:09] N'&AOLEUIP^UEF* M@6H:S\2@FEDEC(J! $OH>L5YCD@LAQ[*N<]F]>0(TW6P;.*P(QYX[R?VU-"7 M@ZX]R[A?*.K7;=]WT#D=BBF\:;J#+U<+4W7V6+1^5N4\31&X("R M,ZJ[S1:"@_#N0461DMJM MGJ1&#_MQE^>V,HD6_75W%V!@HYS82*DC&UW=W2(1-5\ZNMSW8=H=4V_BG]?\ M=Z;B[5"#.NY6K-F#UDYCP)\STWQE9HDN]1$<6$$'ZY&YND&$;>DZ^M[_@;HY MQ+ !=4)MXONDPA7S*&'QDTTX+>F'3]AFW.&#LXD ;]BEE-V).H+U8N:!4*<. MG;-/"["ED[TDVA%18F?6V50C[0[:%V=<)1;X0<%H*.AS5%N;^ &.8!^J;W>I MUJ2,O1!V-_"JZ?IAE3K-4^ZS+)V; ZON>SO!.R5T*Q:0/+/U9NB0 9V9KM'Q MK!8X)8M%?.S,F1BSBCC;U"7TP] I]$<$V[I&V8NRV$(SL(^5=DTSF(0(';#[ M-Z?'W):9;2[XQ8^S&5%%JQ46)?(HH^I<'^A$H.@57<5CG-4BY "SXN37_* H ME&!""2:4CD$))JP1E&!6;XV@!!-*,*$$$THPH9:M_K5L4(();%M#MHU=@MF# M$DPHP3RB!'-!)Q1 A%Y'&O1]N']D9N*DRA.[S2I/W#B F4WMT--21)?WOGK9 M)R[BG1&/V7?4\U[]MUMXSO9&()F OJ/0&;OBQT#5]"1E"8*#3%RB)\@]>;6< M0N9'*U@]O. S_F];,Z;DU[@]ZG85Y8+JS\&@H\CR17\PW(/^ ]'>"@WZ7-21 M%/;QMG[8 /;#@33:&V)8>TF[(W5ZX4?NBQ6L'JDMGI!CJ^_/W,6DS=SQCJ+( MO\@ON3/M=SJ*]&_KZ0QAW7U_=KN@JE<^VS> K2=O+4+P#:4G=5=TD48'1BR- MPBO1D2[Z<4;=BQYU,(;M1Z]%)C(TT7D41%6ALFZGV+?0][EFHA\/5RWJ!\V( M[2 FW8?K*UG:\)45T)$GFV=LK'44/"7/1#[&DLHL 27P%@M41O!"@PQ2V:WT-QTT8+H+J)\9WNLS$]4-+%9N]I_ M12J<51/BA>FG9L-O$9FYH :#967Y.K*)BR0O.Q&PZG6#N[EBCAU1K6J3)\UQ M^:26Z< ?#^CFXQ5/_R]8':$[QP92.NB5&A"ZC/_+[O/O6>=@\;#@'>>..B=3 MNICH]I;E7O]\0U=H=0+1WIM7]TY9':IK:Q-^F,.!QR^_PU/OU#ODG6,U![%R M!LL2-:U"MEC^<[$PIRQS&6+E*:M:\VL7UJH@I(T<6G9IL[#OCSW77#>__$K2 MS!K_4C@6'F3\5"[T1^;9^M+%\!!X/;GHOYPTI9PL(=,=2=V#W4 M?O$E"$@4*6,G2Z(]4GB16 R7J;+Q;_U>?] ?QJ"I?P='N <^%X#WP VBTJ76 M:W9VR>NIS1FZ-1R+E5BOPIMI1!Z6X\CE"#DP5YX[-VW>(".]@H$%.7)!5G*! M'E\MDI\F._5E^8IMEE.2\W$U&DZ\>\]Q-)RL(7YL'Z3AM+N[NLW7,?&5R\D3 M^N_82"_A0,]]0H^^WCX>ZQL 2>/K@H$T!..>SKAWP+BG(-YG@G5WCJZQ@:<8 M3'PZL4;_'_J#&(25B/SQ]0X,?A%D_T0FZ:4>Z D&OP#-X-??W%/=\!(^?QYP M?;9>/YC^-,3[\8 ^W5R!S0>;7Q>RWQ"5BGOXC'BP^25I * FX/M"/?V44G_J MQ ,C#['[JA/Z[Y[.!'P(9CU;*!\NNP 37UV5<.I4]0U\.OD_>>+=7*'S'P]O MP,2G(%X(P?/]>6#R"R+\ [&8R%^ R<^&GE??_KQ]H(K@@XW_J^GIE &0]9!^ M &B?2^K^-;T:.'7B@>4_AGC\;*'V#VLG2@+3GW>Y#IC^K-%^J*0?C'_1QA] M?TK0#Z8?HOI@^$^"\G[V?@"&/RO[9"]647Y^Q#&8?DCE5YFNON^?3@6<.O$ M[Q]9L<N'4J7OE/3$ET =[#_:^>AX\V/G,MN"D%'&@ MYQ8]/WZE4B^@_2M8^=RM?"6/[BFP(6Z"CKAPO'$<]H/CC2-4/QQOG%@>X'AC M6*/--8+CC4M>(SC>&(XWAN.-X7AC."&-@VQJR;>SCC?MPO#$< M;[SQU"3'&R_##V*<<)1QQ,FY2N..,N:-S#X1['HV$2=)7CF.M["BC@0^EFV" MTURW.2%"BT?SUXYG%K@<>R*?06MX19(/F*S*#OOJ[G:,KIZQ@6>:OKN??;:< MH0R:SQG!VQY>%U0@_X?;0WEXT*>IT.@WCSR8TK7@U@5]M%GY-66"FU=GYAF[ M#P@!GCEYGHE[-'8PUQV/2'H$MD5='VVA&0SV4W8E3Z:M.3[;7HO?7U$7F!68 M=8M9B<$&ADI@6JI.B6:)$\AM\JS1>5-(Q\Z07A!UC@W-6; +F"M:?K@T90D> ML4/:4BV+4\)#'TU-A[3\9XKG^P^]-9Z)XVI/[$2A(J?YP3;5.75#D6FC1_.7 MIK+#L1^\!5TJ=J@Y.^>;#8^Z(GR.!M)<=G8V9OXJF2X_MSR; AU^"CK]76,R M;_Z;&B3VKXA^NW/L!NM(M8"!* VG.@F>CF:VN4 8J9YMLS/@56QA 5Q;R,$S M0D?%J*9K*C$WN9-&^!1I6R<7JC-2C?H?Y'5Y5KN% M;;P@+K$1R[LQ&1X?YI1JUHHT\&3Y;C?)AI^>=*HGI/G/[]$7=_S_+Z3N[AC$ MC/]W(.20_(3=GB0K0/DC*/_@4FOVY,[3D'X(I#^*]'S,GTQ[D9SX TD^U4,R M,](XE'3XB?EI/&GVY-E8!"1VY *W3<,@J6DXE549A%:E._1-Z%:^-86&/VD" M]CN+IQ:BK@O[I\O^2:6J3YJ&@OE2:=F3I)OL*[D/GOZSA;[SU ]%R4J'PI8/ ME!0Z*35OG ZH -#N2'(_'=962L;:*0?^2&Q;+(J,6UW9&M;I@#X3_9FP M!62#PX;3WC'"<#Q+CAO/0C^D!^DJ(AQ4H.QTDFR]@"TAL"4$MH34OI0=MH0T M8HU@2TC):P1;0F!+"&P)@2TA4%L?E\NKR\:P)038MH9L&WM+R "VA,"6D(VG MPI:0_/90])JU)835+(5V@"#71!."/FD&7*%A*\I)V+-0%-"_]&W2P)M\A]/LPE2=4S'$E1*3HC[0JBCRZL),>5E M?V<,JYXD,Y/>CY'A+2:LF&LFZ@]]:LWQ,Q4<]MT%GM+;7/]UID:'2Z,%-!)/&K&#L+T+J3<\T0*2O=W#^KXJZ:\T2?R" MDI5Z3.QF][M27X;%R' Q_LYMA*^YWUZIL4M[AI+23RQ$I[M(2^,K7;"_A<-& M9<% )A6%A;= $^RJ<\0>M2S%IV_T9EAUA0'!U#%^RPRNM6!E]=1^"%,IZO+) M5$HE2J>[).$B#O'&1Y.2_)>V8&M 9E0J-&*HK_X>CZFG,JONN%*4; R&095= M.OL"W2E#R[*2%>;V.2Y=#&Q/E]M/YE2-<;?08?*!'$\3ODH@0B&I6LH)^K"Z M*/SSF6=S'Y!0!\W#[KK3-B,X\)3X'J%G;>G1KIP\MA/&7%@ZXK&[>"B/Y( W*RSSB=_?9:0RN"$SAL;4.45>*KU9HVZ,ZC=@^.<7Q#:IND(E8%6E$^/";"[5QL-2C]BF M:U(O27SUA4)!3? &A4<>17;:\C LM#2]Z:NB-C?U.:'-<6"^XU9MO M%AFB'+ *+%&3[5"5;:?UEV%I(_TTG^;,5Q:K8.,7ZE@S+8UUIX6LY8X2YC*9 M!GVD4+];EI;I[PEVA'^5 \=,Z%"#X"%Q)!0,7<<3RD)TS*_,RCO>A(?^J(YA MV\6?J$UAV0FA<#@68_Z$_]4%<>?F5,R'F8XEN'9BX ;P"H[4*@PCK$++=W\* M_Y\$$UW:NA9\UF*Y"&($(3G.5]J5] MP!9=;*S.)?1MU_BXZ*JF1=CU$'9CK0Y\!; <)G4\?[(4!N4E:/D\&721-1Z/9YI&XMH.!?V\TOG5%& M#*,%)FE_8G)3&]1AVUAQH^KVXH\*MKW MA<+RO5AV\M)K1%L>REYC6#;"VQ[ M@6TOL.T%]@_4?_\ ;'L!MJTAV\;>]G(!VUY@V\MQVUZR7O:MS0J1VS)X3&BG M%-@N^C!&'[SI$W']GLBO2S[.J"&YU+R.Y$=LA)&;M:_GSM;8\A_0?45OE$BX MYR%V^(T_<;=%0WTI:";9#[90G%R(($$T_*B( )_9CIT.\9>F.)H,$C6A*CVC M,2@PH3'8D4NB3F.X<>"&SQ6BZ)8BXA9C2E13-&'=<&$V/V7NRICR#K'93UL? M\Y>.>2"!Y;0^?T2?OG_Y\OU_;[_]@:Z_/SP^H*O[C^CJRQ?TSQ_?'S_>H-MO M8_3CX6:I!'.Q^#YU!CVIVX]:Q+":[,1?U!)5]0Z!!NT-VKL [1T6KOHI\Z:J MAB*VNT8H#^$S+]'FH7!&SNHB=%C(MN;(5V-P_AID*QJQ!S<@$0:V9R8OMHKV+735[C$K*()I, MXG<.AC27SD_=V;7@^O'VS]O'?\5/$QREU?/ G3&Y)A8Y]G<(3_:DA D9ME// MPM3=Z9[%TMM[P5!F-(ZL-,Z2ZG?WM]"T*WY[SX&+; M;?^P8F8QRQ7/G? FB;X*TR EULG* ET M"D^\-A5T0^H$@F\0? ,] ,&WT\&T\58 (FT0:3OM!8"P6MYAM?PLQ,F'VB"N M!G&US.-J39?7)(&(:YU@@[6YN2>.-O6P[K!NY_@5G7_U=%>SJ.?^X-DSK-(9 MW)!GHINB62G;%O_GT]4!4Q8AQ*5H%N^LVAU,L KNKVGNH+WR$(?1;=5]@'3#_[5 M1[\['R@)4!)-4!(7K4YO4'4=D8_TWYGNLH'V/8-\9+KZ-/ I]6 M '4 ZJ!)ZD"^:,GRL.KZH%"?X<[O]GDM(O?HAZ'-3'O!VFD%X (H+$D%[*!+@>J@E)DG.-PR$2U&%ZWAQ:X81)4*C:75N7^5+S7.:\O! M<"@I%[#IH/BBR=!N UD:[%7^L 0%[$;>$H?H \*W%/7:N2;[/O5/-=GW<1(3 M0-E!7I[;B^1WS[*/_QE<\'.+K_>7M]__W#[_H@R8+P[EL;ZU YNWR45:[(F28AHST:2:-!ND--UIWDBXAFP5!= MG[>EEDK=85668:[.YA)9D90^B$"I(C!00 3*%8$>[+$J5P3*5$$G*0$KXG>D M89D^T(E3OR\-R]Q@>^+49PV?0?64J'I&X/J4NK5< L>G9-\?U$^9GD^9W45. MDOH;ZD>&\%N)69IDP=!JE)Y&UE7PSS+M91$_7 F]+%+7JT3%(4NOVBN (O&# M@L!H1S#:X6A?'51]-G$U8*)45(T*F)V6IHH*8)T6-2(#2B!S*;M=A7O)2L/\ MC6.AW:XV?=(C'Z@3EPZX[1^0.FYWI)ZH#\EJ=??UY\H@Y $"]Z+=P6B:%-16'K84'KZO3UJLYG"F])6% M/%3C9EKEW%#-X4_Y;79*A$)5FGS!L*CX?F,E0Z1C)MSMU!$LE:NP*]LLK($@ M*J_IIP-4);<-.SI5=(AZ9Y??3"E.KG([6=Q)D"P^NS1G*=[2X5.+_8Y'6\.Z M4\F*S=(#(SY$K'@+O)Q852Z 4^5$XO 5TV^GY]83R>C5FEOOYMA>8-6TB(9K M (<;#H$;#GL+GE[EDGQU Z_E3B]O[%IDDJ0RT!6R>LT%I)4!H:4TJ\UU-][9 MY7>#I'/KNXE<;HX.ZP .2\\XA8!BM9HC)R3.V:52!WA5^GKWJM,,^YA(X-FE M7 .<57Z.9FWY<\=A):=I<@=BF3+PH#5B=6PU &3ELW%Y:*U*1<70J@KW%EI8#K -E# < [ #8 ; #8 ? #H#="0*[O7CM<6Z3XE* @/@ \0'BJ[K##(@/$%^M M$9_2&O:&@/@ \0'B \0'B \0WPDBOK/+3Z9GIT-V"B [0': [ #9G22RJT>O MF+SG#LUC3G3R#6P>4QS.R[-SC'S14N1.19O'5)67 @Y%/E]?[SZ MM2HY[LV]U&3W ?=QKU?2OO[*<;P%F9:U[N]+HWOOV#=?'+7@;U*8_E.V_ #= M3G#N -U.=.Z0P:LKY%N?A>-9%#'7#0=F%=/828QT@8ZJ M/>?$VQU)Z;'I]()M,?M8?/E5X1:R1\5D93YX/I/@L7[C,.KYZMARR#CX(3Q6 M]L*YH-T"_Z+WTE4PUL> /=<,+G"E):X$9[EW_O+N#'%*OS\3BW@644L7/@F> M?GN"U9]/MND9T_%O_5Y_T!]&=I?V/^?#V_NI&.O>CY/T4T-]G@5!JQ]STX(^ MI^21$0,^3\/G:S MQ!?^/>Q*A"@$X_3?+UK>Q\S1#J3!0<-#J;'C\29]Y$PW M7P)"!K^W7VQLC2 M2]:F7=U>MIQ?_+\3E.X-)>4""%\"X:4!T+T$NO ZF!53X7NH&7*H?M(DH'?,Z5[PBW!47&: MHJ>=3X8H68BD,DF1L\NKZ\?;/V\?_Y6FNTE41*)"TQ2UPR7S150DH5K)P^S% M(N_<: M?P0%"Q*3__2CH%&%V,67BGTES#6$(75$'>5/,6_ 4?H,BX8(I:QA\PXV+M=O M+WZ*>;OFI4^P:->@!#G,UU\N?WZ-US/-Y]';S:#$AMF.\4PBZ5=ICW9'D9_^+'EV1P.,K-KP95EW/IF-" M5\:4_H_U5SX?\&#!@VWL#,&#K?\$&Q.A8HYJ5&>92L>O1MU6?W!QE++9-W_7 MQH9C87O5%*7)S'SJ5!#NU9F H%UA.31[V6[+2 V^U?&_U.".Y7@-Q3RS3=J'% M::0S4.46IS9?1&AP>NJN3J/G=R+>3,E1W^*\G5J'MR]:PR[X0M7RA0:A+;MI M\VN5=X1V3++!<;S29UNHU2E]ML56B98^W2*]WM(G6Z@'7/IL"_2&RY_K2>FH M-2^YE&8*V;@;OZ=Q-=8\YVIUDCB2'-WAL'4Q[.\XT_.MBRV>@HZB2RJ,ZP6:$/3#'F)-BT^$/?'^F MDYE+'\)7(GB*SX6JJ>O8I.^$)'Y+GD'1/VO%@GCC0,=XEM(NGP_SZH[%9KU%.D[@C6J-)KI% Y MVHY8P1H5MD;1\:9]2H_[#HE6ZF@2#;# MOBRW[Y68?M,^55+"S)/:YXRX)944E\08$=0YQ"E?B>NI!W8MC9L>X>?".++ND6D]1N'P?0//0V9,Z3(I0L:486/3'@>1F5!,8/T#W_-E369US2!M__?.KM"!?XDCY[XT M' :\X4/GM4O,EBN"9YY(6[C->.82>XSU%_SJ^#PV'$K=E0/@1]DV'&F&WD,N M\QJ %^] M)._58:@O]?RH&?_I)$%1LEAQ"J0J4WZ$%Q3"#N6Q+<,TQ'[\VYS@:@W]?WKW=7][>/MGQ_1S>W# MP_;G97!)65P4@DU'QL6=G3L)>"/==< M=U+XE1@Y@+ R# R_6*4T!GF]55TOHN(^9PO@RQ9_\98QJ*<1B"3\7'-)V[&P M2L:&R0@6K(4$*U'L2OC5+X>1)="], GH#T$;E2(#44510/?"9.!PQ18L1/:8 M+)E#E,?A2JQF2!E$TT#\SCX;:RX=O+JK@NCJFH*BV\=_):\K2^F8Y$61&$QQ M=HF":6;!.]DY#;F'XY=4DI4@6'.( F$@TLF:(JG-^2ER3M$[\)(0I1"NR+DD M.2J:D80>L?3MW?WM]<=CMT"58G8Z,4W;S$A-LM*?3%93K8NEJ7TC5^Y MVXFD>Q65.JGWTI>OT=NE2U+0.4ZY#DHWKJ\?-#I]P M+)_75N:7Y'V7HWV0> M:#=%7]#**.-RUQ6\Z$*5=%[3;Y;"OK--UU1-'?U!#&)C%CT#M9W5_(N)N%28 M *#AJV.YCVEG7I/8Q]EEKW71&>Y6V:==R='N2)WAQ6B@R)W>7Q(5<$CR128U M'*OBI9%TH928,&I:!5^<#W>V;M5$BB>#X]W 7063'$9M$K!,'\(PI_Y+X_4=UXM*O\^PC&R1+=/BI;4_7+5,SQ DYQSRP:_G%UT<^QQ_8 M5WKGW$G<3T<$\6,N>9G==;-;PCW=:5(\*_MDKXCP5WDY"I"Q?F?Q5))XG5WN M;+<5M^\V2Q94>?%.2I9&X2Y&E5R. F2).C)U%:;!=DOF?%?ORM:P3M?J,]&? M"1L86S=L..W$LI2&'[*1O.S>G,<9#+$.M&JX1';K*I$BA0(2V2")%#F:<,>G M"6%_:BVCD=X(_VSO1L8->CF>1=] \96FVN9$,W7SZ37]N2R#\JD-,E6*-RI2 M1?5:_,22=MRZ');+L\NKCX_'25YU*=UT,Z7H=_?B1D%TKL2:U-96\27_.0].S=X=P'64-.9W& MJG+Z:[/W56*R9*S?ZY^=.LQ#_Y>2A2J<]:D:"]4_*9,+"Q4.3VO,0@U((^3 M0R5$YVO,0[4+?%>-@-6(9=>8@-6(!]>8@& TDRF\NH=+#]O,43H6*CS^6&,6 M*B&Z5R@+)>AELUG'WERBR$H_1;,R"$KY0:DN!*4@* 5!J8JS$ 2EP+^&H!0$ MI4K':!"4@J 4!*5J3$ PFA"4@J 4!*4@* 5!J:I2[SK!T4<0E(*@% 2E("A5 M'18"_QJ"4A"4@J!4;0@(02D(2E6" X%:$)2"H!0$I>H0E++]EI_-H5FF,2N0 ML' TZN2IL19M.GEJK(69ZD>-W7N?$])(-77Z ./]F7(6C8=EZ:)7'L&V^RPD MI\[9Y8.WH ]9=F9*]HCNLMU"FF^+ =P3R[3=%$\(=WM(__HT)^WN"8G43V3R M"7D -;;1X\E3PP]& #6 -PY'#DZ>&FLA Z!&."100_AZ/.2OX:1[KTNJX6L#KF5+RSRT?3Q7KBMO< G)H^X9-SJP$X-7W" )R:/^&<@5.V9T3P MG%1"RYL[5,IZBJ.6?#':<23$6Y>=XWCI'P%?T5/JZ=@0I\/[,[:)FCZ4CSIX MJI\7I/Z@CBV'C(,?PN-B]/0/LU_@7_1>2D_##59S)(W6-X;T>_U!?\B&[]K! M:_ROBS*I6$S2D3I[_3/4EWKT[^5/[)ELGMLO,^D+9KKY$I H^+W]8F-K/+$) M_ME^H21X9YF.Q@JWQC;1L:L]DXUG+C_'$\?4/9>\8ZE4-JY@EU_G+V4D&>*J M'\ZB_M^QY72T5Q7!"AR] HEB+$(:=DA9)OT3,BSTI^P@]Y><(?=S0XCA):%* MR[3'OTU'[,_6L5!GEW=7U_^X^N/VVQ_HR^VWC^CQ_O;J2_O#]\?'+Q\?T@7[ M1H-37XTD/E/4^OQXN-D=@CQQ"^NOI."7T-+Z++*M^XXPN+(L*0?C Z#>LS>P M0Z!XH13O2\H(*%XHQ3L1P6,@>=8D[TB#@V% H'C6%*>V?TS7?NS$2+:;4J#B&JSBZDJ["N@\3KI* M27#F[1>!?!%EGIM*,>B%<")Z,4?FBXKP9>_;37(B#+6KMNF:3'6AK8Q_$H76 M'Z2J)JV&OWMV>7[E.![[EHPLGR#GSILW.WW;8P,UU:9$JLW(D9&2>CFD9Y=R M:Z!T3MXN@=$Y(:-3:>)4RA3E2JF,N29O8U0G6N1NI2JLGL%T@>G*BI$J%23* MUQO^8+JN3M =5G]B^HHG]$4S"'IDHVLA!3W\X\=??U-&[YPC@$)4<5E=27<, MD"B7)D4"C>Z@->A<@+H&=5V:W:\UL,B8%E&59"=%BZ@:KSJ%.?EN8G1';/0! MN^I\.]@)QCHO8YUICT*PY,VWY&#&P8R#&0/7E2"->AD&J MM 4'"PT6&BPT6&BPT VST)5.[4(&$S*8D,',)R3>/960>-Y*J$D5G^(T-2CW M%.6>-J?&D<6>$!8^Y1RNTAK)7;!78*].QUY5FCB5,F1U@A< M:H2&JVP[@:[ MEM2N]:01V+5ZV+7"2U*JC\)"DL;[TX5>ARZDKM^&,'=J?;=8:Q96=FN8+M(, M5?>F9$I_0.Z](FXB)-TG#8OV RV2MZYN1*[]_(C2+^E#)3D1#EI&W;B M'3KC],".U]G_0NIW3[VG[/Z%C^H@^^''EW^@S]^_W*#'VZ\?TO$-LH MPH10?0M_E0B@>*)>YYA)^##89&R:C M5H!*>U*OS+:IS=0WB>("TA#ZUA8H">6WKFT@S^^+I4:%4I/Y/AD#'.ZWTTM( M&4131OS./HO1*C3E07KYG@VY9_(QN.+L9(STDZ/ MI"+/?ZT^=W0*X8Y#,#Q'?CG:@N4>@T@R^5BJ\V#+X$I;D$Y,"W)V^O'*,);WXA44X5>QDI623TW3B47.N-F*5[14.(! M+RR=@-ZMA][=7:4+BA<4[RDHWJU(2F3#K/+T\2"Q/@[ZF*,_B$%LS")@E=?* MX5D6+];%!$/V,GF^DZ^94B^7$W)7\ >A?\*Y)]J55)GX1N))*JV+7K_>-1;E M'9_,7]76\:OI^248F1VH/(3SE(NOI("#3PNE..2/CZ%X18<%HE<'BE/1ZP+% MBZ1XKROUAD#R8BOU%&#R@M7*X5,8@.)94SP*4P/%LZ;X "JN"Z9X5P+OL&BE M L"L4(J/I!$8SKR+>A7J@D<$X!;T+3I9B\%ELG4OF\8>&>_$F^PC._\]7.2F M$Y=^G:L[9Y0U^=9+ONH[53JT9 M:Q<0]9"<;7TI^TRW"/:="LD_Z,28QF3+]>01<&8)G-D]'9)?FS9)PYA^_.I4 MR!23,_EG>VO#-^CI>!8=4QX%<,I&\X<)87]JO5AYD/[L\JNFVN9$,W7SZ36U MNF Q+J#VQOZQCX\IZ2DB6'4F7LX6;]M7EA- H_@+(0);I[$0NVEZ=ND76B>% M(7OQ$=4ZB1$-LM9 5:(&-!(XCR6)TF;TK*JK<'1)<)%$70O'B!A95>E:C'ZZ M-ATW2^6TTC7H_$IUM6>Z7D<_?I0RE'-G:RIYLZ[THG?S;-;,-3=>=T@JSRX[ M<;8R[^6%6!NASR[/;PW-U;#^)F71>X7-4[F;7^H?'CO,./\'#),YPU0X:E6- MK59;U5>5)E=IQ*E=_*AJW%6[D% 5-GH";?97%U65-L?[ :D.,*IT6*-T6:JX MWYB$.U(=!%;_N,!AHBBM7G=;; 8QZ7?8SI@+"?!Q>\+>(>\O4\3,!2 ;@#= M +JK"8L = /H!M!=$7X#T V@&T W@&X W3%!=[\'H!M M](!# 6@&T W@.Z: MP"( W4T"W874[G\%^ WP&^ WP.^:\ O [\;#[UY+Z0P!?D,Q^$DJN&I#Y*HA M'N"DNF+GDH(M )&;!)&SW] (B6I RM6D#2!E0,J E $IQZT.#[X6](Q4H@_C M @3=K 0V5(T#.@=T7EE. G0.Z!S0.:#SNC @H'- YX#. 9T#.H^)SJ&,'% X ME)$#"@<47F%. A0.*+S)*!S*R!O">0"_ 7X#_ ;X#? [%E$R+B,'&!&&$2>F M+M8 9^,Y035UQ\+&^[/^6;3A522E/,HD590/WH+>_HKNB67:+OJ#&,3&[/#3 MH_VQ$Q.(-7^K\0*1Q-$Z,4;HE*H9BW>4:N@(*:V^(F?@")V00 M?I[%"VX\X MX[UVZYG<8VGLV@JOI+'3$XY'@U@WEF_1V.7L%**)2IN>OK&Q(@J>7[/8%3R_ M$E7J[XG5:>Z^7M9G:'='+;IZ.X[OBB4[HOU/MN;)\1L>&."'>G['*5[:M ME8TZ>*H?KJ-67L>60\;!#^%Q,8+ZNV,7^!>]EQ+4<(/EI.NY7IS2[_4'_2$; M?EP?>"1U=SXBDXI>6VSKS2)CB_J23$F/5C\6$)VE*V+:X]^F(_;GW287G%T^ M/%Y]N/UR^_@OU$8??GSY!_K\_=B7@T\Y?WIT%2DVLTMFNG?R"%'LY M7[!SX$0HDG(PW,GTZ/;S3?K,F6Z^!)0,?F^_V-@:3VR"?[9?*-G>6::CL03J MV"8Z=K5GLO%,7[;XBX-;\80*@^>2M7D7R2]R G>&LXO_=S:.6\X4WR8S4T&; M;-8@<@.Q@DI@VB/5/S./CNP=>+J^O'V3PISJA@BVC/W%,$& MQ.,,D<3*L]E#D<&T35(5/_&C338P3^%YZD,@O3H<%<,4YAZR.(:;[NYOKS_N M"'L>C.J5;W0Z,8W.V>4W;S$A-C)GZ(OI.E6T*V6D'M96,'^S6=A^K_(5?<,3 M2=7("Q:I?2M6550GW#D^R>*$N8)Y[^;N,F5=+B9>[]H54966U^HGV\U4F M>I%XDDKKHK?=R+W<@HOXG)=?G5;"PHH4E11KY>_U33-?V1K6Z7I_)OHS8?-C M:X\-I[W- /)!YT/J]F,P;QJ!.2IL>>RLDQ=69C?%[=Z27?Y"$?(N[JW^V2!? MZ9US9QD5$U=:;!#'Q>G,^0"--79Y=N"-6&W M7\BT+OI_*7)BA%U"^SBA:,!Q@/,!Y@/()I#31- MAS9R4F 8&FL8.F 8ZF,8NM0R'.QIT"3+4'U_.\T2#B6EOKMP&K>",,T,IMF5 M^J/XN2S_G%"9^_DJHKJ9OWTJ*5U^13/H6]UQ M6Q&^:UEI7C_A:A$[9]<969ZN6Z9FN$UTH65*R),2XH!]Y:$4#DUP?BI0CO

Y M+GAU(4X/U3^'XO0)Y%Q4UX"81]-7 3&ODYB?0)U& C$?@36/2=]N'\2\3F+> M_*Q[PI1V186\^HFO=;HZGD6'E_T>=I&U#G?$GA#VIZKK%J&6NA;)$^JN@B5%&@KTW'+4^:3S6[="!UT_-'%+]?06,3-]GIH[/+ M3J!0LGOH7L9&V;_K[/+\UM!<2MTWJ0['J6^*)0=>N$]#POI&KZM"P4H'!BNY M ^@4PC&U(W;=HBH-(W^M0B5ET#Z3FOLDM=5 ^R+XOM+AA7 SY7CMP];"P">RY3N]E#S_B\Z7D-<#H)P0 ]Y^?& EBN,;6;A(WSU;FG X/+M6P)3EFI(]3- MLY5],Y!NSOREM ;* , N@%T NT=I7 "[ '8![ +8K0(E:PN_ .P"V 6P>[J6 M#< N@-U\P>XP"=CM ]H%M-MPM*N<'MKM =RM%4&;AW?KR*& >P'W-H/:S<*] MN>H* +X%J>1>PY%O'/*=./3-FQ#HA>@[ZE"W^U(4..A;P5Q1:V1 M+P#?.M$3<&_%\ #@7L"]D.\]787<=-0+H+=<_AJTAH!Y ?,"YEV.?]0\S%MO MIPS@+\!?@+^G*?L ?P'^ OP]784,Y)W]J2@6>Z)X^,RV7M[,?B5]4,TO@)N!MQ<=TX'W RX.>^T M<6^XS6.P31B \^D"YR$ YVIY!Y4&SO4F;:TQ-.P=/BUFK1M(;MBI,LU"Q["9 MN DZNNGXSE\UA_5:W&QSJ'*DT/(>9-4_ YYYFHP^/9J;$%L2#3GO0@ I0M2YHV&TG(\\ITRE(Y) MHO2"O$XRQ[/HNWD&>K"=<=N-KR\D@-=R[@=" [PN=_P[-C( O 9XW4S2UA=> M4T4\ GB=*;/F35* UU5B<(#7%1 )@-<%*?-&P^L.VU(+Z/I@HCH.A;(&UQ>M M0?[@NG(*LU;QR#785J8(9TVH?9CYP5O05[X6 =*[_;Q0^K[)W1/+M-WA M=J'HJ?U!#&)C5S.-HR%TM31&U57$J$P-47/ IIHZ963C_5GW+)+."N51&0B= M#S(^50[.#U\!'8^A8QA851XX'0$[CX=9IP2CV+FY?47.#3$!*$H"BAKC$.YV MJ7-)4C6&9KDXT4VUCF7XR4#+]*YP4VF7@[<+I$K@T.9,K()BV5EK?N;,GAQE MP&5MELNZ':J?9&COUI/NCR8U?'][.P$'-(4'U8OVH/JR-+C(FUFB*)47^^S+ M'WRW6.X ZY12CMM"ANDBS5!U;TJF] ?DS@GZX$V?B(LX^XW1[_UAJS_J).9# M\!K :P"OX0BOX:V+)SJA_TZUYWTS33 *N;-ENL*3BSL\/ACZ5_ ]52?8IBK' MG?L/#PI"%/:20!507;!WM9+.(23U-M-WQT^*38<_\/T9VX+ _#)&^N I?@26 MFA8=6PX9!S^$!\94O>_<+? O>B]51\:27<7.AA#_MOG(^17^JK:.7TW/'<^T M7V2Z0;4M[U&.[3MV%4D9;%7J,'8,XLADJG24W@$)"RUUZ/4F?>5,-U\"L@:_ MMU]L;(TG-L$_VR_TK>\LT]&8P1G;1,>N]DPVGKG\'$_HB#R7O&.![KQ8)\)) MX3<.=UG31-+A_QU3Q?44:JQ@C2J]1HHB*HIAC4I:(Q]&IU!Z/&^6:*6.)M$P M B.NH[P[VZ2+1QWRW]!U^_K^NMT=#OJRW+Y7$KOU2\R6*X)GGDA;N,UXYA)[C/47 M_.H$^P*'4G?E (AKG0U'FJ'WD,N\!N#%.]Y06YOV0+N9^E,Y+]@B00 J!]#K0O MP85).=RB36R,3$!8Y^TPN8DK!*F[HZ0H!4B2V5I;F67N3!E$+Y/X/5S?M\-+ MOKI^O/WS]O%?:62\(PU3I Y+Y\OXZ75IF"]>BE.]]]JX[ MVU2)XZ1ZTR#)B_YD)**K$=Z>G>AM4?WLUMYV?GWWYYM4K^DFI-Z3C1>I7M1+ MM$X/+K;=MF=54N_%:-)P_):_ZEOULTNEWZ*0Y63TE$ZP04=3@/*@E)D>H3H2 MB=J5XU"-N*"K#\)6:6%K*;)R*K+V%3N4/BFX/T8GV.Q$K9W4?NHX5:\6$+*B MA*S7&G;W[C:/-\N1-,HW>WN48/D.,%KQ/4JSEH-AWCG:I"QYKJ03X*1^J4V, M)W?NO $YKK0<=UJ=WMY3XIIF+3_^Q].LL >7'](\R@GN'6>90=0J*6K=5D\9 MU4C4R@U;0E2V[*CL281<)_MFSW_/8G=Q"1HVR:1^3[%-M0K*-OX<][08EKO] MUD#NEUY0F%+LRBEX&U'4=B#7'LTZ4$8"9205+2.AO#W:/-4E"[/ ZL, MJE(<&*E8LU[PY?1+B3T4@,TK,=5(=9([F$LR^5A<'ET@64E)CQ_&_N8M)FF3 MODJB-(XY2Q6_CCSC8^TE7TS7J:9&2A:[WA-GV [Y5E #-4[KE!;]K*1NB>M% M+&.8\.J(42:+0;$JD0\II]Y95#?,?CSC9=4S73 MZ(>$ZN&X,[L*QRI-PR>9.#YI,_DEXY&4LY4[K=YP ''Y K=W)HS*+^CD=;+L M^=P[F'RBWLX&)6KRGB;Z_/+FM6@ M_Y0TD[-@P8UHOM: M?%BF'%R],LO*!8B[E$SE:4^Y,.U9;'!'*4%U-FW1SJ]4*E94.Z [6U/)F]K9 MA]WGX':[02>&1(FN3#98)=E!U< $U=GE71D24Z5$6.(L4TR^JP9G%<5&O@=!%9#K&LWJ%%*;Q^4-085^WI7;?P5NT)7MV05NU)6^D02=%^1((V%VM$K'\D)!=\$XDPNX P,_WW-Q[]]G!H@X\1$_#] QL<3\1J0<04],$#&@(P;26] QH", M2[)T"=JR @ & )PK*[9&HQZ 8 #!)PV"MX\B!A ,(!A ,/BQ ((!!#>8W@"" M 00#"*XO$0$$9Y(#Z[0N9$#!92\#H.!RQZ\ "@847 DB-A\%5Y@M >P"V&TD MO0'L M@M"V$, >T"VJT&%;N=5O<""I_+7@9 N^6.?_O03$"[@'8![3:!HH!V M*P@& .T"VFTRP0'M MH%M%LU*G:55E\&M%OV,@#:+7?\::MM*HUV:^\R P& M& PP^*1$'F PP.!&$QQ@,%0X PJN&!7E?NNB#Q7.92\#H. 8X\]O^'(C]_G6 MWF, % PH&%!PA45>_,Z>%)P"=?*XN(+'<'T%A%P/>P<(&1 R(.2*4;';:0W[ MVS6A@) !(9\20DY;N0,(^601Z04:X]QU=6 MF0!>KB$1 2]#1KDQRP!XN52\W-V6 ,#+Y7L,@)KB.WBM\AU0RIYBJ0 MOMJJ&J S0&> SO6C8J)4\T : 70&Z-P\Z*PTL@%7[3T&@,X G0$ZUY%; 3H# M=*X.Z:NMJ@$Z W0&Z%P_*G;[+?DB+G2F*K.?&CN#OCS"M945J2>71DK&E/FQ MX(.WH ]_K3?XOB>6:;L%S$');PY_$(/8V-5,(W,P!L*?'H4UG';%H2P@9[8% MNR=!SSQQ$)#N& #4;-=\@PR.9]&7985Z3I)T%ZUN;*23*DEXJH*;#LL M9+X MT:=*K9BNUZJFH[;*I8&O8J1 MP##=$V<"S5!U;TJFQ9)A4#TRG#@!W#DIE@(7%2/ !V_Z1$Y=&W"W=?S7W^1! MYYWX^W?Q3QF#D8>=UJ W2.-%0U3DA*(BN;C1)Q@FR9Z./&[RUL43G=!_I]KS M/IHD&*OG&&LF1<.HS_6::C ML=X0@7 <\D[)@^;DZ\LTPB.]O^.&1"4AY)RT)W:%"[,3'LQYC_1 M;Y/S3JM-/WK3M!4)R\ 0%'VQMA5(GBG)_2J"F(G.@ZHGFRDG#BWD67L9JBSL MY#KU&'OJDNZ$O[I^O/WS]O%?:5+:D>Y4T>P=8\899_6CW)OF4R#2U\B$ZX^1 M]T1R@.[N;Z\_IF.%PR:GJKH^*Y-:CW7>O;QA^[;4]TH,?5^(L:NR^(,- !M0 M@ TXVNDK@RW 'C1JS2MK)**J@P_7^_8[BR?TR!(>KH,^>/K/F%4+%;8!#5?P MIZ>]034W3#4?K76Y#)EV@*CXN M!?9[XI17-:IADLQQB88FH'1!Z8+2;>JDJ^O_;BFETW.(CR)!997U<<97[D ! M2M7SA=50;15++5:#*-75]Z>GWJ&J!:I:*F*P*EO5 FG5TLEP9%JUTVGU(:UZ MHA:J"GBCZ<&A<@MB3D0SUU#S*AT9-"]H7M"\#9T?A.6;.VE0Q?5="QY9!Q\$-X*(R(_G&M"_R+WDN): 2C:^MDYHZQ MYYK!!9O?R:^$CUU%? G>GXDU.+N,>[ I__8$JS^?;-,SIN/?^KW^H#^,N]67 M#V_OI[9_"&T&^X117Y+I4J#5CU6W*COXMF@&\>DG[@D1U+^'*V VFK:.7TTO M'E<%(P^=,'P6B].&U3N\F[T[/-WJ,E2*XZ(525& XD52',[G+IKBS,7I VAG5*L\]$?R9L3(Q^V'#:$0XX"OY7!KL\U33N M\#Z_]L^K+[7GET^?+S_\_;Z MXT.QRA4D27QT@5O>I6FW:' S\JV2L-^WL3MCSJMCBSO MS*-N>3(C<&3 D=DSNP]7C]>?P8\!/P;\&/!CP(\!/Z98/V9_]FO+CQGZ9@/\ MF'2D_N/^ZMM-L;:C#[8#;$<5:0NVHP&V0VXI"K4>\5 P6(_CB/W=8CD?OTJN M89CJUB4+IXD(&-NDB=,R3+?8:2G%.#*:H>K>E$P+!OA%3:Z)<0MWWD@)^^!- MGT@SA2Q=K3>@!4 +@!;JC!:4;J_5'XWJ6F==W+#D(&[S__Z_=SK!#D'4WR+( MG6,7W6%J\$P#V80^_YF^FOZ*N+Y!KHG4.5%_HFM=HPL=C'WK'1Z_?[2#5)E/-?3%M=ZX9Q'%X6SR;_,(2E[%B0>, M[N8[+%F.E<4]1>J.8(TJO48*E:-MCP_6J+ U"F^!3J;TN/N=:*6.)M$P M KVLN\AWMDD7C_HYOZ'K]O7]=;L['/1EN7VO)-\;O:9*2IAY4ON<$;>DDN*2 M&".".HKM&^ANCNT%5HG'YXF^?+G>W]HEIK141AS^C@T/VZ](5EJH MV^EVTPK!J7-Y==GX@7K&4QL'QR/'.=0SO7XOPS]?").LOV/7-:@9_&MA50!E) MG=66TR2'K6SULYC-PF'_RO2SR,5VK&<5!J&@Z*8F]>5_QO_;9(M=WL'CU;>; MJ_L;]/#Y]N[KQV^/Z.''W=WW^\XH>YIK%0^X/GF69MHL^$8+.L67I&LM,F%3D=.3X-[&@OD9? M2/6:\81FMKE >)G.F&&5JYPWR1-P/6DT@(6+M7"_#_L=J=/AQ_<$:Q='E.3N MX BUV,1EB!_Y*C3%.%K7S/_V'%>;O6XQ##=S*YX)A/!%H^)JV>8S!2[(\46: M2K'()R*-)=R(A?GY5BSM&$@VH!E+V]$G\!0'FE&M85&67#[/<>F=4X0GYC/5)^DSF(+(W4Y Y(.*Z^C7 MR,%KWDCHD4[NL)KTZ>RL:$'=)?.%T398#\?/8!9#@B!?FB$=Q@4G+T>)W%/5KG[5M\^7@Y^P%H=!% M?UM';657=SQ@4_,RT>?J=ZZYA%=VD;%ALOQ!H)$OI-&.=V6Y1(&F#UT)T@^[ M%BYXV+-+9&[,.L6I1''G;' M/U&'<,++OY'EV9;I$*=%H?)A=Y+[[A."!/B>NK%']_%K#B^6HU^P^9S(",89 *+2:C5,(76Y;Q63!AW6%!^0>J&=HP& '.'V-4\ MKGO4/,.YMK 6$?H@K$6"BJ.);6(JT[:->=;BF1A3DZJ8A1^_9(+X'RJJVHQ% M49=6FIE#0;G4V?'-\<;:2RUN=<20W%=_F*)(XM5QR:(^F9:N5)R$"M1? //* MPK@U7DB/FN<^(55-RIJL(%"8^V7*>R.92&]VYZ&\C4@HU(KQP3;5D^WSL4U! M91US\43=JX!]O% ND F_9,0@U.USV":X]9H1[/ ^&II-)8*ZT,S'58GVS)Q% M:O ,UWYM(='-+*C6>R(&L4,OLLGR)=R%#I[O@&2!9%5[GN$*E#7,%N NEX*K MG[XWQWZF/SYKF(O!'[HY8?MDEPB.^FL6NB'.3^$ABB)UAA19UQF=):I=7QY! M,,H4C).0BLR-#78*MH@C/6 :*/W"Q-,?QZ+BQ3:$_M1=33Q1YL["D MYG(QXD\C#F4-YJ]QB^%_B8H*>_*J2ARK*I4#'EEY85O4ES8LYUJ;I VVJA8N MZZY%RW;%D_[CF3PB)9P'E[YP?14I[?F7/MD\J(K^R>Z7@J4)GD)YP#+IPK*2 M$QY:,UYY0.J)OXDR"KN!PV=S58/.NX^]$)LW(T.\WF1AZ;Q.GU?P:(X8WO!CNEZ%5U]=?0'C//">"JW\0R=;AU,\#J<+>$(F-D>(L) ML<^=-RUA/_QNF26ML3/'PBI3^2"4%IO&F='";XO).UOR *UCWLH7VP];,K, M425+RJK99N'D1Z4D/UH<.I)"1])Z%_H>\%DLZ$@*:P0=22NU1M"1%#J20D=2 MZ$@*K1WC*"X!FL'4 MU+CM7]N(GLK=_?L0?2=I*WRT@\.[$KKFH>I;_\Q'EC/\PV;AU/4#ZD2P)7YE MQZ:!\*V!+ UV5&0<5C^1Q1>[GYI+ >B.YAM)2A.6AT)U)?F J[33"@TFGJ\ MY9WAS=@&#YM,6\@ECNM7'M'U^BF*RGE!A+\!A0?T;9.51+ KFN&XML?WKJP? M5;6M-G?.B&7I3/^'BTJTLQ\LS*8F4;!;E!/]; ] M$+[)3.>U,?[5.7YFM":&7[/+NO6PI"Q/TWJ\?X\-JJ!@5: T1!50HT1EA-=4 MM>AM)JN88I7@S_2"2=F>I7YL4^>L^<]K;JV8%?(SR\N2\C690'_%"^N=;\[8 MW:M/Q-F+%D7*HLQ@YZ&+P+ZYLV^O(>S[3['U3EWM4\ >J^Y;L>BUN5CP+?(! M"[*;'CR_YSCHSY(8L-\0!OS =Z!1PTQ9@ZHV2_-+59_I@Z:"*R?L%E!Q17/8 MH"$<]N>*DSX(3N(J;/,RZ_6H]'++O- M!_U%*68R%^Q#/THAH=O9LGC3U2Q/Y_ 0^WOG6VO;"[BY%H;;8F!)N(7B3GZ9 M& [U3\6! -QUU-A&$?Z.8"0:]RMM(LX^QP9B,Z!?%V6.FR,)@=XE8LT+JJ[Z MZ$<1_?:&CD-_S6T@@FXK53<.&Z*9/FDWU41!)O>(J@PKRK<$W(#&&/"]? MEN^N;LN7XS?^]G"+MRWY='.%[@G;1BZAJZG8_T3I1D>ZW%X>A*P<;_)O?S,7 M7MW)MI5%"&T3LCQ*D.7Y9KK[,CWH_)MIM#_^FF/&ML_D#:1^\A%VI3&IGUN7 M+!RD:R+5XU3 WQ"-T5G:LFQ%%>R]_"!:V#]XB\7FUE_P#_(6M*9DMFX>EOZK M']J;AJ+/3(7;9$9LPO::KW)"U-1-R.H+U)?UGX'9?F2>T@DA'XE:TNUGL(08 M]8 __J(VPZ%6 3&9!S>W6#9N2E;FN_%D,E2%#8.W@=P,[3"H_63C!8.^H;3E M5%IB8A4;/)U#1$\3AN(W.BWP;9;TTI--"&\FZ9JJG^BYO?Z,GCQM2EA5$P0N M"V;BIN1FKMC^WQ6"X)U539LJ8 XW6#A!E+ZLU.V$O)J,6UEBFR(7WN> !7Z$ MYA;I=Y:+9VAF&=^QR1.+Z[ X WZB2IE%X/U8Q7J3GS"P,3:PC6\"?&'P+-X8 MUGUA,8M HE9[?T$@BA6(IN2*F$ $I2?H67,\?CK?,G+AMS&<>/I/SMTS_\A3 M0W/F0D.SH(>#3,]UV(FKK E($(,-@I\0^B^%0YN2:[I?Z=(@+'0>=->QUL^F MO!*NB0@J">4X)PN*<%DGP:_+$D?>U\=ON\,*29PJ!.BNOUZ7CWO?4-'6B?.& MP8DMJK,>XH?.W/[^_8%U7?)TYHO;H>#, MC%I:SV9GC+B;7]>,Y=<9IF5I<*SQ#HS/[-:G4 %XJ,3V+G#Y>3-%[/=2Y#NK MQ) J5&D?.A^ED#QA]GT[H1D0- .RH(D)- ,ZJ36"9D EKQ$T X)F0- ,")H! M05>5N%Q>73:&9D# MC5DV_C-@)9U8M ,")H![0J31#<#@IAKUD72G88%7:2T<(5/65$=;;6=0&>YD-3T&Y3>$T?7W!W3N MY[)8!06K,WIS CL;>A+Z!WE%=[;&! O=L\@TE4Y^1C1L7\B#G7N-V;[ #\US M>=+A3ZRS,[S>HEOCV>2G+[&TA&:@'P\WZ/SW*$D"%LN8Q9I2N/^XV@&BL9I+ MVT4?6N@AJ&YI,>V^W*[+C^IR'&]A^>=XT6^9GKOL4G5GF[QJ)H@_2>AA;GKZ ME+=U\NOJPM_W-Q[S$E"VF]EFY\RTEI6?-F%'C?$SS0CBGA&OQUD0OU9U?><* M2$"Q$M"4FO]'HLX-:M:?7M$C.T=QQMP5RO[/U(4FSI([N=;E4N!XDX7F.'X] MWCEV0L?7O1EGRX7Q\H794'070;<3B3MH'$(>8IS!NN^2('X.Z;;,'#6/+ Y# M_>MOH\'%Z%T$)^_-]"<:\LI7Y(^B8V.]Y]:\1_]2L/-Z:E/HR5LKK0[L8MM$ MZ,PY1YT3B7KGP6:2EE_LWUI5ZY-?1/7XM\+'4[]9H,R<4 M.XOVR(32X94J0_KS@DR9=RF.N[9,>JV55!MVA7=6"W4(UKJ*UOJ['70L\T&V MC\K,)YKRF;UUF GFTZ9?M++3^^+LZ+YT>-:XZ(G%NL MYV-P8 1E)%:N,#5?#-%$AWV98+:?>*E(=S5_.H%T;%]"U]C27+Z%>M6L8IF+ MS;PD:M_9\E*WOYI0! _<4*=,YKP9$W],RT+0T,;L-A]H4-TN));+[QC3UMV M:PKW,^6C<:A?ZFA,SS%^9$^;+B?&1K[>/L3OVA;DEG:M6K +>[6FJU-16'HT MM(L[(! =+B]U( Y=G, W7H2WS0?M=#F=7GCZBI'&H!/#D]E DX),TVUKD@P670.V,J:T >Q?,WKS:$PB>"<']ROP-@G5' M$>I]0=^ADW4-OZH;'O_6[_4'_>'6UKK.:E^.7SKLWR$\T?V?"S-UX :1 ]C^ M.._*^TV?DO[?ER[ZNYWD&?]O3TQFW4E>^9N\(&C-Y6JC:]X/CJ+=3PST3MO+ M>IWO+P8+P<3:I;"VALQHP **_R^D;O3ZK2_7/SW,#XU(17H%Q.C M['2<+W8/ /G3DG_]$. #9B4(PB\"G^*5HFK0QY2Z?7&4S 4[!&0==UO M4M*JY%,BW.;..<2D-6!(^L;?Y4Z+#BFM>@52ADBI;)!RC[J\D$;](QWQZ8C] M.0'R'U"BU^;"LHDH%WX4(=MCW>.3(6M>FO7$:1FI(;K]8Y0M4/V#:A-B.."DIE"E,CBIX*16F919*LE3-% '/52#[>,GAOH*GFDVZC15 M/Q3P8VM >?!QXZEON=4''S=[7?W1H)\0PNN4'D19%OB[%503)^@=EZB-3XG, MT:KWHM7M)U&]JLD*RXWW9\I9'*(/68D!I"PW-?,Q]1;B>.LV2E1W@3(IO#C= M]',"F4J0COY=[BFM"R9_6QGI2G9A+*K>/5R^'U'M?F=KK#S<%.7HO%R;%5RK M08FWN.J*$S^6=>J\S)PU%&)']/G5VJ*IP.J\#O8CK^ZFTL//8>6[;OU2^* 8 M?-=[5N>[\M=PQN4W&X25BK/FPLO*?%%?[P]$"[IUT3TC@\.[( #.YI:U H'=L :P8$=%5LC.+ ##NR SO@P XX^2 NEU>7 MC>' #F#;&K)M_ ,[EMUQX< ..+!C5Y@D^L".7$+6B=IH\*#03C&P770]1KM: M)_\5+ZQWZ!/! 4^AJV4SY-DZ5.O#::B?K$*4$;4>@39\3I$_>@:J+SFXIL\JS1%[!@.E-*HL]A MN+=P"U%E1&S,.]?X=VL&LFQB85LD"L(MEC36?F[Y9:G);3B!17-DT<$N7:^&P)MXSRLSFBY.B MD7(GZ.E:^=:A7VM:/'YRI.K0B1$"M76^&S%61VK/LI, MA]=39P-;%=88.>J<3#U=M#MEG5 96@@.&5!MDX$(SU#]5MG\JPM" M./+@Y79A@/U34W_2K\UJ"JV!2ZO I=W+V?RW,<71MK M!K.C](,@)$>5VFS&^6[]$+V@73M[N$U4HEGN6D=WUA^=4?^0!H3P'(":Y-[B MV^\6$;D4JA=OPDQ93UL+/%0@#WWP'.:6.<'^F8V33H"#@(/BY-I$.8H;E*,$ M9RH*MG*\B4/^X[%DFK"L=44!P%=%:B:^YV^V12M&EKO'B'75. M>"T.JSVCB$%SN.9=WR2P;$_UUG,UO]R:-;?2GU>'CN_>5N"Q30O+ \@MWZT, M3H7VMQ2(0ZJ)X;#=.?]A ARXG.)XZ^5@)6H1ECMV1%!WM?5G/=CK1WA9/M94 M-=Y6CU>#L%GR,G&ZQ@:]N/:ZM\\K7ECM;."G26N&JGM3,LWUA.?H39IDMAQF?GU-[,LO,RR\!'OC'@,=2(7$\;P3$O?T!_0 M#7:QO\7TUIC2*VRPZ//K$\6X).-#W).(6/".A]<%'?O_ MT^&7PW,/IH$/OI]0WGYG\$LV>BA,7*3OC*;AWWKLW0A$<< MV4L<],2*I'B_.JK3Y/[/)Z0Y ?-+Z':&INRQ])IGX&>LZ4R[M995!BK]$NMD M9F-6#3C7;'%6^RNB1'L.6MN9$Q=KAH2NJ-!85 I_\4/84;_3:0\ZG2?D8+:= M+MB?<7CTO":"'T*28B4^<^9BJZ+9 M8A&89C[75J(S%Z+S!BV(.S>GX8J4[:6A))F0H+RKV(/#"8L\BW$+JVVV MJ;;5M?^*G9.,P0PS>#Q;R@QX3# 0G0L=E8AN"0;;R4S^JZ?DF>@FMV&4"?SV MBUN\54[WQ<"[@OZ+T'^QL^4P0]\XZ+\(:P3]%TM>(^B_"/T7H?\B]%^$1G9Q MN;RZ; S]%X%M:\BV\?LO]J#_(O1?W'AJU?HO1L3M?I?Y0=$L]O6[/. _LHBG M1>P=L6^VO8M%N6($0+]NQ<-*CX:N+;"\5!*:P33YN"T/#Q/RB'Z$7190Q/JK M\.(>_'ACQIF$3/-WGX)4VJH#UVH"?JQ3!&J#31 VF;807F;'1!;,LDE[2F8: MRX!A5266*W*!ML:+W%<).IYN(X*S,$NI^VFTP!-N\4],@[(+#P'SYF">RG)_ M,T\/N";(Y''^>L;Z,A>P2LXMQ[=*WK5$7E%,*AC1E&7UIZ%WZ*_AJ4KH8>?; M%P3__^Q]:7/CNI7V7T%E)O/:5;+:2[NW.S-5OK8[UTF[VV.[[E5__G@4@08E:K86V,:E)W!)%@L#!P5F?!Q$V^C(S<>?U-ZGJS-?[14/S M*:4MX&73/,Q2,< 45T?1_.J<:MW2)%1@9;=T_M^Y""5H5)G%R:ARS\IF?2KL MJM4N/F88S+$PFH[/NG3*I5%PK'.$[!R./>H=!I$(_!S[5V#7R9'95U;&.TA+ MD$$I4O@11N#SI"LQ\W[5!0D-LV!8?IB._=HD7D IP&SH3M".BD!=]>,\ 1&' MYW9LWBQ*[U/)8&K@"8<)Z.!BNWL8C^-LDQ2ZN!!D_\Z+AZJL\6E/K$S%D&N@ M'K_BY%.:YE3]@'I)FME$N!^S:K2;R_19%&=E"JURW.L#7:OJ\DXP<5KAP1). M/I2K06]QSZL"*KR$#8Y#&-_ R;!S+E> M8'HKP)4/^ B3K=1O:NI3'E&!I@BL!!_F0R.$92;32J9C]0D?4BU]0NDJ>^7E M.RL9F3$91XLG%:V&_J>GW&RW0>997/4:Z),%LG)VU-SD!IEE]FD9N=/#63[N MJTL2+"$DJ^1MW&RO;;:G4/F^:[\_+82_8/,]7HC-ERM'Y_*_#G_.8G^=]JWF M?IWV-47_)[[<8O2MEK+Z"3R^LSS).0LX1WE5UNST<"(-^AK79Y$5T;&.LL!W M%99D-]_+SO,O1^5VUE'X[OVT8+>\=B ^9]SJ^['/.J% B:%+WM;^+)GZ,NN MDNUP4C,F-<=KDIK3QHD-5K."&WQUVXC0]Z$S_32:A^!P@_G0R.]"[ MG8R]=>'QXO[\[LQ!*K%[>K+TI"VN R^).P&AK&VLWZI)TST_YG^(=O*"0?]J M5%J'Z.U)I>#!][N;-YHFZO,'0F<@1IEO+]^ 2Y3LL/WXK?X!9Q!&/R"_'>T[]Z=T2_ MP2OIG\?XSWW,1TY0DYV)?GF?"DQ-F<0T8X'_H_N:7%F:]WJ*:-*RF#@*])Y[ M\]>;VI0[,1=4*WZ'XWW(:6'HUEV>IXK;SGBBK5>G,=$4XR!:XO*&;@*Z3/?79>8-,4ME8=E!"R*D6HR1GW'.7$_3C'1EJBHE_5% MVH_ST$?!+*0CCT)-%.E-T+!DU#L>:M3$L;X&''2UZ3J$Z7L-]7;0+\4_ZL; MYXD>%140U!8(X/W3IR3\=YMRWKK +C2J$]=2ZEI*7=[57.A:2MT:N9;2AJV1 M:REU+:6NI=2UE+K>O$6EO+EB[%I*G=@^0[%=O*7TU+64NI;2L;ONI*5T=]V2 M;]OBLY)&M#2OR;4-^]GDSLG;0U$@3%/F"B.U <4RAXE*,2XZU$DOC*\>C0&: M=JTWYY:0 M54IZPX(EH&0)F!4=^;A*!XP#!/0$(HSV9G8SP\:Y*!2"G824%; MO+'.>A'THVF@["CXIQ+=($*P/>H4HMXI=CO:UK)HX$6*UHZ_ ZS&HXD]5[!8 M \S'47,P=1.5#334+Q1;1'^ZD:8MSLKF%YTT_%1E :RD$/D2'#=/9L+T.*VR M#[2G(OV45MEBT\)F1YW"A+_/#/PKCK*Z7IQ>W':<>%FA_#Z9_2Q>JD630FSQ M.L!N8N0#Z2N66YA[7C#3SU0VY+W!'E^K/P^A'6.XY8'B\EQ5<,J;'X^GA7'> M8:6#8@5;)1 P99,?7.*K 6Q'6E\6"-@5L(H*D\8=E3TJQ>W;!9JVH5,96%JY M@R?H""0"=9=6WN,7V>V;F ZSIM4OIU472$RD_3A]-^5+H9OU:P2]5;;]V]VC MUD+B6+N8:MX[(4IU,8P#4AC1_QP=[Z,^.+'2C? T"U+ CR-5G)TO2O#?H2KP M?L@>+OD7+'FX)Y".7\'^Q2*) _%MR JRR1NA? 6JVF"_>U[ _ 3 MN$Q)<>MYQ=!"/ZPA@VQI=_?VQ4@?1@W M.16DW$L9*J2 #5//;J4OQ:'-;XO^#)YH!M;],2Z]H]:$^T2 \*G8X\ ]?!@& M<*SZ^RW- 8$D0&_0BLTC+Z;>@HQCC1J!AF^"DPZ[@:7;G*@R$_?_<]@21Z?" MER/^PKM;#Y:AW5D?@:CV:OT:NUF/':^1J/5RMAZOU<+4>+FG^_)/FKM;#B>TS M%-O%:SW>N5H/5^OQNFL]/F ,SS3@UC-Y^D]B#YWZY)GLH8N_@!5_?0Y9EWM* M "HO2*UHO\Y&^O&PB*%20L]NC,9ZB[Y,)](+%91NDV-,.%V0*M#BF#! )-@A MUQ;T)9)R8N:2J@LD43&F^+">&HOL#P@J7L=$$7 6'IBF1;5(F@^'X8@J A!. M%I.DE."@@"RF:_A% JP]27X(SB9R L3$@JG*Q'2J5YM[J]WL=KE"XVL,[#GT M58JHNM)Z%YB%7B('8L\@+^M8> MAA);:89*&W8Y:%,LJ @98DN&:4Q*$O'"*U]FG%@C!!&JS"BWSX25ZN32R>5, MN?S.4 1@<^(1S(4+$\>*1D6WN$B(5KQ*ZVUATL !1")JE1!P'6BE^*DDZRAV M19Y:=V.\V=P(T]?Z:(\A>^@NC!4Q7C#1M8U?-U/]Q>B-[!WD_[*())&<:0F;(=XV(2] MM*7-'$%O 2WP?O:ZK)7O MJY/YP%=((F-A3-[&S)_;(3>QF)G;1 MD@LWL4M.[*(%76YBEYS8=ZM-[*D[O.9,[,?5)O;MB9O8.8?7BDK6B>S(#5M"2XB:T8!H<+Q1B6(E \JM20O>")GQ&0.SY=O9J# M2%S>OS,QAW/Q1KP[_+.X_:TB_T7@]&2A&)V+1-!3;E?T+JP8F?\1_^.F^K MS9LSWI\@;\YXWW[\UDW\CB:>-(6;^!U,O)MW%R9H8)C@[7K#!.]=F,"%"1JA M65QVU,V;F[<7.6_.>W#>P^N:>"?Q;N)?U\0[5>,"%2]BWG< "+R2A[D#F)S; M3^)6HX%IN)L=#^@?G\1-?Y3BYGASWE<#@C$KD'@(YI&X'#4B66K(A,TEB>K! M8/;%]2=Q'7A)W GB,$84U\V_W;* 2>>?$%\%1Z4B;U1@5FT,Z/-H4:#/8C(9 M^,AFJPQ'(N@*1$TE,%BXC=>7\ +(_A=W8 />%G"R+6*H.<0_S#N%BBX;6& MHAA2"Z%V]9O#/:(X,\3%A''7(2ZP77%ZF0DY\[+<$D,;[U; )# ^L"1\8'AQ M*4()RDL0:B_AP"K%TV% ="MWV+A('K8/3^<*Y?'B:NKY8TO-B5!;= (?VQ\_ MS(+3?W5\1,L$3%>@B#H%83UR$[ZF"9^2H?G8/CTMMD"!X[4@MAKA6SH0KZ> M>)68_N8HO*V\<1B7,=!2C3V>W_[O+^J1+MYG9C7FS@CEPPQ M8F_14 ##_B[OH+/IJ=0IY\W,^M4%*I*KI;OOG6KFIWP'GQS\=+ KG@,75M.Y M81@J?(SJAP,5;7'7C_-0D_F@]Q]$:=X%QQZI800AK5=@\Y'\)R-NH?@/Y64: M,C]3:0L_CHH B(XET*.1?1TC+9GBF(*YF1PBLC@2K_>#Q$=:>!P8LOT$*D&^ M*$;NC;L6"/HH9N8A8J@(\[06T#PEMG@#7^[U81KA*7@\8 RC(#$*B%$(-@+J M0B8XPOM\43T9@CV;#!A:NT0.?G,M4PR'G/42118N\K?3;_(H#'ZH<"34 \Y; MUH<7+9ZC0T=I+3L/!Z;@KH,@(NT,5ETX0NH#Y+NG7X&9X@7T73%&K'\BCEAX M=[P2#&X)2P'VMY_DO8*H'OGF^\&0J)1JK]QI-,HQS >.8=X%1AS#O%LCQS#? MN#5R#/..8=XQS#N&>4?5O:B4-U>,'<.\$]MG*+:+,\R_=PSSCF%^[*X[89A? M:Q33A+$F(G?;".TU/,);O.I CC!HFR4X4R:T"G,AX2W\\< H_,+/0R5D6G"I MML7G.!'7003_?4X5<*E(X=9X3=:/L9P2HYE!Y"5<7 EWC/)!!R8+],D0F=4U M[V GSP0&%Y$\G"XS568XU>5/##,XW#_.,]R3OI =<$,QZ G/>8@#6C->XB!- M*CMNB^]\9]7^F3>G=Y7= M+L:VZ15&0S4V_HQBN7LP?+P5"(\9__Y$E2&%NWNPP2*+';.E ^CXEG"I]3JT MEAVL-3Q0#S+,,>;;%F=S7V=\LF 8GAQ2.A4?5?.>39?N2OY",YE6PN?,4CHR MI*4JU4=*^6"I)TH0_I4] M*I/8D6 MP7L\!!)>8[K(!=U"@^QO0)HJ9^!184?!/,/#/QT<5,XJ8M_@YBK%FD[U3R$%"FO-/8S7(?"U\-8CP#0 19 G$I2^YK MH@Y.8H^(MS$Y-Z1D RRKEGXF>N?SEC0V<@H'($5^D4NBVV+];THW_UJ>*J).@54=*^Q;DC :GO!PME EF;\Q=GGGP54#B MJO=&A<^VR43<1^WW'\L/'1=WK9AOG(O[$A089T?/P5BFK&BY]Y\GP[L3K"8( MEG6"_,K:ZI.X/11WIL>'2A_0>@!M#(<_'-XI2B$:A2B$:%R!4"9A!N&[VRQNL\S>+%=\=J>BIR*5%":W1.G*8ECWEE _ MR0[ HB&PF]DPAC$[L7-BMT8=O8&&Q07',J^K<>.3<5+X!W/.&;?CW(Y;5X,W?\7.JB@1#*8(PNC[R8JGHSSDJW2+1CCIMT\O#'1 RF+6Y5 M%X.0,8P5]L=%$1;_H1 7P.M'%! <2MA#*E-)*O)4^3.LI$H2JI#(HV,M36O, M!ZXWXL4%X%J96"=6X5>9M?*#U,M!>?@TN3K>675S?/:O.&%AIC"#14MQKG6A M^Z[Z]D]TJI5VEM"LY??XEIZY2VHGM M,Q3;Q2NE/[A*:5Q M"_+VO@WQ?V6XW^B2/*J-4%Z F*!4EH? K3'#:\8$KVE"MU78"JQEPZ)1OK:, M7E9#EC+2B!U4DY$J4-Q@:E(X>\B5GGWY@' >5!_N*PY4!ZD@(,^Q,I"!_(&U MM;[*9!!BH+2::R% #JQ7Q8KZG"H,$P6:B<+26,/,+P(W!U_X!\:OL6(DL)$Y MNECA;(+IU>H_>D(Q S:8Z+,J4?85 LG6 GSLI?#6%*_D!&I+Z _B).!*'E*!_$RH^IZ+R01P%V82\:,RRM"R87#"'*X9P-L@>56G"W4_$W=^^ M;PRK]_VB6+V;6/&G[> RKS-]:[F*4Y=X7"+Q>*>1C(I<8@AOHUL#4) ;F0I"O@KQXVNQI-@ M?HTXO$6],*81I+!I$@W$#P<3R>CX>625MG(6O7*8PK; M'5Q-\88"ZT6*K%W M_S^'^UR@RH6LNHWOF6X!5Q&R<_D_JY'T4DMS!QI9O#'57Y2(=%1@/:;%27%S MK72EB\N^53Z$R^NZU<8,R+:XP#W&K6N!?72@F>W7WPFW,7R95W;-K-WQ7 M! MM%-Q+;,D^/FIX2[#_5BM$.,;EMJ+_3IXI0/=W8I=CVG>Z_'Q3_K0\(>P@ZA+ M^)6_OX%W7ZA Y56Q+;S5/+>HN)+X<2FT>1W=>HUX\^,L'L.2,7@IK'G>+V73 M_D03_FHQ7N>= M[J4M;99C:[/,UL"+*^!%TSU;X\UNZA:HF?Q9Z:+#I1.*KYZN=\D9/G(SO+BZ M.'HW?T*7+]UX+1.Z+I%=OD+,S?!R,_QNA1D^?14'6ZU2:+\[G3^G'U>84V+7 M??%SNK:C;!75^SK$=FU3_,%-\1*:X:3]80'-KUXE@9.+H_3L3F#@7;\2[PS^+ MV]\JNZ"(KIXL%,A[]1$+?LK2A&/:Y7#$>9/Q3UO UQ)?7H?O,&_>KIW N8W:<(%S.W75B7,FX%I-0.?7/S]B+G MS?D3SI]X71/O)-Y-_.N:>*=J7.CB1^K ;-/&90?PIW$O^9PD^V+ZT_B.O"2N!/$88Q@ MLYMZX=7AC\X_"68 [*G(&Q406AM#'IW!IUF]NIA,!E4J^=WB*!R)H"L0W)4P M:^$V7E_""R!]7-R! 3S@98EA@D,D/,1CC+L%6&];&) J1OA"1&#]YG"/*,X, M=SU![G5ROZ=VQC9F)N3,RW)+#&U87@&3P##&DF",B3DOE!G!RR(\#\+5*L73 M8;!^*W?8T;LMH:J>/U#5PG'KMQ_;'S_,0O9_==1(RP1-5V"K.CUL'QZY"5_3 MA$_)VWQLGYX66Z !5L0J(WP-1TBV((MMPO MAE 2W,.WE8.@P6:\L1B7,=!BH#18N]OG_=7E6@WKQ/S>A-GY(\A^.PM&@U@U=_E M'?0T/94ZY;R96;^Z0$5RM73'OE/-_)3OX)"#DPYVQ7.@Z-IUZ*6"K\\8Y6/< M0QR2:(N[?IR'FET(_?P@2O,NN/#(52,(XKV"UX]L1!F1'1%-NL;JSU3:PH^C M(M2AHP;T:%_$78RI9(JC!^9F1-Z.\92L'R0^LMCCP)!^*% )10&/U0X$NH!YRWKPXL6S]%! MHK26+HA#4'#701"1*@83+APAY\((WI%^!3:)%]!WQ1BQ(HIX:N'=\4JPKB4L M!1C;?I+W\.9^#JL3@_;N!T/B=JJ]Q<1<2SW;HT\=R[UCN'5WXHE+>7#%V+/=.;)^AV"[.*B'3@L2U+3[' MB;@.(OCO@R6FR,<^+5 UAI?A_\Z,Z+A\H.W.)+WUEE?N;5Z65EMXO! M;7J%T5"-C3^C8.X>#!]O!=)CQK\_45!(\>X>[+#(XN5LZ0@ZOB72M)>O0XO9 MP;+" _4@PQR#OFUQ-O=UQB<+AN')(25/\5$U[]ET\:XD,#2':B5^SORH(T.W M6M)LUE&LYOZH+9"-<^Q7='NPKS)%P]!T) M6E$@2T)NPZ-L!,B4C?91R#UB\=9\L>8%4*9PK$0.BPRSNG:2GLBCM4=I%8Y2 M'!]NE,&HR1L+,%T&DY1)IA6EL+\*NR(,NLIZ#Q!:+DA]I)P/5G6B!.%?V:,R MF1T)YA*\QT,@X36FBUS0+53(_@:DJ7(('A^W3XR$P4S#XS\=Z,]FB-AXS9+V MMJT'G92,P6,&U5%;W*I>#L=C#.)R+2,XY/&U"^NI07N&@_/6<#&'AH*CM4E! M' Q2=AX&G* "&ZI'BM/.YG5&],_+/(&U!EULW?.LVY5!DH+^S1[CY$>+Y 3E M8L&::Y#G9!!_#D PDSD_X?6_8 MP+!I$[.1<+?V$LKGI>9%AA21PY+P%$[1(,R8Y!G.8?@V[>9(*SVQO-)+XA2S MBG3_!V2+!KV"AS+G%END8U (X!##B0LQI0CND-CKT(E)2B4,!D%&PE'E%&XR M?_I1^^AM^>&Z*-2)O?Q/$_[CRN.F0M?U4*B_/WZW%0KUH^'"!.J6;NCE 1G: M+1)R/(2[23P0/16I!+:K^9K,$MA.\0">Y5^7U(S)-+F(O)_-X[_S^8E_\7R[1V']S'9/;?2+V+K ^IRBW?$/_ MO.$XQ[Z0.3BSB>X=\\ SIGMJ3V&@$B_ ?V*!E*<->O1"!O(/^N_DAT*_]/+[ MF^]W9V_^*HG-^MN]DV\GVB@=\0 =S0);H4/O9"7@%:780=P]^CQ/P(O=N MX]_WWURA"QK1M>,BNL=N*\6!4O2TBYA<$(F_7-^PQQ[0IQ[.IG&"TVG((RE2&(Y!"-$;1U\7Z]S2K&J/<?JQ58F+K7;!6/>7GR;/UC)RK MOGN!_+M$AX<$[B8&97=&A?=%0B$5\&X_)/U!D7:Z]IG*FS,;=Z[]BI/4,NQT M"L>/%$8LO2QX8%5(^BYD75>&ITWB]R91)+$'A<1>19@G(5EN3Q?02FZ]D(6C M8[V.:RQS6&.D&#.2W3RA+%-9(X%)HSA/1#\.*=UC6RIQMZO06TQ;8LBP-^KG M,,1F'_Q%?4G(V'I6TQ[6VA4Q]FL5Y?4U*/;@6P(DU^N;OI\BY8#!%Y&R4@&5 M(='RLI//C8[=GZ5D(L(-*PTT$X%X\S;F[?,(_1A,@LMJ?@6;EM20'2H$3X&% MD[A+.D%4)!I)07%VF(L4^K"8(3R7LHLZI4,.%ESFJZ&*R+6B? %E.RE/ATU3 MUNC WFC\9-?/;9$B*5ZCDNN-P%""B54_E<=MVQ3JJS:GX<<&Q8;SG7B1KST$ M^">F.G'JQI.=9'REF\B5+]0E=>RZI%R7E.ON6$M)J.N2>I%KY+JD=KQ&KDO* M=4FY+BG7)>7:39Y_NXGKDG)B^PS%=N$NJ>-#UR7ENJ2>29?4$4&:+ES*?ORV M/J)[@U7:%Y_$W]3(JE*"3^5 P2JD3:QGMTK&K5A?5HQ^6(R>XJ CD\K760,= M1QT[S2CFAU<-$+L:#H)4Y*G2P%=!U!8W28#YJB+"ZN,+<-%\HKHAQA,Q_%L. MP]/),S^GBJVL'Z1%Y''L1Y7>#FS/T)%%"K_\>#(W M]\0VC?:TX_Q9OLXUF-A=Z64L4#6;].FIV!D9SK$IFV,?S)6JXZ/VN^W(U6'[ M\+1V*>;HEZ/VT0R#J,$#_Q4;*,4=?/;FGX$*_49P*MP3*!]V')+"%2S:U.L( MG[)#/*@(./6!"KR-R=I0TG?$KT1M>2#5V)XV*C$#$]/$1ST$NL_4.B7PX>V) M9:WLF6VF;XYWB=_I&[ UZ^RNM$!F$;H'6 MNT!EX,8F5>BH+BY>SIC]A M4#QAT3"4?B#*6"/%2<7>GU==,S1FW9I-K)EMVZ[!HJ VM!G+56\/'C_5&M1# M?(V+N9 %;V+\)J5Z>CCH+5Y*,L_R<[._V.Q_?-]^M^JLLS7G9GCV#!^?OFV] M/SU>7;0=4=LBD_R$^3UQ$SQ?3YS^>?49)CO'S?"ME<^."=B36[6%YSUULG12>OPY/W33!8W\RM8,2O; MXI,!(#?IV[)LW*1OU-@Y:G]8Q=QQ2["8;7.\!MO&S?7LN3[Y>-A^Z\(LFYSB M]\>'K9-W'UR89:,&RH=9Q>TNSM($:\3-\*JF1R-[,5U?P6;["ER%\I9+\#^X M"=]J"?ZIF_ MUX2_GA+E9DRX4RG;+L)WA^:&B]%/VF]/EPUZN=+:^?V2NZM, M_^!69Y.KL]XJ]5.W6C-6ZV/[Y/3)"[:%JG577;O1+;?V$G:G(^>5L-L+" OS M_NG;<.TE[:_5"JGOUERHQKV^?W,')>\GA6)?SNI\\8O;C!+W#VZJ-US/?NJF M>!L%[2Y-M=F*=J C/\<>$:+U *3XUWN=*[Y8R1I]:T?W#3OX.: M]O'(E)OV!:=]#47MKM9W^U7M3LWLRKIQD[Y9@^>MB[0TMZC=.5 ;+VIWL9:M M5+6[6,N&R]J=KG#!EB;,\#3;HY%5[8YA8BK5QY1UYJKVHYFQ@P;PDRR:UQ3=S\G@S 449QIUGD_]Y@6HAAK'H7(M!,CT<]C MD"I#QC/&A^ZH51:5H1J.IP6".NV3YNV&^C=9:H/\!O\C,AK9KC?%52:"5,@T MS0?$:R4SPXI%5%/PG2>3!.1>Q'F&=4!)' ]$I@9#E4C8X:J@R.K#2Q&9"KU7 MUD_BO-?'']GW8R:6@'=)-T[H2XO294CTN;#+Z@861^$(W@4>*!-?A%0$"#_( M%--WP>4PK# >P?4\*/A-%//610:P1'DRQTMY'(GZ5QX@4XSFXH+A#/*P9-LR M119M\3E/4!$(7V4R"$$M1,4;T^O2XV!@?# *7V:R>#D_R7L%2TT*$P*_8:WS M$/A,4V.88)O#0,/BL53-\S1V/'L[$:??ABE5YO%@/H<&.'K402A'L'T^=8.? MRE]?3UR53]N1GR^R'[9-4%]E_G9KU,0UJM*/NS7:^AJMP"U=B0!LG2M^"N)Q MC7UX0U80F"S_(*IW*QA/H+$VIJ.X MZR)Z:$L&I7GAF8@(&$@:1.M#_/JR+'>B/R'4^;7\H< &T[USY" _S$Q:: MGCI@NUEV,Y5\DN&C'*5:R#Y\:!^7%@!_=CAF2:/[;MG,%0^>GUGUX?5G<^SS M2IBD^H"Z7[K(\N"3]YV:?%V$X/7PU^1F7:F6)Q3F,D7[3^ M,/1FWV>%T2\;05\N_O2*9.Q)E1/-@^%[@EQ,HXMHGY;=-:!6X8P&37;\I[E" M1.NTR7;N1G1K+Z^6%@!26)AK=]91ODC7]MO#.>=.I9P*U<++KZ7:PJGSI_\] MN[D2=UF<@/NP8FW;ZUB,)Q:VG0TZ ?Q,G,>13X=*NF"-_3VT2;VT17D1?F?LU)[G9&HW;&YR *TK[RA88L M=5[*YO?&+98]WUMESWM'IPQ'2$,XT<2V:.\P@+I.;>%Z9($C_."7]7#C_8]Z?O-QL#?[9'XM/ MU*G?YRY3PXFZIR)#\79^AN+]A_9;A_.\49SG0A7@ORL<8>=O;/B.8HUR&CLW"08;G(>VFZ7X^Q?N8KS5!3+O/V$/ZQ_I;W-8^8![N^%++;E*L>^D=FQ9S?O*5!YCG(OO!\2VY-7)\2PU;(\>W MY/B6'-^2XUMRQ#6+2GESQ=CQ+3FQ?89BNSC?TK'C6W)\2V-WW3+?TM(0='6P M=MLBM:]!$-*VV$24JFZ[M:?IVF?Y.C>&^7TV4X/1$NL!-:P'('Q&L(8TFPL# M&YHH\7'[:,91U=QQES*"!3QQ!"9'^LFA 38##7#AX.SI8?O=Z:OA45HW(MDJ MD=:/)6I-XH>M\^/?B+ M#,7G %2RN$CRP1-W@YOH^HE^=RC./?';QW+7$5(3<&PIS<*3FE M#,F="!M>CE_S#GJ6Z"V[HV C,_Q%=E0(ZE^^ Z=;^.^;WK)T'T0_R>R$F@ M0Z?K=[0HZ.D*.HB=GM_>1@B&0Y6TQ-[QVWW!#O'2T1^G^]>Y)#S?G"JD+KB'$L(_LC3+.B. M%JH3.=YMG:=\N+(QVKK85%10K5&G=IW6)H)L^:1!37FQ%/F_'!* MZ>48A$*>9'V5")FF*DV)-E-&OO"#U,N9D>8Q"$--MBGBR%,"KA=IS3PDR+R9 M*+Q'*B3XE=T\#$?"5]T@4GY;W$CX)=P0'I7CTF9]"0\3C_T8=Q[F9#LR\_K\ MP(ZB.RM?Q-VN"*(LADM3> Q<>Y?%W@_Q-Z6&^-CO49")O;N_?9]'K>NV^(SZ MNREB6R)KZ18%P*D$7UA&S9J58@L1E?28] M_D-YF28_EJ'HRP>0+Z4BH>#1 YG!Q9V148:FZ#[^!D>CAW.CAF.:]#>^&5U3.??*R MRKGO43JI4#?RJ?C/%7-O3=6<[+J\>WU*4TM1-TY$(A\%JCLTQM-6G2Y-R>@% M+1:D?=!;?'IG9,1V9(I&: 1*#^XU(&V(%SP$/NO/HL<4;Z&5Z50>^Y4= ^T' MO/]EZJVK5Z>@Z=.LT/2I,S[6;AN7FZ:!ON[\8=<8L_]W+C*4FH'*^K%O.W$/ ML%@^60PHY4G<@8THX!=X^(.$*30$8.!Y5WI9GB@G;8NTLJPF;#MVQ58:-9JP M$DS$$;??HY"EH%"],/>-Q:HF#584OS!(R4Y5V$[@&G:>6N#Y]3B3H=Y8S](AV K?2*K:>RX MJWQWD,2/,[_'!QCLECK/91PHM.;7C0UK+NB"FH?=C08@H?^/SN&C#W, 4VOF MH3EO-%;VTQ^EY.($BGI%@+OY24V7S M-YGX$9S(3C)W)YD?7Z)D+OI24R7S]D$8L'"=(YP6#B M9'.+LKE@^/D9R>9* 75+-N_[@?=C_F&^9 31^7&O_\N.9)I?/C;-F, M,Q5Y([%WEJ9RM"_>B*L+)YK.D6N (W>+64'EB[N\DV:H,E.4SL$P3X(L4"[< MX([UW1[KWZ, B_B";(0%2Q=QZLYT=Z8WX4R_"%*JE\#BTM]NOIR+/=WK-(R# M*-MW4NKB#4V)-_Q-)@@9F7I]E;SY'J<0N8MEK$=.LY1QSGJRCK-A8YSU*V1 MXQQMV!HYSE''.>HX1QWGJ"-O7%3*FRO&CG/4B>TS%-O%.4>+/EK'.>HX1^O" M))OG''T9L<,UHH^<-@](X4GH(Z'LQ'DB!G*$H&!IWJ$&]RP6'F$M"1)^"T%) M]A*E ?3BJ(A*C@,](0*#U>KHD)36!3WT]F4A*=WEPV$X0ERO('(82MO:^V]? M#(:2 >PDZ+=A$GMYHL3E3R_,4S@ Q56F!JR-SN/! *Z[-AA+]"%)7P#O@1!, MJ.(L?!@TJTQ':C>)!P4VZ+]R&&0W4#!?_/,D;8N[?IR'?@FTI)5?\2/0IRFH M60\Q1D83 X2GSQD?#D#K6/O!+1PU09.DJOS4 .$-8%,)L*FT_J:!9R,AD0]#\V@1T MX#K;WK>,0_ M4%&*.QP^@3V8C&@O!%&.FT.U>VT+.EC?L=SI3K"W*M@-!/5=Z4V6/Y(,Q+06 M/1L'%=&HI.>!E&']*D&8UL&AD@ZW0*WICD&:YDH03&!8?#/V0]3SJ/(+1$(G M]=N5^I<""WR)0A3&&:K?( *5'DPB6JJ?7C ,Z)^%R,O!,-0X?NA@XI\D[OAS M#?W+PCTFN4Y.MRNG+R86 @)U<5>B^AOHU"[(&&O,-XD*%<&L@OP9M6DCJX+* M#$"$)YT#)Y/;E:I]L7&/58COW^YOA&]1/J*(8/1=[R_ MNWSSZ]TE2!/( ,LG6;9.96Y9/-^_$/'\/ Y$;81O0'+W((.01 ?Y)YH#.,VX MK3#J^POOV!Z0%K\EB4EW^ M^[?P4O"4R4?-_;70/YPS&<>'1X?SZ&BV5^-UC"B'KG+850Z[BD=7.>S6R%4. M-V^-7.6PJQQVE<.NS$]AF*[>*5PV]=Y;"K''Y:Y?#:-[L) M+I:2(/#_,20I%JTDI#A1[0A M0#"KLZ)R:P_S __])AA__-.8O\?&BAOU^/"7FL?,^^6U3+&RN!CO5D9ZM,I( M]]NBLB3>CRA^#)7?XP0+I:*9G2X?8G5&E@KU4WD$E=-B_KE"(+U"( VGV/@\ M<"2]AV[X%%Y:NA%=E>9#E:3*QT)#W "MR@;X+SD8_F)M@1974=4QW0I*U>LB MJ^)%<4A$MING"JL TSC"@Z$E?%#7/1RKZG;C)*-KC)0J76*%+T6DZ+4OV1D) M8V:?')&9?=2FI=G(%GTZ2\F7R[^_Q:MZT]4?HY_37S-ARP%OM CU_8+ MS*I M1C-]R[#&.AOE]2,$XAJ)+ &SLPN63&KL;5^E7A)T#$=LG;FVM\;2!WZ;PNJN M<_)G[9?*-EOO<([FE&'PI=J6QM-PJC5:U))0Z1*NSV6W"Q=@^?0%&IAYE 4A M%9*&BO HK=IH;<.:%]U*?9/3$9V7I".XF-14/ M'CV;L 0Z5U/R&]B-Z2G D>-AD"+=0&$H9#%3BP5$5C@3\7G'! MH8F-V-WL<-_ID<'I6T!<86$W#MB4V]:,#DP)&E?-8%IB+]B?]KL!S"T73!8S MYNO&>5UJC@\M[TMWA1NV5=N^G;E-FGM(8-O-<0#Z:%3^/MUQ+X!A2/M>8_6/ M1I>4;9][I-QDFL9>0'CY1?>HN62?']V7<"H3("GYS:1C:$JR1_S0J#48A1$1 M'9=LBDET7LZ*%8O>#M$9(8U\83K1;)\??A'2&IUUY'Y&HD MDOIM^BI(*-Y7$V1<=1^YHV0>1/!A#4;P"J>)O^O39$TO8H?;2* MGERV._V8SEQ)KA=G,4 2,)0CZ%Q*J:W/3/1^<>AZ6(*0#+AC%1;)RY(X"CPX M,M&RF%$] /A9ZL5# M51[83@UOQ:)7N];!ZW@++<\D:F3A@;03ORB(E21#TVA:8]6!-4E) >,X4^M, M11-32[ELD.7W60]YAQH937S"8\'I&N8)=B>!C@N#09!QLVD,JH 16Q1A562/ ML1@IF:06,E<0!5CPI:_3*"X;F>>C=PN]&'DN,B^YB]8[B'D=7WPIAU_2(N Q M=B:H29>F\%H*5X4#*[KPP@KEG'6[(#K@&+&#Q=L%;'=<@-1L 3Q1BO:WEHCS M# \:AFI@U6Q &J:.J%5J^S[L:;CR/X]/#P_Q"<*7M-EXU>/M-!H[]=Y]">J= MJCW0HAJQ?%&\8,0!34O*N^#T)1B823-3UQ'&F" )Y:,.AD81!N8I:*I12+3P M4X1T:KU)4_H./[B$]I,3VL4D(^Q?P?RC*Y*KF#/C%>MX7$TU6<'Y/Z87+""5?BU]SOP6=W M^6" A7]3\[\-BQ"/S=\.W86.@OG4%F2&%9^F8I-GGI2**:9TIH8]/X(?MTNY/462Y=J-;_\(\ M+RVJP*O,& :\>&(KKBO7&]3>"A\6^,;GFA.\XMJ'\7L8"U_FL/\EZ598":G! M*/C9ZF+0TLDECN'!DW7]H;MT=JR5J?KX2L8(\$S1.:IX43 M;7O"J*U"TX)NBO,LI!KHJ9%[0K7"P%DT*L+RL-K@TAI5JO4BS),"UIGX5A2YVZ;!2]JGID@64U/%EIDMTVAB=*AJA38' M.0:P;09#3LLB&)&'"5^SH%/.+9(=F+"^M2.V,DA1N&+TAL?HZ3Z;WV? M,9=,41;<^E[HS4(_I8.F,/'Y6IC&!%V+ I2TR#8[4=^.9G_8M9BOXS6NNF0N M6;$;RYX!=>P'Z3 '[[ EIMEJ*))Y9*X3BC&2_G[".5<5U@E> ?V M/'"X^OJQ,N(PWCC5UXL,'+WDOH$EZB-SL. C;[1 ?N(,-@!HJ3JYQ!M M.O:&K %Q8W@+CV;T?1YD2-X8'XZ:H<_4@>B!V:.V:TE SH_.T"*$3\)AYHFF=9BT!*ZB MYJWFY,XODKP'QZ9^NQVFSBL]L/412.[DFPRTB#V$6^<&]'#$'0C-F6$>XX%A M#O/'5-]N9GN,*K*NF;HMT(I+^\%0LPEW]70?3+X)(P'HU6A(D8$A^+$9@2HD M&!<7-V*OH(Y B*O#_0V08:PR](! %*98JDLL2U&ZX&$V3$::ITZSS'APW5ZZ MSSI.AJ,T2$M(!ZOM-1%EF;5N:I%9G(P*I]578.RG6<(0>.,=^.-WV_'<5AG) MBG":3!*)\UDD5>;/:IH'&;<1I[++46AL\._+?\O$CW.N^L!8F_8%%L2\6,^1 M6@&E//I0?X;21T&$@+2?#HZJ4+;"_/_;]^VCC_/\!1N)\W!Q_Z&13HTC,'$$ M)D-'O. (3%[5&CD"DQVOD2,P<00FCL#$$9@X)HA%I;RY8NP(3)S8/D.Q79S MY+0^$.H(3!R!R:($)BY=MYYT70/;EIZ*[9HG7E^FC-I(95LF](HQ5AW83TT! MNC\M@]&D/-LYO\EUY4UT;'GG:,^$8V7Z;V:.%$M1BYX6C.X'T5AKS3"ABM6Z MLAQ7>N9*SQ9.W\^40HU]9V"500P37^.E/(#AK:'9^$<,.(?2S3UHE(X*HF"0 M#S1X+(F_^NDIY:?B/X]:".!322DW*)O\-8X.KLP&O,)7VV7.7D/MP=P%0\R6 MI2W8_^J@"THY[.$D MQ%M= %F6.Y<@6[M-_=($@!RF!!:F(4EA\H]._\R D;#R/I5/\SNT*[T6=N4J M%6Q[*AAFID!H9) ![0E-. ]5+&EJ+,/Y%N_2J)Z(+]X5L*PJ8-CY($60.\+L3*C. M0+?TU;Q%L<1M<=6MWI!X\>*,I^D!\4>L"A%M..CNK'+ L)=!QJBS43&>(95N M-:&:!&6GA2]LS0_MX,EU=U;.-JRSKN]$,#F9AI"$&8(I-&8DE>]GB+Q35=8ML"N+ M MQ4UXCX[JR[#+EBX7J-*KT&@3A6V=UFGI3@@']+QX7_!TE0_B7RJ^U'Q?UD7# MOH^Q/-VHL](L*RXF./,1WFD*L FR6SP@P'JE<+)%6MYN06R--2 F!#D61,7) M97!1_$E'HN"!B>V#@V@O)NY::7MDK)@*]H7!R7J[U]UO5 #0'O=GM=N@WW@/ M.>%Z8!LK3RCQEF#\Q*#X=&40LC="#%9Q9!#$BZ6DLEFIL>^X+A@7W5==)L4R M9[#]>VJP"*)9-@T1;,5YZ)/4EKVW8(5[6$=4=: Z(XL%&?V1H18&1(3 (]R MGG,I]0%#H6@S8:# D_=3@NV!=W8(:PZO>?$F]"GP@JA3B_B(H1NFWM%A 3I+ M34E@)N2)LOF=FJ2Y>-@-8%]J"=Z<-5-I32,?<_.R0P62!G;U@G;P@X14E>5W M!!'8_RVA.>/9Q&L12H#N)!O7E67?0#'"BM_4,.!4/52SP+?64'=Y.BT"DHJ] M)#(L8IHSWL1$_"I.J?0Q!< M*P^J8D?,IJ69001ID'4UNFEJ.L(+02SA5VL' M.GDLVS!\*'6F/SU^Q .K"#FG1622_6A+"FLGQ)A=\6-4-1>\EG.466690K3$ :=6H*LD/0NKUL7D6W'T_9^?% M8/C6GS.3&H,"8,5&JS0GVHS)DQM,1[#&=Q6A[A'JS%@T"+9#B4/S"+]+8V2K M*;1I[1MQIV']RTZ.>I@HPO*HJI-IN,L6 Z45!1R+]<01>*;#4'H42ZD2?=8/ M*X[X6OV4G+&!E,&;AA&S^V"R$DXO;$4O]%^(7B@-B%8-*"T+;>& 8HXY!L,3 M+7\V00(Z^+O;F+V8&9*X*466NQD M!*<9@AFR/5S-2.U;5F7=%M/GDSXOK&.JW-4UR;GQ#O>Q+%BK0%TT[DGY PR3 MAMPG3QL9CO D#HM2@]WNR[@#"E%JNBCRO;B^*NX@.+ )GB'%B$H,[;&5E*R! MN"CQ!*PY\D#AQDA/W&-D+"JQZ>4A5^;(/.O'"1@J[G!V /8+$Q+':/R"0V_A M!$]CNAR#4-79NC*OBZZE3HMT9=JGW 9O\S LTR$!Q;!YL\BT@C!IF0!V>A-= M!X/M2/F6PEV 3P,BCXR[]GU;.G&K4SUL"AA"7GXRE:9I]\2$+$P&A(/GR/*( MM4U+Y6H6S-!,Y#3:XJ(R/'QM7V;2RC?%=K2>\[<3WLV>+((G\R,R^Q-X' 7N MAHF0U"(!5CCU-/OZ>"F#5DM4T61Q3>)O,-U$ 0BI)QN+@JJZ?FF,;]. L_AE@LUEOI(M* M*B_ DWA 2DBQXJ5X<"4G6CORH@+*+% 5,ME7#RJ,A_:-Z%<-JU:4?DR\!-O>0V &ZF0N5O7 ,U!943@P55X'UF M =*'$M^(V@8+\U=@\S(">VO2BX(I[538GM5, ]!E.*ICS$1^+6K$W7]TTO;YXML6,RFLQCK[;)+Z\UL)5-IV,$B M/0S)\NYLB[-*;*+,+IH?\'5FH_=EI+W^L@Y4[K?JXAB3P0NWW5Q[\I)P!:L= MD$4GP";$VPNP M$ZLH).,<6C]^I,*0VHHM5JQ1;.>)T'3Q/#7,M#*N M@ZWMHV,F@TLY*U( C&BJNX))O1DQ*+T;?P%CWXGZ=D3]1Z&(^;'PPRONIV&4Y%/")E]V2SF95_LY)6 MU?+Y,BS_[>ZWLR*C9:7IRMH+BZ'+3N-I9*(BCPMS#L89/&K?M,J:4529 EJV M[V"&Q&HDP.ZS(5O*C8:_R*,#J;-H9[K)X4:7U(Z7 M/P[E:"M.S0MC;ZV3&?.PN]&@$X?_C]3PT8>9R*/-&;QMSF$#J>DK+1JGD!?8 M2A6;NN[B8$L4>AM4Q&VJ*7P;J4)Q1I2VR6BLA&4KWH:3P. PB_\"/'R,#B1AP:YDN,>V,[(:'7W D3EB=L(ZI M2^J2U_%I*K$95Y_.X'00(JN4;A'+64\5Q^TP\'[ 5ND+HU&(P8Z3,_";V8W MJ)!%2=:H?@Z7AW.@9B(SJS.IY)_)A.CY=)S2/M0KU:@)G_%%;>J4MMRJM4OX M?>A^@F>'F.:P@5 )^RKUDJ##A57&B?MH=YX6H\=?(D=U-CDOY3N<'!KY2//A MY/RCTJT!@__3_X*[^]]OX">S%PXF#(86AMSNNX9).=>Q!HYWKD=KY'CG7.\.>-D MHA*6,".6:\ R)L@&W;M-P0J\K S84J>?, M0B5Y=(';@C9E5PF2)9X*RSO6C"T='B,6H[+&)K;THP_ZDAD5Z99[%6J1^?'.<]?=_^<#3+>'IU MT:6VP%C$=KA3Q/*_,U'W0XJZV[;+"X* 4IVS>I M\**4C5&CX3"Y0 S3N[R#99G8/YU:9!E=@HK*"A"0$@&R:D[ 68@]S+,PCTK0 MV=G6BN?E2;J\D\W;]L5*R>HB<:,2#]&<>E12@:4(_\KC3*]MI1A=FU:Z_C_% M:EJV1T=%97]-0&=L;W]L'[F]O="JG1P=?#P4>U*SRL*^0N;0 !' +*)1 A,P MGS,7J38\4X(HWG?;9-$)/S[\\WSI/732N]!D'KT[P/HC)WN+3=?;163OQ(G> M(G/Y[N#HU$G>PK/EM-X:M=Z!D[R%)^NCD[SU3>8W;JULIV+*%Z(/Y?XZO5FOYPS0NV1M56=1O08YBT)JX9[5# M*=,T]@)J(RT8/G4P@%&I2R21@J>SW=R*:0>?.25C<^K@,VO@,Z^B# 6=.P%O M=*>' ])L6D[V90!I8F89\XX-RN-.E_]=I'$-O4C:J@79)AN&\O)#F3$J-_]A M.G0U+ =BHN2A5"V1)=)7![!P/U+['V/7\Q>1'"CS#Y$J+U$,^XVXFWR=%P]' M-(8*K#<,%V0 OF8 [,@72.IVT(\?74NF0^M<]"T^:TN-],.T H%Q@MH)"LR6 MD-0IK'[J%!/ND !IK6'WQ",99J.#;H)-ZW@5B'J4=E7"#!=@UT4V><]N(8-J M%5-AM-8"]:*Q:_7?UX(CN2VY+7C%G8-ZKNE%D/&R7AA[*B(NOPKP ]4+>7!< M8%%8Q(C04TDJ=-H6QD0(.R3:!F.JA-YI!G:7V7H4V]"X5V. DJT*?U^A@ZS^ M[Y+/ISDF$#R(6$KTR)IE$>TSY>IF!%#3JFBFCT7F88$%-N-HT J;(35N:,_5AC;L!1K$;U8)1#LH4XTV\YB2,H"))U( MQ=?/+#*/#6 MOF8$3M1# #-%J02FS\*=1[CV/NJ(B)'"*YQ^IV- )Z792W8RW1"=TH'\P5#0 M7CQ@[$P/N;&3@L13CP7.CS3F<\2RLH<)8E=I#*PQ@#^$( &%@^]@8[=)F_I8 MO[RO'JC,J8+[9O"SVC"WR'B1,?[@(_9>6B7VB'T(*V8>H0;#,!ZA\GOLQQ3( MCK2SSA2"BRT;S&8\Q/IZC2%MQ\87[OT3M15X85,=@QS?*C MX3QUE'7-U@1+Y=S>N9Q;;<[-5X,H<'FVYNG[YY-G6R;%1>)F8-O+ROGV#'G: M?AW'W026?"K>[748@_[=GK=/_ 95L]!7716Q-1WHMQQ9M.5PR)UUT:R7F08+ MA6\"JN@8:N1]'ZQJ#RQF1!6'2\$?0#):;4)J.,<>(^UC=Q[_*D3#&8[@_\*F MA5_FM/&;X /O><5-HOS+?;8'T%$ (R+Q#QB]?,]B[BK&OT_V*Z?AN,<6NS$U M"6Z:=X:QBB1!\@\&,8/X,K"OQ1!@>2.AZH')@6V^,*5>*(,!)? &\++P!SR1 MCKU@'*)Z;!)6MQ;F1+.JD_@E3M.G-M>.AZ;V*WXNNFO:*<$E^;268_U%X@P_ M1Z*I=;R%CDF .=_)3=-T@^*!0KO#>7,RF&9DFID!.1ET12BZ)'F6!GY9+.J! M[V/ZR\%!B:A4C^H+4@==[XBR%GX-\*#QB O!'O@C9_):%*DB*&0E:/CH#YF, M-BK^1:>K;_<7-F 3N3W@&+268(L#B1\$::*&8.EBFRU;B9'JP5TX)YJ0 =W- M0[S0BR/2U"65K&:219JY+1G12R.2_:ZG:;:3N;Z>&E["4-6V-M MCV986"7I*$5S'XG*@)RV&9 'V^)C=!O@Q<@_Q0>8<[2+35S$/2C KS,6.T4O MF'OMO_[CY.,O*66:B\Q&41Y3%C C#4:C+"Q*9S)@".X0@?:P56X94IE166BZ MVS$WR,NK3V'M50FD%DGX[D^K6=UT1FCI2.4]JM7 !/$Y$HD%9(R+5ZUI-/@R ML& U]AT+LSTC&MLK@G7 M6.XW&+5E^RMUU<4V.=Y3A&Y;,V&X23"FT-*M =IQ5'JGT?)^HC@@;+#!$+.G ML-AF48HE(BQ>J=OC"%X''_L+A]@PE$4=&8D'6PSN8!4IJ2[( 3>$#8*,%I\% MJ-MEJ-'QVP7[=L^&%^-6DIDJ@7UJQE244W?MIC%]3W0D46'B[H,A3+L'L9U3 MK7;E7OCK5&596.BJXM8M\CSEM#MJ)8857'8!E@ONK#.XL_,.[?4'=[X4:"$H M;5]T&=]H5F3'V5"NRLUN%2Q:5P!]=-30SU8NQB>V7BL:'<-%<^V M7&JW+WY]&?O"M-UJ03-=M\,$MP7_JW[/M!@>PS?=U22Z^I*IXKF5UEQGJC0Q MR+C\:USDRD04@HC0 3*1!.D/:G^M4A9;O;)EPA!L%M"CB/U2]+N,"@$WXHI& M3TA_8\7C,(1[DB^G15A,RG!+].-'>)[>&N6M,:&H['Z<>I"_,<*U,NVT[W:' M*P)>_#V^4S@'A-L+$B\?%*@2:"KHEHPRBH-6-$IJ6&RI>)HE7@IDR^+S@]MG M.5PP$GZ.X V=D14&M*UVVF&L 5N1X0 /RW\& M&=48F_9VVC"T2PT,!2R3?(#EXM>8N*@:5$.E,V\M[OE/ M.;*%\Y,B 58 $XN G-K;PNGK\/3Q&A4:QC3PM;3V2DS8R-SN1T!U$8PV8O+5 ML24*=%VQ%!J"@(&TD&5:1!*SE2U03SV9^*%*BY%BW,\KHF?@[IFPI_XH5::[ MT&DQ5WV]\&M\G0>S$:0:U(C3 G205M2;CC-43OA/I(!\ MG1K>MNGKH9>SX!S=5G)C$QD7YE"81IEM"S(1?6^"YW(..[S]BDM0T3:#;[8; M_%3^V*P]@7'V^*1]\FZ""00).PUCA_)/#D_>SF#L>'44J;4I@DV2U)ZTCS^Z M-6KT&IW /GKKUFAW:Z09IU90>L10M-1*K9FC:#(3.09U8FRR_Q#G!^>WYP?' M']Z='AT=W)XL3YQ;424[>/-ES^U;+[+[);&;(>_RBA'5/ZCDY8X/CP^7G43O'8I;ZX8WZ'?F4AQCX9OEKX< MT3V/HV[@<\S'B>U+$]L;9%VOQTJH7GC\?A%P+@SPG1S-*##:#EOA"@99O_!' M.]+[T4OB//+'/2 N#/#L"9-4'U#W2Q?.74\X]Z5$]T,RUA6'J&N;),#85TR4@?ZM!['X+O='NV/X&"F[$ JS% M#C:FU)TM9E4(=U_U D\3[>GF9E"U_!K#OL2R@BXEZT"@@ZBH_RV ]%*N4DB+ M3*P )0[SX:L!WFT8RHAH$(HD(Y4N8#N&WF5(69#65G\Z-'U'1+):K?K76/S. M?8"N/GT;">'G(D&SW@(99(ETA/ :O+@7P7=%)UEYO$MF09!VY1<>YE@0D03\ M+\WM#9K0Z^O*!HO:I1$5(8::K$AQLY8WW5)8P](6=1P5#+F7J$*5(\0TO#?Z M*CP[6 V#QA08/@JF?H#H?A.$7$3"@]C0=$A97;N3,VZJB-+<0PRE;AY2!]9@ M&*I,^53:4O\5&5_:8*%L(WS.77[!@,Z?((:?P]DW#$J"G5V78<_M5_-CD<:N MU,65LR[\&C=G][]=?OLJKL_^=GDGOGX3OY_=WIY]O?^G^'8KSK]]O;BZOX*O MOWT69U__*?YV]?6B)2ZOX#>WXO(?-[>7=W>7%WCIU?7-EZM+^/+7?XK/9^?W M^-F7L]];XAM=>__;V5?XKV]WE^9G7_XI[B[OQ>=OM_>_B2O\\NI.W-Q^^^LE M_!C^]^;;W=D74 W3Q_=9?+ZZ_PJWPIN(,[CT]O[J_/N7LUMQ\_WV!I\%G]O7 M7U_>GL- [L]^O?IR!1_A[\YAV%_O=[FSZ;4OOI_?MW"\]"XPU=;;P'1]_W(/ MKWG[[1KFZ5+<7-["9==G7\\O\;7JI\YI 5>VNT39+I55:A9DPQAC&L>0?$#J)V*?BN>$\'#BM$(KN-\JH#_>&G!%GF'";MDR+1^7 M)1.#O5A7Q:]CZ9L2B'OO6/IJ6/IN2_WWF?93ND:ZOBWB_1P5R Z5^+,(M"&D5Q^G[CT&BV7(&*(+SJO+[!+"HP-G='S8R\?%,:[@?^R3E"V MB5)ECS&=P;P-"QL/"]"E_\LE)1"O8^Q8*5JQ8Z2+$_?*Z_,L7.A1B#W\>DL$ M;^?W%^MF=Z/Y8R%/C35ILYQ+L!\4GFXI!4L8=OP[)*4P:PX@](L%8NG-:(536C<7-0B#KQ@[*# M\;1,\.1ASK8CY9W+L\ "6NO@OG@8$ZYU*GNN* )MUP^&MFZO4>DH2' N_:%B M$"T?9M.ON'^HTZFMCX"'<*\FBG4]M1U3.V"<9K##U?1G@!\PU+8RJXB ,NMU MVAI=HW7.!.B< U!CL+C4KUB,(X^R(*RH!]YZRM>O89:YNORTIC 9\*^4HDTT MN3@_NO$K=9MPB4U84,LI+&BB7%L1>-,';D A-%VZP7O4(IOC?E9S&*!0^0J\ M7_XJHOO L".%Z)@R2V/"F=CF27VAAP/_OVY"UC$H?XTD:>:E.!7,1-HC:8OO M)/_CGU?.;MCQ#XK:=NF@(2,'-XK^6GI](_\6V W]+&<-46H^K)/1YS/53D[7 M*J %2!OC,<<(!67P8Z9FH5 $G:$,S]G:A%Z-P.LIAX8BJ0=G:SA35-:A_&R: M)3E7 TD+_F$*U/,LDZ*YK<$N4##%H_W@ @4U@8(+L'Y@R;DD\PXLE"',Q!IC M!:Z$C@.!:TB=$9@G\0Z>N MWQ:W&J.+<7T2C0N#)V6JQZ]#^UD"AU=745S'C &#/6$LT6B"-V(3VY-)$JAD MMQ'Y!P6> .[3DDY)7.+I:%ZJF#_81S_@A77=-;XC1A[JLC%-2"X%=.)K_B4. M--0&",:$!-EAX1^^G!^$EDD1>8G##S$0=)U<6QM_5O;*)'"R AV:G89,8E0KO!"OETAOU2Q M-M)YLC"TLU2A?.1[#R4'%:WO^([D'P[H+RR\;R%,5F#X=.5/5T?M"-U65?_G MO O$==$[X,JI-R](SZ;8**]_A0T:Q),""=HZB?->7]S?7__WFWSVU)+G&U H MA$V&FIAUT>F":ID9Q;GEI0E'IL4H.]"HH"(G+L%&U [H4S,EJ-%4P3CS;$:5 M&>77*IU%A2%CPE=F=1OQ>OV7U3I= MV$KQ(UED9-67Y1]SP/0;&<;95@28JU0(\;PL:K-Z+ZSD.?'$%)J+DBR%_;_) M++FMBG1U5I4V%;L5**8'AG.OPG#/)G.V@;$Q]0,Z@S;#C;B"(<#IR4EPMO-9 M&O$JY-H,-(U//Z,B4'%PAF10LU5$EN@ ^@RD%6?32H@O8 M_)"<$WR.9LZM-G0^(H$CAG(K?3;3L37+HC(X(?!W!*_)M1_FB?0BU-<3TT%7 M/)$2OC!9F N)BF23KP9YDA!(+2)IFA6BC);QSS0N]P;BW5R\HDV%K'I$#&*? MBR3U^0@#]/8G1:B']=1E-A^K"G1G=G5S>Z M8I!:PDL@=SPYX_\78H(Q/ABK3D89Z^%SDE4]0&F8C,&H?^*$<= M.HXBOU)YNW:%I"@LP=$ #%&5J,J^*D(AG)G#A+&9)H9,#D=%G2B7+Z/%3 M< M2!5GC/4_*5W-H+68.RG:_$D-1K%0#\52&)'3:1@PO#"R(0O= >-]E.C5$6RS MOKU.YY"EEFJY!V-CG3QBS]D5/#I>CR^X:V=P\??8@3?(.H8M\#)!(O;T%]I; MW%_,+]0_ FL!3KD4MANI'%.H314OE(1\C,;T>[5.[IGZC^;5"F7"_(3[56N. M>H63B8AI$U[-Z"59!I8Q$(X=2(UP'L/8E [+85L0L,D M4(;6X6L\1+$,R!Q796ZE*$)IA(ALN>%@+1ZGPQ1WF.)#AX7L,,5?U1HY3/$= MKY'#%'>8X@Y3W&&*.W#F1:6\N6+L,,6=V#Y#L5T<4_R#PQ1WF.)C=]TRIGAC MTQ%/[<_XZ/HS:A(0=UF,"6==6'RK0-A2:JTS">]SAJ(,,/CLNC8:5F>Y\Y:- M=;S%]_I>"-%1V2-V'UJ=\*WQBI1*K4%9H95JJ288]Z!;17UJ0AR_ .A(%!;D M$S,S[C-XPS0S-1/%1V,H'%:Q$G&N=^)6E<2]"YLX,+3'*?Q0'>1#(B8."#"= M,GX/L$A^@[;M(=4#]\V7O#5+T!WT4$:9H;5$/$PJ)ZN_+B FJ?B[$8 M=S@.(H/!#V-&7)6HV'-%Y8O8XY8=C;;%G NTLTL1!PG)8A"._1)=SL/!A&&! MTR_U_>'27B('IFK#D\RN,+Z!"$YC? LUJ9SUCH9DCMK="=ZPA1HS_&/_7'&I1IGP],?6 Q#D,2(]"O&L!-"#IU,A3E M1&R!=NUY4O;KKJ5LE5'_YY$6-"_O!!X(3YRU2L%C8;._*H1OEL!5*X2/-V"@ M'+U_MY I<+X9B_QH0:*G#[M\]5^P7,QM];6?)N>[WN?+;_+C#6SR;A+_FSH$ MS5[?=.5>->]4H'#I!BQDIRM\7O2DT.;2];WH56H_M'0\/U89T] ^.Z637=_.^U[&^SX]%" ^"$,$?LRC#'\$A8U',^LASKL4MB JBG(][JZ?$!Y$BBP"V(G:D6G@<. <#MSBE*%3 :DQ&YVH;IXRKB;J5JI=L H< M9%:'6"TT6CDEPX'VNJ3^K.& -@6K"I5%!D#$0-(IYH%8)3IN$]2O2,)E3B%+@S M!4X)$W@@Z,H0'DR8Y!503GP=F$HJO=%%$$CF 2MJ-^'+]$'KKZW)N)S#8<75E-%*L[7R='F3*U75L&[N-B[R#A7Y2$_35FU8IIP_^FP"X+/>XJL*F ^M'KTP,O7&7:$O1+=QM&-; M$K!+-!8A5R/R4>63QE.&=^RKT"_0VI"/X%1Y5 M>3ZQA!''GWDN41$9XD!M<%4>SF]++$"/?72H8OZJ12Z6GC/4% N2XQ M9R3. MNDAGR410='-XOZB@Y4$8>C%020^G'=\\MJO=X2[D NGD'[9=AFRPZMGK(*04 M&I3P+,:DJQ^*YE!LZ3'AA#)N)%R>^#P#;8'!OV&>(*NPA@.LE>GFU"@7<[NS M\F18.TF<"@*[8D'P3*$HX4):5:-,SV%*JHBO4W_+4F \@H*J T$&$>K37(6L ME*I+[H@D #&5H /=*E&@R'4V_VKA I9.R>GAGXW,/,3$P*4%6CO;/'J7^W4E M#TL'KO"P2$OCJ4IX6APJ$]H0<GTE"?.?=\BA%A5S<.!+OU.!?%8PY^T%Q/KF:CY< MS<>*&U^&B#EN[5!D(RPWN65>V.(;)XUJ=;JG4=[0*.\JH]QAO]U,I;9G@+D- M-S3I(!F.TB#=GVF4-H:3JO #DJ:$A74^L=T0%%,#(TW;:KJ(5@XJ"^<;O00" MI=9' FS8AKW7 LPE[F#:%JOB[HL#UO0FDR3W46P+71(0"C/!%5-T@I6L:2TN M5"P8:-,W'1MDC-*+/AK6%D16<;E-!_T+66=T+;(A&7(% W6=4*!#=[ESB"7/ M8*S_YGN8U^$@BHY;^!1.F&)HLD'H[9N+809U$03;YE/?"H=GLN /E2=J5J1]B_SO= C\Z7\O?R)O"1VY0SGBEI'2 MKVJ!!U>-"+\]:\<"5 R##:V*'Z51]JKA%\P%D^>$2H5? ^J"G_S*(F?S&, \TPE M20S*=] 275 K\$TWC&.?D$1@7E(<,5Z3#TV%2C&1P20/@*^ZC-,AD!Y4XXF$ MTONA?QA$%J.+9A/MYBILB6'\J.DUX@$L&C+5MLP_X9@H>%LIU&"H.#3/NX%Z M@*]Z6&+!V:,B=K:V6D6G];R7I_7N%]!9:(GI;1:2EM0Y80DU7%.F9]/ M]#L;+K,:>*.$L](6U=N6.&V)=RWQOB4^TE='AV!?IE;L;G_JDYS:6:?:\5^> MVKD"P1\BF0S2])0>3+.TT+VU92792^6@[5C'5.[R4B%I:BUP6#3''1@E6)>M M*[>+RKN2VL_6(WS(8V+-<-^UT M[E)S"_\G5?'$44K9:4AH;2?CBD4H.]!^J MA8HM\H(A9DN)BK$E_D LJ@-D @-[D'*]!_C"$?4C<0(A!?,LE-51N.V]SNVM M7M[V'CMCFK>MIQ^""NU]2OY1F<=D9T5)76L"FIYU,_@=.51<\=XIJDV,&M'. M5!'0X5H2;!!APJI947+SX^F##S!AY\7)$.L9X6YHU("/ ;JB(!:E,NO9=R'+ M@KTP8U9@Z$EU.7&_BNE1]+(8FL=XWB"TZHP47$;5R:AQ@RBG)"?[.?;,KH^M ML6HE=BNK:P+?YCVFFZ*X5GAE%\VUD0*G$W\$6A_KKYW^7*?^[+X\_?F-#OY[ MW"G-TIU?8]Z_K9+X,^4XA8W'A';#,$^\/L,AZW"%1D@UQ6&41+1*\&2>]>,D M^# @]N'56]/4 M5Z)Z,O$9:Y=?T$312CYK:Y 4WYD@M[5GK56=-J<2ULJ;VGLVM*G+^$RZDVJC M*L&Q%SKV0L=>N,IFF-BRCKWP5:^18R_<\1HY]D+'7NC8"QU[H:.!6U3*FRO& MCKW0B>TS%-O%V0L_.O9"QUXX=M[@4=!6$RNHT-40#MA MGPK5Y)5WF%EV"@?@YA>Z?AJ/H ^_XZ8:U!YE3YB"FI?7@'K3$X M<4.ZA1,Y YDA=!;AO.5#E:3*QX0^PA[P)J>RP?(=,&>$XX._=?X)?TH#,P6) M*;73\_3I+!CFI!)20USS+6UN1ZV(IG@10)"7D& MS M.Z.0!" -6)02,4X&*G-Z:8#66FU"F]=7=$[5KO M+?$B2U0A*X0&Y-.Y66KO2F>S3=YVNB5#4!A<"Z-W"77-9UQ#,A@J:GCZ PRC MU \\ _A"VXSZK%H"; W5PTU,F!P*"XD\15LGB&@46C7I(C_S-*E16W2I83 8 MRB!A2DC*C1.\!CZ!&$WI$?07EC.;9[!=I(T6;MO$;6^GJSO*DXCZ27@"Y7R@ MAM0PLRWXB]8QU&B5V+<11%[FM, Z39\_=JT"-F#Z_%1>3F(,DGX.OB%(-IX@ M#:M^J;6!#"Z5HG?0A_-C+ S\IF>]3HL1=X(>T<'B!D1BWR2. D_L%;U1XJG% M;"7>P,W%YR??K, &V"<3@ C^6L+ BK /9GK.L,@9VT<)H+IX4V[VT@A1&A&J MM!NY@A+F/LNQ@3121:%C"J:+[O/4!K%3(VM3(S]>GAKY&E?ZB']5D>H&9/;> MXF7-4B9?P4S&S3X59NV?4^#A@%O29L2#N>#(P M@)5:/?)53"DR.E8I[&[J2B=_RTS/@T3,:6K.>I3! Y<=IBK+M,7QPY=;1FWR;*(.!;:%$AGT:=$H.O]'7IL7%Z7X!:H$]$*;_>0)GDG4(T054XRQ8 M.U\T4L PN>2?/2OL=S0 MFB)N =-/SP7'#%!' ([=$+S&]"#N'OS_]JZTMVTDB?X5(OLE!AA:AV4EG@.( MXYE,=C&9(.?GEDA9W(BD0%).!.R/WZZJ;K*;LBY;EBBJ @2&)9DBNZNJZWQ/ M/I^>Y9H$*A9$3(S,!%?3$::(R6B9D>?NIB4RV C/N39R/IB &R"T5A3F)>"' M0JNS0V!EYS%2+M#F#'BX24)/0H>#_H:1_#0\4YD!I'.@F+3]\AY&2V"P#;\D M+H8,LV)^XQUXY10\2P'^I$!-W\+TOS%(K.=\>,SUR1W2Z-#F?_>V7QL&J?.C M4;UL_\V&%3JW&&6"R PFF12'!-AL(P'EEH.K?A5$4JO33C&8"W]Z-Z_A@GF F3@>EWJ6NQ ;FISC$;/+-ZWEG#?S#],@;. ME$P#L2?E_WEZ[E$#L$D5(.R&'EDQZ7,$@*&-1B#,<:*JYB_<*C+T04 M;.QV:>SBYAF[UU+\7ERGX2!(:Y;$MP;YP5&X8@H_IDRPGP+[1J*IPO+'9*7I MALIH S"A1(Y1#O$P:?2E3%E3.$[!WY9J," U4+&4?&&8%"!2912U"($%MGL/ M5)M6?U)[B3[A2R'"75R]:-M=C54-^^)]0J1^:1# U\9GE2X$Y*#@H'L]S(ND M[I?_.,I(X,O/83"*.G0(OB+88?I[93,=L%_=P;DOX_)'8NHN9,I_80/#T/2+ M%D:-+?MEHUS!A9>/TV1V6T#IK>Z:(P\/W,\I.L[*)$W39!CXLY02I@%TIP4+ M$')P=4OTG>>HFDG1YP:%Z^G\'CH2!QDAL<'M3('_D9G4;'^3,GM,S*;+;J^T M@?2E:#M3JCKOC<>:%:LAV.^8]HD3(\(KZQTNM3R%V Y&J$>#-/D.OV(#!&;L M4(Z3T8CRCE.!3)-4GI$Z>"@W+V-@V#N\ W6WG1 M %L5JS "E#ZR765$O205HI.S$""7[<2+AI)CY5U:J>18;-06Y [B9["RN85/ MN!.+36?W/\(3LIM^??WYU_/9ZO7;"YQZ[^+4I?3UL4CIJJ?X$]BJH%!0Y+?M M]GX-7>Z3,Z43S*N:,B@-CFX#U3-U\<[JQS7!]%0NWN HD-7$_<;*$I7\OTO^F M"=+_;F3Z#V4K;1T8X0:S.=X-);,L/:6Y=6M3IJI""WN)_FNSJRQ9NU%LVZ:H%D?-1"U%J_">]>-\#J7ARR> MY&-B+#&':1EBB%510( 3T_G\3+<1%M<"#0!&6AI2%/OG)6^SQ*T79 MU?VG!NN8ZH*1GJZ>=M6&4G;.PD1M$ 5G>1BD7PH]I?A#-,6YHHCJX'E@@WH6,HG%++K<-V@9;>O MK,K]T@(5W>MSZ_OX8.%2^*%/EF_2FHREQ00;@)DQ+AO4068;43;XAM5]I)J: M1;HX, @HWC2RF"5!GP'*H\:C?ACR:>>I7/**$U0AAQ2*,W?B0/KTF:!$'#'G@)RK2T"ON)18K1QX.>H#2E=[Z# M.JMD.S9;V@PCF+/&?*-WV**@2HEOJR(TZAZA6'@\BR MD )(XW0R#P+7$94RSL(D!N#(&$>$*D@O.2DJQ.;V6;#,[+LJIZ'.)O))=/M! M 7]AD)MC)D6/5%9N[JF;-W>)U\LT/4S3P_0B3--S*GO$-#T'WB.FZ6&:'J;I M89H>YCO95,KK*\9,T\-B>X1BNS%-3[?%-#U,TU.YZKYI>G:S[;C?N\J%F/LI M9GEB;R>^LD&ZQ QG=-)FB-P>CTN57'K=SBKS(T)J*1C95,C-Z3Q; M?_:UO'Z7%W]WB[_6<_(Z*QTG7N_=KC<;EP,:EPNOV^/%W]'BF_%9L0O=#7:A M[[7D+I0>X]6_1B-T"95'03!CTY\Z&Z,<1O5NJO9ER=N8RUEX\ZEC*77]KL8\ MD?_[7F=QY94+/,)_1@> G<;)G'?QT+M_T-B^@G736\.=;7!G3W,+][<[5V]A M5;U[S7GV*$G:D[#0-9T'Q6!5X[>!VO5:WF6?U0XE:TGZ-(/\Z6'5;GG_^^&T M[K&&_CATL0"LTA+4:;=;SA\BRYVW8C)(!?2E?$R$WVASM&]K=!P+LR@;K9:\ M"-!=O'+>)VD^=IU/\I=>JW7R:O,&F"9B0'EWG7_^8^ M\M'9 FR;73U%F:?49B/V>;V1B^0E)D$M]WS!DE_/KQIER<+HULG2X6_/\FCP M MJR6MUN^V?PL]WR9?C3\_X[O85J;/[;L[>IF([#8?&8P/HW$?.K,,:"_V"2 M#+_KZG"OX[UJEXGP?L>C>1&VA%M9PI-1C!J:N]6*R2^@/HBR MX\0F(5VL/-F5I4ZK[_4[%8TZ7F=R098L33*[2UI;%+@:8J#9U3Q!5[,^&E%# MR_QTCNC1B,-[$057V^EZWWNY..ATV)W\$ "5Z!^I%,APJX=I=[ ULQ%2R7:Z M27;Z 8KYTNNU:Z:8?PI_[EPG@(6YG5[VO)=-\9_4:5%I(%MVW%KG:K\X5^]# MN&C0,<1^.MM_MO^UT CVT^LH#I\!"O3X'?6O &+Z(0TR'()TSIVW08S@4= % M#X:3 M/1C8JV>OWA"'&Y$WP*EO7S@:D@?*V\[_G/;E5;OO?/CTF?UY-MNGJ:$Z=]J6345A?JX=2O6[?CEE,^/1Y^>K!&/2PH:+9&U1TWC>'2 M&2Z]J6 R#)?.>\1PZ37;(X9+9[ATADMGN'3&G=Y4RNLKQ@R7SF)[A&*[.5QZ MF^'2'PJ7_EAL]+LDU.'S4FCT\T'BS^6/<1Y-?O\_4$L#!!0 ( ):"L%1[ M$KRQO @ )&5X,S%D,2YH=&WM6VMOVS@6 M_2O<%#-- 3_SZ&3D-$!>Q01HFV[J8G<^TA(5<4.)&I*RX_WU>RXIV[+CMNGV MY702((E%7I*7U#F\YU+RX3_:[?,BXT4L$O;'\/4KENBXRD7A6&P$=RB=2)>Q MH2Y+7K#7PABI%#LQ,KD6C/W>Z>]U>IW?G[?;1X?HZK1NHXN([7?[S[L[O9T= MUN]%^[O1W@X[?LVVWP]/GWGKL\O3X9]OS\.H;]^?O+HX95OM;O=?NZ?=[MGP M+%2@^SX;&EY8Z:0NN.IVS]]LL:W,N3+J=B>326>RV]'FNCN\ZF8N5WM=I;45 MG<0E6T>'5(*_@B='A[EPG,49-U:X%UOOAR_;![!PTBEQ=-B=_0^V(YU,CPX3 M.6;6395XL95SL;EM3V3BLJC?Z_TR*'F2R.*ZK43J MHOW.P<&BR,CK;%ZFP]0B(Q1W'9=SR&T:,=:*5Y:$CX7>SJ9! M[X1;KPQ8/F4W\%X)2(A60&"-NT1CX$)#>Z #+@O&BRFK"FX'8SW(0X8[:B/XOV$V%$W0E-()<689N6.^@G(VPI8N\@]5O" M-9U@FKC36)31M+D,CY3:4$KM/AA*"9;* J E_"] V@*?8(YJTZB714K]D9#$ MYUA5"?H$$1J(;(%$DN)#"1P3!8F:2 /F'*OA;5>&!HT3KU!;9%$I&(!8&NCW MPUGO3\QMQE*E)W;&.B.NI770_(YQ*@Q^IR1P%N2Q,V?N>/M ^=/[V>FSMVGT M&2YAS>O[WP:V)D@MI6D'UVDJ<>E1>,&X$1[OP*\D- &73%BZ5=)F9$YF.:(7 M13"Z3J2-E;85VE%<,UH%X)=&(^M&L67;P'DB0)P YO-;I*D%$NQCA(RK2L&B MO\OK!*2_ORV>^0[Z^TFS+!1*RH**0#X:BU&,:7 R<(3\^LQ!TS6#IAB4YK_* M6MB1SHP^S,3UJ;6/(?/4>I/9^LVC78-&6T>KQ/GA7-[FSS:,S&?"8C: LE=F MG^9GD2!#A%RT!ZX?9HC] MNY-VM-FDO7?HNL/=^P>]>U,8M!_+A)C)K2X\J+D%JRD5)+IRD\RH S)+/I)* MNBE)V'7#TD;B6>8)%/: )=-&*ND%Q6T]H;(R)0ALO>2.8V#/.^"3RFM10$DK M\!@UHJ0-@DR0, >N8B.1)>+X(UL?)%OC36/K^9BKRLR:;1ZRP@]RX#Z!2TSLU\S5J:?48()%6JX[@RA/.& M!%S3:ZZM0SD]6T-?%FL^>UK MC_0) 5A$9Q6K&O'8]#('^#2V6Y1S?UZ%KS* MN)WK90IKGN B\?'>KT<=BZ=,R1NAZM/<%?O6%R_1)TC]T'/7G_ZD:?_G.&GR MC^J2V:[06L0@"HE-9B["$7'K,V3TG>QS[AI'!NJTL7/EZ@O099Y+YX3X2, ? M:6ACJD\D_/.=;(._B*^6XC?^4QX\VW3$7Y6$^WZ#J8K8GPL_>SPX^FG#[L8= M'!TK9%^8CP3UZ/"2CD1C*<"56IG.#W F@M^0U S9F!>;/H_TCQ]G#S4^BX'U M64LX4EX3VWB"AE;,0]L'V5IGGV@"R@$ M_M8YV)OM.7-M4-XR?]C/GO3\S_>=1M=VFZ\3+J;D";'!H%G:WN@,-X3#*(-7 MHH ![0B]W<4YZ,8CZEO/: E]?D/[L=![A-W?"';?=4JGF10I.T7>*HP/^I>- M'/MM>$:"TO-;$5=TECRK7X'A3 Z$@+\I2^^="7\S,]<>/+ZY-KHJ$M(?VD0S M1C>^2;!<4:L0TC1*%J)=7_>6M$CXML*2&%DJFG\UHH2.:X^0S]RT>0K!$?&Q MEDD-@8.#SLYBYPEE/:^DPE&5X,S%D,BYH=&WM6VMSV[@5_2NH,KMQ M9B11\JM>RO&,X\?4,XGM.DK;_0B1H(F:)+@ *%G]]3T7H"1*5C9.\Y)3>\:V M"%P %^ YN.>"U.%?.IVS(N5%)&+VM^&[MRQ6496+PK)("VY1.I$V94-5EKQ@ M[X36,LO8&RWC6\'8;]W^;K?7_6V_TSDZ1%X>.W['MCX,3UXYZ].KD^'OUV=^U.L/;]Y>G+!6)PC^N7,2!*?#4U^![OML MJ'EAI)6JX%D0G%VV6"NUM@R#8#*9="<[7:5O@^%-D-H\VPTRI8SHQC9N'1U2 M"?X*'A\=YL)R%J5<&V%?MSX,SSL'L+#29N+H,)C]][8C%4^/#F,Y9L9.,_&Z ME7-]*XN.566XTROM "T#5*_8W'[!P:)( MR]MT7J;\U$(M,F[E6%#?C5ZC3' =CI1-!ZL#K&M9SMHEJK"=A.MGT)_ANA9?)RX*R-_(] UYB>%?>VPS-YB\[)UX&??X@Z1K_] M;?^!1APMC3@1;FXCE<6H/+M/Y4C:7U_T]WN#G7YW^S 88>7*;^!G!- *_;\Z M>G)V,[PXOS@Y'EY<70*.-^\_'%\.V?"*O3^^>7-\>?;^UQ<'V_W^X.I?;\]^ M9\'LP^"+)E@S"8"V M*@]I,H,&N=P2D+^=C$]59<-$WHMXW:HTB. =#>O;;#5^XZ]R,\:TEA'/ZJ&= M%_!R,$FE%1U:,A$6:J)Y.7/G *WJI:W]Z7>QN<1-EY;K#VG,K^*MOZ2.X)3. M>39H KTN FA8RL>":3&68H+-VJ;2L#\JKD&?;(KR4FF++9R=HP4V[\[?F4K8 MM;!:&7:-_3/'M"NW+J;-+HIHF^X<>J MY5-V!^\S 1G1]@BL<1#%E56%U)> IU(43)P D9SFNM.09 M2WB$(LU4+BVSRML],"A$)(SA>DHF.;\3&+?1IT%9#&TQAD$$D-100S M:"0#3W"[&6Y"E#)3T9]%^XG0HNZ$)I!+@]!-R^TUE!:F%)%SD/HMX9J*,4W< M:2S*:-I.4ZZ._%S3)?*"D3*CSY:"Q&,:;!2<\1\NLS!TW6#)I@4)K_*FMA1SHS M_#@3UZ?7+H;,T^M-9NLWCW8-&K6.5HGSP[F\Q5]M&)E/A<%L &6GS#[-N3:) MQHA7YO%-2+V-!#A3C^3UH*HT.D!0&DOC0AVL1.'ZH31\$22;@=:?VH"$M2!< MD*==!V&JE B8\,6H3,;N;,U4(R-CR;6D"4@O6UWH+ZBGRI"4=/N7<;K3!49E M!!RR",34J.1T]ZN,4SS'M)P3"TF*%E[@-G4Y/HT$&2+DHCUP_31#[/\[:4>; M3=I'AZX'W'U\T'LTA4'[L8R)F=RHPH&:&[":4D&B*]?QC#H@L^0CF4D[)0F[ M;EC:2!S+'('\'K!DVD@EG:"XKR=45KH$@8V3W%$$[#D'7%)Y*PHHZ0P\1HTH M:8,@$R3,GJO82&2)./[,UB?)UFC3V'HVYEGEXA!!620)4CXY!@C-FM1M+J4,"KNDU M5\:BG)ZOH2^#-9\]+6!;'VF2@+ (3BO6M>,1:.0.<.ELMZCF?KWR7J7._6HX[%4Y;).Y'5I[DK]NTO7J)/D/JIYZX__4G3WL]QTN0>U<6S M7:&]B$$4$IO,7(0CXM9GR.@'V>?<-8X,U"IMYLK5%:#+/)?6"O$G 7^DH(VI M/I;PSW6R!?XBOAJ*W_A/>?!LTQ%_5!+NNPVF*B)W+OSJ^>#HIPV[&W=P=)PA M^\)\)*A'AY=T)!I) :[4RG1^@#,1_(ZDIL_&G-AT>:1[_#A[J/%9#*S/6OR1 M\IK8QF,T-&(>VC[*UCK[1!-0#N!H>[UK('9-E0-N6!4WF5I2K'W\\ZQEGRJI M-NY@YQB2-=&(&6U 7+@P!Y*X)^,UF]I>\X+D+[5[I7OOG'PCSY_. M?^7SZQ7@S4*]#^:;LNK.&?\WU7-=P:.[6ZVJ(B9MH70XXW'CFP++%;7"(+V2 MR4)TZNO>DL[PWT98$AI+1?.O/I30:)T1G>\W MOJSG5)+_2H7[CL;1?P%02P,$% @ EH*P5 YDNVU[)= M^[AC6?T>##4L^XC41VW'ZS@-M]% GNNWFW[K%S0X1T?7X?"E:7TZ&89O+T?% MK)?7)V_.AJAF.<[OS:'CG(:G104,[Z%0XC1GBHD4<\<97=10+5$J\QUGM5K9 MJZ8MY-P)KYQ$+7C+X4+DU":*U/H]70)_*2;]WH(JC*($RYRJ5[7K<&QUH85B MBM-^SZG^%VUG@FSZ/<)N4*XVG+ZJ+;"Q\MMVMWM;)-D\V9:)PC5?4HX5NZ%Z[)U1(TZQ]&=")<'= M">[KF57]8I$J*\8+QC?^BY M:(XNZ I=B05.7]2+$OB?4\GB%X%IG;._* P- M[BFZ5A;F; Z#:UN#PG\?ZI#^>(WBBYYQMC?CBAK?9H(3J!RM$S9CZODSK^,& MS4;/F4'* M19CG=7261C8ZTEVT=PTW&(H%I*"-N?*"EY!CT%C(!607ZU<4"VF&S\!P01!- M"62ANE=5&)A:_!"W9R MM,%5VVMQO!%+Y<=L35.5WH58:VM,>S88\BNR;MU_?TG%_$VN)2#P1&P:+DP6X&*HMJ M?0U.N8SC)>> *"Q0K@G=+BU)WR^9I%I.Y)JH"CVO>81A 4ODM8_(RRV%MPMQ MNPA+%+WC9BO0BZ7G:%OZ12@KS--3MO5F17DGT1N$;(.#)$4L='B48\?+-A\P;#H5@'0!UQHR.(%\-4+G V3O4%T7)W:/HRL-R4*VV#W/J*R"KF@I=:M0X;,[_=F?8)++=MK?U\>M3MVHW,H M+AT @*>P/?CP?+%!7J=XL#@ QDXV_O_DIMQI*JV=K5$N."/HF6M^'M8-)W?0 M&),-.A&1$O*@N'E*7)\%H%%%WY:^)_)^+/(>U*5APFAL#IZH-$\9DSAF$97F M&>-2,GCTR*!TM(8G97W>6]4_D?A$XB-QZ0 ?!)OWU:\G3,5)91S-)"IX.2@ MV'E*7HU"7?@-%!F*-YHSHURA$C,;FU)C>47'C[5GR_2JN.APN MCG\?2^R-,<7?1&Y/HG'T;B[%,B7Z-%I(OUK9.^\N[%>49]+ZA)NSE%KE=94+ M=M^9V#N:WBO:OHR1X3FU9I+B=Q:.%94^OA&,5*?17;O1VF:@HLPUY^K%2Q[F MK9'^WU!+ 0(4 Q0 ( ):"L%0(6/N!0AL 'T^ 0 0 " M 0 !T;6(M,C R,C S,S$N>'-D4$L! A0#% @ EH*P5#5#"R(O$0 M_^X !0 ( !&UL4$L! M A0#% @ EH*P5*]YH^JP, \"(# !0 ( !T2P '1M M8BTR,#(R,#,S,5]D968N>&UL4$L! A0#% @ EH*P5,OM6ARH?@ ;DD( M !0 ( !LUT '1M8BTR,#(R,#,S,5]L86(N>&UL4$L! A0# M% @ EH*P5.CEO&UL4$L! A0#% @ EH*P5%;0O'C7&P( XR,6 !0 M ( !@C,! '1M8BTR,#(R,#,S,7@Q,'$N:'1M4$L! A0#% M @ EH*P5)>%.D8*2@ ,P " !< ( !BT\# '1M8BTR,#(R M,#,S,7AE>#$P9#$N:'1M4$L! A0#% @ EH*P5!0SJI\<% #;( !< M ( !RID# '1M8BTR,#(R,#,S,7AE>#$P9#(N:'1M4$L! A0# M% @ EH*P5$H357[Z%@ YY( !< ( !&ZX# '1M8BTR M,#(R,#,S,7AE>#$P9#0N:'1M4$L! A0#% @ EH*P5/H3$#-&Z0 ,M$/ M !< ( !2L4# '1M8BTR,#(R,#,S,7AE>#$P9#4N:'1M4$L! M A0#% @ EH*P5'L2O+&\" ES( !< ( !Q:X$ '1M M8BTR,#(R,#,S,7AE>#,Q9#$N:'1M4$L! A0#% @ EH*P5(=T2=^X" M=S( !< ( !MK<$ '1M8BTR,#(R,#,S,7AE>#,Q9#(N:'1M M4$L! A0#% @ EH*P5 YDN#,R+FAT;5!+!08 #0 - &D# # Q@0 ! end